{
    "5bc844fc-e852-4270-bfaf-36ea9eface3d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these. In the Primary Trial, participants undergo FLT PET scanning with [F18] fluorothymidine to assess tumor response prior to standard endocrine treatment and surgery.",
        "Label": "Contradiction"
    },
    "86b7cb3d-6186-4a04-9aa6-b174ab764eed_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00ac\u00a8\u201a\u00e2\u2022, ANC <  1,700/mm\u00ac\u00a8\u201a\u00e2\u2022 and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial. Patients with a Zubrod performance status of 2 are also eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "dbed5471-c2fc-45b5-b26f-430c9fa37a37_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events were recorded in both the primary trial and the secondary trial. Two of the participants in the primary trial experienced confusional state, which is not mentioned in the secondary trial adverse events.",
        "Label": "Entailment"
    },
    "20c35c89-8d23-4be3-b603-ac0ee0f3b4de_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial. The primary trial also allows for patients with a history of prior adjuvant therapy as long as they have completed treatment at least 6 months prior to study entry.\n\nExplanation:\nThe provided statement in the question only mentions",
        "Label": "Contradiction"
    },
    "f17cb242-419d-4f5d-bfa4-41494ed5ac0e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy. The Primary Trial also included a control group receiving standard of care treatment without laser therapy or manual lymphatic drainage.",
        "Label": "Contradiction"
    },
    "fc5c4554-7ce9-4c16-b374-a3cd9d15b021_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT01027416",
        "Statement": "Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial. The Primary Trial also requires that patients have a documented Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of enrollment.",
        "Label": "Contradiction"
    },
    "96b77cdd-aa9f-4770-8447-8a04d9ca5da7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial. Patients with hormone receptor-positive invasive mammary carcinoma are eligible for the primary trial, regardless of tumor size or nodal involvement.",
        "Label": "Contradiction"
    },
    "c73faed2-371b-4238-bf7d-293fae380203_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "the primary trial and the secondary trial have Hypnotherapy based interventions, the secondary trial also used pain medication in its intervention. The Primary Trial did not involve the use of any pain medication as part of its adjuvant radiotherapy intervention.",
        "Label": "Contradiction"
    },
    "8765009d-ffc4-4395-ab7a-11ecdfd43a40_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of an investigational agent in treating hormone receptor positive breast cancer.",
        "Label": "Entailment"
    },
    "0ad7293d-df35-42e8-881d-f2afc3f7d3fd_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02606708",
        "Secondary_id": "NCT02504424",
        "Statement": "Only patients in the primary trial receive 40.5 Gy of brachytherapy, patients in the secondary trial receive no radiotherapy whatsoever. Patients in the primary trial undergo radiation therapy using prone position IMRT with tangent fields for a total dose of 40.5 Gy to the entire breast over three weeks, with an additional concurrent boost to the t",
        "Label": "Contradiction"
    },
    "2bc1e094-41a1-46d9-9b0c-b5a47f23323d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Certain drinks are banned for patients undertaking the primary trial. The trial is a randomized, double-blind, placebo-controlled study evaluating the addition of enalapril to standard doxorubicin chemotherapy in breast carcinoma patients. (This sentence does not con",
        "Label": "Entailment"
    },
    "83b83400-1439-462d-bba3-42817b5b1fa1_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "Most of the cases of CHF in the primary trial, were in cohort 1. The frequency of Thrombocytopenia in cohort 1 was higher in the Primary Trial compared to cohort 2 (16.67% vs. 0%).",
        "Label": "Entailment"
    },
    "c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for the primary trial must have a life expectancy over 6 months. The trial is recruiting patients with early stage breast cancer only (T1-T2, N0-N1a, M0).",
        "Label": "Contradiction"
    },
    "17a821f8-5e68-4bf7-ac01-3f96ddfc5187_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Statement": "Patients eligible for the primary trial must live in the USA. The primary trial is a randomized, controlled study investigating the effectiveness of a new intervention for preventing breast cancer in high-risk women.",
        "Label": "Entailment"
    },
    "d76d6c7f-ba39-483c-a89e-152af5ae2878_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT. Subjects in the placebo group of the primary trial will not receive any intraoperative injection during surgery.",
        "Label": "Entailment"
    },
    "65f3e755-3e23-4e84-a218-87922759094d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "the primary trial administers letrozole for 28 days, whereas the secondary trial administers is intervention over 4 cycles of 21 days. In the Primary Trial, both letrozole doses were given orally once daily.",
        "Label": "Contradiction"
    },
    "d3590771-806b-4754-a455-38113bfedfca_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion. The primary trial also requires patients to have invasive breast cancer with stage IV disease that has progressed or relapsed following prior standard therapy with trastuzumab, regardless of HER2 status.",
        "Label": "Contradiction"
    },
    "941b960f-8d57-4830-9d4c-8e96765ba76c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient. In the Primary Trial, Arm 1 (Yoga Intervention) does not involve the use of Bevacizumab.",
        "Label": "Contradiction"
    },
    "f79a9011-0a68-4255-a40f-5d73af412bf0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial. The AeroForm Tissue Expansion uses carbon dioxide from an internal reservoir for inflation, while Saline Tissue Expansion uses saline injections for expansion, both interventions being part of the Primary Trial.",
        "Label": "Entailment"
    },
    "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial. Two of the patients in the primary trial experienced constipation (1.72%).",
        "Label": "Entailment"
    },
    "57f3a264-9119-4931-9f9c-9cb20e945973_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of lapatinib in combination with paclitaxel compared to paclitaxel alone as first-",
        "Label": "Contradiction"
    },
    "589e2f5b-9286-465b-8162-bb1549cd5ece_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR).  The objective response rate was higher in the Fulvestrant 250 mg + Loading Dose arm compared to the Fulvestrant 250 mg monotherapy arm in the primary trial. (",
        "Label": "Entailment"
    },
    "8275f846-59b6-404d-a6d8-e01335279f1a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "Less than 1/4 patients in the primary trial experienced adverse events. The most common adverse events were palpitations, GERD, and fever, each affecting approximately 4.17% of patients.",
        "Label": "Contradiction"
    },
    "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Statement": "The both Cohorts of the primary trial receive their treatment via Subcutaneous administration. The primary trial compares the immunogenicity and safety of two different dosages (300 micrograms and 500 micrograms) of the Mimotope P10s-PAD",
        "Label": "Entailment"
    },
    "18d9991c-ca96-4bab-93af-77654857a07f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "the primary trial does not accept patients with grade 1 alopecia. The primary trial accepts patients who have a body weight >25 kg and a body surface area >0.6 m\u00b2, in addition to the other inclusion criteria. (This is not mentioned in the provided passage.)",
        "Label": "Entailment"
    },
    "6fb9056d-277c-4dc2-9b45-d7661bb41831_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography. In the Primary Trial, participants in cohort 1 received mammography alone, without any hormonal supplementation.",
        "Label": "Contradiction"
    },
    "52b23601-2276-4634-96c7-8b6e55596085_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat. 2 patients in the primary trial experienced diarrhea as an adverse event. (5.56%)",
        "Label": "Entailment"
    },
    "95e05332-4926-4381-90a4-87941269e7bf_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of the primary trial participants achieved partial response (PR). The partial response durations in the Afatinib 50 mg arm ranged from 3.5 to 17.1 months.",
        "Label": "Contradiction"
    },
    "20d51467-b059-4f39-b636-d32f2dc692da_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "Both the primary trial and the secondary trial at least partly administer their interventions orally. In the primary trial, suramin is given intravenously while paclitaxel is administered both intravenously and orally, with the suramin infusion occurring first followed by paclitaxel.",
        "Label": "Contradiction"
    },
    "15c83d26-f9ba-44cc-a920-6941781cdd8b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia affected the majority of patients in cohort 1 of the primary trial. The frequency of neutropenia in cohort 2 of the primary trial was lower than that in cohort 1.",
        "Label": "Contradiction"
    },
    "e100212f-5bef-4f84-a3c1-d18a6b3e8355_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation. The duration of moderate neutropenia after the first cycle of chemotherapy was significantly shorter in the 80 g/kg/dose F-627 (TC) arm compared to the 240 g/",
        "Label": "Contradiction"
    },
    "56d2a387-49dd-49b9-93bb-bcb092bf2714_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "the primary trial is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions. The Primary Trial also uses the novel radiotracer 89Zr-pertuzumab for potential specific visualization of HER2+ lesions in addition to 89Zr-trastuzumab.",
        "Label": "Entailment"
    },
    "2485a3e1-7520-47d2-b941-32ebf91e5b65_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of the primary trial are assigned an intervention depending on their prior treatments. The Primary Trial is a randomized, double-blind, placebo-controlled study comparing two interventions of Neratinib, one with prior Trastuzumab treatment and the other without it.",
        "Label": "Entailment"
    },
    "b97d9465-db14-43af-9451-4b824e67abb8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. The primary trial allows for the inclusion of patients with non-progressing distant metastases on concurrent systemic therapy, while the secondary trial does not have such a requirement.",
        "Label": "Contradiction"
    },
    "798c0983-5265-47ea-bfcd-735738793482_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. Patients with prior radiotherapy to the breast are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "127e9179-6781-4b9a-abe9-080d2ffad591_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. The primary trial focuses on the effectiveness of text message management prompts for managing hot flashes and vaginal dryness in postmenopausal breast cancer survivors (INTERVENTION 1) versus no text message prompts (CONTR",
        "Label": "Entailment"
    },
    "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. The Primary Trial is a clinical study evaluating the efficacy and safety of Taxotere in treating early-stage breast adenocarcinoma in eligible female patients.",
        "Label": "Entailment"
    },
    "16dc5a77-5758-4d19-9801-6e9932d9fbc9_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. Some participants in the SC (Subcutaneous) Herceptin arm of Cohort 1 expressed a preference for receiving oral Herceptin tablets during the continuation period, but this was not a formally assessed outcome measurement in the t",
        "Label": "Contradiction"
    },
    "2ed770a0-fe98-4029-9511-ad04a94a1a69_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. The Primary Trial's second cohort had a lower overall incidence of adverse events compared to the first cohort.",
        "Label": "Contradiction"
    },
    "b4c97206-66fd-468b-8388-fac076222c10_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2. The total number of participants in cohort 1 was 482, while in cohort 2 it was 238. (This information is not explicitly stated in the given data, but it can be inferred ",
        "Label": "Contradiction"
    },
    "6e22d118-af77-41bd-bd47-9385779f33aa_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial. The trial permits patients with positive lymph node status (N1 disease) if they undergo axillary nodal dissection or sentinel lymph node biopsy prior to randomization.",
        "Label": "Entailment"
    },
    "ccc5362a-33d0-4f1b-be46-d31729ba9194_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group. The PFS analysis in the primary trial was based on a intention-to-treat population.",
        "Label": "Entailment"
    },
    "fa530b28-9142-49f2-aa80-4d04fa532910_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "Participants in group 2 of the primary trial receive taping to anastomosis regions., but no  Complex Decongestive Physiotherapy. Participants in group 1 of the primary trial underwent Complex Decongestive Physiotherapy without taping application.",
        "Label": "Contradiction"
    },
    "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 had Pyrexia. In the Primary Trial, two patients experienced pneumonia in cohort 1, while none did in cohort 2.",
        "Label": "Contradiction"
    },
    "41cf791e-ed7a-48e5-af84-eefc9fa41ba7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, alcohol poisoning was reported as the most common event. The types of participants or conditions being treated could differ between the two trials, which could account for some differences in adverse events.",
        "Label": "Contradiction"
    },
    "d417aa7b-6d2c-46f8-812c-426ea60e0328_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "There were only 3 adverse events in the primary trial which occurred more than twice. Two of the adverse events, atrial fibrillation and chest pain, occurred in the same participant.",
        "Label": "Contradiction"
    },
    "2744cc0a-86e9-4764-ae1c-f10f635dc283_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months. The decrease in bone mineral density with Letrozole was statistically significant compared to the Tam-Let group at 24 months. (This additional information is not explicitly stated in the provided text, but it can be inferred from the median per",
        "Label": "Entailment"
    },
    "2e4717fd-b349-48a3-b751-88674dfaaa18_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy, or have no standard therapy available, and cohort 2 patients must respond well to standard therapy. The primary trial was designed to determine the maximum tolerated doses (MTD) of Alobresib in two different dose levels (0.6 mg and 1.4 mg) for participants with advanced solid tumors and l",
        "Label": "Contradiction"
    },
    "b0c65cd7-8cad-404d-8704-ee074e480f57_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "the primary trial and the secondary trial do not have any overlapping inclusion criteria, apart from the mimimum age limit of 18. The Primary Trial involved treatment with an investigational agent.",
        "Label": "Contradiction"
    },
    "28e20650-e100-4e30-a319-5eceb69a979d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "1 patient in the primary trial had toxic hepatitis. 2 patients in the primary trial experienced constipation as an adverse event. (Not mentioned in the given information)",
        "Label": "Entailment"
    },
    "8cf0c320-9486-4531-9212-bb3284b734f1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP.  The primary trial also reports the sensitivity and specificity of SentiMag and SiennaXP in detecting lymph nodes compared to the standard of care.",
        "Label": "Entailment"
    },
    "34a75478-e7cc-495e-86c3-d0accdaf1ddd_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months. Participants in the primary trial must have received at least one prior regimen of chemotherapy for metastatic disease.",
        "Label": "Entailment"
    },
    "47780450-1202-4934-8e50-b29416b124f5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen. In the Primary Trial, the Letrozole intervention was given for a duration of 3 years.",
        "Label": "Contradiction"
    },
    "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "There were 2 cases of severe back pain observed in the primary trial. 2 additional patients experienced headaches during the primary trial.",
        "Label": "Contradiction"
    },
    "c5e6497a-2e2f-4663-97fd-e73ba8904b0c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis. In the Primary Trial, there was one additional case of hypertension reported in the Adverse Events section (1/73, 1.37%).",
        "Label": "Contradiction"
    },
    "c4dd814d-f525-465f-abe1-a7975771d57e_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered Methylprednisolone 3 times per week for 6 doses. The IL-2 dosing regimen in the primary trial for participants in both cohorts is adjusted based on body weight, with lower doses given for those under 45 kg.",
        "Label": "Contradiction"
    },
    "cfd93077-87c5-458b-8712-e1896929309d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets. Two patients in the primary trial experienced gastrointestinal adverse events, diarrhea in one patient (1.79%) and nausea in another patient (1.79%).",
        "Label": "Entailment"
    },
    "a3faaf85-62c6-430f-acf2-9c5992ee5221_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, progression of disease was reported as the most common event. The types of adverse events reported in the primary trial were similar to those observed in the literature for the study drug in this patient population.",
        "Label": "Entailment"
    },
    "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "Less than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar. One patient in the primary trial with thrombocytopenia also reported high blood sugar levels.",
        "Label": "Entailment"
    },
    "335936e4-9eaa-43b3-84fe-6f112c0d0226_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial. The trial randomly assigns patients in the primary study to receive either real healing touch therapy or sham healing touch therapy in addition to radiotherapy.",
        "Label": "Contradiction"
    },
    "19921113-538e-4fd2-81a6-6053f2dd6459_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1. The occurrence of DLTs was not statistically significant between the two cohorts in the primary trial.\n\nExplanation: \nThe previous statement only highlights the difference in the percentage of patients with DLTs between",
        "Label": "Contradiction"
    },
    "6a013bb4-0688-4f02-96c5-062f3ca67ae1_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were 5x more adverse events in cohort 1 of the primary trial, than in cohort 2. The types of adverse events were also different between the two cohorts, with more cases of gastric volvulus reported in the secondary trial.",
        "Label": "Contradiction"
    },
    "c103a786-0b1d-4124-aa5d-4945ded2c384_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "the primary trial and the secondary trial are not studying PFS, PBR or DLTs. The primary trial aimed to assess the concordance of Lymphoseek and blue dye in detecting lymph nodes during surgery.",
        "Label": "Contradiction"
    },
    "2746a75c-7f01-4dc3-a05e-5c7499e75555_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial. Patients with HER-2 positive breast cancer and who have already received trastuzumab are eligible for the Primary Trial, but only if they are enrolled in a separate clinical trial evaluating the combination of the primary study drug ",
        "Label": "Contradiction"
    },
    "df64a4c5-08f3-40c7-a4e7-2a6271bc9e53_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "Patients with a prior malignancy of skin cancer are excluded from the primary trial. Patients with a history of in-situ breast cancer are still eligible for the primary trial, as long as they meet all other inclusion criteria.",
        "Label": "Contradiction"
    },
    "682f5e80-75c4-4a36-9bc1-b389a98ad160_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "None of the patients in Cohort 1 of the primary trial suffered from Hypotension. One patient in Cohort 1 of the primary trial experienced a Diarrhea adverse event.",
        "Label": "Entailment"
    },
    "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "Only White and Asian patients are eligible for both the primary trial and the secondary trial. The Primary Trial also requires participants to have stable cardiac and pulmonary function.",
        "Label": "Contradiction"
    },
    "348c9273-6aa1-43a8-840d-3cf080874669_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of the primary trial, there were at least 2 patients with a fever. Among the total participants in the primary trial, one patient experienced both febrile neutropenia and thrombocytopenia.",
        "Label": "Entailment"
    },
    "dfe6228e-6bfb-49d3-b0b4-397aab177bea_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "We cannot compare results between the two Arms of the primary trial as there were no patients in cohort 1. The Primary Trial is a dose-escalation study designed to determine the Maximum Tolerated Dose (MTD) using the specified regimens in each arm.",
        "Label": "Entailment"
    },
    "9f424ebb-63b8-4930-b2c1-cd46fff4d706_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "Only one patient cohort of the primary trial had a positive median Insulin change from baseline. The Metformin + Lifestyle Intervention group had a greater mean percent change in insulin reduction compared to the Placebo + Lifestyle Intervention group (difference: -4.1% [-8.1%,",
        "Label": "Contradiction"
    },
    "c1f8c7fb-22de-4501-af86-d9eb59542ae3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1. The time frame for evaluating stable disease in the Primary Trial is 24 weeks after the start of treatment.",
        "Label": "Entailment"
    },
    "6630047b-7ebc-4435-8203-cf6bbe6b6ee7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Left ventricular ejection fraction > 50% is required for participation in the primary trial. Patients with stable angina pectoris are allowed in the primary trial, as long as they are not experiencing unstable angina.",
        "Label": "Entailment"
    },
    "039c3fc2-f798-4d97-b904-9aa7d363eeef_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial. The primary trial also requires patients to have a sufficient bone mineral density to receive denosumab, as assessed by DXA scan within the 28 days prior to enrollment.",
        "Label": "Entailment"
    },
    "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "the primary trial requires participants to have undergone PTR. The primary trial also requires patients to have recovered from the effects of preoperative chemotherapy before starting protocol-based treatment.",
        "Label": "Entailment"
    },
    "f8028143-35d1-4cc3-895a-acb577db4715_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD. In the Primary Trial, participants in the Arimidex Group received 1 mg of anastrozole daily for a longer duration than those in the secondary trial.",
        "Label": "Contradiction"
    },
    "907f7e56-b6ec-4a43-bf3a-14f93c644bc1_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study.",
        "Label": "Contradiction"
    },
    "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial. The trial also requires that potential participants have regular menstrual cycles or be using extended regimen oral contraceptives or a contraceptive device to ensure consistency in breast tissue assessment throughout the study.",
        "Label": "Entailment"
    },
    "a41bf7b0-9a09-4ce0-8832-f13758581f20_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2. The primary trial's Adverse Events 1 section reported a higher incidence of diarrhea cases in Cohort 1 compared to Cohort 2, with 5 cases (2.48%) versus 3 c",
        "Label": "Contradiction"
    },
    "5f2d2015-eaf9-45a8-9583-fddbc9807287_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia. The number of patients with both Hyperbilirrubinemia and Neutropenia or Leucopenia in cohort 1 was 1 out of 436 (0.23%).",
        "Label": "Entailment"
    },
    "609ddd08-ebd5-4661-be43-874b65dbfe52_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial. The primary trial also requires that patients have no history of previous radiotherapy to the breast.",
        "Label": "Contradiction"
    },
    "b6ac985d-87ae-4e0f-83e1-38033c1db5cc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status. The primary trial allows for participation of pre-menopausal women who have undergone surgery as their primary treatment for ER+ve breast cancer.",
        "Label": "Contradiction"
    },
    "43ff9425-5e6e-4a85-a8ca-0c0c67a96623_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of the primary trial participants achieved Objective Response (OR). The duration of objective responses ranged from 3 to 34 months. (This information is not explicitly stated in the provided text, but it can be inferred from the time frame mentioned in the Outcome Measurement section.)",
        "Label": "Entailment"
    },
    "b3ccde30-cdfc-4e18-aee0-8b3a921dde39_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV, but only a subset of participants undergo axillary lymph node dissection. Some patients in the primary trial may receive radiation therapy in addition to the mentioned interventions.",
        "Label": "Contradiction"
    },
    "8697a59e-0f1c-452a-b15a-6d24e2df387f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "None of the patients in the primary trial or the secondary trial committed suicide. Five patients in the primary trial experienced adverse events that led to treatment discontinuation (3.51%).",
        "Label": "Contradiction"
    },
    "4ab74186-5f4e-4139-af05-d4a9871a251d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her husband for 31 years, she is eligible for the primary trial. The study does not exclude participants based on their sexual orientation.\n\nAdditional Information: The provided inclusion and exclusion criteria for the Primary Trial do not state any condition regarding the participants' sexual orientation. Therefore, it is essential to note ",
        "Label": "Entailment"
    },
    "082ee581-f420-4892-b098-ce82c6ad0210_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in the primary trial were cardiac related. None of the adverse events in the Primary Trial were related to cardiac issues, as indicated in the description, but the given statement is incorrect. The actual adverse events listed are related to various conditions such as neutropenia, diab",
        "Label": "Contradiction"
    },
    "7bf084eb-873a-4011-9b98-3a899ee582ee_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Pre and Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy. Participants in the Primary Trial must have a confirmed diagnosis of DCIS and be scheduled for definitive surgery.",
        "Label": "Entailment"
    },
    "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "the primary trial and the secondary trial are testing completely different modalities of interventions, but utilising the same 21 day cycle. The Primary Trial also includes randomization and blinded placebo control for the administration of tivantinib.",
        "Label": "Contradiction"
    },
    "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with ERBB2 positive tumors are eligible for the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of neratinib plus capecitabine versus placebo in patients with ERBB2 positive metast",
        "Label": "Entailment"
    },
    "f6c85ce8-e0fc-4186-a961-6207dd4cacd2_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "Most patients in the primary trial treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR). 11.4% of participants in the primary trial achieved a partial response (PR) to Eribulin Mesylate treatment.",
        "Label": "Entailment"
    },
    "5bdd61d9-aadf-4944-afe3-a04242d9c2b2_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial. Eligibility for the primary trial also requires histological confirmation of invasive cancer.",
        "Label": "Entailment"
    },
    "b8ce7d6a-d707-48e0-816c-de7ac3a63823_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial. The trial involves the use of Lovaza\u2122, an omega-3 fat supplement, as an intervention to reduce breast cancer risk.",
        "Label": "Entailment"
    },
    "53d88010-e7d7-41c7-b20d-6328c8e507d1_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "For some adverse event types in the primary trial, there were no recorded cases. Two participants experienced more than one type of adverse event.",
        "Label": "Contradiction"
    },
    "8257bf5c-fae6-44c0-a86d-293746fdc468_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2. The primary trial had a higher overall incidence of adverse events in cohort 1 compared to cohort 2 (21.54% vs. 15.38%).",
        "Label": "Contradiction"
    },
    "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "Patients with HER2 positive breast tumors are eligible for the primary trial, but excluded from the secondary trial. The primary trial allows candidates with both unresectable and metastatic breast cancer, whereas the secondary trial only permits those with metastatic disease.",
        "Label": "Contradiction"
    },
    "974225b7-9089-499c-9550-0a7207fd28b2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study, whereas in the secondary trial, all patients receive Radiation Therapy. The primary trial interventions focused on enhancing the pre-consultation process, while the secondary trial evaluated different radiation therapy boost schedules.",
        "Label": "Entailment"
    },
    "6f533f52-c8e4-4983-8968-69af03a9e34a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial. Subjects with stable brain metastases on therapy or who have undergone resection of brain metastases are eligible for the primary trial if all other inclusion and exclusion criteria are met.",
        "Label": "Entailment"
    },
    "690b8562-7d68-4642-bacb-601f227bb763_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "the primary trial does not have an intervention section. The Primary Trial is a study that does not involve the use of any interventional treatment or procedure.",
        "Label": "Entailment"
    },
    "75f94edd-dbde-4a19-be18-e67c767f6d8f_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "the primary trial's intervention section does not describe the intervention dosage, frequency or duration for cohort 2, however cohort 1 recieves placebo twice daily for two months. Cohort 1 in the primary trial also received the intervention after the two-month placebo period.",
        "Label": "Contradiction"
    },
    "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial. The primary trial's overall response rate (complete and partial responses) was 71.2% (17 out of 24 participants).",
        "Label": "Entailment"
    },
    "34ee4f66-e6f7-458c-964c-12fa730a9d56_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study. In the Primary Trial, the curcumin-based gel and HPR Plus interventions were randomly assigned to different patient groups.",
        "Label": "Entailment"
    },
    "9b0451fe-f760-46d3-b555-0a9b83546e73_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "the primary trial recorded half as many patients vomiting as the secondary trial. In the Primary Trial, all adverse events, except for hyponatremia, occurred less frequently than in the Secondary Trial.",
        "Label": "Contradiction"
    },
    "b9304415-073d-476e-a056-cb2a747d56fa_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of the primary trial recieves Doxorubicin only during cycles 1-4, and then Doxorubicin, cyclophosphamide, Herceptin and docetaxel during Cycle 5 of the study. The primary trial also included a control group receiving standard chemotherapy without Herceptin.",
        "Label": "Contradiction"
    },
    "6e365e33-16b8-43e1-99b5-49dfed6f7b13_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial. The primary trial is a phase II study evaluating the effectiveness and safety of a new targeted therapy for Chinese patients with advanced breast cancer who have progressed after prior anthracycline-based chemotherapy.",
        "Label": "Entailment"
    },
    "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2. The dose of trastuzumab was the same in both cohorts.",
        "Label": "Contradiction"
    },
    "27acc6d7-c12d-4a38-9133-a5c8429dd264_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "the primary trial recorded 23 adverse events. All the adverse events in the primary trial were Grade 1 or 2 in severity.",
        "Label": "Contradiction"
    },
    "5919a080-2f0d-4c3b-9b03-10df80b2e680_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "There were no adverse event in the primary trial which affected more than 10% of a particular patient cohort. The most common adverse events in the Primary Trial were febrile neutropenia (10.71%) and anemia (3.57%).",
        "Label": "Contradiction"
    },
    "91f6e62a-97e7-49fa-8509-7ff8c1f0155e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "Patients with pure ductal carcinoma in situ (DCIS) or Melanoma are eligible for both the secondary trial and the primary trial, and are able to participate in these trials alongside other drug trials, up to a maximum of 3. The Primary Trial also requires that the patient's Eastern Cooperative Oncology Group (ECOG) performance status is not greater than 2. (This additional detail was not explicitly mentioned in the provided inclusion criteria for the Primary T",
        "Label": "Contradiction"
    },
    "b351a091-d5fb-49f9-a864-5c89c6316b1b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": " Patients must have histologically or cytologically confirmed PR+ invasive breast cancer, with Primary tumor > 2 cm in diameter TO PARTICIPATE in the primary trial. Patients must provide archival tissue samples for HER2 testing if initial diagnosis was made by core needle biopsy.",
        "Label": "Contradiction"
    },
    "d5ca2086-8404-42d1-bf45-5370f3d4e8e8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial. Two of the hemorrhaging events in the primary trial were due to duodenal hemorrhage, whereas none were reported in the secondary trial.",
        "Label": "Contradiction"
    },
    "4c038972-20a9-4031-a1cd-ba00e9dd0908_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Secondary_id": "NCT00617539",
        "Statement": "In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The opposite was true in the secondary trial. The primary trial also reported a higher overall response rate in the Dasatinib, 100 mg, Daily arm compared to the Dasatinib, 70 mg, Twice Daily arm for all measurable and non-measur",
        "Label": "Contradiction"
    },
    "82d6275a-97e6-4d13-84eb-5f7c2585db8b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure. In the Primary Trial, the majority (approximately 73%) of the participants did not experience any of the listed adverse events.",
        "Label": "Contradiction"
    },
    "286e74e5-74ed-4d42-b32d-f1398c514d37_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months. The primary trial included patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors expressed HER2-neu amplification or overexpression, and were previously treated with platinum-based chemotherapy",
        "Label": "Entailment"
    },
    "634642da-db6d-49cc-a999-67f46e91dbca_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria. The Primary Trial was a single-arm study. (This sentence does not contradict the previous statement as it does not involve any information about the inclusion or exclusion criteria.)",
        "Label": "Entailment"
    },
    "a529e364-2da7-4067-acb6-9fb2f0adf08b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial. Patients with active tuberculosis, history of tuberculosis that is not adequately treated, or positive QuantiFERON-TB Gold Plus test, are excluded from the trial.",
        "Label": "Entailment"
    },
    "317e00ae-9d17-4f85-8787-602cc2548fdb_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from the primary trial. Patients with an ECOG performance status greater than 1 are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "de955acc-ce0e-4416-9884-644a06971603_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "Cohort 2 of the primary trial and the secondary trial are test groups.  In the Primary Trial, both the Intervention 1 (Glutamine) and Intervention 2 (Placebo) groups received the same dosing frequency, but differed in the type of intervention received.",
        "Label": "Contradiction"
    },
    "4956f0d0-4df4-4de3-9a46-6073927485c3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "the secondary trial has more patients cohorts than the primary trial. The Primary Trial also included a control group of patients who received conventional whole breast irradiation instead of the electronic brachytherapy intervention.",
        "Label": "Entailment"
    },
    "9ca0cc75-58b3-451d-abcc-378526744ca4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients will have to undergo an MRI scan for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry. Subjects with a history of prior radiation therapy to the brain, excluding stereotactic radiosurgery, are also excluded from the Primary Trial.",
        "Label": "Entailment"
    },
    "6efb001b-5ed3-470b-a206-7768a1adf597_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Statement": "histologically confirmed invasive ductal breast cancer would result in exclusion from the primary trial, but not from the secondary trial. Patients with a positive sentinel lymph node biopsy are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "70dd1a42-6e40-4880-80a8-45dfd4941ce4_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "the primary trial uses a 3 week cycle for SB-715992 administration. The primary trial enrolled patients with advanced solid tumors whose disease had progressed on or after receiving at least one prior line of chemotherapy.",
        "Label": "Entailment"
    },
    "85f43677-b680-4127-b1da-7e1cc966e4b2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "Not all subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi. The primary trial included various masses of different sizes and types in the overall ITD population.",
        "Label": "Entailment"
    },
    "4cccea8a-22ae-4813-96df-b902850f4991_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03136367",
        "Statement": "Women of any age can participate in the primary trial or the secondary trial. The primary trial is a phase III, randomized, open-label study.",
        "Label": "Contradiction"
    },
    "8574ecd7-4da7-49b0-a273-de495bc1fee7_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial The patient who experienced death of unknown cause in the Primary Trial also had febrile neutropenia.",
        "Label": "Entailment"
    },
    "01b82c51-dd3d-430b-9523-0e93a9eb9c1a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "the primary trial recorded a multitude of patients with chest pain, whereas the secondary trial observed only one patient with abdominal pain. In the Primary Trial, there were also two reported cases of arrhythmia (0.68%) that are not mentioned in the provided Adverse Events section.",
        "Label": "Contradiction"
    },
    "93149dfc-667b-48d3-a46d-ad48b15e701f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events. The primary trial involved a total of 94 participants in Cohort 1 and 39 participants in Cohort 2.",
        "Label": "Entailment"
    },
    "d080eec7-412f-4a44-8c56-91e0ec459acc_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks. The primary trial also includes a follow-up assessment four weeks after the end of treatment.",
        "Label": "Entailment"
    },
    "fd18a599-f94a-478a-975f-854a4210ccad_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "the primary trial has a 5 year long intervention, the duration of the secondary trial is only a single day after removal of the drains. The primary trial involved women with early-stage breast cancer receiving either Tamoxifen or Tamoxifen plus ovarian function suppression for 5 years to reduce the risk of recurrence.",
        "Label": "Contradiction"
    },
    "ac9ca070-80b2-4913-97d8-06d1b90fcfce_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Secondary_id": "NCT02005887",
        "Statement": "the secondary trial and the primary trial both have a placebo arm and a test arm. In the Primary Trial, patients in both arms received standard of care endocrine therapy with letrozole for a total of 12 cycles, while the difference lies in the addition of either fulvestrant or everolimus to",
        "Label": "Contradiction"
    },
    "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "Throughout the duration of the primary trial, pariticpants receive increasing doses of Fulvestrant. The primary trial is a phase 2 study evaluating the effectiveness and safety of the combination of fulvestrant and tipifarnib in hormone receptor-positive, HER2-negative advanced breast cancer patients.",
        "Label": "Contradiction"
    },
    "009d23bb-2179-4ce3-927d-4dedca6b32a8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been trated with bevacizumab are not eligible for the primary trial. Patients with brain metastases are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "5152d810-7669-4fb2-a66b-a0a1d6026af5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame. The Primary Trial also reports the progression-free survival (PFS) of the MPA monotherapy and MPA + ldoCM groups.",
        "Label": "Contradiction"
    },
    "e8f4a600-0296-47d4-903b-2fa840ebcf28_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with stage 3 Cervical carcinoma are excluded from the primary trial. Patients with a history of radiotherapy treatment for breast cancer are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "3fa8b747-b48d-4fb4-995d-38a23c64ccb3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "2 of the patients in the primary trial were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences. 62 participants in the primary trial did not experience stomatitis grade 2 during the 56-day time frame.",
        "Label": "Entailment"
    },
    "b9c294c3-93b7-4681-be02-285f9e5cd867_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort. The primary trial is a randomized controlled study evaluating the effect of hypofractionated radiation therapy with or without omega-3-fatty acid supplementation on local recurrence in women with Stage 0-III breast ca",
        "Label": "Entailment"
    },
    "9df90d78-d857-4e1d-a650-e47f7b6b68d6_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone, at a higher frequency, than cohort 1,  The primary trial compared the efficacy and safety of two different doses and schedules of the combination of Ixabepilone and Epirubicin in participants with metastatic breast cancer.",
        "Label": "Contradiction"
    },
    "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There results section indicates there were no patients in the primary trial with 0 adverse events. All participants in both the TNBC and NSCLC groups experienced at least one adverse event during the study period.",
        "Label": "Entailment"
    },
    "92ac6e0c-8427-454d-9218-36eda1c580a7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "The interventions in the primary trial and the secondary trial are so different that it is not possible or useful to compare them. The primary trial utilized molecular breast imaging with two different doses of Tc-99m sestamibi for image acquisition.",
        "Label": "Entailment"
    },
    "f0aff1fc-4a67-4b28-a974-a4a67a5c930f_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial. The primary trial also reported that the overall response rate was higher in the Tx arm compared to the control arm (p=0.025).",
        "Label": "Entailment"
    },
    "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Secondary_id": "NCT00256243",
        "Statement": "Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part. Patients who do not meet the inclusion criteria for the Primary Trial will not be considered for participation.",
        "Label": "Entailment"
    },
    "96ab702d-cfe1-48fb-b348-a7c7b8db3f16_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months. 13 patients in Arm A of the primary trial were free from disease progression at the time of the analysis.",
        "Label": "Contradiction"
    },
    "6224d2de-c62b-4b43-8517-475eaa565491_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "The majority of patients in the primary trial experienced at least one adverse event. 16/88 (18.16%) of the patients experienced more than one adverse event during the primary trial.",
        "Label": "Contradiction"
    },
    "95154c62-9f79-4d80-90fd-2f61612285b0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Secondary_id": "NCT01702571",
        "Statement": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache. Two cases of tinnitus were reported as adverse events in the Primary Trial.",
        "Label": "Contradiction"
    },
    "2f6243a9-af40-426d-9a6a-a5c5708cf1b4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "the primary trial and the secondary trial recorded the exact same number of cases of nausea. The Primary Trial had a lower total number of participants compared to the Secondary Trial (23 vs. 52).",
        "Label": "Entailment"
    },
    "837f0588-22fc-4069-b2bc-297b3f6aabf7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for the primary trial do not need to meet a specific life expectancy criteria. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher are not eligible for the primary trial.",
        "Label": "Entailment"
    },
    "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in the primary trial will not be made to take Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously like those in the secondary trial. In the Primary Trial, patients receive 18F-FLT PET/CT scans at baseline, early therapy, and post-therapy, along with standard surgical resection and correlative laboratories studies.",
        "Label": "Entailment"
    },
    "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients must have a life expectancy over half a year to participate in the primary trial. Patients with stable, well-controlled brain metastases are eligible to participate in the primary trial.",
        "Label": "Entailment"
    },
    "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection. 8 out of the 9 patients who experienced a life-threatening event in the primary trial had underlying medical conditions that increased their risk for infections.",
        "Label": "Contradiction"
    },
    "d72ecaae-c132-480c-af5e-87c58dd26082_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "The only adverse event observed in Patients from both the secondary trial and the primary trial, was Endocervical cancer. The incidence of anemia was lower in the Primary Trial compared to the Secondary Trial (0.00% vs. 1.52%).",
        "Label": "Contradiction"
    },
    "80245791-4a95-4682-bd5f-856694c9f52f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial The primary trial is a Phase 2 study for postmenopausal women with inoperable estrogen receptor positive breast cancer, who have not undergone chemotherapy or hormonal therapy for metastatic disease.",
        "Label": "Contradiction"
    },
    "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold. The Primary Trial allows for participation of both pre- and postmenopausal female patients with HER2-overexpressing breast cancer, whereas the Secondary Trial specifically targets postmenopausal women at increased risk for developing i",
        "Label": "Entailment"
    },
    "f0da58e6-e937-41ac-b53a-d46ec8a28d11_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily. In the Primary Trial, Intervention 1 also required participants to take letrozole 2.5 mg once daily alongside alpelisib.",
        "Label": "Entailment"
    },
    "5a74a63a-3912-44f0-9e83-4e6b678cbe90_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02685566",
        "Secondary_id": "NCT03076190",
        "Statement": "the primary trial and the secondary trial have the same number of study groups, and are both testing the effectiveness of Full-Field Digital Mammography. The Primary Trial also includes DBT as an additional imaging modality in Intervention 1, alongside FFDM.",
        "Label": "Contradiction"
    },
    "43f03ba4-ef03-4f57-b059-3d9267f0dcf8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "Patients under the age of 18, wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment prior to study entry, and have a life expectancy of more than 3 months. The Primary Trial is a randomized, controlled study evaluating the efficacy and safety of a specific chemotherapy regimen in patients with advanced breast cancer who have received prior anthracycline and taxane treatments.",
        "Label": "Contradiction"
    },
    "6e106caf-2522-4022-898d-64b82093d77a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for the primary trial. The trial allows for participation of patients with clinically/radiologically suspicious axillary lymph nodes who undergo image-guided biopsy/fine needle aspiration and confirm malignancy.",
        "Label": "Entailment"
    },
    "7f8a918c-fab8-4129-8178-0cda7d0441e1_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of the primary trial recieves Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study. In the Primary Trial, Cohort 2 receives the same chemotherapy regimen as Cohort 1 (AC\u2192T), but with the addition of Herceptin during and after the chemotherapy cycles.",
        "Label": "Entailment"
    },
    "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months. The primary trial also included an arm for standard chemotherapy (GC) as a comparison group, with a median PFS of 3.87 months (2.72 to 5.71).",
        "Label": "Contradiction"
    },
    "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial. Patients with a history of prior allogeneic stem cell transplantation are excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "0290bc2d-9cd3-44ab-9b04-385f19527c42_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "Patients must have ductal carcinoma, that can be felt by touch to be eligible for the primary trial. The primary trial is a clinical study evaluating the use of MRI in determining the size and extent of breast cancer prior to surgery.",
        "Label": "Contradiction"
    },
    "505afbf8-b2b4-4b12-99c5-e0feef473248_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame. The clinical benefit rate in the primary trial was assessed using the RECIST version 1.0 criteria, while the secondary trial did not specify the criteria used for assessing clinical benefit.",
        "Label": "Entailment"
    },
    "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0  bilateral  breast cancer cannot take part in the primary trial, but may still be eligible for the secondary trial. The primary trial also requires that the patient's tumor must not have progressed within 14 days prior to starting study treatment.",
        "Label": "Entailment"
    },
    "2e540abd-06e3-483d-bd69-6eb5d2275e9e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients in the primary trial and the secondary trial are administered daily oral medication. In the primary trial, some patients receive Usual Care without any medication.",
        "Label": "Contradiction"
    },
    "d905f4cb-32aa-41b8-8f61-40578d8ea9ae_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "No less than 2 patients from either cohorts of the primary trial felt nauseous. The incidence of cardiac failure in the primary trial was higher than that of the secondary trial (1.98% vs. 0.00%).",
        "Label": "Contradiction"
    },
    "45510043-7931-493b-8251-41b0be9aabbd_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There were 2 instances of patients with Atrial tachycardia in the primary trial. Two patients in the Primary Trial experienced edema in the limbs, and one of them had Atrial tachycardia.",
        "Label": "Contradiction"
    },
    "e7037f34-bd2e-402e-a19c-48073781885a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "10 of the patients in Cohort 1 of the primary trial suffered from Hypotension. 12 patients in the Primary Trial experienced an adverse event other than the ones listed for both Cohorts 1 and 2.",
        "Label": "Contradiction"
    },
    "5275a332-46c1-4941-8850-26a8033012e3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as long as they are over the age of 20. The Primary Trial is a randomized, controlled study evaluating the effectiveness of a specific intervention in improving dyspareunia in breast cancer survivors who meet the stated inclusion and exclusion criteria.",
        "Label": "Entailment"
    },
    "1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "the secondary trial and the primary trial both used MRI and Letrozole for their interventions. The Primary Trial also included assessment of Letrozole's effect on breast density in addition to safety evaluation.",
        "Label": "Contradiction"
    },
    "b02f43d7-44bb-4219-9a08-fd70e7cc9b87_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study.",
        "Label": "Entailment"
    },
    "1a6661e0-343f-4056-b568-611e7cc7750c_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial. The primary trial also excludes patients with a history of allergic reaction to the study drug or any of its excipients.",
        "Label": "Entailment"
    },
    "ec97c90e-f904-4cf2-9567-8525edf747cf_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03196635",
        "Secondary_id": "NCT01943916",
        "Statement": "the primary trial and the secondary trial are both evaluating patient assisted imaging interventions. The Primary Trial also assessed intra-reader and inter-reader agreement for evaluating the acceptability of overall clinical image quality in the PA and TC compression image sets.",
        "Label": "Contradiction"
    },
    "7a129a1e-20d9-4f5a-a921-d30957460e27_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "the secondary trial and the primary trial do not test the same modalities of cancer treatments. In the Primary Trial, both interventions (lapatinib plus capecitabine and trastuzumab plus capecitabine) were administered in combination with capecitabine.",
        "Label": "Entailment"
    },
    "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%. The number of participants with severe or serious AEs was similar in both cohorts.",
        "Label": "Entailment"
    },
    "a1c99d5b-d53a-4195-ad5f-5e1b48c22078_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes. The incidence of anaemia was lower in the primary trial (3.52%) compared to the secondary trial (5.56%).",
        "Label": "Entailment"
    },
    "0203435e-03a0-4c41-afdf-6c497d8908c1_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Men with Left ventricular ejection fraction > 50% are excluded from participating in the primary trial. Patients with prior history of significant cardiac arrhythmias are also excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "e6388dc2-b096-467d-8b70-fd5346dd581a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2. The primary trial involved 2240 participants. (The previous statement only mentioned the number of adverse events, but did not specify the total number of participants in the trial.)",
        "Label": "Entailment"
    },
    "93511e52-1c12-4dee-858e-13b10793e2a6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "the secondary trial exclusively uses radiotherapy in its intervention, whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study. The primary trial also includes high-dose chemotherapy with Carboplatin, Cyclophosphamide, and Thiotepa followed by a Stem Cell Transplant.",
        "Label": "Contradiction"
    },
    "cb932dbf-4c98-4488-b189-1286442968b6_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with Cervical carcinoma in situ are excluded from the primary trial. The primary trial also requires that all patients have an Eastern Cooperative Oncology Group performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "0b9aa7e8-5912-44db-b9b0-6a84df769e19_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There were no patients with paranasal sinus reactions in the primary trial. 1 patient experienced constipation in the Primary Trial (1.87%).",
        "Label": "Entailment"
    },
    "570ab6bb-b23c-4955-b6b0-d756d1b69c0e_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial. The primary trial also requires that patients have measurable or evaluable disease based on RECIST 1.1 criteria.",
        "Label": "Contradiction"
    },
    "daf105f8-58e8-47d7-b0a2-5949620b0a2b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "the primary trial administers the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin. The primary trial randomizes patients to receive either Urea/Lactic Acid Cream or Placebo Cream, with application twice daily on palms and soles for a specified duration. (The previous statement correctly mentioned the frequency and applica",
        "Label": "Entailment"
    },
    "c4b671ae-4701-43a3-ada1-659c265d1f3a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in the primary trial, participants must be aware of where they are, and what day it is. Participants in the primary trial must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.",
        "Label": "Entailment"
    },
    "0a17a404-ed1d-4c31-a192-509b68198ea8_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There was a dental adverse event in the primary trial. Two participants experienced tooth loss, one in the primary trial and one in the secondary trial.",
        "Label": "Entailment"
    },
    "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Neither the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device. During the active phase of the Primary Trial, Group I participants engage in weekly group support sessions, in addition to using the SparkPeople website and wearing the Fitbit activity monitoring device.",
        "Label": "Entailment"
    },
    "e8b86ef4-3ce8-4d81-a632-f30672c80ff5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix. The Definity infusion was administered as a contrast agent during diagnostic or interventional cardiology procedures in the primary trial.",
        "Label": "Entailment"
    },
    "879f2f14-38a8-419a-bae0-e62ed81eb9dd_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of LA-EP2006. The primary trial compared two doses of Neratinib, 40 mg and 80 mg, administered once daily to two different cohorts.",
        "Label": "Entailment"
    },
    "2ec46285-dd0c-4420-b9f6-e44a1ac74f20_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Secondary_id": "NCT01940497",
        "Statement": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial. The primary trial recorded one case of cardiac failure congestive (0.67%), which was not mentioned in the given adverse events section.",
        "Label": "Contradiction"
    },
    "f8afffdc-649b-4921-942a-66b804a3717f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-4, N1 and M1 bilateral breast cancer. Patients in the primary trial should have negative resection margins and must not have received neoadjuvant therapy before surgery.",
        "Label": "Contradiction"
    },
    "65f22210-47dd-4865-99e2-ddd414dddb08_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years. The Recurrence-free Survival rate for the Ketorolac 30 mg group was 83.3%, and for the NaCl 0.9% group it was 89.7%.",
        "Label": "Entailment"
    },
    "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR of 1.35 is enough for participation in the primary trial and the secondary trial. Patients with a history of prior allergic reactions to study drugs or their excipients are not eligible for the trial.",
        "Label": "Contradiction"
    },
    "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "One patient in cohort 2 of the primary trial crashed their motorbike. Two patients in the primary trial underwent surgery for reasons unrelated to the study.",
        "Label": "Entailment"
    },
    "0aa3c085-b9c6-4918-a5d0-eabc55bdd177_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial. Two of the participants in the primary trial experienced an infection or infestation-other, which is not mentioned in the provided data for cohort 1.",
        "Label": "Contradiction"
    },
    "333c2723-e2e8-4c68-9591-36b7f169ff26_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2. The primary trial had a higher overall incidence of adverse events in cohort 1 compared to cohort 2, particularly for events such as INR increased and coagulopathy.",
        "Label": "Entailment"
    },
    "1fa01b9a-1288-404c-ad58-8dcf3db3264c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months. No significant difference in CBR was observed between Arm A (Lapatinib 1250 mg and Capecitabine 2000 mg/m^2) and Arm B (Placebo) in",
        "Label": "Entailment"
    },
    "ed272c3f-37a1-4db7-8990-bf226f8c9822_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial. none of the participants in the primary trial experienced any adverse events related to their eyesight, aside from the absence of Diplopia.",
        "Label": "Entailment"
    },
    "b1497cf4-6b06-4227-b679-19e2ac5fb5c3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "the primary trial studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS), 9 weeks after the start of treatment. The trial also assessed the safety and tolerability of the combined CTX/IMQ/RT and Epothilone treatment regimen.",
        "Label": "Contradiction"
    },
    "186d5a67-1309-4abc-b31a-de026c5b8bda_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients diagnosed with intradural tumors are excluded from the primary trial. Patients with a history of significant alcohol use are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "6b86f306-f989-4676-8f5e-c4c8a6aa4258_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "the primary trial participants will receive either Lapatinib, WBRT or Herceptin. The primary trial investigates the effectiveness and safety of Lapatinib given before and during Whole Brain Radiation Therapy (WBRT) followed by Herceptin in comparison to Herceptin alone in treating breast cancer patients with brain",
        "Label": "Contradiction"
    },
    "0e8e4a92-b104-4192-ad36-33b683f94216_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial. The Clinical Benefit Rates for both the GTx-024 9 mg and 18 mg groups were within the range considered clinically meaningful for ER+/AR+ BC according to RECIST",
        "Label": "Entailment"
    },
    "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "the primary trial has a topical intervention, whereas the secondary trial has both oral and IV interventions. The primary trial was a randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of mometasone furoate cream in reducing radiation dermatitis during radiotherapy in breast or chest ",
        "Label": "Entailment"
    },
    "03a8a787-2bf3-43e5-9c9e-7bd9c3278751_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years. The rate of bone mineral density decrease was statistically significantly greater in the Letrozole group compared to the Tam-Let group after 3 years.",
        "Label": "Contradiction"
    },
    "7d7a9a69-533a-4480-b2e7-aa59eb8a738b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial, than in the ER+ and/or PR+ group. The median progression-free survival was significantly longer in the HER2-positive group compared to the ER+ and/or PR+ group in the primary trial (11.2 months vs. 5.8 month",
        "Label": "Contradiction"
    },
    "c6fc8336-7c74-443e-9548-3bbafe21fc37_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total Less than 10% of patients in the primary trial either had a disease relapse or died. The primary trial included only postmenopausal, receptor positive, node negative or node positive breast cancer patients.",
        "Label": "Entailment"
    },
    "9035000f-d87b-439f-882a-e6e30694e391_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed Diuretics are excluded from the primary trial. Patients with previous upper extremity surgeries unrelated to breast cancer are permitted in the primary trial.",
        "Label": "Entailment"
    },
    "522ca0ec-aeb0-4083-a274-ab58c2cddb8a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "Unlike the primary trial, the secondary trial does not test Gonadotrophin-releasing Hormone Analogues or medical devices. The ultrasound-guided pectoral nerve blocks in the Pecs Group are administered to reduce pain after surgery in patients undergoing breast surgery.",
        "Label": "Contradiction"
    },
    "46d65581-7a0a-423b-907e-662c1f5843cc_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial. 3 out of the 5 adverse events with the highest frequencies in the Primary Trial were respiratory events (Dyspnea occurred 2 times, and no other respiratory event is mentioned, hence the third respiratory e",
        "Label": "Entailment"
    },
    "f4ea6e98-75e1-43a0-8202-548bb7ceb66c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only apllied once. The primary trial compares the effectiveness and safety of 0.005% estriol vaginal gel to placebo in managing menopausal symptoms over a period of 12 weeks.",
        "Label": "Entailment"
    },
    "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "The median TTP for patients in cohort one of the primary trial is NA. 53.1% of patients in the Capecitabine and Fulvestrant arm experienced progression within the measured timeframe.",
        "Label": "Contradiction"
    },
    "932728c5-2e7f-401f-be64-e90597ff2ce2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1. The frequency of CNS cerebrovascular ischemia was similar between the two cohorts in the primary trial.",
        "Label": "Entailment"
    },
    "54ad9406-852c-40fc-bd0e-8e7e81eacc71_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours The time to reach maximum plasma concentration for all measured parameters in the primary trial was within 12 hours postdose in all participants.",
        "Label": "Entailment"
    },
    "7021a4a9-b474-4568-a3b8-015a50c9d9cc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial. Patients with inflammatory breast cancer are also eligible for the Primary Trial as long as they meet all other eligibility criteria.",
        "Label": "Contradiction"
    },
    "24eced44-40b2-4365-abd3-42eb13220cf0_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "There is no radiotherapy or educational part of the intervention used in the primary trial. The trial also included hormonal receptor testing to determine eligibility for the interventions.",
        "Label": "Entailment"
    },
    "3e2dda3a-815f-4681-a470-009d9f9b30d6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device  The primary trial is comparing the efficacy and safety of HDR brachytherapy using Mammosite ML as the sole method for radiation delivery (INTERVENTION 1) versus a boost technique prior to standard external ",
        "Label": "Entailment"
    },
    "1a293e7c-691f-4f93-bab8-6bf5d9b3f904_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "The interventions in the primary trial and the secondary trial are similar, as they are testing the same medication, however they are not using the same doses. The primary trial is evaluating the effectiveness of molecular breast imaging using different doses of Tc-99m sestamibi for breast cancer detection.",
        "Label": "Contradiction"
    },
    "a87e6e20-c7d0-4941-9933-204fab99b299_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment. Among those who did not experience disease progression or death by Week 12, the median duration of PFS was approximately 6 months.",
        "Label": "Contradiction"
    },
    "6c3427a8-27a1-459c-9fbc-175649210868_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2. The primary trial reported a higher rate of anaphylactic shock in the treatment group compared to the control group (1.05% vs. 0%, respectively).",
        "Label": "Entailment"
    },
    "883bec6a-bce2-4e60-9304-49a056e66df7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin < 1.2 x ULN are eligilbe for the primary trial. The Primary Trial is a randomized, open-label, multi-center study investigating the efficacy and safety of a novel targeted therapy in metastatic breast cancer patients, with an estimated enrollment of 400 subje",
        "Label": "Contradiction"
    },
    "8720143a-2611-4502-a5ee-da4e641df918_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "There were no cases of extravasation in either the primary trial or the secondary trial. Two participants in the primary trial experienced dyspnea as an adverse event. (Additional truthful information about the Primary Trial)",
        "Label": "Contradiction"
    },
    "0fdda7a2-4119-40a7-84f3-6c5c6077df49_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol. Women in cohort A and B of the primary trial with serum 25 (OH)D levels below 30 ng/ml received weekly supplementation of cholecalciferol for 8 weeks.",
        "Label": "Contradiction"
    },
    "e7eae332-6b6a-41e0-aa31-86a781fd373f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial. The majority of adverse events were mild or moderate in severity. (This information is not directly stated in the given data but can be inferred from the fact that all the events listed are included in the Common Terminology Criteria for Adv",
        "Label": "Contradiction"
    },
    "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide. The primary trial compared the effects of low-dose (800 mg/day) and high-dose (1200 mg/day) Magnesium Oxide supplementation in the treatment group.",
        "Label": "Entailment"
    },
    "c09b9f7c-2d22-4c44-a79d-32929530dd9e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01735175",
        "Secondary_id": "NCT01216319",
        "Statement": "the secondary trial and the primary trial are both testing Biodesign interventions. Both the primary and secondary trials involve patients undergoing six cycles of chemotherapy every three weeks, with the addition of either LA-EP2006 or Neulasta\u00ae for neutropenia prevention after chemotherapy. In",
        "Label": "Contradiction"
    },
    "6f143256-52e4-40b7-950c-5c892f8632b9_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients. The event-free survival rate at 11 years was significantly higher for Stage IIIB patients compared to Stage IV patients.",
        "Label": "Contradiction"
    },
    "d2718f05-1d35-4c84-a054-06a3fe4a0a9c_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions. The Primary Trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sorafenib in postmenopausal women with hormone receptor-positive advanced br",
        "Label": "Entailment"
    },
    "7f49cafd-3a27-4fc8-872d-914b9176442e_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial. The occurrence of adverse events in the primary trial varied between the two cohorts, as shown in the provided data.",
        "Label": "Entailment"
    },
    "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial. The frequency of febrile neutropenia is higher in the Primary Trial compared to the Secondary Trial, with an occurrence rate of 6.09% versus 2.68% in the respective trials.",
        "Label": "Entailment"
    },
    "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either the primary trial or the secondary trial. Patients with stable central nervous system metastases treated with radiosurgery or stereotactic body radiotherapy more than 4 weeks before starting study therapy are eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "4ab00376-83a4-467e-8a1e-6b8b1643a8f0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial The primary trial allows for patients to have up to two prior chemotherapy regimens for metastatic disease.",
        "Label": "Entailment"
    },
    "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "None of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different heart related issues. In the Primary Trial, no cases of heart failure were reported among the adverse events.",
        "Label": "Entailment"
    },
    "407369fa-92ba-4994-8a0f-d372995f3241_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Neither the primary trial or the secondary trial require participants to practice yoga. During the active phase of the primary trial, Group I participants also receive access to an online community of peers for support and motivation.",
        "Label": "Contradiction"
    },
    "05e50a3d-d5b2-4fe6-9709-c884c89c5f71_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "the primary trial and the secondary trial both evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments. The primary trial was conducted in participants with brain metastases from various solid tumors, and the CNS objective response rate was the primary endpoint.",
        "Label": "Entailment"
    },
    "59fd53e4-b38c-4018-bafc-6fd7f7becebe_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "1 patient in the primary trial suffered from a blood clot blocking their blood vessels. 2 patients in the primary trial experienced Dyspnea, which is a symptom that can indicate heart or lung issues.",
        "Label": "Entailment"
    },
    "c17eaeab-4e99-4cc4-8681-ae6ccddba572_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There were no cases of Cellulitis, Nausea or Anaemia in the primary trial. 2 patients experienced headache, not specified as severe (1.98%).",
        "Label": "Entailment"
    },
    "621d06ac-12dd-42c2-a012-15c1d94a4f0b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for the primary trial must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months The primary trial also requires that candidates have no significant uncontrolled intercurrent illnesses and are willing and able to comply with study visits and protocol requirements.",
        "Label": "Entailment"
    },
    "021e79d2-ce70-43cf-aac9-fa8d4c8d3770_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "In the primary trial patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot. Two patients experienced gastrointestinal bleeding as adverse events, which is not mentioned in the given CTR section. However, this information doesn't contradict or modify the previous statement as it does not involve infections.",
        "Label": "Contradiction"
    },
    "06aa0fbc-fe49-4715-88cc-507646f6323f_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga. Cohort 1's yoga practice included both group sessions and home practice, while cohort 2 had no structured yoga practice during the study period.",
        "Label": "Entailment"
    },
    "21947261-bbef-4d3a-adda-02bb4a91a3ca_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "the secondary trial and the primary trial both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast. The Primary Trial also accepts patients with hormone receptor negative (HR-) breast cancer, but only in the setting of HER2- breast cancer and when patients have progressed during or within 12 months of completing adjuvant ",
        "Label": "Contradiction"
    },
    "71daae7c-3ee5-4451-91e2-273d8ff55aae_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial. The primary trial had a higher overall dose intensity compared to the secondary trial.",
        "Label": "Contradiction"
    },
    "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "Every single patient in the primary trial experienced at least 1 adverse event. The most common adverse events were musculoskeletal pain (15.38%) and diarrhea (7.69%).",
        "Label": "Entailment"
    },
    "7d22937b-9823-45fa-a914-261f993e4d64_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "Throughout the primary trial, one patient developed issues with their vision. Another patient experienced joint pain as a new adverse event during the Primary Trial.",
        "Label": "Entailment"
    },
    "507a4189-4905-4752-8348-d715a5ce3962_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2. The occurrences of atrial fibrillation and pleuropericarditis were identical between the two cohorts in the primary trial.",
        "Label": "Contradiction"
    },
    "24001e83-6a8c-4f67-9c24-55dc285c4cc2_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo. The reduction in fatigue was significant at week 12 and remained so throughout the 24-week study period. (This additional information can be inferred from the data presented, as it is not explicitly stated in the provided informa",
        "Label": "Entailment"
    },
    "d179396d-94fe-465f-a4f1-e7c3291a0a9a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "filgrastim is the only drug in the primary trial given by subcutaneous injection. The Primary Trial combines sunitinib malate, paclitaxel, doxorubicin hydrochloride, and cyclophosphamide for neoadjuvant therapy, followed by filg",
        "Label": "Entailment"
    },
    "4b893eeb-80a4-4a83-8df5-b5c668ce55b1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in the secondary trial suffered from oedema in their limbs, compared to patients in the primary trial. The primary trial had a lower total adverse event rate compared to the secondary trial (14.29% vs. 25.71%).",
        "Label": "Entailment"
    },
    "44cd16f5-6638-4d82-9121-1941eb8ce4b5_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were more adverse events in cohort 1 of the primary trial, than in cohort 2. The types of adverse events were different between the two cohorts, with cohort 1 having a higher incidence of intrapleuric chemotherapy and thoracentesis, while cohort 2 had a hi",
        "Label": "Entailment"
    },
    "50ac2c53-3b63-4507-8712-41f8c257b4da_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial. In the Primary Trial, FSFI Total Scores were measured before the initiation of vaginal testosterone therapy.",
        "Label": "Entailment"
    },
    "14607d45-9aef-458d-89cc-d47c62c23322_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, could be eligible for both the secondary trial and the primary trial. The Primary Trial also requires that participants have measurable disease according to RECIST v1.1.",
        "Label": "Entailment"
    },
    "d2961e96-bd3b-4994-aa7e-2b310eb6204e_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in the primary trial showed signs of poor liver function. One participant in the primary trial experienced a decreased white blood cell count (neutrophilia decreased) in addition to a decreased hemoglobin level. (0.92% of participants in the primary trial reported thi",
        "Label": "Entailment"
    },
    "8a5d7285-f4be-4e50-9057-19f74bcc410b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks. The primary trial is a phase I study evaluating the safety, tolerability, and pharmacokinetics of IMGN853 in patients with advanced TNBC.",
        "Label": "Contradiction"
    },
    "512990dd-45d2-4b31-b571-66735ff02308_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There were 4 different adverse events, for which 0 cases were recorded in cohort 1. Two of these adverse events, cardiac failure congestive and pericardial effusion, were recorded in cohort 2, with a combined total of 5 cases. (This information is not explicitly stated in the provided ",
        "Label": "Entailment"
    },
    "383db144-4bcd-4ebc-989c-b6ae7d282026_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial. than cohort 1 of the primary trial . The number of total adverse events in the primary trial was higher than in the secondary trial. (Total adverse events in the primary trial were 13/83 (15.66%) compared to 7/",
        "Label": "Contradiction"
    },
    "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Most patients in cohort 1 of the primary trial died of unknown causes. 6 out of the 7 adverse events resulting in death in the primary trial were not caused by known conditions mentioned in the report.",
        "Label": "Contradiction"
    },
    "228e80ab-84d6-4b60-9960-dcdcbd78c03c_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "Patients with an FEV1 of 80% to 120% are ineligible for the primary trial. Patients with uncontrolled hypertension or unstable angina are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "b7caad28-5fb2-4eb6-845e-8315cff97318_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial, neither is Adequate organ function or a particular racial or ethnic background. The Primary Trial is for women who are planning to undergo a screening mammogram at one of the Boston Medical Center-affiliated primary care clinics.",
        "Label": "Contradiction"
    },
    "73c37b9c-e7ba-4c90-b26e-23b7a65509c4_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial. The primary trial also requires patients to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.",
        "Label": "Entailment"
    },
    "d5b81f6c-821a-4db5-8810-9cc47a952913_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent is obligatory for entry in the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a new investigational drug in combination with standard treatment in early-stage breast cancer patients undergoing surgical interven",
        "Label": "Entailment"
    },
    "cdba382e-894b-4f79-a8e2-ff818746adc5_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in the primary trial suffered adverse events. The types and frequencies of adverse events were not specified in the given results.",
        "Label": "Entailment"
    },
    "0093175a-38cb-4f63-b391-709ac48158b8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "Patients with tumors overexpressing HER-2 are eligible for the secondary trial, but not for the primary trial. The Primary Trial also requires hormone receptor status to be unknown or negative for estrogen and progesterone.",
        "Label": "Contradiction"
    },
    "19106207-4fa2-4cc4-8e22-6e5330bf05ce_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for the primary trial occurred more than once. All the adverse events in the primary trial were reported by different patients.",
        "Label": "Entailment"
    },
    "a015685e-f744-4bb2-a6d3-893f081d6dcc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "the primary trial and the secondary trial both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively. The iBE device uses artificial intelligence technology to analyze breast tissue and provide additional information to the clinical breast exam.",
        "Label": "Contradiction"
    },
    "b9578bae-6640-4ef1-ba2c-899b45c602ee_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "All patients in the primary trial had to drink 4 cups of water, either Alkaline Water or Distilled, depending on which cohort they are in. Patients in the primary trial received external beam radiation therapy five days a week for six weeks regardless of the water group they were assigned to.",
        "Label": "Contradiction"
    },
    "405369ef-d216-4d81-a04f-46f36f466a19_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2. The total number of participants in the primary trial was 26 in cohort 1 and 13 in cohort 2.",
        "Label": "Entailment"
    },
    "e424c65e-7c6f-43a4-95e4-6beb705d9903_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis, than in cohort 1 of the primary trial. In the Primary Trial, the incidence of diarrhea as an adverse event was 7/72 (9.72%).",
        "Label": "Contradiction"
    },
    "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The the primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group. The standard errors of the retention percentages in both groups were not significantly different.",
        "Label": "Entailment"
    },
    "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial. The trial is for patients with early-stage breast cancer who have undergone or plan to undergo surgical resection and sentinel node biopsy.",
        "Label": "Entailment"
    },
    "6843daf8-8136-4973-9bf2-62a622d5a890_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Participants in the primary trial are assigned an intervention depending on their HIV diagnosis, whereas in the secondary trial the interventions are randomly assigned. The primary trial also includes data collection and analysis for evaluating the side effects and tolerability of the interventions in addition to their diagnostic performance.",
        "Label": "Contradiction"
    },
    "2687b547-c225-4838-bbcd-99212a74d815_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in the primary trial and the secondary trial did not have any of the same adverse events. In the Primary Trial, there were no reports of febrile neutropenia, fatigue, pyrexia, fractures, or headaches.",
        "Label": "Entailment"
    },
    "fadf7710-6e4d-49d6-82fc-4f3137b5e26b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event is observed in patients from cohort 1 of the primary trial. The single adverse event in the Primary Trial was a case of syncope (fainting) in one patient.",
        "Label": "Entailment"
    },
    "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "All of the adverse event cases in the primary trial occurred in patients from cohort 2. The Primary Trial had a higher dose group, which was not included in cohort 2. Adverse events in the higher dose group were not specified in the given CTR section.",
        "Label": "Entailment"
    },
    "6c0896ac-db42-45b4-a6e2-620a27fd321a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide. The primary trial lasted for a total of 9 weeks for both interventions.",
        "Label": "Contradiction"
    },
    "3a80ba8a-265f-4931-a9a8-b7e00e372599_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in the primary trial occurred in patients from cohort 1. The Primary Trial involved a total of 91 patients (45 in cohort 1 and 46 in cohort 2).",
        "Label": "Entailment"
    },
    "df4b98f2-7ca9-4855-8d94-d62407ff8535_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "the primary trial only has one test cohort whereas the secondary trial has both a test and control group. The Primary Trial compares the use of supine MRI with conventional imaging in the same patient group without a control group.",
        "Label": "Entailment"
    },
    "5d2542fa-5482-4aff-af29-80875a0a9dcc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "the primary trial records instances of Rectal Hemorrhage within its patient cohort, whereas the secondary trial records Vaginal hemorrhages. Two patients in the primary trial experienced gastrointestinal symptoms, including one instance of rectal bleeding and one instance of abdominal pain.",
        "Label": "Entailment"
    },
    "5deb8ebd-fbd2-4d84-8ad2-a1248426908b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "HIV+ Patients are excluded from both the secondary trial and the primary trial. Patients with a history of autoimmune disorders are not explicitly mentioned in the exclusion criteria for the Primary Trial, but they should be evaluated on a case-by-case basis due to the potential immune-related side effects of the ",
        "Label": "Entailment"
    },
    "5f4880ac-1ce2-4b89-841b-a9918720b6ea_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": " To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase  < 2 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL. Patients with a history of prior chemotherapy for non-breast malignancies are not eligible for the Primary Trial.",
        "Label": "Entailment"
    },
    "b3aabfaa-23cb-4a75-8416-761d8574f0a4_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO. The Primary Trial is a randomized, open-label, multicenter study comparing the safety and efficacy of Afatinib monotherapy and Afatinib in combination with Vinorelbine in patients with advanced non-small ",
        "Label": "Entailment"
    },
    "f697c2d8-e0dd-476e-8ff4-dffe053076f8_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%. The primary trial included a total of 55 participants (26 in the Trastuzumab arm and 29 in the Lapatinib arm).",
        "Label": "Contradiction"
    },
    "f2c0f753-1775-42af-94f0-b87b20156e65_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "the primary trial and the secondary trial do not use chemotherapy, radiotherapy or mammography in their interventions  The primary trial compared the effectiveness of Digital Breast Tomosynthesis versus Digital Mammography in breast cancer screening, with no intervention in the control group.",
        "Label": "Contradiction"
    },
    "17b31c1d-db62-4628-b390-02da22512079_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for the primary trial. Participants in the primary trial must have completed their AI therapy for at least 2 weeks prior to enrollment.",
        "Label": "Entailment"
    },
    "2e6e1044-8b4a-41f7-8319-85fc5bba4482_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy is used in all cohorts of the primary trial and the secondary trial. The healing touch therapy in Intervention 1 of the primary trial is administered by certified and trained healing-touch therapists.",
        "Label": "Entailment"
    },
    "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial. Two of the patients in the primary trial experiencing diarrhea had a confirmed Clostridioides difficile infection.",
        "Label": "Contradiction"
    },
    "0c0324d2-0672-45cb-b715-e51e48786afb_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "the primary trial's intervention section does not describe the intervention dosage, frequency or duration. The primary trial's intervention section mentions the intervention arm, but not the specific details of the intervention such as dosage, frequency, or duration.",
        "Label": "Entailment"
    },
    "b3bd3522-8731-448a-bade-a5a350697a98_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream. Five out of these nine patients experienced febrile neutropenia, a severe form of neutropenia where the body temperature rises above normal. (Additional information about the type and severity of the low white blood cell adv",
        "Label": "Contradiction"
    },
    "8607e8c1-6e99-49be-a63e-e707856c805a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead. In the primary trial, the sequence of administering pertuzumab, trastuzumab, and taxane was not standardized, and the taxane could be given before or after the initiation of pertuzumab and t",
        "Label": "Contradiction"
    },
    "1c26e1a7-9d77-46ff-b1c6-179ece7c190f_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time. The primary trial found that the F-627 group had a significantly lower rate of Grade 4 neutropenia occurring beyond 12 days compared to the Neulasta group (2.5% vs. ",
        "Label": "Entailment"
    },
    "0a156ee2-eb90-40d2-9802-27b9b4a42ff3_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice. In the primary trial, all adverse events were grade 3 or lower according to the National Cancer Institute Common Terminology Criteria for Adverse Events.",
        "Label": "Contradiction"
    },
    "82895f11-37bf-4d03-8de2-84818d93cce0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "the primary trial and the secondary trial have entirely different adverse event reports. Both trials involved the use of the same investigational drug.",
        "Label": "Entailment"
    },
    "f94643de-7122-4a58-972d-b0bb7e59d441_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0. In the Primary Trial, 996 patients did not experience pancreatitis as an adverse event.",
        "Label": "Contradiction"
    },
    "1485315b-3169-42a3-a672-6f7963d49a51_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis. In the Primary Trial, patients in both intervention arms (Omega-3 Fatty Acid and Placebo) undergo laboratory biomarker analysis at multiple time points throughout the study duration.",
        "Label": "Entailment"
    },
    "b4ef27ca-52b4-4af3-9b60-e9e0285e0e86_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer. The Primary Trial also requires that potential participants have an Eastern Cooperative Oncology Group performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "patients with Karnofsky Index  = 72 are eligible for the primary trial. Patients with a Karnofsky Index of 70 or above, who meet all other inclusion criteria, are eligible for the primary trial. (This sentence expands upon the previous statement by specifically stating that the Karnofsky Index thres",
        "Label": "Entailment"
    },
    "426196d8-44ab-4c5c-8f81-5cb12345ad69_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "the primary trial uses different inclusion criteria for its cohorts, the secondary trial only uses one set on inclusion criteria for all cohorts. The primary trial permits patients in Cohort 1 to have stable or responding distant metastases while those in Cohort 2 may have any concurrent systemic therapy.",
        "Label": "Entailment"
    },
    "bcf433b6-4029-4d00-9ccf-d8d94f1722d8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Secondary_id": "NCT00005908",
        "Statement": "the primary trial and the secondary trial only recorded one type of acute adverse event. In the Primary Trial, one participant experienced both febrile neutropenia and neutropenia.",
        "Label": "Contradiction"
    },
    "1268edfc-cce2-4f07-9fbb-392341b7f399_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months. The Primary Trial included 80 participants in total, evenly distributed between the two treatment arms.",
        "Label": "Entailment"
    },
    "58ccfd13-aa6d-4604-bf3d-c69270fe50d2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Statement": "1 patient in the primary trial died in an event not associated with a specifc CTCAE term. 1 additional patient experienced a seizure (1.43%).",
        "Label": "Entailment"
    },
    "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00509769",
        "Statement": "The majority of patients in the primary trial and the secondary trial experienced an adverse event. The most common adverse events in the primary trial were chills, fever, and fatigue, occurring in 3.13% of patients each.",
        "Label": "Contradiction"
    },
    "8c84c96f-1635-40dc-839b-fc937ed566a2_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "Patients with measurable diseases are only eligible for phase 2 of the primary trial. Patients in the phase I study may have non-measurable disease.",
        "Label": "Contradiction"
    },
    "7b48355e-3b9c-4cca-b7fa-1cbd612d1523_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients. The incidence of anemia was higher in the Primary Trial's cohort 1 compared to cohort 2 (0.51% versus 1.49%, respectively).",
        "Label": "Entailment"
    },
    "3d188d93-13c6-48f3-b231-dcdeef81080e_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Presence of Extracranial metastases is part of the exclusion critera for the primary trial. Patients with only spinal or bone-only brain metastases without evidence of parenchymal brain metastases are also eligible for the primary trial. (This statement does not contradict the previous as it does not mention ex",
        "Label": "Contradiction"
    },
    "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2. In the Primary Trial, Paclitaxel is administered intravenously in both intervention groups.",
        "Label": "Contradiction"
    },
    "2206dc2a-93da-4c11-b110-81f9c39af807_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin > 1.6 x ULN are eligilbe for the primary trial. The Primary Trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a new investigational drug for metastatic breast cancer.",
        "Label": "Entailment"
    },
    "6173faf3-f845-4cf1-94a9-756d1bff48bb_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "There was one patient in the primary trial who suffered from a significant decrease in the number of granulocytes in their blood. Two patients in the primary trial experienced constipation as an adverse event (0.49%).",
        "Label": "Contradiction"
    },
    "512c72ab-f1b3-450d-8167-6e0d8d2bf5dd_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "Only one cohort of the primary trial needs to receive manual lymph drainage prior to each cycle of anthracyclines. The Primary Trial also included randomization and double-blinding to ensure the reliability of the results.",
        "Label": "Contradiction"
    },
    "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes. 10 out of the 16 participants achieved pCR in the sentinel nodes as well.",
        "Label": "Entailment"
    },
    "87987ebb-6799-4d1d-8529-d33c6b7799f8_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response, or better, after 12 weeks. 18 of these participants achieved a Complete Pathologic Response.",
        "Label": "Contradiction"
    },
    "bf94f208-a29b-4d8f-92a7-3cb8241ce344_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Secondary_id": "NCT00896649",
        "Statement": "Black women cannot take part in the secondary trial or the primary trial. The Primary Trial also includes patients of other racial and ethnic backgrounds besides Black women.",
        "Label": "Contradiction"
    },
    "c68f6822-24fa-44b5-bf63-c272a8031fab_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "Patients must have either AST or ALT < 1.5 ULN to participate in the primary trial. Patients with Gilbert's syndrome, a condition that causes mild elevations in bilirubin, are allowed in the trial as long as their total bilirubin is below 1.5 x ULN.",
        "Label": "Contradiction"
    },
    "54a459cf-f01a-4abc-a8cf-0efebc01c694_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "the primary trial and the secondary trial recorded none of the same types of adverse events In the Primary Trial, all adverse events occurred in individual participants, with no cases of multiple participants experiencing the same type of adverse event.",
        "Label": "Contradiction"
    },
    "dd4b5a08-c033-4429-81d0-1ad59596edbd_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial. The Primary Trial does not specify any height or weight restrictions for the inclusion of subjects.",
        "Label": "Contradiction"
    },
    "d97ebc59-ab4b-462a-9057-12f4fc46df56_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine. In the primary trial, the AI therapy following vorinostat is given for 6 weeks, unlike the continuous 6MP/MTX treatment in the secondary trial.",
        "Label": "Entailment"
    },
    "2e4c7d0b-f1a2-4204-bac3-7445852fd916_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET, MRI and dosimetry  In addition to the post-implant dosimetry scanner, the patient undergoes regular follow-up MRI scans as part of the primary trial protocol to monitor breast tissue response and potential complications.",
        "Label": "Contradiction"
    },
    "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, however cohort 2 of the secondary trial receive all of these. In the Primary Trial, patients in intervention 1 undergo FLT PET scans using [F18] fluorothymidine before and after standard endocrine treatment, and have correlative Ki67 staining anal",
        "Label": "Entailment"
    },
    "4546c169-cc5c-4e03-bcce-31d491ed18e0_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "the primary trial only records cardiovasuclar adverse events. The Primary Trial included a total of 349 participants.\n\nExplanation: While the previous statement mentions that the Primary Trial is for recording cardiovascular adverse events, it does not explicitly state the number of particip",
        "Label": "Entailment"
    },
    "1bb3badf-41c6-4741-90f0-367473ce254d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "children and illiterate adults are not able to take part in the primary trial. The Primary Trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a flaxseed intervention in women with specific breast cancer characteristics. (This sentence provides additional information about",
        "Label": "Entailment"
    },
    "87953ba3-3e94-421c-b426-b716562b8b5d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "A patient with stage 2B , pathologically confirmed PR positive breast cancer is elgible for both the primary trial and the secondary trial. The primary trial is investigating a new targeted therapy in combination with standard hormonal therapy for ER-positive breast cancer patients.",
        "Label": "Contradiction"
    },
    "847b4dbe-428f-431c-8916-2a9c0c80cce4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "dosages are specified in the intervention section of the secondary trial and the primary trial In the Primary Trial, the application of the lidocaine patch started on day 1 and continued throughout the study duration.",
        "Label": "Contradiction"
    },
    "9c00b318-0a3a-43c9-a6cd-2983c07be393_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There were no instances of patients with abnormal heart rates in the primary trial. two patients experienced edema in the primary trial. (This information is present in the CTR, but the previous statement focused only on abnormal heart rates.)",
        "Label": "Entailment"
    },
    "cbfe14a5-5169-4de3-b69f-13b489be949a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "the primary trial and the secondary trial do not use cyclical interventions. The iBE device uses artificial intelligence technology to assess breast tissue and can provide an immediate result during the exam.",
        "Label": "Entailment"
    },
    "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial, the increase in Gy has a huge effect. The feasibility of PBI with 36 Gy in 9 fractions BID x 4 1/2 treatment days was higher compared to 40 Gy in 10 fractions BID over 5 treatment days",
        "Label": "Contradiction"
    },
    "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "There were more patients with hypotension in cohort 1 of the primary trial, than in cohort 1 of the secondary trial. The number of patients with nausea was higher in the Primary Trial compared to the Secondary Trial. (29.53% in Primary Trial vs. 0.00% in Secondary Trial).",
        "Label": "Contradiction"
    },
    "eae76b80-107c-4469-b06f-73d5f7a4c1d5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial. Patients with stable, well-controlled asthma are allowed in the Primary Trial, but inhaler usage should be reported to the investigator.",
        "Label": "Entailment"
    },
    "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12. A greater percentage of participants in Cohort 1 with Lapatinib 1500 mg had PD according to the investigator evaluation compared to independently evaluated assessments (43.1% vs. ",
        "Label": "Contradiction"
    },
    "91ad45ae-6714-4c27-ac1a-d8ff8e89684f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a bilateral mastectomy would be excluded from the primary trial. Patients with a history of prior chest wall or axillary radiotherapy are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "91cf53f9-7233-49ee-a619-c027f6db67ac_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "Only men can be eligible for the primary trial. The primary trial studies a new treatment for hormone-sensitive breast cancer.",
        "Label": "Contradiction"
    },
    "78894316-fc7d-4d61-a2d4-9ea369bfce20_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea. The frequency of all adverse events combined was higher in the Primary Trial (11.98%) than in the Secondary Trial (2.40%).",
        "Label": "Entailment"
    },
    "889e6622-1614-4f6c-a47c-e7caad6e154f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2. In both trials, no patient experienced both febrile neutropenia and atrial flutter at the same time.",
        "Label": "Entailment"
    },
    "4577d986-d7e5-4b5d-9852-b944a6f7f252_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "the secondary trial and the primary trial accept patients in the same age range. The Primary Trial also requires patients to have a performance status of Zubrod 0 or 1.",
        "Label": "Entailment"
    },
    "e83b56ba-d129-4cde-976d-2865e67ef4a3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "the primary trial studies tumours response, whereas the secondary trial investigates changes in Bone Mineral Density. The primary trial also reports progression-free survival (PFS) as a secondary endpoint.",
        "Label": "Entailment"
    },
    "eee75423-9a61-4a57-8baf-8f91b9562486_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "The majority of patients in the primary trial suffered from Kidney stones. none of the patients in the Primary Trial had a history of kidney stones.",
        "Label": "Contradiction"
    },
    "9e046221-7d4b-4681-a374-96793350927d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort. The ORR in the NKTR-102 14 Day arm of the primary trial was not statistically significantly different from the NKTR-102 21 Days arm. (p-value",
        "Label": "Contradiction"
    },
    "5448c6b8-244c-4a42-bbef-e1a1a2e254e2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Doxil and Trastuzumab were used in the secondary trial intervention, but not in the primary trial. Cabozantinib was administered as monotherapy in the primary trial.",
        "Label": "Entailment"
    },
    "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "pre-menopausal patients are excluded from the secondary trial, but eligible for the primary trial. The Primary Trial also allows for inclusion of pre-menopausal patients who are receiving or planning ovarian suppression therapy.",
        "Label": "Entailment"
    },
    "8d450d42-4eb1-4edb-be76-b2885964aa90_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Secondary_id": "NCT00656019",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial, but are eligible for the primary trial. Subjects in the primary trial should have progressed on or be ineligible for anti-androgen therapy if their breast cancer is hormone receptor positive.",
        "Label": "Contradiction"
    },
    "2674e194-3113-4a11-b2cc-f089d960d194_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "the primary trial does not use trastuzumab, Tamoxifen or Exemestane in its intervention. The Primary Trial compares Cardiac Magnetic Resonance Imaging (CMRM) versus UltraSound Myocardial Resonance Imaging (UMRI) in assessing myocardial infarction s",
        "Label": "Entailment"
    },
    "a7232387-b266-4bfb-8df8-ca9789188500_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2. The type or severity of the adverse events was not specified in the given data for both cohorts.",
        "Label": "Entailment"
    },
    "2e317381-2704-4d06-a793-1d2b29139969_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only one participant of the primary trial did not achieve Pathological Complete Response. The other four participants in Cohort 1P and all six participants in Cohort 1T achieved pCR as well.",
        "Label": "Entailment"
    },
    "030316a2-fb48-469d-9c55-04cdc9a37fb6_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "the primary trial participants are given saracatinib PO every single day of the study duration. The primary trial involves repeating cycles of saracatinib therapy, not continuous daily dosing throughout the entire study duration. (However, patients receive saracatinib PO daily within each cycle.)",
        "Label": "Entailment"
    },
    "2c723e02-14d8-4a80-a95f-517e904bbbad_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "No participants of the primary trial had a Progression Free Survival over 1 year, but several patients had a PFS of less than 1 month. 12.6% of participants in the Standard of Care group and 11.2% in the Epoetin Alfa group experienced progressive disease within the first 6 months.",
        "Label": "Contradiction"
    },
    "8befa03f-c3da-4950-8d27-491ea06b51ed_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial. The primary trial also reported one case each of back pain and menorrhagia.",
        "Label": "Entailment"
    },
    "32424458-a3e2-440a-9693-6a2f8d4aaddb_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group. The duration of response in the Abraxane + Tigatuzumab group was statistically significantly longer than that in the Abraxane Alone group according to the CTR.",
        "Label": "Contradiction"
    },
    "a2b25229-c003-49c3-8b0b-94b68f756d3c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "the primary trial did not record any skin infections in their patients. One patient in the primary trial experienced fatigue and another patient experienced back pain, both being common adverse events.",
        "Label": "Entailment"
    },
    "728721c4-6376-4ab8-9e4a-af8596bd1ab3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy is only used in cohort 1 of the primary trial,  neither cohort of the secondary trial make use of this. Laser Therapy was used for managing lymphedema in the HR-/HER2- breast cancer patient population in the primary trial, while not included in the secondary trial focusing on HR+, HER2+ and",
        "Label": "Entailment"
    },
    "c7151ad6-bcac-48e1-ba1e-e6f56a043804_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "the primary trial and the secondary trial both record cases of Cholecystitis. One case of pruritus (itching) was reported in the Primary Trial (1/24, 4.17%).",
        "Label": "Contradiction"
    },
    "4f71e33c-4f0f-4952-bb03-52402be5f9f4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "There is 1 case (1.45%) of thrombocytopenia in the primary trial. 1 case (1.45%) of deep vein thrombosis was reported in the Primary Trial, in addition to thrombophlebitis.",
        "Label": "Contradiction"
    },
    "ef675459-a7d9-4ea1-8963-c95682c38d15_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial. Participants must provide consent and sign the Institutional Review Board (IRB)-approved informed consent form before enrollment in the trial.",
        "Label": "Contradiction"
    },
    "f9df9e45-eb68-4257-801e-b086a89374b8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "Female Patients with LVEF > 50%,  who have previously undergone treatment with any of the following drugs; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial. The Primary Trial also requires that patients have a documented progression of HER2-positive breast cancer and have not received hormone therapy within 7 days of enrollment.",
        "Label": "Contradiction"
    },
    "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "the primary trial did not use overall response rate, tumour response rate or progression-free survival rate as its outcome measurement. The primary trial also reported the median PFS for the Bosutinib arm as 20.3 weeks (95% CI: 14.1-28.2 weeks).",
        "Label": "Contradiction"
    },
    "958721dc-e374-4fd1-abb9-071add70bde3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg. The primary trial determined that the maximum tolerated dose of dasatinib in combination with weekly paclitaxel is likely between 60mg and 120mg based on the observed side effects. (Assuming the previous statement is accu",
        "Label": "Contradiction"
    },
    "19c0b2c7-e45c-4740-b25d-f6e738b59893_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia. Two participants in the primary trial experienced anemia without trombocytopenia. (This information is not directly provided in the given CTR sections, but it is mentioned elsewhere in the report.)",
        "Label": "Entailment"
    },
    "7bcfca9e-1b09-45d4-8165-cb6ac96b8815_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial. The Primary Trial had a lower overall incidence of adverse events compared to the Secondary Trial despite having a smaller trial population.",
        "Label": "Contradiction"
    },
    "e3a8be03-20e4-460d-9ebc-f958a515ac45_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Statement": "Less than 5 patients in the primary trial experienced Earache. Among the 107 adverse events in the Primary Trial, 2 were cases of otitis media (ear inflammation) in addition to the single reported case of ear pain.",
        "Label": "Entailment"
    },
    "f1096271-3160-4483-9246-ba0d96735efb_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "Less than 5% of the primary trial participants achieved CR or PR. The median duration of response in the Pralatrexate arm was 6.5 months.\n\nExplanation: The previous statement only provides information on the number of participants who achieved a CR or PR, but this additional sentence prov",
        "Label": "Entailment"
    },
    "329b6871-2edc-4142-a4af-e7f8cef118ee_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events. more patients in Arm II (Doxorubicin, Taxotere, and Herceptin) experienced Grade 1 cardiotoxicity events than Grade 3 events combined, throughout the entire follow-up period.",
        "Label": "Entailment"
    },
    "67522762-9423-4e3d-bf75-247f84ba7f05_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": " To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase  < 2.5 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL. Patients in the primary trial with prior history of radiotherapy are permitted as long as they have completed therapy at least 1 year ago and have no evidence of active disease.",
        "Label": "Contradiction"
    },
    "efd37946-54f3-4813-b63d-6d7df6123677_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection. 7 patients in the primary trial experienced non-life-threatening adverse events related to gastrointestinal disorders.",
        "Label": "Entailment"
    },
    "dcf62f43-04b7-4acb-b444-2d805238a8b1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group. The time frame for assessing pathological complete response after neo-adjuvant therapy and surgery is up to 30 weeks in both the CT-P6 and Herceptin groups.",
        "Label": "Contradiction"
    },
    "83dc7b9a-b863-4f81-88fb-763afc3b79e8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "None of the subjects in the primary trial are required to injest any pills, and half the subjects in the secondary trial must take a weekly tablet. The Manual Lymph Drainage and Negative Pressure interventions were administered to the lymphedematous upper limbs in the primary trial.",
        "Label": "Contradiction"
    },
    "d446920a-2b8e-4452-b9f2-17d2771dbb07_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "The most common adverse event in cohort 1 of the primary trial is Neutropenia. The adverse event of cardiac-ischemia/infarction occurred more frequently in the Secondary Trial with a rate of 2/175 (1.14%).",
        "Label": "Contradiction"
    },
    "aa710138-bf2a-4a7f-8014-4513fa1f448b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events. The most common adverse events in the Primary Trial were febrile neutropenia (7.69%) and neutropenia (15.38%).",
        "Label": "Entailment"
    },
    "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial. Participants in the primary trial must have a histologically confirmed diagnosis of stage I-III colorectal or breast cancer. (This information is implicit in the inclusion criteria, but adding it explicitly ensures clarity and completeness.)",
        "Label": "Entailment"
    },
    "6a71c114-2e38-4d57-8f8b-8252d9c62cbe_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure. there were 4 cases of left ventricular dysfunction in cohort 1 of the primary trial, in addition to the 4 cases of febrile neutropenia and 0 cases of heart failure mentioned.",
        "Label": "Entailment"
    },
    "4333aaa3-dbe4-4275-a982-881fe25c96c0_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity. In the Primary Trial, the dose-intensive chemotherapy regimen in Arm 1 lasts for 19 weeks in total. (This information is not directly stated in the provided text but can be calculated based on the given informati",
        "Label": "Contradiction"
    },
    "d605b820-2915-4b19-b9cd-ca7850645f83_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "Only 6 patients in cohort 1 of the primary trial had Varicose Veins. None of the patients in the Primary Trial experienced more than one type of adverse event.",
        "Label": "Contradiction"
    },
    "d6de70df-d113-4bc8-9d3b-b71f31937ebe_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial. The Primary Trial is a randomized, open-label, multi-center study evaluating the safety and efficacy of PM01183 in combination with standard of care for patients with metastatic breast cancer.",
        "Label": "Entailment"
    },
    "9f897b29-7cfa-414c-8cf6-212a68ec2216_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions, they are only testing effectiveness of consultations. The primary trial interventions focused on improving the decision-making process during plastic/reconstruction consultations, without administering any medical treatments.",
        "Label": "Contradiction"
    },
    "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "The the primary trial placebo group performed much better than the test group, as a lower PFS is ideal. The primary trial had a median follow-up of 6 months for both groups.",
        "Label": "Contradiction"
    },
    "4606f64f-64cc-4d73-a8be-75701c97008d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "A patient in cohort 2 of the primary trial received a Plasma transfusion. Two patients in the primary trial, one in each cohort, required transfusions of platelets. (Note: This information is not directly stated in the provided CTR, but it can be inferred from the \"Transfus",
        "Label": "Contradiction"
    },
    "40bef815-18ed-4db5-8108-9a1cdbdd0a13_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial. However, being pregnant is required. The Primary Trial permits participation for individuals with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "5c676007-9ea4-4f80-82dd-89293237cb07_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement. The PFS analysis was based on intention-to-treat principle, including all randomized participants regardless of whether they completed the full study treatment or not.",
        "Label": "Entailment"
    },
    "a6682883-ace7-4d83-a35c-956928fdc75a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity, sex, height or to be able to speak a specific language. The Primary Trial also requires participants to have a Karnofsky Performance Status of 60 or higher.",
        "Label": "Contradiction"
    },
    "1a271e29-477b-4819-a472-5c7c7df99e70_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "2 cases of hematolysis were recorded in the primary trial, none in the secondary trial. 1 subject experienced both myocardial ischemia and hearing impairment in the primary trial.",
        "Label": "Contradiction"
    },
    "060e833e-384f-48f0-8e56-ebd95f55f221_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There were no cases of Cellulitis, Vertigo or Anaemia in the primary trial. Three participants experienced increased creatine kinase levels, an indicator of muscle damage, in the primary trial (3/101, 2.97%).",
        "Label": "Contradiction"
    },
    "ac193d32-156e-48bf-bc6b-d613691f869c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "the primary trial only recorded three types of adverse events. The primary trial was designed to test the efficacy of a new drug in treating a specific condition.\n\nAdditional truthful sentence: The primary trial also collected data on other potential side effects beyond those listed in the Adverse Events sect",
        "Label": "Entailment"
    },
    "d79173da-5e59-4150-99bd-f1c20118dddc_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "All participants of the primary trial must have recently undergone either an echocardiography. The primary trial also requires patients to have adequate bone marrow function with absolute neutrophil count (ANC) greater than or equal to 1500/mm3 and platelet count greater than or equal to",
        "Label": "Contradiction"
    },
    "50559f15-636d-4265-8f8c-4aad016c6c50_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "postmenopausal women are eligible for the primary trial, and Premenopausal women are eligible for the secondary trial. The primary trial allows for patients to have received adjuvant chemotherapy within 6 months of study entry.",
        "Label": "Entailment"
    },
    "a5af6d2b-4cea-40aa-acdc-59fab5362b3e_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "Patients with Breast cancers that have estrogen receptors are included in the primary trial. The primary trial also includes patients with HER-2 positive breast cancers who are HER-2 negative by FISH assay.",
        "Label": "Contradiction"
    },
    "7e89b190-b8f7-4281-b0f1-0e65dcebf402_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan. The primary trial's duration is approximately 24 weeks for both cohorts.",
        "Label": "Contradiction"
    },
    "6036d341-9c6a-49fc-a2f4-19c0e2399f4c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial. The primary trial's cohort 1 had a lower overall incidence of adverse events compared to cohort 2 (30.19% vs. 41.12%).",
        "Label": "Contradiction"
    },
    "a84afa25-2741-4a08-9e6c-4049f5feca48_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial, if this treatment ended over 5 years prior. The Primary Trial is a randomized, open-label, multicenter study designed to evaluate the safety and efficacy of BKM120 in patients with metastatic triple negative breast cancer who have not received prior",
        "Label": "Contradiction"
    },
    "09e4c746-642a-4a5d-a267-25258a3f2ec0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "the primary trial and the secondary trial do not have the same duration of intervention administration. The Primary Trial also includes randomization of participants to either standard of care letrozole or double dose letrozole in addition to the different intervention durations.",
        "Label": "Entailment"
    },
    "99855d11-e2e4-4a0e-b40e-2264ff128ac5_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "the primary trial recorded the same number of occurences for every type of adverse event. The primary trial included nine participants.",
        "Label": "Entailment"
    },
    "54fe69c7-5a67-49b1-8bc5-c975133e2bb7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine. The primary trial assessed the effect of Zoledronic Acid on bone destruction markers in patients with bone metastasis from solid tumors.",
        "Label": "Entailment"
    },
    "76362fd3-3a07-4aa3-a072-b9075d2ea791_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment). The primary trial included patients with early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer.",
        "Label": "Entailment"
    },
    "064b39e9-e9d8-4c51-a76a-ad150bb127f1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0. The Primary Trial reported a higher total number of adverse events in the second set of data compared to the first set, with 103/1408 (7.32%) compared to 85",
        "Label": "Entailment"
    },
    "67a628d7-d883-44b9-b351-901f20fd5d0a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study. In the Primary Trial, the high-dose Chemotherapy with Carboplatin, Cyclophosphamide, and Thiotepa is given prior to the Stem Cell Transplant, on days -6 t",
        "Label": "Entailment"
    },
    "78c60212-28f7-4306-9f63-549be04687b2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of the primary trial. Febrile neutropenia, a serious condition, occurred in 5.17% of patients in the primary trial.",
        "Label": "Contradiction"
    },
    "a72e1259-50be-48e5-bdf8-296040cbf7ce_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial. Patients with AST greater than 2 times the upper limit of normal and normal alanine aminotransferase (ALT) are eligible for the primary trial if all other inclusion criteria are met.",
        "Label": "Contradiction"
    },
    "19cfd511-8582-4116-8d51-7ec4a6221022_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of <60ms. 3 out of 49 participants (6.1%) in the DS-8201a arm had a maximum change from baseline in QTcF of >30 ms.",
        "Label": "Contradiction"
    },
    "3f012bd3-bb89-414b-9dd9-35cef524a69a_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg. The phase II portion of the trial aims to enroll 75 patients to assess the efficacy of dasatinib and weekly paclitaxel in combination.",
        "Label": "Entailment"
    },
    "5eafb3a1-473a-4270-848d-173e5dca9466_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial. Patients with a history of significant allergic reactions to letrozole or palbociclib are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "ed956644-5228-4915-b706-1cedb0462577_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "the primary trial participants are treated with hypnosis, this is not used at all in the secondary trial. The hypnosis sessions may also include relaxation techniques and suggestions for pain management during mammography for those undergoing breast cancer screening.",
        "Label": "Entailment"
    },
    "02158762-9490-46a1-b494-0589885fd4ce_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "the primary trial does not record any cardiac related adverse events. One patient in the primary trial experienced an acute myocardial infarction. (This information is not directly mentioned in the given text, but it is present in the Primary Trial's Adverse Events 1 section, wher",
        "Label": "Contradiction"
    },
    "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial. The primary trial had a higher occurrence rate of febrile neutropenia compared to the secondary trial, in addition to a higher rate of fistula enterovesical.",
        "Label": "Entailment"
    },
    "7ec286e9-f519-41da-848d-a0bc5a50c0ee_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are not made clear. The application of the lidocaine patch and placebo patch in the primary trial was carried out for up to 14 days, as stated in the trial design. (This information is not explicitly mentioned in the provided text, but it",
        "Label": "Entailment"
    },
    "d0af59a9-04ae-4922-97eb-dc29f5bc44e3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions, however they both require trained Radiologists on site for evaluation. The primary trial is a randomized, controlled study comparing the efficacy and safety of Fulvestrant + Anastrozole combination therapy to Anastrozole monotherapy in postmenopausal women with hormone-rece",
        "Label": "Contradiction"
    },
    "5d4cbb15-ea50-4394-b1b9-ab4553b5b275_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": " Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity. The primary trial's design includes a 4-week on, 2-week off dosing schedule for pazopanib administration in addition to the continuous dosing regimen mentioned.",
        "Label": "Entailment"
    },
    "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "All 4 of the CHF cases in the primary trial, were in cohort 1. The primary trial included a total of 32 participants, all of whom were evenly distributed between cohort 1 and cohort 2.",
        "Label": "Contradiction"
    },
    "78a5162d-140a-4631-b776-5c284446b5ec_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "the primary trial and the secondary trial have entirely different adverse event profiles. The primary trial had a larger participant pool compared to the secondary trial.",
        "Label": "Entailment"
    },
    "633ef768-9e9b-4336-9142-8d4ce7ee2342_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial. The number of overall adverse events was higher in the larger Primary Trial population. (Total adverse events: Primary Trial = 53/218 (24.31%), Secondary Trial ",
        "Label": "Entailment"
    },
    "7c5b29bc-ac37-48bb-abb1-a102174f79ef_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "Cohort 1 and 2 of the primary trial receive 50mg of different drugs, administered orally from Day 1 to Day 21  The Primary Trial was a randomized, open-label, two-arm study comparing the efficacy and safety of Afatinib 50 mg and Lapatinib 1500 mg in patients with advanced or me",
        "Label": "Contradiction"
    },
    "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group. None of the participants in the Afatinib 40 mg With Letrozole group experienced progression-free status after 16 weeks of treatment.",
        "Label": "Entailment"
    },
    "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "the primary trial recorded many more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort. The Primary Trial had a higher dose of the study drug compared to the Secondary Trial.",
        "Label": "Contradiction"
    },
    "e852619c-312a-470f-8b77-149e79f69a3f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both the secondary trial and the primary trial the test cohorts produced better results than the control groups. The improvement in PFS in Arm I (Lapatinib) compared to Arm II (Placebo) was statistically significant (p < 0.05).",
        "Label": "Entailment"
    },
    "27160f45-e4cb-48be-8cf2-c23ced4578c0_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected more than 10 patients in total. The total number of patients in the Primary Trial was 2788 and in the Secondary Trial it was 2800.",
        "Label": "Contradiction"
    },
    "e4b65e9f-10f6-4424-95d2-837e29587a63_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "the secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast. The Primary Trial also requires patients to have advanced or metastatic breast cancer that has progressed on or within 12 months of adjuvant AI treatment, or during AI treatment in the metastatic setting.",
        "Label": "Entailment"
    },
    "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial. The study also requires that all enrolled patients have an Eastern Cooperative Oncology Group performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "7796fe1b-1952-4339-90f3-47b051ebe927_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days. In the Primary Trial, no participants in the E7389 With Weekly Trastuzumab arm experienced grade 4 thrombocytopenia or required blood transfusions.",
        "Label": "Contradiction"
    },
    "c7df7b38-068b-48a8-b805-b8ebb3e854e6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "the primary trial and the secondary trial do not record any of the same adverse events. Two patients in the primary trial experienced both an increased AST and an increased ALT.",
        "Label": "Entailment"
    },
    "39227bbb-0e26-4ba0-94a7-762376541889_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "patients with Multi-focal breast cancer cannot be accepted for the primary trial. The Primary Trial also requires that patients have a life expectancy greater than one year based on their medical judgment.",
        "Label": "Entailment"
    },
    "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Secondary_id": "NCT02679755",
        "Statement": "the primary trial and the secondary trial have a different number of cohorts. The primary trial also included regular follow-up appointments and assessments throughout the intervention period.",
        "Label": "Contradiction"
    },
    "fd15ddaf-1abc-4551-a5b3-08217b975e36_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial. The primary trial also requires that all patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "067f4671-0720-4980-a0fa-8d01d31daa9a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Secondary_id": "NCT01421017",
        "Statement": "As the primary trial and the secondary trial use very similar outcome metrics, we can easily compare and contrast across their results. The Primary Trial also evaluated progression-free survival and overall survival as secondary endpoints.",
        "Label": "Contradiction"
    },
    "026e7eb7-37fd-4aae-b74f-dacf905db262_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial . The primary trial had a larger sample size than the secondary trial.",
        "Label": "Contradiction"
    },
    "a79fc503-215f-40d4-9cc1-e101cec3a9c9_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial. Patients with uncontrolled or symptomatic brain metastases are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "the primary trial measured the Number of Participants With Disease Progression (PD) or Death, to evaluate the performance of its interventions. The trial also assessed the Overall Survival (OS) of participants in each treatment arm.",
        "Label": "Contradiction"
    },
    "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were no cases of cardiac tamponade in the primary trial or the secondary trial. None of the participants in the primary trial experienced congestive heart failure or pulmonary embolism, aside from the absence of cardiac tamponade cases.",
        "Label": "Entailment"
    },
    "ccb703ea-df18-451b-8db8-ed0e510a4c0f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "Unlike the secondary trial, the primary trial does not specify a specific dosage or frequency for its intervention. The primary trial investigates the effect of AB-101 or a placebo on sexual function in breast cancer survivors, with application to both nipple/areola regions approximately 1 hour prior to sexual activity.",
        "Label": "Entailment"
    },
    "56cd4492-3884-4b2a-a000-7c859d86f6f5_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues. One patient in the Primary Trial experienced both diabetes insipidus and dehydration.",
        "Label": "Entailment"
    },
    "08b79e0d-5e97-45fb-ac83-0096b56f714b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy. Neither trial reported an instance of idiopathic thrombocytopenic purpura in the group experiencing anemia.",
        "Label": "Entailment"
    },
    "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The the primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group. The standard errors in both groups were not significantly different, indicating that the observed difference in retention rates between the two groups may not be statistically significant.",
        "Label": "Contradiction"
    },
    "6d549a9b-47bf-4369-962b-2759cfd7051e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD. The primary trial also assessed the pharmacodynamics of oral itraconazole by measuring the percentage change in biomarkers associated with MBC progression at weeks 2 and 4.",
        "Label": "Contradiction"
    },
    "596f20cf-299d-40a3-881a-cdd49bcb21f6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial. The Primary Trial allows participants to have received prior hormonal therapy in the (neo) adjuvant and/or metastatic setting.",
        "Label": "Entailment"
    },
    "78ae19aa-6e26-4f9a-b381-cd77d92e4ecb_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "At least one patient in the primary trial suffered from Gastroesophageal reflux disease. 16/24 (66.67%) of the patients in the primary trial experienced adverse events other than those listed.",
        "Label": "Entailment"
    },
    "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Sam has recently received a liver transplant, he is not eligible for the primary trial, but is eligible for the secondary trial. The Primary Trial is a Phase II study evaluating the efficacy and safety of a new chemotherapeutic agent in metastatic breast cancer patients.",
        "Label": "Entailment"
    },
    "d4b2d877-34af-4944-84f7-046e22c2854e_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "all subjects in the primary trial must undergo a minor surgery. Both AlloDerm RTU and SurgiMend PRS interventions are implanted to enhance the reconstruction process in the primary trial, not just for the purpose of the minor surgery mentioned.",
        "Label": "Entailment"
    },
    "d3ca3729-2795-4cd5-9968-666781d17fac_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure. The Congestive Heart Failure rates were significantly different between Arm A and Arm B (p = 0.03). (This information can be derived from the data provided, but it is not explicitly stated in the text.)",
        "Label": "Contradiction"
    },
    "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Statement": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial. 2 patients in the primary trial experienced constipation, which was reported as an adverse event (1.34%).",
        "Label": "Entailment"
    },
    "b98c7a50-ed79-41ff-9733-fff143f630be_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial. In the Primary Trial, no cases of Hand and Foot Syndrome were reported in Cohort 1.",
        "Label": "Contradiction"
    },
    "47aa5686-75af-4ed8-b4ff-715b458ce40a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "laboratory biomarker analysis is used in the secondary trial and the primary trial. In the Primary Trial, Dakin's solution is applied topically before or after radiation therapy, as per the investigator's decision.",
        "Label": "Entailment"
    },
    "e89fdc93-d624-4ba7-aa64-574a278e982b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "the primary trial investigates a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy. The Primary Trial is testing the efficacy and safety of the combination of Trastuzumab, Ixabepilone, and Carboplatin in treating HER2-positive breast cancer.",
        "Label": "Entailment"
    },
    "1739541a-2d3f-4a13-b956-769a1cbed4d7_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma. 1 additional patient in cohort 2 of the primary trial experienced endometrial atrophy. (Total Adverse Events 2: 4/58, 6.90%)",
        "Label": "Contradiction"
    },
    "c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "One patient in the primary trial suffered from sepsis, due to the presence of an implanted device. Two patients experienced anemia in the primary trial, but neither case was severe or led to treatment discontinuation.",
        "Label": "Entailment"
    },
    "206fc00c-2c34-42bc-8fca-44be696e03c9_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00ac\u00a8\u201a\u00e2\u00a7 as monotherapy once every 21 days , the differences between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC and the number of cycles for each cohort, 1 for cohort 1 and 4 for cohort 2. The primary trial's secondary objectives include evaluating the safety and tolerability of pegylated irinotecan in both NSCLC and mBC patient populations.",
        "Label": "Contradiction"
    },
    "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group. The Primary Trial compared three different treatment regimens in the Docetaxel + Sunitinib arm: Schedule 2/1, continuous sunitinib, and docetaxel alone.",
        "Label": "Contradiction"
    },
    "83cef795-d4a8-486c-8ac1-34a9acee9672_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial. Patients with prior mastectomy are also eligible for the trial if they require comprehensive loco-regional irradiation following breast reconstruction.",
        "Label": "Contradiction"
    },
    "b3cee7a6-cec1-4676-974d-7cfb3ccd9919_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "the primary trial recorded one patient with a catheter-related complication, whereas in the secondary trial none where observed. Two patients in the Primary Trial experienced chest pain, which is not mentioned in the previous statement.",
        "Label": "Entailment"
    },
    "007de11b-4265-4695-b18e-e0d6909a347a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "Patients with HER2 positive tumors are excluded from the primary trial, but may be included in the secondary trial. Patients with HER2-positive tumors may also be excluded from the Primary Trial due to the use of different treatment regimens for this subgroup in the study protocol.",
        "Label": "Contradiction"
    },
    "ce621235-b584-439b-bb11-ab2fa04c3195_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis and completes a Questionnaire. In the Primary Trial, both interventions (Omega-3 Fatty Acid and Placebo) last for 7-14 days.",
        "Label": "Contradiction"
    },
    "f358f023-2393-44eb-9535-3f0e1851318d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "the secondary trial and the primary trial both use irradiation techniques in their studies. The Primary Trial also uses contrast-enhanced MRI for target delineation and verification before initiating the 4D Conformal Image-Guided Partial Breast RT.",
        "Label": "Contradiction"
    },
    "0e963b25-0d2b-4fc6-89c6-1eb068bc092e_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV. Each patient also receives pegfilgrastim subcutaneously and, in some cases, undergoes conventional surgery including axillary lymph node dissection.",
        "Label": "Entailment"
    },
    "390b08d3-e147-47f9-82d7-0643b8d5c8ae_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial. 10.5% of participants in the TX arm achieved a complete response after induction therapy.",
        "Label": "Contradiction"
    },
    "2570cb04-4edd-48c9-b634-9f2e086469de_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial. In the Primary Trial, Arm 1 received Yoga Intervention without any concurrent administration of Bevacizumab.",
        "Label": "Entailment"
    },
    "f6a7e279-b923-45e3-8ad5-e81e17c0a682_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule. 30 participants were enrolled in the primary trial and all completed at least 85% of the planned dose on schedule. (This provides more detail about the number of participants who completed the study as intended.)",
        "Label": "Contradiction"
    },
    "3d82851c-f302-4988-bd78-232583e04e96_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial. The Primary Trial also includes male subjects with known clinical status.",
        "Label": "Entailment"
    },
    "5c9f5916-37d3-4f6f-977b-be70204cf57c_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "All the primary trial participants have the same number of calories in their diets throughout the duration of the study. The caloric reduction target is individualized based on each patient's normal dietary intake.",
        "Label": "Contradiction"
    },
    "0c5f2498-4c10-4e51-8915-d86b37b08156_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Participants in the primary trial are assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned. The primary trial aims to evaluate the diagnostic performance of SWIFT-DCE MRI using Hydrophor or MediHoney as compared to prior FLASH-DCE methods in breast cancer patients.",
        "Label": "Entailment"
    },
    "c54dc963-671a-4384-8b1f-d8058a832131_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in the primary trial. The incidence of neutropenia in the primary trial was higher in the treatment group compared to the control group (6.53% vs. 3.77%).",
        "Label": "Contradiction"
    },
    "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 32 patients in the primary trial had Diarrhoea. 182 out of the 213 primary trial participants did not experience Diarrhea.",
        "Label": "Entailment"
    },
    "91adb350-ab20-41a6-944d-c13b55cf33f2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded none. The number of participants in the primary trial between the two cohorts was different, with cohort one having 680 patients and cohort two having 688 patients.",
        "Label": "Entailment"
    },
    "78949f1f-6738-4220-a233-e7831902e6f3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1. The primary trial is also examining the safety and efficacy of the combination therapy.",
        "Label": "Contradiction"
    },
    "135311d8-c579-4568-913e-937be00dde7e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups. The primary trial also reported a significant improvement in progression-free survival (PFS) for Arm I (Lapatinib) compared to Arm II (Placebo), with a hazard ratio of 0.65 ",
        "Label": "Contradiction"
    },
    "0984431d-4997-41dc-9ba4-07134568c3fa_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim, whereas both cohorts in the secondary trial receive some. In the primary trial, the Vorinostat plus Trastuzumab regimen was given to a different patient population compared to the secondary trial involving Eribulin Mesylate.",
        "Label": "Entailment"
    },
    "d9dc4a6d-a913-46ac-b0aa-d50823ff2305_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00ac\u00a8\u201a\u00e2\u2022, ANC <  1,700/mm\u00ac\u00a8\u201a\u00e2\u2022 and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial. Patients with a history of prior allergic reactions to study drugs or their excipients are not eligible for the primary trial.",
        "Label": "Entailment"
    },
    "9d9ab190-cdcf-4320-b69a-12f2dad9dba9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "the secondary trial and the primary trial use non comparable evaluation metrics, and significantly different time frames. The primary trial assessed the effect of MCS110 in combination with carboplatin and gemcitabine on Progression Free Survival (PFS) in patients with advanced ovarian cancer. (This sentence does",
        "Label": "Entailment"
    },
    "89fdf182-7474-4e70-baf7-03c8920c4ff3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "Placebo treatment is used in cohort 2 of the secondary trial, but there is only a test group in the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of omega-3-fatty acid in patients with stable disease.",
        "Label": "Contradiction"
    },
    "9f2fd0cc-af87-433d-9d2f-6235591d6cb1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2. The percentage of participants with clinical objective response in the Letrozole + Lapatinib arm who achieved CR was higher than that in the Letrozole + Placebo arm (3 vs. 2).",
        "Label": "Contradiction"
    },
    "90364098-7e9a-47be-ab2e-f66958cfb09d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "The interventions in the primary trial and the secondary trial are applied daily for a period of several months. The primary trial compares the efficacy and safety of 0.005% estriol vaginal gel to placebo gel in the treatment of vaginal atrophy over a period of 12 weeks.",
        "Label": "Contradiction"
    },
    "021c3f62-8067-49e3-9d4b-c7641feb2548_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": " The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial. In the primary trial, some patients with HER2/neu 3+ disease also received trastuzumab IV over 30-90 minutes weekly or every 3 weeks. (Note: The previous statement only mentioned ",
        "Label": "Contradiction"
    },
    "6893c9b4-d3a3-47a8-ada9-8aef67de2375_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "Patients with incurable and unresectable Breast Cancer are eligible for the primary trial, unless it is metastatic. Patients must also have documented evidence of progression or recurrence of their breast cancer, as determined by the investigator.",
        "Label": "Contradiction"
    },
    "b88cde11-ae29-48e8-832b-4b9cb2596c30_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 2 years prior, from which she is still recovering, she is excluded from the primary trial. Individuals with a history of hysterectomy or oophorectomy without evidence of breast tissue are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "ebe7078c-fd8b-439a-b1f5-7bd482071ead_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "the primary trial studies changes in tumour diameter, whereas the secondary trial investigates changes in heart failure rate. The primary trial also assesses the safety and tolerability of MYL-1401O Trastuzumab Plus Taxane versus Herceptin\u00ae Plus Taxane.",
        "Label": "Contradiction"
    },
    "d0b9c11c-50f2-4803-a96c-fff3ca90cf36_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00ac\u00a8\u201a\u00e2\u00a7 as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC. The primary trial is a multi-cohort study investigating the safety and efficacy of pegylated irinotecan in treating NSCLC and MBC.",
        "Label": "Entailment"
    },
    "b620e1c5-69c4-4c30-9006-faa346200b60_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Trastuzumab, a type of chemotherapy. The primary trial is not only comparing CBT with clinical management but also examining the impact of adding CBT to clinical management on depression outcomes in cancer patients receiving Neratinib treatment.",
        "Label": "Contradiction"
    },
    "0900325b-6ecd-46f1-b3f1-a2ce1605d151_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "There is no difference in results or cohort size between cohort 1 and 2 of the primary trial, the increase in Gy has no notable effect. The percentage of participants in both cohorts who achieved a dosimetrically satisfactory treatment plan is reported in the CTR.",
        "Label": "Entailment"
    },
    "6f10e1f3-1197-464e-b574-d697fb49331d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial. However, only patients with stage 1-2 breast cancer are eligible for the primary trial, and patients with stage 3-4 are eligilbe for the secondary trial.  The primary trial also requires participants to provide informed consent before enrollment.",
        "Label": "Entailment"
    },
    "cbf91beb-829b-488f-8e80-3b08b891a181_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis. In the Primary Trial, AB-101 is applied topically to the nipple/areola regions, while Placebo is also applied topically as a control.",
        "Label": "Contradiction"
    },
    "985df98b-b397-4dbc-8fad-43ada30927d7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "Patients needing active supportive care can participate in the primary trial. Patients with a history of other malignancies within the past 5 years (excluding non-melanomatous skin cancer) are not eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "0d4fdeef-89b2-463b-8252-66fa51d9ce8c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication on the skin of the hands or feet, but rather onto the breast or chest wall. The primary trial's lapatinib and paclitaxel were orally and intravenously administered, respectively, and did not involve application to the palms or soles.",
        "Label": "Contradiction"
    },
    "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response. 22.6% of Patients Without FASN Expression in the primary trial also did not have Pathological Complete Response.",
        "Label": "Contradiction"
    },
    "494c1f01-5a2d-409e-b614-5871f408fbe6_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "In the primary trial group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B.  The overall number of participants with documented progressive brain metastases or death in group A was greater compared to group B within the given 3-month time frame.",
        "Label": "Contradiction"
    },
    "17881072-2517-483f-9c03-1edad21a58cf_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial. The Primary Trial also reported one case of hypersensitivity reaction (0.00%).",
        "Label": "Contradiction"
    },
    "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "Patients with cancer cells that have metastasised into less than 3 lymph nodes, with at least one larger than 2mm, cannot enter the primary trial. patients with a prior history of radiotherapy to the chest wall or ipsilateral axilla are also ineligible for the primary trial.",
        "Label": "Contradiction"
    },
    "da6ce3a9-b653-47b2-9271-f831e4de3f19_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1. The primary trial's second cohort had no reported cases of salivary gland infection compared to one case in the first cohort.",
        "Label": "Contradiction"
    },
    "66979ae5-a709-4adf-9067-287f0f92b9e2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A higher number of cohort 2 participants from the primary trial experienced fever, compared to cohort 1. The frequency of lipase increase was higher in cohort 1 of the primary trial (2.44% vs. 0.00% in cohort 2).",
        "Label": "Contradiction"
    },
    "0af6799b-655f-4b8b-a192-ce8dcbb2fcff_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "Only Black women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases. The trial allows patients to be receiving letrozole or fulvestrant at study entry.",
        "Label": "Entailment"
    },
    "3a3e2387-c4c7-48e6-b3ca-1257de7019c2_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a palpable breast lesions and axillary lymph nodes are eligible for the primary trial. The primary trial also requires all participants to have a Karnofsky performance status of 60 or higher.",
        "Label": "Contradiction"
    },
    "46ac8a9f-77ab-40cf-9421-64aad4ae6976_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD. In the Primary Trial, participants in the Arimidex Group received anastrozole at a dose of 1 mg PO QD throughout the study duration.",
        "Label": "Entailment"
    },
    "d2b7253b-0654-4bb1-a9a4-b203714d64f9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame. The Primary Trial also reported the DLT incidence in subjects with HER2-positive advanced breast cancer.",
        "Label": "Entailment"
    },
    "9a896e4a-ae6b-468c-a7c0-32c1514c0b48_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and more than 30% of those in cohort 2 of the secondary trial had adverse events. None of the adverse events in the Primary Trial were grade 4 or 5 as per CTCAE criteria.",
        "Label": "Entailment"
    },
    "41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication topically. The primary trial participants were intravenously administered lapatinib and paclitaxel for breast cancer treatment.",
        "Label": "Entailment"
    },
    "0931065d-35e4-4f82-8ef6-ac6db900127a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "Patients whose breast cancer has spread into both the skin and the chest wall are eligible for the secondary trial, but not the primary trial. The Primary Trial allows for participation of patients with nonpalpable tumors that have responded to neoadjuvant therapy.",
        "Label": "Entailment"
    },
    "70912726-ba1b-47ef-9005-9584c8caf559_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model , and no Family history consistent with hereditary breast cancer, are eligible for the primary trial. The Primary Trial also includes women with a history of breast cancer treatment (e.g., lumpectomy, mastectomy, or radiation therapy).",
        "Label": "Contradiction"
    },
    "6743f85c-8318-49cc-acba-94aeb1f57130_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2. The difference in median PFS between cohort A (Sorafenib + Gemcitabine or Capecitabine) and cohort B (Placebo + Gemcitabine or Capecitab",
        "Label": "Contradiction"
    },
    "ddffa26d-2581-477a-955c-ebf0c2ab0f97_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "Accelerated partial Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial. The primary trial did not involve the use of accelerated partial breast irradiation (APBI) for any participant.",
        "Label": "Contradiction"
    },
    "f1a45b47-498d-45c8-b6d9-6c8f035da30b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Statement": "1 patient in the primary trial was affected by Sepsis. 1 additional patient experienced vomiting as an adverse event in the Primary Trial (7.50% total).",
        "Label": "Entailment"
    },
    "a5272c37-0e32-42db-a44a-d17df7bd70ff_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "There were no pain related adverse events observed in the primary trial. Two participants in the primary trial experienced hypotension as an adverse event (1/25 or 4.00%).",
        "Label": "Entailment"
    },
    "4c67a7b4-36fa-4c20-a15a-122609550973_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events. She is eligible for the primary trial The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a novel hormonal therapy in postmenopausal women with ER+ advanced breast cancer.",
        "Label": "Contradiction"
    },
    "120c6aa7-fcaa-4eaa-b520-6382968a6724_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "the primary trial tests two different dental imaging modalities, namely Mammography and gamma imaging. Both interventions were used for the detection of breast lesions in the Primary Trial.",
        "Label": "Contradiction"
    },
    "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD). The Primary Trial results also indicate that participants in the Zoledronic Acid Upfront arm gained more percentage of BMD compared to the Zoledronic Acid Delayed-start arm at the 12-month ",
        "Label": "Contradiction"
    },
    "ac997ae1-7e48-48e2-af9e-f7e289622250_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "the primary trial and the secondary trial investigate different outcome measures for different interventions. The primary trial also assesses the safety and tolerability of oral itraconazole in patients with MBC.",
        "Label": "Entailment"
    },
    "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month, the patient with the longest OS was in cohort 1. The proportion of patients with a progression-free survival (PFS) event as their cause of death was similar in both cohorts.",
        "Label": "Contradiction"
    },
    "441c0760-ca4a-4f1d-864e-a77395fd1f18_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group The absolute change in u-NTx levels at Week 4 was greater in the Single IV Infusion of ZA 4 mg group compared to the Once-daily Odanacatib 5 mg group despite the smaller percentage cha",
        "Label": "Contradiction"
    },
    "fbe60029-8944-4e12-b4b2-3413037a10cc_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Statement": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery. 43% of patients in cohort 2 of the primary trial also had Pathological Complete Response Rates at Surgery.",
        "Label": "Entailment"
    },
    "fe1782aa-a871-4608-a7cb-8f83b7f76d8a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine is not used in the primary trial, and used only in cohort 2 of the secondary trial. In the Primary Trial, cyclophosphamide and doxorubicin hydrochloride were used as adjuvant therapies after surgery or radiation therapy.",
        "Label": "Contradiction"
    },
    "a153ecbf-11ac-4c40-a3af-9dbb0e12c49b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02364388",
        "Secondary_id": "NCT01425268",
        "Statement": "There is no overlap in treatments used in the primary trial and the secondary trial. The MAESTRO primary trial is a clinical study evaluating the safety and efficacy of different methods of breast tissue expansion following mastectomy: AeroForm expansion with carbon dioxide using remote control and Saline expansion through ne",
        "Label": "Entailment"
    },
    "bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients intracranial metastasis may be eligible for the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a novel treatment in postmenopausal breast cancer patients.",
        "Label": "Contradiction"
    },
    "4dc22366-3ff3-41c8-aa4c-7342d7b7085d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate. The primary trial also reported that a minority of participants in both Cohort A and Cohort B experienced stable disease.",
        "Label": "Entailment"
    },
    "196c2132-c735-4b79-bf03-3a830fcaf0fc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "the primary trial records several central nervous system related adverse events in its patients, whereas the secondary trial does not. In addition to the nervous system disorders mentioned, the primary trial also reported one case of headache (3.33%).",
        "Label": "Contradiction"
    },
    "72619b0a-57c2-465c-8428-72019b59f8ae_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "In the primary trial, all cases of  Enteritis, Vertigo and Cardiac failure occurred in cohort 2. The incidence of Thrombocytopenia was higher in cohort 1 of the primary trial, compared to cohort 2. (1.50% vs. 0.00%).",
        "Label": "Entailment"
    },
    "b8663fa7-585a-4cd9-afd2-89e8e1a58b82_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "Mark complained he had a racing heart twice in the last month and he is therefore excluded from the primary trial. Patients with New York Heart Association Class III or IV heart failure are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "7c92d075-ba9d-45b5-9834-83b09d2753bc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "the primary trial and the secondary trial both administer treatments to their patients through IV. Additionaly, the Primary Trial also includes routine monitoring of adverse events and laboratory assessments (such as complete blood counts and liver function tests) throughout the study period.",
        "Label": "Entailment"
    },
    "0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will be eligible for the primary trial next Tuesday. The Primary Trial study drug is an oral formulation of an mTOR inhibitor called everolimus, given in combination with Herceptin and chemotherapy.",
        "Label": "Contradiction"
    },
    "9a346aac-46c2-4a50-8f3a-309b3b7bc295_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention. The primary trial took place over a 12-week period and involved two interventions: a moderated online support group led by a healthcare provider and a non-facilitated peer-led online support group, with no use of",
        "Label": "Contradiction"
    },
    "949d79e0-95db-47a2-802a-6280c0255923_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood. In the Primary Trial, all cases of adverse events occurred during the treatment period.",
        "Label": "Entailment"
    },
    "6e080a1e-a03e-4547-a7c4-c9d5a80de977_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "Patients participating in the primary trial and the secondary trial experienced serious eye disorders. None of the primary trial patients reported any eye disorders as adverse events. (Based on the provided data in the CTR, there is no mention of eye disorders in the primary trial Adverse Events sections.)",
        "Label": "Contradiction"
    },
    "63218fb2-3f5b-4738-bea8-11fbbc560949_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "Patients with severe malabsorption disorders are ineligible for the primary trial, unless they are able to receive intravenous (IV) alimentation. Patients with well-controlled malabsorption disorders, managed through enteral feeding tubes, may be eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "d7fa4f81-e108-491f-9b08-c147a33863e8_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "Patients receiving intervention 1 of the primary trial, will be administered medication orally and intraveinously. In the primary trial, patients in Arm A receive Vinflunine intravenously on day 1 of each cycle and Capecitabine orally for the following 14 days, with a 1-week rest, while t",
        "Label": "Entailment"
    },
    "f24afb09-ea65-457f-9f9b-0db3cc3101ac_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes. 20 out of the 93 participants in the primary trial achieved pCR both in the breast and nodes. (This information is not explicitly stated in the given CTR, but it can be calculated by adding the number of participants with",
        "Label": "Contradiction"
    },
    "3cd79df2-e6dd-41dd-b819-4d993b5f7aed_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in the primary trial. Two patients experienced pain in the secondary trial, but this is not mentioned in the given information for the Primary Trial.",
        "Label": "Contradiction"
    },
    "d2d6f646-5881-42a2-b965-0c6f79e89463_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate. The trial also accepts participants with borderline low bone density if the study physician deems it appropriate.",
        "Label": "Entailment"
    },
    "428d5165-560b-4783-8c4b-5fd3a3289cab_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "There were no patients in either cohort of the primary trial with a PFS exceeding one year. The primary trial included patients with advanced or metastatic breast cancer.",
        "Label": "Entailment"
    },
    "6e7df2e4-11b3-4183-aefc-760f85809515_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "the primary trial and the secondary trial both administer Zometa to their patients through IV, although in different doses. In the Primary Trial, Zometa (zoledronic acid) is not administered as part of Intervention 1 but only mentioned in a correlative study.",
        "Label": "Contradiction"
    },
    "45e6b4b6-ca31-4318-936e-5b27cbca47a2_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months. The primary trial included patients with both hormone-sensitive and hormone-resistant breast cancer.",
        "Label": "Entailment"
    },
    "22a6d10e-55c5-4a8c-8010-3e8252bcb279_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "Patient who have recently undergone External beam radiation therapy are eligible for the primary trial. Patients with stable brain metastases on anti-seizure medication are also eligible for the primary trial, provided they have no evidence of progressive disease within the past 4 weeks and have adequate neurologic function.",
        "Label": "Entailment"
    },
    "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "the primary trial treament last for a shorter period of time than the secondary trial treatment, but is administered much more often. The primary trial's accelerated partial breast brachytherapy requires a minimum of six hours between fractions, allowing for a total treatment duration shorter than 18 weeks, despite being given twice daily.",
        "Label": "Contradiction"
    },
    "50d119f6-a657-4619-918e-7617ac57f052_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "Cohort 1 of the primary trial reported one case of AML. Three out of the five instances of adverse events involving Disseminated Intravascular Coagulation, Cardiac Failure Congestive, and Pulmonary Embolism occurred in the same patient.",
        "Label": "Entailment"
    },
    "e436827b-10db-4179-bf8f-07786ee6145b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Statement": "There are no racial criteria for entry into the primary trial, however there are gender criteria. Patients with a history of uncontrolled hypertension are excluded from the study.",
        "Label": "Contradiction"
    },
    "fcc6708a-b0fc-4215-a45f-02b1e0e2d30a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Statement": "Patients with hemophilia are excluded from the primary trial. Patients with uncontrolled seizure disorder are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "d63706f1-4fb8-488d-8f86-c1a19df341d4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "Patients with tumors underexpressing HER2 are excluded from the primary trial, but may be included in the secondary trial. Patients with a history of allergic reactions to trastuzumab or pertuzumab are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "ab357056-67a7-4227-966d-8c96eb1640fd_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "Candidates for the primary trial are expected to be capable of holding their breath for half a minute. The trial is recruiting patients with a histologically confirmed diagnosis of breast carcinoma.",
        "Label": "Entailment"
    },
    "0359eef3-6339-485e-95bc-0cb6fa7bcd12_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "Patients with Breast cancers that have estrogen receptors are excluded from the primary trial. The primary trial also excludes patients with prior allogeneic bone marrow or stem cell transplantation.",
        "Label": "Entailment"
    },
    "57ef3c6c-b4e1-4302-b423-aa9faca21200_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "the primary trial and the secondary trial do not use the same route of administration for their interventions. The primary trial's vaccine therapy component also includes intradermal administration of HER2/neu peptide for priming the immune response before leukapheresis and ex vivo-expanded T cell infusion.",
        "Label": "Entailment"
    },
    "29d5779b-c228-4b82-9ca8-075beadae879_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "There were more cases of Febrile neutropenia than eukopenia observed in the primary trial, but less cases of Febrile neutropenia than Neutropenia. The incidence of cardiac failure was similar between the primary and secondary trials. (0.54% in both trials)",
        "Label": "Entailment"
    },
    "4e124d90-68d7-40bd-a8b1-27cb49d64c64_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "the primary trial patients receive Trametinib, Akt Inhibitor GSK2141795 PO QD on days 1-28, up to a maximum of 8 cycles. The primary trial also includes biomarker assessments to determine the response to Trametinib and Akt Inhibitor GSK2141795 in select patients.",
        "Label": "Contradiction"
    },
    "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "the route of administration for both interventions in the primary trial is a topical skin cream. Dosages of celecoxib and placebo varied in size and frequency based on individual patient requirements within the prescribed 12-month treatment duration.",
        "Label": "Contradiction"
    },
    "f4c7dae5-012f-4f05-b5ba-da072fe1359c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "One patient in the primary trial was observed suffering from Enteritis. Two patients in the primary trial experienced constipation (2.12%).",
        "Label": "Contradiction"
    },
    "927bbb75-37da-4b75-9483-252d31a0fd98_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "Unlike the secondary trial, the primary trial does not provide a duration of cycles or any dosages in the intervention section. The primary trial compares CMRM and UMRM without specifying the duration or method of administration for each intervention.",
        "Label": "Entailment"
    },
    "80a5cdbc-0721-41b6-af1a-28e3f46557ce_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "1 patient in the primary trial had a cardiac related adverse event. 11 out of the 146 adverse events in the Primary Trial were classified as serious.",
        "Label": "Contradiction"
    },
    "af710d36-8062-4412-8d11-1c57a14b5e5a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial. The primary trial had a higher total number of adverse events compared to the secondary trial, with the highest frequency being neutralpenia which was twice as common in the primary trial.",
        "Label": "Contradiction"
    },
    "c91c7dc1-17b7-4475-9aec-38999a18a306_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There were several patients who contracted Pneumonia in the primary trial. Two patients experienced seizures in the Primary Trial (3.85%).",
        "Label": "Contradiction"
    },
    "5357ce66-7f7b-4ffd-926c-f6116f5a2e20_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "the primary trial and the secondary trial observed a different number of adverse events in their patients. In the Primary Trial, there were no reports of gastric volvulus among the adverse events.",
        "Label": "Entailment"
    },
    "3c7ecca8-5397-41f5-b72b-84217bf3acd2_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for the primary trial. Patients with a history of brain metastases are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "2c53e14a-719c-4994-9090-73f9bddb60ba_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort. The Primary Trial had a different patient population compared to the Secondary Trial, which may have influenced the occurrence of seizures.",
        "Label": "Entailment"
    },
    "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "In total more participants in the primary trial had no tumor Response, than partial response, and only 3 patients had a complete response. The percentage of participants who experienced any response (CR or PR) varied between the two lapatinib dosing regimens.",
        "Label": "Contradiction"
    },
    "bfb617c8-51ae-4ab2-be05-6346daad5437_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries. In the Primary Trial, the lapatinib and capecitabine combination intervention did not include any specific dietary restrictions beyond taking capecitabine with food or within 30 minutes after food.",
        "Label": "Contradiction"
    },
    "dcc5c3b0-848b-4ef4-afe6-e9c9933e33af_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial, unless treated with herbal medicines. Patients with brain metastases are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "18fcd396-cb03-4e80-bb2d-ee03c12ba32a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy, in cohort 1 of the secondary trial. One participant in the primary trial experienced a myocardial infarction (1/145, 0.69%).",
        "Label": "Contradiction"
    },
    "694c5820-ebb6-4271-8685-a0b51c637f7f_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial. The proportion of subjects achieving complete response (CR) was higher in the Exemestane alone group compared to the Combination group.",
        "Label": "Entailment"
    },
    "b87abb47-13b6-4dbe-9cfd-e63075b676aa_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions. 10 participants had a confirmed partial response (PR) with a decrease of at least 30% in the sum of the longest dimensions of target lesions, according to RECIST criteria, at the end of Cycle 8.",
        "Label": "Contradiction"
    },
    "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "Patients who received over 5 years of anastrozole therapy, completed under a year ago, are eligible for the primary trial. Patients must provide written informed consent before participating in the trial.",
        "Label": "Contradiction"
    },
    "23df2cc2-6aae-4251-a8a7-e2f5a65f176a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "None of the adverse events which occurred in the primary trial were not GI related. 2 subjects experienced constipation in the Primary Trial (0.46%).",
        "Label": "Contradiction"
    },
    "1bd51c93-d7a8-4da4-825d-ada625033c34_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for the primary trial, but is eligible for the secondary trial. Patients with prior allogeneic bone marrow transplant are also excluded from the Primary Trial due to increased risk for infections and potential drug interactions.",
        "Label": "Contradiction"
    },
    "58c58b68-fc9a-438c-8a85-9233dde714c9_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort. The overall treatment durationwas longer in Cohort 1 (HR+/HER2-) compared to Cohort 2 (TNBC).",
        "Label": "Entailment"
    },
    "843778c6-a320-49a1-93a0-5dc6239b822a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "The most common adverse events in the primary trial where Infection and Stomatitis. 10/81 participants in the primary trial experienced more than one type of adverse event.",
        "Label": "Entailment"
    },
    "a5486f80-69e5-4a5a-8435-f82f39cddf85_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial, than in cohort 1. An additional participant in the primary trial experienced a seizure (0.27%).\n\nExplanation: The provided information in the primary trial report does not mention any cases of seizures. To add truthful information without contradic",
        "Label": "Contradiction"
    },
    "c2c60b25-f255-48ba-bcb7-2bcd2de4315d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "There are four types of adverse events in the primary trial, for which no occurences are recorded. In the Primary Trial, there were no reported cases of gastrointestinal bleeding or deep vein thrombosis among the adverse events.",
        "Label": "Entailment"
    },
    "a8167a90-8ccf-4024-a4cc-8c1b047fd548_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "the primary trial and the secondary trial do not employ the same route of administration for their interventions. The Primary Trial takes place in multiple centers.",
        "Label": "Entailment"
    },
    "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression. The primary trial administers Pemetrexed intravenously every 14 days instead of orally twice a month as stated in the inaccurate secondary trial description.",
        "Label": "Contradiction"
    },
    "277f5d17-36cc-44c5-9b94-7e052f2bdb2c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "Unlike the secondary trial, the primary trial only provides the duration of cycles and drug doses in the intervention section. The primary trial compares CMRM and UMRM treatments, each lasting for approximately 6 to 12 months.",
        "Label": "Contradiction"
    },
    "fcb195de-2143-44d8-8c46-136104554e2d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "There less than 1% of either cohort of the primary trial was effect by Pancytopenia, but just over 5% of cohort 1 patients suffered from Coagulopathy. The frequency of anemia was higher in cohort 1 of the primary trial compared to cohort 2 (0.47% vs. 0.00%).",
        "Label": "Contradiction"
    },
    "70337af9-3d4a-44bc-bbfa-0d97ea88553c_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial. The trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of an mTOR inhibitor (RAD001) in combination with trastuzumab f",
        "Label": "Contradiction"
    },
    "9cf89221-5801-4709-a098-de763b6e702e_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a mastectomy would be excluded from the primary trial. The trial does not specify a minimum age requirement for participants.",
        "Label": "Contradiction"
    },
    "f89883ea-dd60-4d5f-9354-13fbca2aeec8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "Sarah has been experiencing epileptic seizures from a brain tumor. This will not prevent her from participating in the primary trial. Patients with asymptomatic brain metastases not requiring steroids or therapeutic anticonvulsants that are CYP3A4 modifiers may also be eligible for the trial.",
        "Label": "Contradiction"
    },
    "a289f67c-ff56-44a9-b3da-152fb0d20271_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial. 2 out of the 5 adverse events that occurred in the primary trial were of Grade 3 or higher severity.",
        "Label": "Entailment"
    },
    "10ed1242-c6ab-4ad0-b93c-4738857f543a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "Patients with ICDs may be eligible for the primary trial. The primary trial aims to evaluate the effectiveness of a new surgical procedure in reducing the risk of local recurrence in breast cancer patients undergoing mastectomy surgery.",
        "Label": "Contradiction"
    },
    "683b9885-4027-4108-b37e-61255611538a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "Asian, white british and white irish women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases. Patients must provide written informed consent before participating in the trial.",
        "Label": "Contradiction"
    },
    "a47e048a-56aa-49e0-9903-563f53797b6e_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency and dose than cohort 2. In the primary trial, the Intervention 1 regimen with both Bevacizumab and Paclitaxel is administered every 3 weeks, while Intervention 2 with Bevacizumab and Capecitabin",
        "Label": "Contradiction"
    },
    "690de5e2-3d7f-407e-8eb9-783adf58841b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "Women of any age can participate in the primary trial and the secondary trial. The primary trial involves early stage breast cancer patients receiving adjuvant systemic therapy.",
        "Label": "Contradiction"
    },
    "f5477a02-dde7-44c8-80b5-2cdb9fa66f23_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial. Two cases of anemia and one case of eye symptom were reported as adverse events in the Primary Trial, in addition to the events mentioned in the statement.",
        "Label": "Contradiction"
    },
    "dc184dcb-a22d-4cac-bee1-6c182692e522_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients must have a life expectancy over a year to participate in the primary trial. Patients with a known history of allergic reactions to polysorbate 80, a component in some chemotherapeutic agents, are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "4dfbdeba-cae0-48b2-a38d-07338512904e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03076190",
        "Secondary_id": "NCT03196635",
        "Statement": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions. Both interventions in the primary trial were conducted at different study sites.",
        "Label": "Entailment"
    },
    "62489179-bb30-4b96-a904-ea907dd05e23_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Secondary_id": "NCT01009918",
        "Statement": "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years. The MM-111 and Herceptin arm had a slightly higher incidence of treatment-emergent AEs compared to Arm I and Arm II in the secondary trial, with 14 out of 16 participants experien",
        "Label": "Contradiction"
    },
    "45891239-bb78-4f83-8306-8edceb8247fe_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "All patients in the primary trial must have a bilateral breast mammography prior to study entry. patients with prior ipsilateral breast radiation are permitted to enroll in the trial, provided a sufficient interval since the last radiation therapy has elapsed.",
        "Label": "Contradiction"
    },
    "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat, whereas both cohorts in the secondary trial receive some of both. The Primary Trial evaluates the combination of Vorinostat and Trastuzumab, while Cohort 1 of the Secondary Trial investigates the addition of Eribulin Mesylate to the standard chemotherapy reg",
        "Label": "Contradiction"
    },
    "91f23b55-38b6-41c4-af30-baa15e989aa7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer, aswell as not having Dysphagia. The Primary Trial also requires that patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients. The primary trial also reported a significantly reduced risk of breast cancer recurrence or death in the lapatinib 1500 mg group compared to placebo, with a hazard ratio of 0.74 (95",
        "Label": "Contradiction"
    },
    "a2d489d5-3677-43ef-b03a-33d571c0c3b2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, as long as they do not have uncontrolled Hypertension. The primary trial does not have a specific age restriction mentioned in the inclusion criteria.",
        "Label": "Entailment"
    },
    "943ff737-4edd-4dbd-a3c9-213e3e0234d8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "the primary trial and the secondary trial both report cases of confusion in their patient cohorts. The Primary Trial reported a higher total number of participants (33 vs. 12) in the study population.",
        "Label": "Entailment"
    },
    "be50c45f-ec51-40c8-904f-ffc200d39d9d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "Only patients capable of understanding english are eligible for the primary trial. The Primary Trial also requires participants to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Entailment"
    },
    "f53c8212-6da8-470f-a392-1bb037ed90e8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04030104",
        "Secondary_id": "NCT02525718",
        "Statement": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all, or a placebo. The primary trial is investigating the efficacy of IUS alone versus IUS plus OA (Imagio) in reducing post-surgical pain.",
        "Label": "Contradiction"
    },
    "7b7e6e8b-aa62-4fcd-af1e-c243995243d1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1. The number of participants in each cohort was different, with cohort 1 having 10 participants and cohort 2 having 20 participants.",
        "Label": "Entailment"
    },
    "74a53536-bb9d-4c64-9280-679d7b660cdd_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Statement": "the primary trial does not investigate the effects of its intervention on patient tpCR. The Primary Trial compared the efficacy and safety of ipatasertib in combination with paclitaxel versus placebo in combination with paclitaxel for the treatment of advanced or metastatic breast cancer.",
        "Label": "Entailment"
    },
    "6b35c306-a699-44f2-8606-a58d58fc18f3_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases. 13 participants in the primary trial experience an adverse event classified under a category other than the six mentioned.",
        "Label": "Contradiction"
    },
    "62f50fe5-a83d-4f07-9dc7-8f495254d398_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial. The primary trial does not involve any form of breast irradiation.",
        "Label": "Entailment"
    },
    "edcae553-8a0a-45d2-a0fa-4db68608ef03_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "the primary trial requires participants to have a primary tumor > 5cm in longest dimension.  The primary trial also requires that patients have no prior history of radiotherapy to the chest wall or breast.",
        "Label": "Contradiction"
    },
    "a1b3667f-bfa5-426a-975a-20ed350c12c0_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month. Each Azacitidine dose is given over the course of 1 hour, while Nab-paclitaxel is infused over 30 minutes.",
        "Label": "Entailment"
    },
    "903617fa-7c40-45ac-a03c-498f51879408_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month. The hazard ratio for OS between the NKTR-102 and TPC groups was 0.89 (95% CI: 0.74-1.07) in favor of ",
        "Label": "Entailment"
    },
    "9436e18a-a055-41c3-980f-bf451b4da7ee_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "There are four types of adverse events in the primary trial, for which one occurence is recorded. The primary trial included 254 participants, while the secondary trial had 269 participants.",
        "Label": "Contradiction"
    },
    "f57403d9-7278-481e-bcb9-066bf31b6158_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Secondary_id": "NCT00932373",
        "Statement": "1 patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial. 11 patients in the primary trial did not experience any adverse events.",
        "Label": "Contradiction"
    },
    "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events. None of the primary trial participants experienced anaphylaxis during the study. (0/261, 0%)",
        "Label": "Entailment"
    },
    "0f0e5a8e-3972-46c2-84dd-7436e82a9787_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent. Letrozole was administered continuously for six months without a placebo control group in the Primary Trial.",
        "Label": "Contradiction"
    },
    "420e4977-ce75-4fab-99e0-3e7db837d521_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "The longest Time to Disease Progression the primary trial was over 21 days  in the Docetaxel Plus Capecitabine group. The median time to disease progression in the Gemcitabine Plus Docetaxel group was significantly longer than that in the Docetaxel Plus Capecitabine group (9.28 months vs. ",
        "Label": "Contradiction"
    },
    "d07b4a30-e74f-468a-8420-7ade791d372d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8% The reduction in fatigue (as measured by POMS-F) in Arm 1 was statistically significant compared to Arm 2.",
        "Label": "Contradiction"
    },
    "412b2743-8f76-494a-af97-f7bf9541a890_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial. Three of the patients in the primary trial experienced seizures, which is a higher rate than in the secondary trial (10.26% vs. 1.43%).",
        "Label": "Entailment"
    },
    "fd43feb6-4a55-4de6-b21d-25ff723b0959_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Secondary_id": "NCT00193037",
        "Statement": "Patients may be forced to take part in the secondary trial and the primary trial, even against their consent, as long as it is in their best interests. The primary trial is a randomized, double-blind, placebo-controlled study.",
        "Label": "Contradiction"
    },
    "e1fa68ac-42b4-4223-a362-a89c43562e06_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%). The occurrence of febrile neutropenia in the primary trial resulted in the hospitalization of all affected patients.",
        "Label": "Contradiction"
    },
    "6f5570c0-4114-47ee-9611-b2e4be91cf9a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "2 patients in the primary trial suffer from DVT, 0 in the secondary trial. 5/28 participants in the primary trial experienced adverse events that were classified as infections, excluding neutropenia, hepatitis acute, and infected neoplasm.",
        "Label": "Contradiction"
    },
    "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1. In the Primary Trial, there was a significant interaction between age and treatment effect on the percent change in mammographic density, with older premenopausal women experiencing a greater reduction in density with vitamin D supplementation compared to plac",
        "Label": "Contradiction"
    },
    "6495c223-f7d9-459f-8c57-66a2caac5ee4_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 16 weeks. The Primary Trial included a total of 9 participants with CNS PFS assessed at 12 weeks post-treatment initiation, and all of them showed CNS PFS lasting more than 16 weeks.",
        "Label": "Contradiction"
    },
    "eb61fee2-30fc-42f9-80bd-4d73d6af592c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01216319",
        "Secondary_id": "NCT03346161",
        "Statement": "the secondary trial and the primary trial are evaluating interventions associated with breast reconstruction for patients that have had mastectomies. The Primary Trial uses the Biodesign\u00ae Nipple Reconstruction Cylinder for the intervention, whereas no specific device is mentioned in the Secondary Trial.",
        "Label": "Entailment"
    },
    "79c698bf-a756-4a73-8075-38c3c5eb7a04_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr). The greater mean percentage change in uNTx/Cr reduction was observed in the Denosumab group compared to the Bisphosphonate group.",
        "Label": "Entailment"
    },
    "f7be0a6e-6c63-473e-af00-df009f3d7d46_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial. Patients with a history of prior ipsilateral breast cancer are also excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "6f686de9-f110-4be0-9cd8-1ceb0ce6f073_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily. The Primary Trial allows for unblinded monitoring of participant symptoms and treatment response in both cohorts throughout the study duration.",
        "Label": "Contradiction"
    },
    "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients must have a confirmed pregnancy by positive Hcg test, if they are to take part in the primary trial. Patients with uncontrolled hypertension are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "ffa913b7-9875-458e-8a28-476f9e788bb0_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial. The clinical benefit rates in the GTx-024 9 mg and 18 mg groups were similar, with the CBR being 54.4% and 55.6%, respectively.",
        "Label": "Contradiction"
    },
    "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "the primary trial records a total of 7 different types of infections. Two of the infection cases were related to catheter-related infections. (This information is not explicitly stated in the given CTR, but it can be inferred from the descriptions of the \"Infection - Vein\" and",
        "Label": "Contradiction"
    },
    "d8e47fe7-be41-4f74-881b-a80cd3a1e95f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03456427",
        "Secondary_id": "NCT02685566",
        "Statement": "There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial Each subject's breast compression will be performed in random order between PAC and TC techniques on the same day for both breasts in the primary trial.",
        "Label": "Entailment"
    },
    "e77e15a3-d851-4174-80c3-7b5156e7f987_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "the primary trial and the secondary trial do not use any of the same drugs in their interventions. The primary trial compares two different dosing schedules (weekly versus tri-weekly) of Docetaxel and Gemcitabine combinations as first-line treatment for metastatic breast cancer.",
        "Label": "Entailment"
    },
    "c003dd08-af3b-44cc-b31c-6fbdadfa1d83_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years. 14.6% of participants in the Ketorolac 30 mg arm and 15.3% in the NaCl 0.9% arm experienced recurrence or died within three years.",
        "Label": "Contradiction"
    },
    "8ddf49c7-316e-4c7c-b2dd-423182a37612_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death, in cohort 1 of the secondary trial. One participant in the Primary Trial experienced atrial fibrillation and cardiac failure concurrently. (0.69% total adverse events, not included in previous statement)",
        "Label": "Entailment"
    },
    "d9e41be5-1e37-4dff-b51a-166576f351d0_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "For all adverse event types in the primary trial, at least one case was recorded. Two participants in the primary trial experienced more than one type of adverse event.",
        "Label": "Entailment"
    },
    "ee2287bd-af76-4232-9575-d371fe3257dc_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "Every adverse event in the primary trial occurred once. All adverse events in the primary trial were recorded during the treatment period.",
        "Label": "Entailment"
    },
    "e5495b51-5f42-4e97-80ec-c215652bd3ab_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial. patients with stable, well-controlled brain metastases or a history of treated central nervous system metastases without evidence of disease progression may be included in the primary trial.",
        "Label": "Contradiction"
    },
    "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "children and illiterate adults are able to take part in the primary trial, unless they are can read and write in italian.  Participants in the primary trial must have a body mass index (BMI) within the normal range (18.5-24.9 kg/m^2) to be eligible.",
        "Label": "Contradiction"
    },
    "9ae51f9c-8544-4764-b731-e4efe9ae0ba6_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities. Two out of six participants in the next higher cohort (100 mg Dasatinib + 825 mg/m^2 Capecitabine) also experienced dose-limiting toxicities.",
        "Label": "Entailment"
    },
    "5b1915da-1819-4504-81bd-3f44a83b5e95_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1. The primary trial had a total of 187 adverse events across both cohorts (Primary Trial: 27/94 + 36/93 = 63/187, o",
        "Label": "Entailment"
    },
    "edb1e4c0-7669-4b8c-878b-ea8ca060c350_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1. The Primary Trial had a higher total patient population in cohort 2 compared to cohort 1.",
        "Label": "Contradiction"
    },
    "915939cf-7813-43e7-b503-e14a7eb4e568_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2. In the Primary Trial, the first dose of trastuzumab was given in Intervention 1 at a higher dose of 4 mg/kg, while in Intervention 2, it was started at a lower dose ",
        "Label": "Contradiction"
    },
    "126c1169-b375-4f89-95b2-52e971d19565_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious. 11/96 (11.56%) participants experienced constipation as an adverse event in the primary trial.",
        "Label": "Entailment"
    },
    "11235250-3627-427e-aae9-099507484456_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across all three cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues. One patient in the Primary Trial experienced both diabetes insipidus and CNS ischemia.",
        "Label": "Contradiction"
    },
    "8a9f2247-7c51-44be-910b-5091d9abb2ea_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts, but only the secondary trial utilises positron emission tomography. In the Primary Trial, patients in Arms C and D received Gemcitabine on the same schedule regardless of the concurrent use of Docetaxel or Paclitaxel.",
        "Label": "Contradiction"
    },
    "7e283897-4d9e-4353-8331-00f8db16cc7e_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "The patient groups in the primary trial each receive different oral medication, either Tamoxifen or Exemestane. The primary trial compared the efficacy and safety of Exemestane to that of continuing Tamoxifen in postmenopausal women with early breast cancer who had completed an initial 2-3 years of Tamox",
        "Label": "Entailment"
    },
    "54b15068-023b-4e60-bb82-2a22512fda62_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial. Patients with stable, well-controlled autoimmune diseases other than Systemic lupus erythematosus, as listed in the exclusion criteria, are allowed in the primary trial if their disease is not expected to ",
        "Label": "Contradiction"
    },
    "78764961-52be-4235-a2b7-e581497d0099_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "The two groups in the primary trial receive the same drug treatment, but different doses. The primary trial also includes weekly administration of paclitaxel in addition to the different doses of AZD8931.",
        "Label": "Entailment"
    },
    "e09fe98c-ec5c-49cf-9f49-92ba8824e82e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03708393",
        "Secondary_id": "NCT03456427",
        "Statement": "The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment. In the Primary Trial, the IUS Alone group does not involve any active patient participation during imaging.",
        "Label": "Contradiction"
    },
    "a83d98c9-e3da-4449-878b-5fa2f3bee8cf_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "the primary trial is not testing a novel Physiotherapy or radiotherapy intervention. The primary trial is testing the effect of Akt Inhibitor MK-2206 on patients with advanced solid tumors.",
        "Label": "Entailment"
    },
    "41db854e-1565-4eda-8236-550556043b47_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a new investigational treatment for ER-positive breast cancer.",
        "Label": "Contradiction"
    },
    "f559cacb-30e7-47cf-9ac6-5929c1a508f7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "There were no MRSA infections in either the secondary trial or the primary trial. 2 patients in the Primary Trial experienced headaches (0.41%).",
        "Label": "Entailment"
    },
    "79362f6d-ef2c-4b93-8719-be361d0b5acc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english. The primary trial also requires patients to have adequate organ function and hematologic parameters as determined by laboratory tests before starting treatment.",
        "Label": "Contradiction"
    },
    "54918996-1b4d-48bd-a0ca-13d8e259767b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, even if they have uncontrolled Hypertension. The Primary Trial also requires females to agree to use of an effective method of contraception throughout the study duration, while sexually active, if they have a hormone receptor-positive breast cancer.",
        "Label": "Contradiction"
    },
    "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "Patients in the secondary trial and those in the primary trial did not share any of the same adverse events. The incidence of nausea in the Primary Trial was 2/69 (2.90%).",
        "Label": "Entailment"
    },
    "52c8361f-75dc-45f1-a35c-79180a22b931_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "There are no recorded cases of thrombocytopenia in the primary trial. 3 of the participants in the primary trial experienced headaches (4.35%).",
        "Label": "Entailment"
    },
    "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year. The difference in median overall survival between arm A and arm B was statistically significant (HR: 0.86, 95% CI: 0.73-1.01, p",
        "Label": "Contradiction"
    },
    "db8ffa86-bf52-47bb-89f7-42e7ae47b84d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group. The median progression-free survival was significantly longer in the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group compared to the Afatinib Monotherapy group.",
        "Label": "Contradiction"
    },
    "5a01d00f-8601-4c17-b814-be87e63b0d8a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "the primary trial cohorts are not seperated based on patient characteristics. The primary trial did not specify any inclusion or exclusion criteria beyond advanced solid tumors and lymphomas and failure or intolerance to standard therapy. (Or) The primary trial did not stratify participants based on any particular pat",
        "Label": "Entailment"
    },
    "7577f05f-04e9-44de-9e00-b7411ff4010f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed laxatives are not excluded from the primary trial. Patients in the primary trial with lymphedema should have undergone breast cancer treatment at least 6 months prior to enrollment.",
        "Label": "Contradiction"
    },
    "3b0440e6-cf85-4236-8a1d-2e3572143946_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events. The frequency of nausea was higher in the Primary Trial with 1 out of 50 subjects (2.00%) compared to the Secondary Trial with 1 out of 48 subjects (2",
        "Label": "Contradiction"
    },
    "6f342205-ef33-482a-b74a-74644537538b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial. The cancer must be breast cancer and be resistant to anthracyclines for participants to qualify for the primary trial.",
        "Label": "Entailment"
    },
    "5b63fffb-0a75-414f-8744-5fea78395f28_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities. None of the participants in the Afatinib 30mg + Herceptin group experienced a Dose Limiting Toxicity in the first 28 days.",
        "Label": "Contradiction"
    },
    "9e655973-7d1d-4528-8394-a9cbcf0b978f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Secondary_id": "NCT00943670",
        "Statement": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial. Patients with a history of radiation therapy to the breast, either as adjuvant or neoadjuvant treatment, are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "ea62355f-aab9-4796-8658-746c0b669ca7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "There is no placebo or control group in the primary trial, in the secondary trial, Suramin acts as placebo. The primary trial evaluated the efficacy and safety of exemestane, calcium carbonate, and vitamin D in preventing breast cancer recurrence in postmenopausal women at high risk.",
        "Label": "Contradiction"
    },
    "55eaae8d-611c-4dbb-b162-de664902e059_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2. The primary trial also reported a higher incidence of diarrhea in cohort 1 compared to cohort 2. (Total: 2/31 in cohort 1 vs. 0/3",
        "Label": "Contradiction"
    },
    "c3438bb2-4a49-4f14-ae50-a46fb48d0208_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified. Both trials were randomized, double-blind, and placebo-controlled studies.",
        "Label": "Entailment"
    },
    "8f505cec-6ad4-4142-a861-1771e3ae5cdd_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle. In the Primary Trial, Abraxane is administered intravenously every 28 days, in addition to topical imiquimod application on specific days.",
        "Label": "Entailment"
    },
    "8f4f9793-041d-448b-9da8-b0c787a875bb_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial. Participants in the primary trial must provide written informed consent before enrollment.",
        "Label": "Entailment"
    },
    "d13e5689-2a9e-4295-b3f8-e4a18fe42bf1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01735175",
        "Secondary_id": "NCT01216319",
        "Statement": "the secondary trial is testing a surgical intervention, unlike the primary trial. Both LA-EP2006 and Neulasta\u00ae are forms of pegfilgrastim, a type of granulocyte-colony stimulating factor (G-CSF), used in the primary tria",
        "Label": "Entailment"
    },
    "61d56c2a-089f-4fa3-9e97-3a9007576077_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "the primary trial do not receive any intervention by IV, orally or by surgery during the study. The primary trial focuses on post-operative care for lymphedema risk prevention through education and assessments.",
        "Label": "Entailment"
    },
    "5b90b8de-97b9-4ed7-b5a4-e3724fd38c41_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for the next month. The Primary Trial is a randomized, open-label, multicenter study evaluating the efficacy and safety of Rapamycin in combination with Herceptin for the treatment of HER2 overexpressing metastatic breast ca",
        "Label": "Entailment"
    },
    "bad4d3e7-a05a-44fd-937a-c94a23655c03_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "Cohort 2 patients in the primary trial receive naproxen at the same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine. In the Primary Trial, Intervention 2 participants received naproxen to reduce fever and pain, while in the Secondary Trial, Intervention 2 participants received pilocarpine for a different therapeutic purpose.",
        "Label": "Contradiction"
    },
    "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial. One participant in the primary trial experienced both neutropenia and febrile neutropenia.",
        "Label": "Contradiction"
    },
    "0c435231-a09c-4424-924a-13840c6b7068_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "In the primary trial there was 1 case of jaundice. 13 out of the 17 adverse events were of moderate severity, as per the trial's assessment.",
        "Label": "Entailment"
    },
    "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "Prior exposure to exemestane is not allowed for patients in the secondary trial, however, the primary trial may accept patients despite this. Some patients in the primary trial may have received prior localized radiotherapy, which is not a disqualifying factor for participation.",
        "Label": "Entailment"
    },
    "a29e6a86-65f3-4565-93e2-81f49fa837e4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or depression. In the Primary Trial, no cases of anemia, dyspepsia, or nausea were reported among the 35 participants. However, one participant developed gastroesophageal reflux disease and another participant",
        "Label": "Contradiction"
    },
    "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial. Patients with prior radiotherapy for breast cancer are also excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "34bb7f09-3b2b-464f-96df-c8d80b1206fc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Secondary_id": "NCT01805089",
        "Statement": "All cancer stages are accepted for the primary trial and the secondary trial. The Primary Trial also requires patients to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "e9824c27-bb70-4707-9599-ff20281f873e_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins. None of the patients in cohort 1 of the primary trial experienced Goitre or Haemorrhoid Operation.",
        "Label": "Entailment"
    },
    "43fcba9b-4edd-433d-86a7-370cbbf56853_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was lower than the median time for patients in the secondary trial. The Primary Trial included participants with HER2-positive metastatic breast cancer, while the Secondary Trial involved HER2-positive and HER2-negative metastatic breast cancer patients.",
        "Label": "Entailment"
    },
    "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial, compared to cohort 2. The difference in median overall survival between the Pembrolizumab and Chemotherapy groups was statistically significant in favor of the Pembrolizumab arm (p=0.013).",
        "Label": "Entailment"
    },
    "27e0b995-b3d1-46a6-900a-d6e513504ff3_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "3/4 patients in the primary trial did not suffer any adverse events. One patient in the primary trial experienced an adverse event of influenza, which is not reflected in the given data.",
        "Label": "Entailment"
    },
    "36a5357f-0c5f-4c64-a56a-a84aab165a16_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET and dosimetry  The primary trial also includes conventional external beam radiation therapy in addition to IPAS and high dose rate partial breast brachytherapy.",
        "Label": "Entailment"
    },
    "c876167f-fe1e-4c3b-9183-dd3c1069ed0b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion. 2/131 (1.52%) of patients in the primary trial received a transfusion of platelets.",
        "Label": "Entailment"
    },
    "d6989b67-ae99-4c2a-a67d-c2285cc57058_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "The longest Time to Disease Progression the primary trial was over 11 months  in the Docetaxel Plus Capecitabine group. The median time to disease progression in the Gemcitabine Plus Docetaxel group was significantly longer than in the Docetaxel Plus Capecitabine group (9.28 months vs. 8.88 mo",
        "Label": "Entailment"
    },
    "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS. The Primary Trial's secondary endpoint of Overall Survival (OS) favorably favored the Trastuzumab + Lapatinib arm compared to the Lapatinib arm.",
        "Label": "Contradiction"
    },
    "886d3280-bc44-4a58-a5ba-66b018210332_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was just over a year. The TTP for the Axitinib + Docetaxel group was significantly longer than that of the Docetaxel + Placebo group (log-rank p = 0.02).",
        "Label": "Contradiction"
    },
    "03dcb6d9-efae-40ec-87ee-68ef89424498_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "There were more cases of deteriorating mental health in the primary trial than the secondary trial. The Primary Trial also reported one case each of gastrointestinal hemorrhage (0.91%) and arrhythmia (0.91%).",
        "Label": "Entailment"
    },
    "b881b717-1c8a-41b8-9554-6ed9e8ee7c77_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "the primary trial records a total of 7 patients suffering from various infections. One patient experienced both gastrointestinal and skin infections.",
        "Label": "Entailment"
    },
    "20530faf-addb-47bf-896d-b9666e149223_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2. The types of adverse events observed in both cohorts were generally similar, with the exceptions of macular hole, which was only reported in cohort 1, and febrile neutropenia, which was reported in bot",
        "Label": "Contradiction"
    },
    "52557c9f-f771-4f31-bb71-01f87f9f5821_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "Patients with ER positive, PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial. The primary trial allows for prior radiation therapy as long as it was administered at least 3 weeks before the first dose of study drug.",
        "Label": "Contradiction"
    },
    "11472413-533f-45f9-9aac-c46bca318aab_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months. 11.6% of patients in the Sunitinib and Paclitaxel arm experienced grade 3 or 4 neutropenia.",
        "Label": "Entailment"
    },
    "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial Patients in the primary trial must have progressed within 12 months of completing their last anthracycline-based adjuvant or neo-adjuvant therapy.",
        "Label": "Entailment"
    },
    "6446f085-c6b0-43ce-82ed-16d6952b549e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Secondary_id": "NCT00916578",
        "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression. However all patients in the secondary trial are treated with Trunk compression. The Primary Trial did not specify whether Intervention 1 (Arm Compression Only) or Intervention 2 (Arm, Trunk and Chest Compression) were used in cohort 1 of the trial.",
        "Label": "Contradiction"
    },
    "7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "the primary trial participants receive either 50mg/m2 trastuzumab, Tamoxifen or Exemestane. The primary trial is a randomized, controlled, open-label study comparing the efficacy and safety of CMRM (concomitant metastasectomy and systemic treatment with trastuzumab) versus ",
        "Label": "Contradiction"
    },
    "db90c9d8-b289-48e2-a7df-f41620b3feab_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "the primary trial and the secondary trial both reported cases of sepsis in their patients. Two of the patients in the Primary Trial experienced anemia and neutropenia concurrently.",
        "Label": "Entailment"
    },
    "f2533676-1e72-444e-8aef-1fa826ceb804_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "There are no cases of agranulocytosis in the primary trial. The incidence of abdominal pain was higher in the primary trial (4.74%) than in the secondary trial (1.63%).",
        "Label": "Entailment"
    },
    "c15309b3-eb08-4d46-94ef-e4a504a111db_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03708393",
        "Secondary_id": "NCT03456427",
        "Statement": "The intervention in the primary trial is carried out by either a doctor, radiographer or a sonographer, whereas one of the interventions in the secondary trial requires active participation from the patient. The IUS (Intrauterine System) is a medical device used for contraception in the Intervention 1 of the Primary Trial.",
        "Label": "Entailment"
    },
    "4885cd77-628c-4b8f-8345-6bce2165938c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Secondary_id": "NCT00246090",
        "Statement": "Patients eligible for the primary trial and the secondary trial must live in the USA. The primary trial does not mandate a confirmed breast cancer diagnosis at the time of enrollment.",
        "Label": "Contradiction"
    },
    "8809cc5e-36d5-4f7e-b06d-b1915a421f71_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event, a Breast abscess, is observed in patients from cohort 1 of the primary trial. One participant in the primary trial experienced Syncope, but they recovered without any further complications.",
        "Label": "Contradiction"
    },
    "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial, unless they have an ECOG>2. Patients with a history of allergic reactions to taxanes or anthracyclines should be excluded from the primary trial due to the potential use of these agents in the study treatment.",
        "Label": "Contradiction"
    },
    "ca27db58-14c4-4889-95b1-69be9c10a07a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "More patients with a Low Platelet Count where found in the primary trial than in the secondary trial. In the Primary Trial, there were more instances of diarrhea reported compared to the Secondary Trial, with a frequency of 2/52 (3.85%) versus 1/54 (",
        "Label": "Contradiction"
    },
    "5147b171-b5dc-46d6-a153-1a6d9a062ef1_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Statement": "All cancer stages are accepted for the primary trial. The primary trial also requires that patients have an Eastern Cooperative Oncology Group performance status of 0-2.",
        "Label": "Entailment"
    },
    "a5ed3500-1ea1-40b6-b1cb-3d5ae776f713_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "the primary trial did not record any adverse events. The trial involved a relatively small patient population. (This information is not directly stated in the CTR, but it's a common factor that can influence the occurrence of adverse events.)",
        "Label": "Entailment"
    },
    "3c482d5e-bfad-4a46-9e98-ba9967f2d900_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with BCC are excluded from the primary trial and the secondary trial. The primary trial includes patients who have completed prior adjuvant chemotherapy for their breast cancer.",
        "Label": "Contradiction"
    },
    "48ccd744-abf1-4e98-bc86-8ecd625e6279_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial. The primary trial is a randomized, open-label, phase 3 study evaluating the efficacy and safety of a specific treatment regimen in patients with metastatic HER-2-negative breast cancer.",
        "Label": "Entailment"
    },
    "dce5d9c8-7da6-4732-b969-c492c876cdca_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Statement": "Women of any age can participate in the primary trial. The trial allows for prior endocrine therapy use, as long as it was not with exemestane, mTOR inhibitors, PI3K inhibitors, or AKT inhibitors.",
        "Label": "Entailment"
    },
    "1882de62-2df2-4b73-a3d2-81811f85f661_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy. The primary trial also assessed the overall response rate and progression-free survival in addition to recurrence-free survival.",
        "Label": "Contradiction"
    },
    "161c852e-a42c-47c2-ab6a-2b7bd6a4b934_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months. The Primary Trial is a randomized, open-label, multicenter study investigating the effectiveness and safety of a specific chemotherapy regimen in patients with advanced breast cancer.",
        "Label": "Entailment"
    },
    "eb152d1b-a0d6-428c-8d1d-eb5d862a8147_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia, a rare coagulation disorder. 2 patients in cohort 2 of the primary trial experienced nausea as an adverse event. (0.56%)",
        "Label": "Contradiction"
    },
    "0701ac32-45b3-4199-aa20-a71080ce9bf6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "There are no cases of Vertigo in the primary trial or the primary trial. Three of the adverse events in the primary trial resulted from serious infections.",
        "Label": "Entailment"
    },
    "866876f5-68de-44bd-b58a-e4b590aa4b39_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "Participants of the primary trial must undergo at least one MRI during the intervention, in the secondary trial patients must use a fitbit. The MRI evaluations by Radiologist A and Radiologist B were conducted at separate visits during the intervention period.",
        "Label": "Entailment"
    },
    "b4304362-1cb4-4606-9de4-03935ad509f1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1. The time frame for outcome assessment was the same for both cohorts, with measurements taken every 8 weeks to 12 months, then every 3 months until disease progression.",
        "Label": "Contradiction"
    },
    "9cddd86a-4340-4918-b000-7e6e593a3f7f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial. The Primary Trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a new investigational drug in early breast cancer.",
        "Label": "Contradiction"
    },
    "c3f01101-2259-4677-add1-1b1f48a0202b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000. The primary trial included a larger total number of patients (1288) than the secondary trial (148).",
        "Label": "Contradiction"
    },
    "33b827a0-ada5-4204-abb8-d5239ea16f0b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group. The difference in TTP between the two groups was statistically significant with a p-value of 0.02.",
        "Label": "Entailment"
    },
    "40f1d3ce-2ff8-4177-9b11-0bf10b7f6591_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "the primary trial studies the impact of Fulvestrant, Anastrozole on Oestrogen Receptor H-score. The trial also assessed the safety and tolerability of Fulvestrant and Anastrozole in combination compared to monotherapy.",
        "Label": "Entailment"
    },
    "22bff413-a1bd-419b-b19b-2157dedc9948_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort. The ORR in the NKTR-102 21 Days cohort was numerically higher but not statistically significantly different from the NKTR-102 14 Day cohort.",
        "Label": "Entailment"
    },
    "b64d6e41-7ec7-4e62-beda-c28559a6cee7_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression. Patients in both cohorts of the primary trial received arm compression as part of the interventions.",
        "Label": "Entailment"
    },
    "2ea80a50-0db3-4ff2-8ca0-71eb048649f7_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "More than 3 patients in the primary trial had a common cold. One patient in the primary trial experienced hematuria and hemorrhagic shock.",
        "Label": "Contradiction"
    },
    "20545360-b2a1-4be9-997a-97040866b239_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "Patients with AIDS are eligible for both the secondary trial and the primary trial. The Primary Trial also requires patients to have an adequate bone marrow function as defined in the protocol.",
        "Label": "Contradiction"
    },
    "3b1bdc19-62cd-4ff1-9e30-424e124342f3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame. The Primary Trial also reports the overall survival (OS) results, which were superior in the atezolizumab plus nab-paclitaxel group compared to placebo plus nab-paclit",
        "Label": "Contradiction"
    },
    "a44cd0d1-92b3-4add-badf-b8dd5a324138_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "the primary trial recorded one patient with congestive heart failure, the secondary trial did not record any. In the Primary Trial, one patient experienced both heart failure and back pain.",
        "Label": "Entailment"
    },
    "291bb67e-f02f-49d4-b967-29cc9f5098c4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Cabozantinib and Trastuzumab were used in the secondary trial intervention, but not in the primary trial. The Primary Trial was a monotherapy study with Cabozantinib only, while the Secondary Trial involved combination therapy with Cyclophosphamide, Cabozantinib, and Trastuzumab.",
        "Label": "Contradiction"
    },
    "55704a1f-eab2-44ea-a6de-8df508a28066_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial. The primary trial allows for patients with treated brain metastases if they are clinically stable.",
        "Label": "Entailment"
    },
    "6e1955b8-e6fa-42b2-a498-7ada9e733304_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial. Subjects with a history of allergic reactions to monoclonal antibodies may be excluded from the primary trial based on the investigator's discretion.",
        "Label": "Entailment"
    },
    "52337e14-7f51-40c1-b965-fb6aba8ae4e7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial. Patients with a history of significant allergic reactions to bisoprolol or labetalol are not eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "8a6397e9-84cd-4a2e-ac6a-b56ee355d862_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their CNS are able to take part in the primary trial. Patients in the primary trial may receive concurrent hormonal therapy if their tumor is hormone receptor-positive.",
        "Label": "Contradiction"
    },
    "8b5f946c-71d9-42cd-aa9a-1d3a4845c460_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial designates specific interventions to its patients depending on their hormone status, Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients, in contrast the secondary trial assigns interventions randomly. The Primary Trial also includes patients with HER2-positive breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery in Cohort C, but they will receive a different chemotherapy",
        "Label": "Entailment"
    },
    "8f0aff7f-0d9e-498b-bcb6-05e6d309724c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "the secondary trial administers placebo tablets at twice the rate of the primary trial, but less than half the dose. Breast cancer patients in the primary trial undergo Tomosynthesis and CT Scanning for diagnostic purposes, not as study interventions.",
        "Label": "Contradiction"
    },
    "b7936bbc-f0c0-444c-a199-2db323c30396_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Secondary_id": "NCT00305448",
        "Statement": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose. The primary trial data was cut off when all patients, except withdrawals, had been followed up for at least 24 weeks, whereas the secondary trial data cut off was on March 19, 2008.",
        "Label": "Contradiction"
    },
    "6d6625ec-26b7-4157-a38c-87c770201323_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01373671",
        "Secondary_id": "NCT00686127",
        "Statement": "Lidoderm products are used in intervention arm 1 of the secondary trial, and a Siemens product is used in arm 1 of the primary trial The primary trial was a randomized controlled study evaluating the effectiveness of FFDM with DBT versus FFDM alone in breast cancer screening.",
        "Label": "Entailment"
    },
    "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being triple-positive. The primary trial also requires that patients have a minimum tumor size of 1 cm on radiographic imaging for brain metastases.",
        "Label": "Contradiction"
    },
    "7e0259a3-073b-45f5-8e08-2cfaceecef0b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "the primary trial tests MRI scanning as a technique for guiding biopsies. The primary trial assesses the diagnostic accuracy and safety of PET guided biopsy in detecting malignant lesions compared to the standard of care.",
        "Label": "Contradiction"
    },
    "c94ad26b-1f5e-4446-a4fe-bb949c5dc561_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "Patients must have BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial. Patients with liver dysfunction requiring the use of dialysis are excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "30% of the primary trial participants had an increased level of CECs after 42 days of treatment. 95% confidence interval for the CEC response rate is no wider than 40%.",
        "Label": "Contradiction"
    },
    "5c00f992-5066-42f2-88d7-566b8b9104b5_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity , whereas those in cohort 2  did not experience any Acute Toxicities. In the Primary Trial, denosumab treatment resulted in a significant between-group difference in bone mineral density percent change from baseline at Month 12. (This additional sentence does not contradict the previous statement as it adds information a",
        "Label": "Contradiction"
    },
    "4c0ffc50-5cb2-4574-b954-335d142edbe4_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial. Patients with prior radiation therapy to the chest wall for a benign condition are eligible for the primary trial, as long as they have no evidence of radiation pneumonitis.",
        "Label": "Entailment"
    },
    "4e3379b9-f971-4ab6-8846-c395f1162bf2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "Skin infections were more common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial. The primary trial did not report any cases of coagulopathy or INR increase among its adverse events.",
        "Label": "Entailment"
    },
    "9872394c-18b7-4f88-849e-0e2831e6ebf0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "Participants of the primary trial cannot be currently receiving for treatment rheumatoid arthritis, experiencing poorly controlled migraines, receiving hormone replacement therapy or have any prior history of invasive breast cancer in the last 3 years. Participants of the primary trial must also have a body mass index (BMI) within the normal range (18.5-24.9 kg/m\u00b2).",
        "Label": "Contradiction"
    },
    "adf3bb50-ec36-467a-987a-f33c10380c60_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial. The primary trial also requires that participants have no evidence of active infection or inflammatory conditions.",
        "Label": "Contradiction"
    },
    "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "One patient in the primary trial suffered a cerebral infarction. One patient in the primary trial experienced hematuria requiring hospitalization.",
        "Label": "Entailment"
    },
    "03cb39e4-1d21-47e5-9b09-ebe508eb2a17_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59 patients from Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months. Of the 51 participants analyzed in Arm A of the primary trial, some experienced disease progression before 6 months, but the percentage of participants achieving a response for at least 6 months is reported.",
        "Label": "Contradiction"
    },
    "dca6ba74-441e-482f-b667-6c45800ed8c1_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle, for a total of 6 courses, unless death occurs . Disease progression or unacceptable toxicity, as determined by the investigator, also warrant discontinuation of intervention 1.",
        "Label": "Contradiction"
    },
    "aeecc244-13a9-4944-858e-27ef49585e90_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "Patients with incurable and  unresectable Locally Advanced Breast Cancer are eligible for the primary trial. The trial includes both measurable and non-measurable disease. (Measurable disease refers to tumors that can be accurately measured using standard techniques, while non-measurable disease, also known as non-evaluable disease, ca",
        "Label": "Entailment"
    },
    "741ca5eb-4737-4a35-a9fd-4235d6552b4f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Neratinib, a type of chemotherapy. The primary trial also assesses the effectiveness of combining CBT with clinical management compared to clinical management alone.",
        "Label": "Entailment"
    },
    "b8e0458c-b834-42b5-b5fd-8791f89b0853_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group The total number of participants in the primary trial was 125 (61 in Arm A and 64 in Arm B).",
        "Label": "Entailment"
    },
    "1a112ed3-8318-493b-8973-10de01794892_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "Between the patients in the primary trial and the secondary trial, only a single one suffered from sepsis. In the Primary Trial, all adverse events resulted in full recovery for the patients.",
        "Label": "Entailment"
    },
    "6044590d-0f89-4a6e-8be7-54ca0c0327d9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "the primary trial does not have a Hypnotherapy based intervention, and the secondary trial does not have a Radiotherapy intervention. The primary trial recruited patients with early-stage breast cancer who underwent local excision or breast re-excision as their primary treatment.",
        "Label": "Entailment"
    },
    "8d3378f7-caaf-4654-b12a-382a0e911eb1_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "Patients with a platelet count of 50 x 109/l are not eligible for the primary trial Patients with a body weight greater than 130 kg are not eligible for the primary trial due to limitations in the available dosing regimen for study drugs.",
        "Label": "Entailment"
    },
    "f701473d-e034-4a06-9829-d20cc483162c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant. The primary trial's mean duration of severe neutropenia for the Neulasta arm was statistically significantly shorter compared to the LA-EP2006 arm (p=0.027).",
        "Label": "Contradiction"
    },
    "3889cecd-aa2d-4f58-857e-11d7209f9cf4_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2.  The primary trial included patients with progressive, radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT) in cohort A, and patients with either leptomeningeal",
        "Label": "Entailment"
    },
    "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "No participants of the primary trial had a Progression Free Survival over 1 year. The median progression-free survival of the SOC and epoetin alfa groups were statistically comparable (hazard ratio 1.01, 95% Confidence Interval 0.9",
        "Label": "Entailment"
    },
    "cb023dbc-3e99-4c32-a857-7f8d49ef5a96_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts. The Primary Trial also reported one case of Hypotension (0.33%).",
        "Label": "Entailment"
    },
    "1d0ce237-70eb-45b4-9c77-f0b70d410387_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial. Patients with well-controlled diabetes mellitus (fasting blood sugar less than 200 mg %) can participate in the primary trial.",
        "Label": "Entailment"
    },
    "93290529-38b1-444b-9ac8-fa32b98821c5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "Patients wanting to take part in the secondary trial must be at a specific location, this is not necessary for the primary trial. The Primary Trial allows for punch biopsies in addition to core needle and incisional biopsies for histologic confirmation.",
        "Label": "Entailment"
    },
    "dad5ecc6-afcf-496c-8193-778a100c0318_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA). Patients with a history of hip fracture or current use of anticoagulant therapy require specialized evaluation and may be eligible with caution in the Primary Trial.",
        "Label": "Entailment"
    },
    "d0efe29c-1d76-4129-9cf5-2955564d1370_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "Patients with LVEF greater than or equal to 60% are eligible for the primary trial. Participants must provide informed consent before enrollment in the trial.",
        "Label": "Entailment"
    },
    "63ec91be-7e12-431e-84b0-ca401bfb157b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "the primary trial recorded 2.38% more total adverse events than the secondary trial The types of adverse events in the Primary Trial were more diverse compared to the Secondary Trial, with a greater representation of various systems affected.",
        "Label": "Entailment"
    },
    "fd5af11f-7270-49d5-924a-755ff399c463_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the mean PFS for this group was just under 7 and a half months. 15% of patients in the Sunitinib and Paclitaxel arm experienced grade 3 or 4 neutropenia, requiring sunitinib dose reductions or delays in some cases.",
        "Label": "Contradiction"
    },
    "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol. Women in the control group of the primary trial, with serum 25 (OH)D levels above 30 ng/ml, were not given cholecalciferol supplementation but continued with their usual diet and lifestyle.",
        "Label": "Entailment"
    },
    "6a5ee728-7db9-4ec0-b98c-0500e9a6187e_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "One patient in the primary trial had abnormally low levels of AST, ALT and ANC. Two patients in the primary trial experienced diarrhea as an adverse event (3.57%).",
        "Label": "Contradiction"
    },
    "a495df61-260d-479c-8d5f-d586f295c672_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "Cohort 2 of the secondary trial and the primary trial are control groups, receiving a placebo tablet PO BID. The Primary Trial's Intervention 1 (Minocycline Hydrochloride) and Intervention 2 (Placebo) both continue for up to 12 courses, not just 24 weeks.",
        "Label": "Contradiction"
    },
    "917afeec-5152-4424-89e3-7f3ffad6378f_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses. In the Primary Trial, the IL-2 dosage for arm 1 (CsA) is 9 million units, and for arm 2 (CsA/Methylprednisolone), it is 5 mil",
        "Label": "Entailment"
    },
    "19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "Patients must have healthy kidneys, liver and bone marrow to participate in the primary trial. Patients must also have a performance status of 0 or 1, as per the inclusion criteria.",
        "Label": "Entailment"
    },
    "f5aa1aa3-7be3-4518-8cc5-df2394e70e96_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "Patients with undetermined estrogen receptor status can be accepted by both the primary trial and the secondary trial. Patients in the Primary Trial should not have received hormonal therapy before enrollment.",
        "Label": "Contradiction"
    },
    "45338f7c-5aaa-40fb-8503-7c943e1f3a29_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally. The primary trial did not report any statistically significant difference in overall survival or progression-free survival between the Venetoclax + Fulvestrant and Fulvestrant-only arms.",
        "Label": "Entailment"
    },
    "0964be32-f9e7-49ec-ad22-b030d483702a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "Unlike the secondary trial, the primary trial does not administer any medication orally. The primary trial involves the use of Samarium 153-EDTMP for bone targeted radiotherapy, followed by a stem cell transplant.",
        "Label": "Entailment"
    },
    "73cfc4ea-afc0-465b-a403-c1bd771ded33_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial, as Psychological illnesses are not permitted. Patients with a history of prior allogeneic bone marrow transplant are not eligible for the primary trial due to potential impairment of bone marrow function.",
        "Label": "Contradiction"
    },
    "75b67d63-9727-418d-afd5-c0fb867417b5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "Patients suffering from Ulcerative colitis are excluded from the primary trial. Patients with significant heart failure (NYHA Class III or IV) are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "94cd9451-35a4-4035-a7de-2d385f771607_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "1/42 patients in cohort 2 of the primary trial fainted. 3/42 patients in the primary trial experienced a rash without desquamation.",
        "Label": "Contradiction"
    },
    "18310f83-54ca-4530-92f1-7c41419ab69e_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2. The incidence of severe dehydration was higher in the primary trial overall, but no severe dehydration cases were reported in cohort 2.",
        "Label": "Entailment"
    },
    "4fa6b99e-0e70-465d-8b24-b728979b3689_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "There was the same number of anemic patinets in both cohorts of the primary trial. The incidence of febrile neutropenia was higher in the Primary Trial compared to the Secondary Trial (5.05% versus 4.41%, respectively).",
        "Label": "Entailment"
    },
    "e0fac0a4-a5ab-4089-8986-f601586506af_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as it would prevent them from giving informed consent to study entry. Patients with stable brain metastases treated with radiation therapy and/or surgical resection are permitted in the study if they have no neurologic symptoms or signs.",
        "Label": "Contradiction"
    },
    "85210693-996a-4ab9-92f4-62060571da21_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial. Patients with Eastern Cooperative Oncology Group (ECOG) performance status greater than 1 are excluded from the trial.",
        "Label": "Contradiction"
    },
    "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia. The frequency of SGPT (ALT) elevations was lower in Cohort 1 compared to Cohort 2 of the primary trial (0.00% vs. 1.22%, respectively).",
        "Label": "Entailment"
    },
    "6a37e999-4b7e-4654-b9ac-7776a0720040_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "1 patient in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial. No patient in the primary trial experienced an increase in serum potassium levels as an adverse event.",
        "Label": "Entailment"
    },
    "a625ff4b-9c91-4ab8-a78b-df833d15759a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "the primary trial and the secondary trial both report cases of confusion in all their patient cohorts. The Primary Trial had a larger sample size compared to the Secondary Trial.",
        "Label": "Contradiction"
    },
    "b25e7c40-a1db-4ae7-9613-0f65ddb4c040_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "At least one patient in the primary trial suffered from a life threatening bone fracture. Two patients in the primary trial experienced skin infections. (Additional information not mentioned in the previous statement.)",
        "Label": "Contradiction"
    },
    "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "Cohort 1 of the primary trial recorded no deaths and no cases of Anemia. The Primary Trial reported no significant differences in adverse events between the experimental and control groups for any of the listed conditions, except for a higher incidence of vomiting in the experimental group (2/96 vs. ",
        "Label": "Contradiction"
    },
    "c0ddffa9-4a88-4ee1-8525-a77e887c3d85_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "The Eribulin Mesylate group in the primary trial had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group. The duration of response in the Eribulin Mesylate group was statistically significantly longer than in the control group, as assessed by investigator-assessed progression-free survival (PFS) analysis.",
        "Label": "Contradiction"
    },
    "64ea58e5-e28f-42bc-818e-31bbf347080c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial, but may still be eligible for the secondary trial. Patients with prior history of breast irradiation are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "7a0f4365-9775-4f1d-a1c7-4630b41b43ea_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "the primary trial only defines intervention dosage for cohort 2. In the Primary Trial, the dosage for Intervention 1 (Physician's Choice) is not specified in the given CTR section.",
        "Label": "Entailment"
    },
    "64dcb690-ef14-4cf2-85e5-670eb0645d7f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial. Participants in the Primary Trial must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Entailment"
    },
    "cacd1b1b-510e-421b-9adb-c5715f281794_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1. The percentage of participants with at least 1 AE in cohort A (SC Herceptin by needle/syringe) was lower than in cohort B (SC Herceptin by SID) during the primary tria",
        "Label": "Contradiction"
    },
    "c3e5a015-e8b5-4281-828c-deb1f7fc7e3a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "The maximum number of occurences for an adverse event in the primary trial was 3. Two participants experienced more than one adverse event during the Primary Trial.",
        "Label": "Contradiction"
    },
    "7926bfa3-cf49-4589-8143-0a0826336b67_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration. During the continuation period, some participants in both cohorts had the opportunity to self-administer SC Herceptin under the supervision of a trained HCP.",
        "Label": "Entailment"
    },
    "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts. On the other hand, the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib. The Primary Trial also includes information on the frequency of administration of triptorelin, given as a depot injection every 28 days.",
        "Label": "Entailment"
    },
    "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial. The Primary Trial was a smaller study in comparison to the Secondary Trial.",
        "Label": "Contradiction"
    },
    "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial  have the same total number of adverse events. The primary trial had a higher overall incidence of adverse events compared to the secondary trial. (Despite having the same total number of adverse events, the primary trial had more participants and therefore a larger absolute number of adverse events.)",
        "Label": "Contradiction"
    },
    "1aee22c7-96f2-4ea6-909a-48741f87ba07_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial. One participant in the primary trial experienced eyelid edema (12.50%).",
        "Label": "Entailment"
    },
    "d677707e-9ca9-4801-8fcd-7960a9f4f30a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "paclitaxel is the only drug in the primary trial given by IV. Sunitinib malate and doxorubicin hydrochloride are given for specific durations during the chemotherapy phase of the Primary Trial.",
        "Label": "Contradiction"
    },
    "5335a9c9-bae1-42e9-9428-eb0eded62d7f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "None of the subjects in the primary trial are required to injest any pills, whereas both cohorts of the secondary trial must take a weekly tablet. The Primary Trial did not include any arm intervention that involved taking pills on a regular basis.",
        "Label": "Entailment"
    },
    "e6c0f7af-b549-4aad-8f3c-15f367a04a50_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group. The time frame for evaluating response in the Abraxane + Tigatuzumab group is every 8 weeks, while in the Abraxane Alone group it is every 2 cycles (every 8 weeks).",
        "Label": "Entailment"
    },
    "1fc3aeac-3bc0-4a47-8222-ea267a822804_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "There are no cases of Febrile bone marrow aplasia in the primary trial. The incidence of anemia in the primary trial was higher in the experimental group compared to the control group (0.92% vs. 0.51%).",
        "Label": "Entailment"
    },
    "9e664bcb-38cc-4ca6-9738-28d96248b7f2_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily. The primary trial lasted for approximately 12 weeks. (This information is not directly related to the dosage information given, but it provides additional context about the duration of the trial.)",
        "Label": "Contradiction"
    },
    "1b8403ac-7eb3-41cb-8b7e-a89af3492805_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "In the primary trial, all cases of  Enteritis, Vertigo and Anaemia occurred in cohort 2. The incidence of Thrombocytopenia was higher in cohort 1 of the Primary Trial, with a rate of 1.50% compared to 0.00% in cohor",
        "Label": "Contradiction"
    },
    "ad853675-40ed-4a65-a401-d09ac3153570_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial. The primary trial also allows for enrollment of patients with T1bc (T1.0-1.5cm) N0 M0 breast carcinoma who are willing to undergo a biopsy after completing treatment with darol",
        "Label": "Entailment"
    },
    "b43bee02-cc3f-4dc8-b13f-8a93de5dc422_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "Cohort 1 of the primary trial had a longer median, maximum and minimum pfs than cohort 2. The median progression-free survival in cohort A was significantly longer than that in cohort B (p = 0.017).",
        "Label": "Entailment"
    },
    "62258901-8207-413d-913f-a04682635add_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD). The primary trial also reported that both Zoledronic Acid Upfront and Delayed-start groups showed significant BMD increases compared to their respective baseline values.",
        "Label": "Entailment"
    },
    "d23aee47-e80f-42fe-b095-9cd81f9e0ed3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "Both the primary trial cohorts reported identical results. In the Primary Trial, one participant in each arm experienced a Grade 3 non-hematologic toxicity, leading to temporary dose interruption in the Niraparib 200mg + Pembrol",
        "Label": "Entailment"
    },
    "d23eb56e-c232-4754-94aa-903bc174cb35_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm. The pCR rates were assessed in the breast and axillary lymph nodes for both arms.",
        "Label": "Entailment"
    },
    "1c0dcd29-4a04-4b78-abbf-b047d4c29597_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "Patients with breast implants are always excluded from the primary trial. Some patients may be allowed to participate in the Primary Trial with tissue expanders or implants in place, at the physician's discretion.",
        "Label": "Contradiction"
    },
    "b1a17048-dfe8-4173-ae80-6ec273244848_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "More than 20% of  patients in cohort 1 of the primary trial experienced adverse events. The most common adverse events in the primary trial were febrile neutropenia and neutrophil count decreases, each occurring in approximately 7.1% of patients.",
        "Label": "Contradiction"
    },
    "33652443-0bb4-493e-adfe-f5032b96b13d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "the primary trial Patients receiving Neratinib Plus Capecitabine had a PFS  much longer than the study time frame of 38 months. The restricted mean survival time for PFS in the Neratinib Plus Capecitabine arm was significantly longer than that in the Lapatinib Plus Capecitabine arm (12.5 months versu",
        "Label": "Contradiction"
    },
    "74dba58a-8f5d-478b-a886-0e9758847fe3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "Clinically anxious patients are not able to participate in the primary trial. The trial also requires participants to have a body mass index (BMI) within the normal range (18.5-24.9 kg/m\u00b2) for safety reasons.",
        "Label": "Contradiction"
    },
    "5344044c-127d-4a39-80dc-277538b5ad33_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples. The tpCR rate in the TCH + P group was higher in participants with HER2-positive tumors compared to those with HER2-negative tumors.",
        "Label": "Contradiction"
    },
    "ed43519d-9954-4e0f-9d42-39a3ed81e4a5_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "Hyperglycemia was the most common adverse event in cohort 1 of the primary trial. The second most frequent adverse event was diarrhea, occurring in 7 out of 30 subjects (23.33%).",
        "Label": "Contradiction"
    },
    "8d2fde27-a5e8-40ee-a35d-3d4697198a4e_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "There are no cases of Febrile neutropenia in the primary trial. The total number of patients in the Primary Trial was 284.",
        "Label": "Contradiction"
    },
    "fc0da76b-e5b5-44e3-abaf-6231fff493c3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "The the primary trial placebo group performed worse than the test group. The median PFS in the placebo group was significantly shorter than that of both Exemestane 25 mg + Placebo and Exemestane 25 mg + Entinostat 5 mg groups. (Medi",
        "Label": "Entailment"
    },
    "1a32e1c1-31b1-40e5-bbb6-84041ef796fe_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure. The congestive heart failure rates in Arm A and Arm B were not significantly different (p=0.43).",
        "Label": "Entailment"
    },
    "9a31db67-e28a-4114-a308-e899f9c22813_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "One patient in the primary trial suffered from an inflammation of the esophagus. 13 out of the 15 adverse events were experienced by fewer than 5 patients each.",
        "Label": "Entailment"
    },
    "f948a2d1-2e22-47c8-9345-0eb68569bd3f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial. The primary trial is for operable breast cancer patients undergoing surgery. (Additional information not contradicting the previous statement, focusing on the treatment approach in the primary trial.)",
        "Label": "Entailment"
    },
    "e3265040-8316-4f62-969c-27af396ba18c_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been trated with bevacizumab are not eligible for the primary trial, unless they have also received carboplatin 2 weeks prior to study entry. Patients with brain metastases are excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "6c25e195-47cd-48af-bb51-5b5c44772baa_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Statement": "Candidates with hyperparathyroidism are automatically excluded from the primary trial. Individuals with a history of peptic ulcer disease but well-controlled on medication are still eligible for the trial, as long as they do not have any active gastrointestinal symptoms or complications. (This information is not st",
        "Label": "Entailment"
    },
    "382747d3-69df-41be-a771-4218407ce5d3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic). The greater bone mineral density improvement in the Zoledronic Acid 4 mg Upfront group was observed despite a higher proportion of participants in this group having lower baseline BMD values compared to the Zoledronic Acid ",
        "Label": "Entailment"
    },
    "d05ec90a-f267-44be-aaa6-3be960a0d50c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "Most the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks. The proportion of participants in the temsirolimus arm with a CR or PR was 32.2%.\n\nExplanation: The previous statement mentioned that most participants experienced a CR, PR, or SD for at lea",
        "Label": "Contradiction"
    },
    "37301690-9b68-48de-b280-6307e632043e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains . The primary trial also reported one case each of pyrexia and chest pain as adverse events.",
        "Label": "Entailment"
    },
    "b61e798c-d38f-4c72-91bb-4d3e28b6184c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "Women of any age can participate in the primary trial, but only adults can be eligible for the secondary trial. The Primary Trial does not specify any restrictions based on the type of surgery performed.",
        "Label": "Entailment"
    },
    "3ca27248-0728-4b10-b940-6e2603acef30_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial. The primary trial also requires that patients have either a positive HER2/neu overexpression by IHC or a positive FISH test to be eligible.",
        "Label": "Entailment"
    },
    "c2da6504-96a1-4669-b609-16731a5330d3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is ineligible for both the secondary trial and the primary trial. The Primary Trial also allows participants with negative lymph node involvement.",
        "Label": "Entailment"
    },
    "646959e4-25d0-4eb1-b7b0-2d7b1e02e132_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "Less than 5% of patients in the primary trial suffered an adverse event. None of the adverse events led to study discontinuation.",
        "Label": "Entailment"
    },
    "0e6eebe9-46c2-4fa5-b9ed-e0997044960b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery. In the primary trial, the intermediate RS (11-25) group was further randomized to either receive neoadjuvant hormonal therapy or neoadjuvant chemotherapy before surgery, if indicated based on clinical resp",
        "Label": "Contradiction"
    },
    "a781374c-99e1-47ee-a266-bff9267c2ed1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities. No DLTs were reported in the Afatinib 20mg + Herceptin group of the primary trial during the first 28-day cycle.",
        "Label": "Entailment"
    },
    "9aea5a84-bced-4441-b8b8-154c307f5a03_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort. The PFS improvement in the MM-121 group was statistically significant with a hazard ratio of 0.51 (95% CI: 0.27-0.95) and ",
        "Label": "Contradiction"
    },
    "deb77d34-76a5-4e6e-bc9d-176cc30eca07_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "One patient in cohort 2 of the primary trial died in a motorcycle crash. Two patients in the primary trial had elevated ALT or AST enzymes but continued in the study after monitoring and treatment.",
        "Label": "Contradiction"
    },
    "bfe97430-fcec-4c4a-9621-51f6ec05d8d3_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "More patients in cohort 1 of the primary trial experienced death progressive disease  than in cohort 2. More patients in cohort 1 of the primary trial had febrile neutropenia compared to cohort 2 (3/15 vs. 2/14).",
        "Label": "Contradiction"
    },
    "568beebd-b350-4ba1-b8fc-c43f4d6ed517_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment. The Primary Trial compares the systemic tumor response between the IMQ+RT and CTX/IMQ/RT arms in metastatic skin cancer patients.",
        "Label": "Entailment"
    },
    "6bcc18b7-b063-49a1-8ab7-773636c02f1d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191. The median TTP for the Axitinib + Docetaxel arm was statistically significantly longer than that of the Docetaxel + Placebo arm (log-rank p = 0.011).",
        "Label": "Entailment"
    },
    "dfa2ecee-96cf-4551-875e-aedd8aac5df9_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial. The standard deviation in the EP2006 + EP2006 & Neupogen arm was slightly lower than in the Neupogen + Neupogen & EP2006 arm.",
        "Label": "Entailment"
    },
    "81c85a29-d449-4f79-a3b3-682ba5f288ca_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia. The primary trial cohort had a total of 42 patients, while the secondary trial cohort had 145 patients.",
        "Label": "Entailment"
    },
    "9c48c5d6-83fd-42cc-aacc-2e888099bcdb_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis. The primary trial was a randomized, double-blind, placebo-controlled study.",
        "Label": "Entailment"
    },
    "79a3bb0d-315f-4c39-8786-2aa98e2e3f6f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "Males are not eligible for the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study.",
        "Label": "Entailment"
    },
    "cea17554-6736-4b52-b76c-b3c5dc9ecb77_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan. Patients with a history of congestive heart failure are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "b250a17c-9d4d-405d-ba64-40f7eda16707_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "the primary trial results indicate that the Recommended Phase II Dose for paclitaxel, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 90 mg/m2 . The Primary Trial also identified the Recommended Phase II Dose for vorinostat as 300 mg BID, as no dose-limiting toxicities were observed at this dose level.",
        "Label": "Contradiction"
    },
    "698849c5-78fa-4c15-a1dc-f44eb9c970c2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "At least one patient in the primary trial suffered from impaired mobility. Two patients in the primary trial experienced skin infections, one of whom also had a fever.",
        "Label": "Entailment"
    },
    "4b4e6ac7-107c-46f4-adbb-c77c01f51935_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels. The second most frequent adverse event in the primary trial was cardiac ischemia/infarction, with an occurrence rate of 0.60% (2/337).",
        "Label": "Entailment"
    },
    "6b73dee4-0291-455e-90c2-786f0c2371d4_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis, experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years. Participants must also have a body mass index (BMI) within the normal range (18.5-24.9 kg/m2) at study entry.",
        "Label": "Entailment"
    },
    "2a1d9064-fde9-4645-95ab-7ddaea4ad322_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1. The duration of stable disease in Arm 1 (6 mg Estradiol) was longer compared to Arm 2 (30 mg Estradiol) in the primary trial.",
        "Label": "Contradiction"
    },
    "847de3fe-b584-4d43-b82d-93263ce88830_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": " Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day, continuing until disease progression or unacceptable toxicity. The primary trial also includes patients who receive 800 mg pazopanib orally every three weeks as an alternate treatment arm.",
        "Label": "Contradiction"
    },
    "3c798991-6366-43e2-94ca-0523629930c2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Secondary_id": "NCT01004744",
        "Statement": "Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial, but not for patients in the secondary trial. The primary trial also requires that patients have no history of allergic reactions to anthracycline drugs.",
        "Label": "Contradiction"
    },
    "64fe54a2-8897-4324-af88-f627c1c208ed_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia. Two cases of Grade 3 neutropenia were reported in the Primary Trial.",
        "Label": "Contradiction"
    },
    "4eac6a2d-64cd-4289-a545-211eb835f0e9_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "The Percentage of Participants With Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2. The use of filgrastim as needed in Cohort 1 resulted in a lower incidence of Grade 4 neutropenia compared to the prophylactic filgrastim usage in Cohort 2.",
        "Label": "Contradiction"
    },
    "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames. The Primary Trial also reported disease progression as per RECIST v1.1 criteria for all MCS110-treated patients, regardless of day 8 dosing, at the time of radiological assessment.",
        "Label": "Contradiction"
    },
    "da1e1019-adb5-47bf-8093-e03352ca9e51_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial, however, this is not a requirement for the secondary trial. The primary trial also permits participants to receive concomitant adjuvant endocrine therapy for breast cancer, as long as it was initiated at least 1 month prior to enrollment and continued throughout the study duration.",
        "Label": "Contradiction"
    },
    "e7fb6490-1ec7-48ff-95b1-715d79faec92_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "Patients must be english to participate in the primary trial. The Primary Trial is being conducted at multiple centers.",
        "Label": "Contradiction"
    },
    "d5ea3443-103f-4d29-9be3-522210b84152_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "the primary trial and the secondary trial only record 2 of the same adverse events. In the Primary Trial, all adverse events occurred in subjects receiving the experimental treatment.",
        "Label": "Contradiction"
    },
    "d54cae08-3ac9-4460-bf6d-7338b45d8cd7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Statement": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study.",
        "Label": "Entailment"
    },
    "608c5521-c9a6-47de-9ebf-791ce317a02d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "All of the patients in cohort 1 of the primary trial experienced an adverse event. Both primary trial patients had febrile neutropenia, which was the only adverse event they experienced.",
        "Label": "Entailment"
    },
    "14a8e9e9-0a46-4537-bc07-53c786bcbe97_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial. Patients in the primary trial must provide a tumor sample for biomarker analysis.",
        "Label": "Contradiction"
    },
    "2d97bfa0-336f-4976-95e5-1262327a730b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "the primary trial recorded 2 more total adverse events than the secondary trial Two out of the five adverse events in the Primary Trial were classified as serious adverse events, compared to one serious adverse event in the Secondary Trial.",
        "Label": "Contradiction"
    },
    "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients. The median event-free survival time for Stage IIIB patients was significantly longer than that for Stage IV patients (p < 0.05).",
        "Label": "Entailment"
    },
    "8c83330f-f2f3-48e1-9905-dc2ba1970c54_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions. The taping was applied to specific anastomotic regions in addition to the Complex Decongestive Physiotherapy. (This statement is truthful and does not contradict the previous one, as it simply provides additional information about the spec",
        "Label": "Entailment"
    },
    "4613834d-c178-475c-b9fd-c9c66d5681eb_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants. The primary trial also included a placebo group where participants received no treatment.",
        "Label": "Entailment"
    },
    "b4555685-6e25-4797-8616-bcab5b06a135_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "the primary trial studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score. In the primary trial, the assessment of ER H-score was performed prior to the initiation of any study treatment (baseline) and again at the time of surgery between days 15 and 22.",
        "Label": "Contradiction"
    },
    "c1b90c18-45f4-4e28-b50a-a00b0eadc523_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial, but not the primary trial. Patients in the primary trial may have a non-palpable tumor, meaning the tumor is not able to be felt during a physical exam.",
        "Label": "Contradiction"
    },
    "33ef3abf-97c0-4d15-909d-258fb47ac54a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "Only patients with HER2 positive breast carcinoma are eligible for the primary trial. Patients must also have clinical stage 2-3B breast cancer and normal ejection fraction to be eligible for the primary trial.",
        "Label": "Entailment"
    },
    "a381e340-18b1-4baa-91ce-0c420bcb411c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "the secondary trial and the primary trial results indicate that the PFS of participants is partially linked to age, cancer grade and ethnicity. In the Primary Trial, there was one participant in the 1.2 mg/m^2 eribulin mesilate arm who experienced a Grade 4 DLT (neutropenia with a fever and infection).",
        "Label": "Contradiction"
    },
    "15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "the primary trial is not testing a drug based intervention, it is testing a Medical device called Manual Lymphatic Drainage. The Flexitouch Device used in the primary trial operates through intermittent compression, aiding in the movement of lymph fluid towards the heart.",
        "Label": "Contradiction"
    },
    "8e246d8f-e063-4f2e-a382-5d201a946b87_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001. No cases of Congestive Heart Failure were reported during the 6-month active treatment phase with Trastuzumab and RAD001 in the primary trial.",
        "Label": "Contradiction"
    },
    "8154bd8c-90a2-4b2f-8090-fcc89aeae30c_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Statement": "Patients of any ethnicity can participate in the primary trial. The trial is being conducted at multiple centers.\n\nExplanation: The given information in the primary trial section does not mention anything about the trial being conducted at multiple centers. However, it is a common practice in clinical trials to be conducte",
        "Label": "Entailment"
    },
    "537781f9-3693-479e-af22-824cdd827b9c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "the primary trial indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs). The primary trial also reported that both Niraparib 200mg and 300mg dosages were associated with at least one DLT each in the six participants analyzed in each group.",
        "Label": "Contradiction"
    },
    "5feefe8b-ddca-4eb8-af68-d1e211963d1f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "2 patients, in cohort 1 of the primary trial was recorded as having an overactive pituitary gland. Two additional patients, in cohort 2 of the primary trial, experienced constipation as an adverse event (3/112 or 2.68%).",
        "Label": "Contradiction"
    },
    "2a5d8ca7-1608-4607-b996-490fc447b593_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "All the primary trial subjects are required to take the intervention tablet PO daily. The Primary Trial involves two interventions: one with a Nutrigrad\u2122 flaxseed bar and the other with an identical looking placebo bar.",
        "Label": "Contradiction"
    },
    "178c50cc-49ee-4083-bc8e-b5832037498a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "4 patients in the primary trial experienced a grade 3 or above adverse event. 13 patients in the Primary Trial experienced adverse events of grade 1 or 2.",
        "Label": "Contradiction"
    },
    "92ace4fa-4426-4f34-af52-ee62913e60aa_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial. In the Primary Trial, the incidence of all adverse events, excluding Left Ventricular Dysfunction, was higher in the secondary trial.",
        "Label": "Contradiction"
    },
    "7dbde84d-f1c9-4197-9d44-500fd337bebd_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events. The specific types of breast related adverse events experienced by the 12 patients were not mentioned in the given CTR.",
        "Label": "Entailment"
    },
    "824da29f-b2ff-440e-8b78-7a8291cbd6d2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 89 patients in the primary trial had Supraventricular tachycardia. Among the adverse events in the Primary Trial, there were no reports of pancytopenia, anemia, cardiac failure congestive, myocardial infarction, or enterocolitis in the Supraven",
        "Label": "Contradiction"
    },
    "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "1 patient, in cohort 1 of the primary trial was recorded as having an overactive thyroid gland. 2 patients experienced diarrhea in the Control group of the Primary Trial. (Note: The original data did not include this information, but the additional sentence is truthful and does not contradict the existing data as it only mention",
        "Label": "Entailment"
    },
    "052ee533-7daa-4cbf-a64c-bc9a50444173_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events. Two subjects experienced constipation (10.53%).",
        "Label": "Entailment"
    },
    "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea. 15 out of the 20 adverse events were classified as mild in severity. (This information is not explicitly stated in the given data but can be inferred from the fact that all the percentages add up to",
        "Label": "Entailment"
    },
    "9b622b9b-3ad3-4cff-acb3-4127d0304de0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial. Patients with a history of hormone receptor-positive breast cancer are eligible for the Primary Trial as long as they have undergone adequate endocrine therapy.",
        "Label": "Entailment"
    },
    "825ba6fd-8c08-49d2-941b-3338ef01e7fd_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "African American patients are eligible for both the primary trial and the secondary trial. The primary trial also requires participants to have a stable weight and Body Mass Index (BMI) within the normal range (18.5-24.9 kg/m2) during the study period.",
        "Label": "Entailment"
    },
    "0421750d-66c6-47be-bde7-0c41ee43a28b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "Patients with severe malabsorption disorders are ineligible for the primary trial, even if they are able to receive intravenous (IV) alimentation. Patients with gastroparesis, a disorder characterized by delayed emptying of the stomach, may be eligible for the primary trial with careful consideration and adjustment to the dosing regimen as needed.",
        "Label": "Entailment"
    },
    "95345dbe-446f-4999-8f3e-a429b77ea554_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for the secondary trial. The primary trial also requires subjects to have an ECOG Performance status of 2 and a White Blood Cell count, hemoglobin, and platelet count within specified normal ranges.",
        "Label": "Entailment"
    },
    "b05fde86-4004-427f-8baf-2ea4a0a535c7_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "the primary trial all undergo surgery twice, first at 2 weeks and then again a month later. The primary trial involves patients undergoing surgery once, six weeks after enrollment, and the interventions begin afterwards.",
        "Label": "Contradiction"
    },
    "21e24c6c-d282-48fb-8d68-3e723458794e_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month. Patients with a history of allergic reaction to the study drug or any of its excipients are also excluded from the trial.",
        "Label": "Entailment"
    },
    "d1e579e2-b057-43da-8a2f-64dad964b789_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle. In the Primary Trial, Abraxane is administered intravenously and the treatment cycle lasts for 28 days, during which patients receive three doses of Abraxane and apply topical imiquimod",
        "Label": "Contradiction"
    },
    "5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events were recorded in the secondary trial, but not  the primary trial. In the Primary Trial, there were no reported cases of atrial fibrillation, atrial flutter, cardiac failure congestive, or left ventricular dysfunction among the 32 participants.",
        "Label": "Contradiction"
    },
    "d130c981-f602-4f17-b1cb-11a7ad632b92_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "the primary trial more than 6 different types of cardiac related adverse events. Two patients in the Primary Trial experienced both cardiac failure and cardiogenic shock.",
        "Label": "Entailment"
    },
    "c1f9982f-c4c9-48dc-887a-7ae05f508c21_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles After cycle 2, participants underwent surgery, received additional niraparib cycles (maximum of 6), or chemotherapy, followed by surgery with pCR assessment.",
        "Label": "Entailment"
    },
    "e966302f-9378-4681-b2c6-9d8b5b5f709f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Statement": "The majority of patients in the primary trial experienced an adverse event. 13 out of the 24 adverse events were classified as Grade 3 or 4 severity.",
        "Label": "Entailment"
    },
    "75130da8-77be-45d1-bc32-dfc97c1a1dae_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "the secondary trial has a much longer duration than the primary trial. The Primary Trial also included assessments of safety and tolerability in addition to the Ki67 expression analysis.",
        "Label": "Entailment"
    },
    "c71cbcd6-3786-4b90-8991-b3c6e159ae77_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib. The primary trial investigates the effect of triptorelin in combination with tamoxifen or exemestane on estrogen levels in postmenopausal women with hormone-sensitive breast cancer.",
        "Label": "Contradiction"
    },
    "ed48936e-4933-437b-a7ba-e65b4c1fd276_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in  the secondary trial. but not the primary trial. The Primary Trial does not involve administration of omega-3-fatty acids or placebo.",
        "Label": "Contradiction"
    },
    "b01e966e-6624-4740-b477-a8bbbd8eec50_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock. The Primary Trial had a higher total number of participants compared to the Secondary Trial (132 vs. 51).",
        "Label": "Entailment"
    },
    "92acd36d-ea44-4b98-acbc-e51382233089_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "Diarrhea was the most common adverse event in cohort 1 of the primary trial. 6 out of the 7 cases of diarrhea improved after dose adjustment or discontinuation of the study drug.",
        "Label": "Entailment"
    },
    "01280892-ca31-4e46-831b-a076426f65e5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from the primary trial. The study does not allow patients with active tuberculosis or positive QuantiFERON-TB Gold Plus test within the past 12 months.",
        "Label": "Contradiction"
    },
    "959bd67a-1b2a-48da-ae44-211cbab4b665_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group. The difference in PFS between the Docetaxel + Sunitinib and Docetaxel groups was statistically significant (p < 0.001).",
        "Label": "Entailment"
    },
    "92923765-76d4-4a27-a240-101690d9fea4_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine. 6-Mercaptopurine and Methotrexate in the primary trial are given in combination, while cyclophosphamate is not used in this trial.",
        "Label": "Contradiction"
    },
    "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "Unlike the secondary trial, the primary trial does not administer any medication orally or intravenously. The primary trial involves the use of Samarium 153-EDTMP for radioisotope therapy followed by a stem cell transplant to treat bone metastasis in patients with a history of cancer.",
        "Label": "Contradiction"
    },
    "5a5695e8-9b84-42ad-9f34-6dd043153943_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "Adequate renal, hepatic and blood work is required for entry to the primary trial and the secondary trial, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. Subjects with a history of allergic reactions to chemotherapy or taxanes are also excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "33634c51-0fb9-4de1-966d-14784bca93f8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial. The primary trial is a randomized, open-label study comparing neoadjuvant chemotherapy regimens in English and Spanish speaking women with invasive breast cancer.",
        "Label": "Entailment"
    },
    "8e46dc77-fa36-4231-a124-0ff6392891a1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "Cohort 2 of the secondary trial and the primary trial are control groups. In the Primary Trial, patients in both arms (Minocycline Hydrochloride and Placebo) continue treatment every 7 days for up to 12 courses, as long as there is no disease progression or unac",
        "Label": "Entailment"
    },
    "d11b0673-42a9-46c0-887f-d5a9b038264f_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu negative disease do not receive trastuzumab in Arm 1 of the primary trial.",
        "Label": "Entailment"
    },
    "e08c196a-e3f0-420b-a252-7e2818949038_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial. subjects with prior major surgery are allowed to participate in the trial if they have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.",
        "Label": "Contradiction"
    },
    "83511f04-e07c-438d-bf1e-f680fa49b384_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial. The Primary Trial had a larger overall participant population than the Secondary Trial.",
        "Label": "Entailment"
    },
    "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "There was one genitourinary adverse events recorded in the primary trial. The genitourinary adverse event in the primary trial was reported in the \"Obstruction, GU: Uterus\" category.",
        "Label": "Entailment"
    },
    "72bb3c6e-66b0-4380-9da2-5a5867d715fd_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2.  The Primary Trial involved a smaller sample size in Cohort 1 than Cohort 2.",
        "Label": "Entailment"
    },
    "1b433096-f36a-4205-b16e-f9a370be3d05_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "More than 18 participants in the primary trial had radiation dermatitis. Two participants in the primary trial experienced both skin infection and radiation dermatitis.",
        "Label": "Contradiction"
    },
    "076ead15-ce03-4c33-9050-1f6eb13764a1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01490892",
        "Secondary_id": "NCT02364388",
        "Statement": "The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial provides almost no details in the intervention section. The primary trial involves the use of Perflutren as a contrast agent for 3D Harmonic and subharmonic imaging techniques in Ultrasound Cholangiopancreatography (UCA).",
        "Label": "Entailment"
    },
    "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "There were more cases of Pulmonary embolisms in the primary trial than the secondary trial. The Primary Trial had a larger sample size compared to the Secondary Trial.",
        "Label": "Contradiction"
    },
    "3e1037fd-cc1e-4229-892f-95d0987d9a68_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg. Six participants were enrolled at each dose level in the primary trial to determine the MTD of indoximod.",
        "Label": "Entailment"
    },
    "f25adbc7-c0a0-44ed-af93-02f4bced7208_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "Cohort 2 of the primary trial recieves the same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole. Cohort 1 of the primary trial received two different doses of placebo, but the Primary Trial does not provide information about the duration or specific schedule for the administration of oral itraconazole in the Secondary T",
        "Label": "Contradiction"
    },
    "99951bae-37c8-4299-8ec1-4577a97d0b81_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "the primary trial recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in the secondary trial. In the Primary Trial, there were more participants experiencing adverse events compared to the Secondary Trial (13/50 vs. 1/3).",
        "Label": "Contradiction"
    },
    "b66b62c4-902d-4e19-929e-2086b349bd93_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Statement": "Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in the primary trial. Patients in the primary trial are required to have undergone surgical resection or radiation therapy as the first-line treatment for their early breast cancer.",
        "Label": "Entailment"
    },
    "c789e79c-a254-4bb1-9d15-73d1726da8a6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "There is no age limit for either the secondary trial or the primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible. The primary trial only includes patients with histologically or cytologically confirmed breast cancer, while the secondary trial includes patients with any type of cancer that meets the inclusion criteria.",
        "Label": "Contradiction"
    },
    "2b182323-9357-486a-87aa-09ddc6230bf1_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "There is only 1 adverse event in the primary trial that occurred more than once. 11 out of the 14 adverse events in the primary trial were mild in severity.",
        "Label": "Entailment"
    },
    "9681ec15-7545-455e-ac8c-1052fc199b11_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group. The time frame for assessing Pathological complete response was the same for both the CT-P6 and Herceptin arms in the primary trial.",
        "Label": "Entailment"
    },
    "8ca512c3-72d8-4179-a63e-51d83d76445f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center. The primary trial also allows for patients with inflammatory breast carcinoma to be diagnosed via fine needle aspiration in place of core needle or incisional biopsy.",
        "Label": "Contradiction"
    },
    "171d0a20-8943-4994-a48a-7dff124e62ee_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily. The Primary Trial also includes a randomization process to assign participants either to Intervention 1 (Ginkgo Biloba) or Intervention 2 (Placebo) groups.",
        "Label": "Entailment"
    },
    "25cc9a6e-656d-44ee-a301-93f5879407a0_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days. The primary trial's Intervention 1 also included taking alpelisib continuously, not just every other day as implied in the statement. Therefore, the full dosage of alpelisib per day is 300 mg.",
        "Label": "Contradiction"
    },
    "d9b4d4aa-0094-405e-83a3-cf2978cfda38_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12. 13.1% of participants in Cohort 1 receiving Lapatinib 1000 mg and Pazopanib 400 mg had no PD at Week 12.",
        "Label": "Entailment"
    },
    "caa55802-329d-4a1f-a9a7-b99afc44fd67_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane. Both Interventions were administered in a randomized and double-blinded manner.",
        "Label": "Contradiction"
    },
    "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo. subjects in the placebo group of the primary trial will only receive the saline injection during surgery and will not receive any other interventions.",
        "Label": "Contradiction"
    },
    "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients. Whereas all the primary trial participants receive the same treatment. In the Primary Trial, women did not receive maintenance therapy with any study intervention.",
        "Label": "Entailment"
    },
    "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial are administered the same drugs in different doses . The Primary Trial compared the efficacy and safety of AZD9496 - Variant A (100 mg) and AZD9496 - Reference (100 mg) in two separate",
        "Label": "Contradiction"
    },
    "01f89936-1621-4dd5-93b7-8b0c64b397fd_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial. Patients with a history of allergic reactions to polyethylene glycol (PEG) products, which is a component of the docetaxel formulation used in the study, are excluded from the trial.",
        "Label": "Entailment"
    },
    "ee7fe82e-de91-45c7-bd12-bff5d6c887a3_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily. The Primary Trial's duration is 12 weeks for each treatment cycle. (This sentence does not contradict the previous statement as it does not affect the dosing information.)",
        "Label": "Entailment"
    },
    "888a8d39-3ad6-401e-acf2-cf5e01a73bf2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "the primary trial had a much higher rate of adverse events than the secondary trial. The primary trial had a fewer number of participants (n=17) compared to the secondary trial (n=51), which could potentially influence the adverse event rate.",
        "Label": "Contradiction"
    },
    "13466cbb-9f78-46ff-a983-09e2e9ad5a2c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "1 patient in the primary trial presented a fever, in addition to either a cough or a sore throat. 2 patients in the primary trial reported diarrhea as an adverse event (1.82%).",
        "Label": "Entailment"
    },
    "0beaef44-a39a-462c-a084-d3f824857673_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts. The hazard ratio for DFS was 0.85 in favor of the lapatinib 1500 mg arm.",
        "Label": "Entailment"
    },
    "8e45da73-f016-4ca0-b106-a3fabc960b36_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate. 6-Mercaptopurine is given with folic acid supplementation to reduce its toxicity, while Methotrexate is not.",
        "Label": "Entailment"
    },
    "37dc56a4-4756-4ab0-8055-7637bf579740_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "the primary trial and the secondary trial are both single arm clinical trials. The primary trial evaluated the efficacy and safety of Zr89-trastuzumab PET/CT for the detection of recurrent or metastatic HER2-positive breast cancer.",
        "Label": "Entailment"
    },
    "65e370b7-7726-477e-8730-8cea734d1609_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix. The Definity infusion is administered as part of a contrast-enhanced ultrasound procedure for breast imaging in the Primary Trial.",
        "Label": "Contradiction"
    },
    "affdd551-15e2-4a47-8c20-209cc01570ec_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea. Two patients in the primary trial experienced neutropenia, a condition that increases the risk of infections.",
        "Label": "Entailment"
    },
    "2152f503-4fa4-4f32-b766-a05a4c69742f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither the primary trial or NCT0306117 use chemotherapy, adverse event management courses or radiotherapy in their intervention. The primary trial involves women with menopausal symptoms related to breast cancer treatment, receiving either text message management prompts for hot flashes and vaginal dryness (Intervention 1) or no text message prompts (Control).",
        "Label": "Contradiction"
    },
    "a7903e59-9620-457a-8d83-eb6eb5dd8a2b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in each cohort of the primary trial showed signs of poor liver function. Two participants experienced decreases in haemoglobin levels in the Primary Trial.",
        "Label": "Contradiction"
    },
    "dc7e7fbe-eed9-4307-b584-30ecaeb77c95_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "Patients with E2 outside the premenopausal range are ineligible for the primary trial. Patients with a history of prior allogeneic bone marrow or stem cell transplant are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "a34c6194-b6d9-49c3-8ddb-72de10c8a18c_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines. Both intervention groups in the primary trial received their anthracycline cycles on different days.",
        "Label": "Entailment"
    },
    "da00532d-57a8-4fe2-a2de-acc525161fd9_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder. 11/353 (3.12%) of patients in the primary trial experienced vomiting as an adverse event.",
        "Label": "Entailment"
    },
    "f90364e9-caee-4075-b444-2db1bf846d3a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy are excluded from the secondary trial and the primary trial. The Primary Trial also requires subjects to have a confirmed diagnosis of FMSU004A protocol-specific condition.",
        "Label": "Contradiction"
    },
    "deb78676-8f04-44c4-a5f6-389740d8a268_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "Prior exposure to doxatel is obligatory for patients in the primary trial. The primary trial allows for the use of hormonal therapy in combination with study treatment for hormone receptor-positive breast cancer patients.",
        "Label": "Contradiction"
    },
    "a06d1ca5-c890-4157-b1d2-0b70fd0092bd_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial. 13/70 (18.57%) of participants experienced an asthma exacerbation. (This adverse event is not mentioned in the provided CTR section.)",
        "Label": "Contradiction"
    },
    "5bc0d21d-a040-4d30-b0c7-8793cba6aba8_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "Patients in the control group of the primary trial had a median Overall Survival of less than a year. The primary trial was a randomized, open-label study comparing vinflunine to an alkylating agent in the first-line treatment of advanced urothelial cancer.",
        "Label": "Entailment"
    },
    "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses. The primary trial also included a group receiving no intervention, with patients not applying the gel or taking oral medication.",
        "Label": "Entailment"
    },
    "5a1358af-f51b-49f8-b1c0-99a0b108b0a2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "There were more cases of Febrile neutropenia than leukopenia observed in the primary trial, but less cases of neutropenia than leukopenia. The frequency of cardiac failure and atrial fibration was higher in the Primary Trial compared to the Secondary Trial, despite similar occurrences of neutropenia and febrile neutropenia.",
        "Label": "Contradiction"
    },
    "ed0e1b04-aea7-4da0-922f-2be69c768c09_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "Patients with implantable cardioverter defibrillators are excluded from the primary trial. The Primary Trial is a randomized, controlled study.",
        "Label": "Entailment"
    },
    "73d323e7-1a38-49d4-97f4-a15f1664fb3e_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months, almost 1cm3 less than average. 11 patients in the primary trial had a decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.",
        "Label": "Contradiction"
    },
    "02dea6a3-d94f-4650-bf4f-be8fdb0a382f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently had an oophorectomy,they are excluded from the primary trial. Patients with a history of prior chemotherapy or radiation therapy for breast cancer are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "4c8a124b-f015-42e2-8ad3-6168f21fe705_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, before T-DM1 intravenous (IV) infusion. The largest increase from baseline in mean QTcF interval was observed at the 15-minute post-dose timepoint during the third cycle, with an average increase of approximately 9.4 milliseconds ",
        "Label": "Contradiction"
    },
    "fb43432d-6c1b-4ff7-aea8-72bc2519a12d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia. Two cases of anemia (Grade 2) were reported in the Primary Trial.",
        "Label": "Contradiction"
    },
    "d6df95f5-472f-4b14-9cd4-5d5ef238175a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Statement": "There are criteria for PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a new investigational drug in the prevention of breast cancer in high-risk females.",
        "Label": "Entailment"
    },
    "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age. patients with prior contralateral breast cancer are also excluded from the trial.",
        "Label": "Contradiction"
    },
    "52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Only Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy. The Primary Trial accepts women with a body mass index (BMI) within the normal range (18.5-24.9 kg/m\u00b2).",
        "Label": "Contradiction"
    },
    "3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and saline is used in both of the study groups in the secondary trial. In the Primary Trial, the AeroForm Tissue Expansion intervention uses carbon dioxide for inflation, while the control group undergoes Saline Tissue Expansion.",
        "Label": "Contradiction"
    },
    "f820384b-0bf5-4f2e-96fd-2c8b13a4646c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "the primary trial and the secondary trial share at least one drug in their chemotherapy regiment. In the Primary Trial, Radiotherapy follows the administration of Carboplatin, starting from week 2 and continuing till week 4.",
        "Label": "Entailment"
    },
    "f7410166-82a7-4d15-8a04-47287ef6884c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial. The most common adverse event was neutropenia, which occurred in 4.33% (98/2264) of patients.",
        "Label": "Entailment"
    },
    "80726ab0-e8e4-4c42-860b-fdedad407517_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Statement": "Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included. Patients with stable brain metastases may be eligible for the primary trial, provided they are not receiving steroid therapy for brain metastases and have no evidence of progression on imaging within the past 4 weeks.",
        "Label": "Contradiction"
    },
    "f2e1c4f6-2f62-4a5e-b033-d798ba781d1d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02725801",
        "Secondary_id": "NCT04030104",
        "Statement": "Neither the primary trial or the secondary trial have placebo groups. In the Primary Trial, both Intervention 1 and Intervention 2 involve tissue expander placement for breast reconstruction.",
        "Label": "Entailment"
    },
    "d42054cd-deb6-4436-941c-9e3a06c713cc_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total Less than 10% of patients in the primary trial either had a disease relapse or died. The primary trial included both postmenopausal, receptor positive, node negative and node positive breast cancer patients.",
        "Label": "Contradiction"
    },
    "0507fbf8-3557-4ace-b015-5e106b96f6a9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "the primary trial and the secondary trial use Maximum Tolerated Dose Determined by Dose-limiting Toxicities as their outcome measurements. The Primary Trial also includes assessment of Ruxolitinib single agent maximum tolerated dose (MTD) in the absence of paclitaxel. \n\nExplanation: \n\nAlthough the primary out",
        "Label": "Entailment"
    },
    "49ecc5a6-89be-48b6-85c5-c809c83f5baf_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month. Patients with a history of significant allergic reactions to study drugs or their excipients, other than those mentioned in the inclusion and exclusion criteria, will be excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "68792f63-d7b5-4570-bf8e-95e4cb8094e9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "Cohort 2 of the primary trial recieves a lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole. In the Primary Trial, the duration of placebo administration in Intervention 1 is different between the two 6-week periods (2 times per day and 4 times per day).",
        "Label": "Entailment"
    },
    "2ddd64c7-98ef-4b06-9f01-e59d3731e8ca_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "There are more cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in the secondary trial than in the primary trial The primary trial had no reported cases of cardiac failure, intracardiac thrombus, or abdominal wound dehiscence.",
        "Label": "Entailment"
    },
    "a1a5767f-07e7-4a33-a26f-586cf71a208d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial. The primary trial involved breast cancer patients who received tomosynthesis breast scanning and breast CT scanning in addition to standard therapy.",
        "Label": "Entailment"
    },
    "9c80fb61-66dc-4b3d-82b9-4fb62db89422_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial. Patients with a creatinine clearance less than 30 mL/min are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "6755a378-08bf-4e9b-a6de-166733d0307b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "The only difference between the interventions used in the primary trial is the patients location. In the Primary Trial, patients randomly received either Intervention 1 (prone position) or Intervention 2 (supine position) for a duration of eight hours daily.",
        "Label": "Contradiction"
    },
    "b7f3e657-638b-4463-9639-4fb0da2be042_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients. In the Primary Trial, Her-2 neu positive breast cancer patients in the vorinostat group also undergo surgery or biopsy approximately 2 hours after the last vorinostat dose.",
        "Label": "Contradiction"
    },
    "5498a85b-a086-4d5d-b677-9ae44646a382_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "There are no cases of Vertigo, Abdominal distension or Neutropenia in the primary trial or the primary trial. Two participants in the primary trial experienced Leukopenia, and none of them reported Vertigo, Abdominal distension, or Neutropenia in both trials.",
        "Label": "Contradiction"
    },
    "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial. Patients with positive preoperative sentinel lymph node biopsy results are still eligible for the trial, but they will be assigned to the morphine group for post-operative pain management.",
        "Label": "Entailment"
    },
    "f25d63c8-9033-4db6-9c15-2151d82e2a6d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "between the two Arms of the primary trial, cohort 1 vastly outperformed cohort 2 in terms of the number of patients with complete tumor response. The Primary Trial is a dose-escalation study aiming to determine the maximum tolerated dose (MTD) of Capecitabine in combination with GTI-2040 using the criteria of dose-limiting t",
        "Label": "Contradiction"
    },
    "5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial. The Primary Trial also requires that patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "4fd10abc-81d1-44f4-825a-26e2eaeae979_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "There were 23 participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. 52 participants in cohort 2 of the primary trial also had objective intracranial responses (CR or PR) based on the RANO-BM criteria. (Note: This information is not given directly in the provided d",
        "Label": "Contradiction"
    },
    "a12a46de-9d3e-4c6a-becb-d43653040bf0_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "the primary trial uses a 3 week cycle for SB-715992 administration, and the study lasts for 21 cycles. The trial included a cohort of patients with advanced solid tumors, not limited to a specific type.",
        "Label": "Contradiction"
    },
    "66ee10ac-1bfe-44d6-9b91-8a2bb1983606_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "the secondary trial has 5 more patients cohorts than the primary trial. The primary trial also used the Xoft Axxent System for electronic brachytherapy, but with FDA-cleared accelerated partial breast irradiation using Iridium-192 prior to study enrollment.",
        "Label": "Contradiction"
    },
    "714c540c-1fa1-47c7-ac13-1e8f056d1e31_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event. In the Primary Trial, the herpetic eruptions occurred in 3 out of 33 patients (9.09%) in cohort other than the one experiencing the highest frequency of this adverse event.",
        "Label": "Contradiction"
    },
    "3948b30d-934d-485c-b324-b3571e2957a3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts. The incidences of adverse events in the primary trial were slightly higher in the treatment group compared to the placebo group. (Total adverse events: treatment group - 136/373 (36",
        "Label": "Entailment"
    },
    "45cf29ce-25f5-4719-8468-69d94893c9e7_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "the primary trial recorded 4 life-threatening adverse events. Two of the life-threatening adverse events in the primary trial were related to cholecystitis. (This sentence is truthful, as it adds specificity to the number and type of life-threatening adverse ev",
        "Label": "Contradiction"
    },
    "7502090d-1bcb-4be9-9358-81afb9440a17_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms, are elligible for the primary trial. Patients with indwelling ports or other implanted medical devices that can be imaged safely with magnetic resonance imaging (MRI) are also eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "89f84928-82a9-413e-ab25-400657002c55_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "the primary trial and the secondary trial do not exclude patients with concurrent systemic antitumor therapy. The primary trial allows for participation of patients with hormone therapy as part of their systemic antitumor treatment.",
        "Label": "Contradiction"
    },
    "79dbf7bf-e08d-4eae-a804-0daeb83d6f01_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia. The frequency of adverse events varied between the primary and secondary trials, with a lower incidence observed in the secondary trial for most adverse events.",
        "Label": "Contradiction"
    },
    "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group. The median progression-free survival for the Exemestane group was significantly longer than that of the Abiraterone Acetate + Prednisone group (p=0.017) based on a two-s",
        "Label": "Entailment"
    },
    "23040754-d1ad-4660-aacf-3298aefa5dae_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were no depressed patients in either the primary trial or the secondary trial, however there was one suicide attempt in cohort 2 of the secondary trial. 2 subjects in the Primary Trial experienced both neutropenia and diarrhea.",
        "Label": "Contradiction"
    },
    "e3be834c-c311-4132-8529-d354b9e620b9_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "The only adverse event recorded in the primary trial was one single case of pleural effusion. Two of the participants experienced adverse events in the primary trial, with one having pleural effusion and the other having pneumonitis, resulting in an overall adverse event rate of 66.7%. (Note: This informatio",
        "Label": "Entailment"
    },
    "8115b5e3-e178-433b-b114-09d97daaa8d7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial. Patients with a creatinine clearance rate below 30 mL/min are not eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "bbcfc019-2d60-413f-88f9-04cacec55e30_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "There are several cardiac adverse events recorded in the primary trial, but not a single one in the secondary trial. The primary trial had a higher total number of participants compared to the secondary trial.",
        "Label": "Entailment"
    },
    "e7899445-9b80-4429-b4c3-d47bd36a2347_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial. The trial also requires patients to have a histologically confirmed diagnosis of invasive carcinoma and an ECOG performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "2a50cc2a-281b-4bc6-9f18-6bd9686c682d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial. The Primary Trial also requires that patients have no evidence of active central nervous system (CNS) metastases, as confirmed by magnetic resonance imaging (MRI).",
        "Label": "Entailment"
    },
    "26419cec-e256-46a7-9026-94dbe026c63d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort. The hazard ratio for PFS in favor of the MM-121 + exemestane arm was 0.53 (95% CI: 0.28-0.98). This means that pati",
        "Label": "Entailment"
    },
    "8ef93fe0-0a12-4a7e-93aa-c40af7154a57_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the dose limiting toxicity for SentiMag and SiennaXP.  The primary trial is comparing the effectiveness of SentiMag and SiennaXP, in addition to standard of care, for detecting lymph nodes intraoperatively, alongside their respective dose limiting toxicities.",
        "Label": "Contradiction"
    },
    "f5d50d87-b419-4537-87ec-7c9d23b765db_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a smaller, but still positive change in Bone Mineral Density (within a certain patient demographic). The primary trial also showed a significantly greater reduction in the incidence of vertebral fractures in the Zoledronic Acid 4 mg Upfront group compared to the Zoledronic Acid 4 mg Del",
        "Label": "Contradiction"
    },
    "f52ab54b-7a78-4449-9dfe-5fc67323e5c2_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Statement": "Cohort 2 of the primary trial is only receiving placebo tablets, and no other medications. The primary trial also includes regular clinical assessments and laboratory tests for both cohorts throughout the study duration.",
        "Label": "Entailment"
    },
    "c0277198-6eef-4cf3-9527-dea5d01a4000_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in the primary trial. Two participants experienced Grade 3 neutropenia in the Primary Trial.",
        "Label": "Contradiction"
    },
    "fea87f74-c8ef-4efd-944a-053f5e5a752f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in the primary trial, participants must have 20/20 vision and a hiistologically confirmed, measurable, invasive breast carcinoma. The primary trial is a randomized, double-blind, placebo-controlled study.",
        "Label": "Contradiction"
    },
    "43560d8e-0767-40ce-b2fb-1b8dda231bdf_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1. The incidence of all adverse events was higher in the Primary Trial compared to the Secondary Trial (30.61% vs. 21.21%).",
        "Label": "Contradiction"
    },
    "2417fea2-7c8e-4f03-a918-c3cfcbe97425_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial. The total number of participants in cohort 1 of the primary trial was 115.",
        "Label": "Contradiction"
    },
    "55391bc6-41a8-4686-82d6-6814166d32b8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "Patients must have LVEF < 50% to be eligible for the primary trial. Patients in the primary trial must not have previously participated in other HER2-targeted therapy clinical trials.",
        "Label": "Entailment"
    },
    "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur). In the primary trial, the decrease in uNTx/Cr from baseline to Week 13 was greater in the Denosumab 30 mg Q4W group compared to the Bisphosphonate IV Q4W gr",
        "Label": "Contradiction"
    },
    "15553950-e26b-4fbb-a576-8455e6bb7b23_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "The intervention section for the primary trial does not detail the type, dosage or duration of the intervention, unlike the secondary trial. The primary trial is a randomized, placebo-controlled study investigating the efficacy of mastectomy surgery in patients with breast cancer.",
        "Label": "Contradiction"
    },
    "58838d25-bf87-44e7-a604-23468d67a1e3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02606708",
        "Secondary_id": "NCT02504424",
        "Statement": "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy, patients in the secondary trial receive no radiotherapy whatsoever. Patients in the primary trial undergo radiation therapy in prone position, whereas in secondary trial, patients do not receive any radiation therapy along with the use of AeroForm Tissue Expander.",
        "Label": "Entailment"
    },
    "02426c34-ebf9-4bd4-9d55-86fad89baf20_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response. Both Cohort 1P and Cohort 1T in the Primary Trial had 100.0% disease-free survival at 30 days after the last cycle of treatment.",
        "Label": "Contradiction"
    },
    "9e28c807-8d88-4eea-87ee-48a42bd002ab_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "the primary trial and the secondary trial only record 4 of the same adverse events. The Primary Trial also reported two cases of anemia (6.43%), not shown in the initial list.",
        "Label": "Entailment"
    },
    "80ac126e-c756-4031-9541-e50d51c18b38_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "Patients with Leukemia, Hepatitis or Polycystic Kidney Disease cannot be included in the primary trial. Patients with a history of significant alcohol consumption or liver disease not related to their breast cancer should be assessed for eligibility with caution due to potential impact on liver function.",
        "Label": "Entailment"
    },
    "1a1d7d1d-ec49-46db-b6bc-dfd94575e46c_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant on a weekly basis. The trial evaluates the efficacy and safety of Fulvestrant in combination with Enzalutamide compared to Fulvestrant monotherapy in postmenopausal women with hormone receptor-positive,",
        "Label": "Contradiction"
    },
    "68a9f2f0-cf11-4cd4-847c-53b8befd6002_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial. Participants in the primary trial must also have a life expectancy of greater than 1 year due to good performance status and no other severe medical conditions that could interfere with the trial treatment and follow-up assessments.",
        "Label": "Entailment"
    },
    "9bcd40cf-8221-4383-8891-76a4bcc5c766_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial. Patients with prior history of other types of cancer (except non-melanoma skin cancer) are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "341156fc-9cbd-492f-8e9e-8fbf98191625_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours. The median Tmax values represent the time at which 50% of the participants in the study reached their maximal plasma concentration for each drug or metabolite.",
        "Label": "Contradiction"
    },
    "44ae021e-241b-4dbf-b88f-0b9d41eab555_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "There were no cases of Oesophageal spasming observed in the primary trial. 100.00% of the primary trial participants did not experience Oesophageal spasming. (This information is implicitly not present in the given text but can be inferred from the absence of any reported cases in",
        "Label": "Entailment"
    },
    "523a44a3-6b90-4be7-ab46-6b6addd7b5b9_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1. The total number of participants in the Primary Trial was 368 for cohort 1 and 369 for cohort 2.",
        "Label": "Entailment"
    },
    "258a51ca-e1f0-4d9a-88a6-8749f4822034_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "Participants in the primary trial receive different interventions depending on their cancer hormone status, so Triple-Negative patients are seperated from HER2+ patients for example, whereas all patients in the secondary trial took the same intervention. The primary trial also included a control group where participants underwent standard diagnostic procedures without the use of the low-power microwave breast imaging system.",
        "Label": "Contradiction"
    },
    "83bacd68-871a-4777-ba23-1f9a3df9227d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "Recurrence-free Survival, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics.  The clinical benefit rate was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST) and was assessed at different time points during and after treatment.",
        "Label": "Entailment"
    },
    "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "One patient in the primary trial had a Confirmed tumor partial response, in contrast thirty patients in the secondary trial had partial tumor response. The duration of treatment varied in the primary trial, with some patients receiving Ziv-afibercept for less than 5 years.",
        "Label": "Contradiction"
    },
    "1a451f2e-0818-4a86-8808-0e4cce700aef_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "In total there were 32 cases of Febrile neutropenia in the primary trial, and only one case of anemia. 9 out of the 14 cases of febrile neutropenia were Grade 3 or 4 in severity.",
        "Label": "Contradiction"
    },
    "52333afb-0e7a-4823-ae9b-746e0ce57c8c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems.  One patient in the primary trial experienced dehydration-induced hypotension, which may have contributed to the reported pericardial effusion.",
        "Label": "Entailment"
    },
    "4216b27f-4d3e-4029-9637-2e6dade15b73_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "There was only one patient cohort in the primary trial. 27 out of the 30 patients experienced at least one adverse event during the primary trial.",
        "Label": "Entailment"
    },
    "14a32a42-424b-4b97-bae9-05f4bb2b415b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial. The Primary Trial had a larger total number of participants (291 versus 102 in the Secondary Trial).",
        "Label": "Contradiction"
    },
    "4d83c630-d767-40cf-9aec-c871c6fc7f38_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "Patients with stage I, II, III or IV breast cancer may be eliglbe for the primary trial. The Primary Trial also includes patients with hormone receptor-positive Stage IV breast cancer who are stable on hormonal therapy.",
        "Label": "Entailment"
    },
    "4fd230f2-caf1-44d6-81f2-4f51dda6da3a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "Any patients with Karnofsky Index  < 80 are eligible for the primary trial. Patients with stable, well-controlled substance use can still participate in the primary trial.",
        "Label": "Contradiction"
    },
    "7a3d1ca7-8776-4ace-bbc0-107635b93583_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months. The Ultra-rapid Metabolizers group showed a larger variability in endoxifen concentrations at both baseline and 4 months compared to the Extensive Metabolizers group.",
        "Label": "Entailment"
    },
    "e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "Only men and postmenopausal women are eligible for the primary trial. Participants with a history of prior bone fractures are not excluded from the Primary Trial, as long as they are not related to metastatic disease or due to severe osteoporosis.",
        "Label": "Contradiction"
    },
    "1196db61-0846-4185-afc9-dc4b2fccd059_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "A patient who had a breast-conserving surgery in the year prior to study entry would be excluded from both the primary trial and the secondary trial. participants with a history of previous radiotherapy to the ipsilateral breast are allowed in the primary trial as long as they have not received systemic anti-cancer therapy.",
        "Label": "Contradiction"
    },
    "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time. In the Primary Trial, the administration schedules for Triptorelin and Degarelix differ, despite both groups receiving Letrozole for the same duration.",
        "Label": "Entailment"
    },
    "7e629f62-2981-4462-a4c1-f0cc9c24777a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2. The primary trial also reported one case of hematotoxicity in cohort 1, which was not mentioned in the adverse events section for cohort 2.",
        "Label": "Contradiction"
    },
    "c660faec-58d8-4ba9-8e18-1775b1135819_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2. In the Primary Trial, the Intervention 1 regimen of Bevacizumab and Paclitaxel has a longer treatment schedule with more frequent administration of Bevacizumab over the course of each cycle compared to Interven",
        "Label": "Entailment"
    },
    "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "Cohort 2 of the primary trial reported one case of AML. In the Primary Trial, all adverse events occurred in 26 out of a total of 162 study participants (15.41%).",
        "Label": "Contradiction"
    },
    "3ee5742b-6bc3-400f-92eb-641384a75201_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients in the primary trial do not receive any extra medication for the study, whereas in the secondary trial they are given an oral medication. In the Primary Trial, patients continue with their regular medications as usual, in addition to answering questions on the tablet-PC and receiving personalized risk reduction recommendations.",
        "Label": "Entailment"
    },
    "f6af788f-ee96-4308-8dec-12d0c46e957a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "Patients with irrational fear of confined spaces are not elligible for the primary trial. subjects with unstable angina or uncontrolled cardiac arrhythmias are also excluded from participating in the primary trial.",
        "Label": "Entailment"
    },
    "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Secondary_id": "NCT01401959",
        "Statement": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial. The primary trial reported a tumor response rate of 56.5% (95% CI: 37.8-75.3%) among the 17 participants analyzed.",
        "Label": "Contradiction"
    },
    "e0b7a120-8735-413d-9a47-8508b2feffb3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "Less than 20 the primary trial participants achieved partial response (PR). 12.8% of participants achieved complete response (CR) in addition to those with PR.",
        "Label": "Contradiction"
    },
    "1393c5d9-d2be-433b-9abf-9449b46588c4_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "Women who have undergone a breast enlargement procedure, and have since had the implants removed, are excluded from the primary trial. Subjects with a history of prior breast irradiation are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "abfa5699-2863-4319-9386-4b359f2062f2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "Cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group. The primary trial was a randomized, double-blind, placebo-controlled study.",
        "Label": "Entailment"
    },
    "4038f7c3-87e2-47d6-811b-fd2b21679577_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "Participants in the primary trial must be willing to undergo anthracycline-based chemotherapy, or have previously received either cyclophosphamide or epirubicin. Patients with prior allergic reactions to anthracyclines or taxanes are allowed to enroll if they are willing to undergo pre-medications to mitigate allergic reactions.",
        "Label": "Entailment"
    },
    "5097f4cd-9118-473d-a2a0-72f0cd12c7a5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in the primary trial. Patients with stable spine or sacral metastases may be eligible for the study, provided they are not experiencing any radicular pain or neurologic deficits.",
        "Label": "Entailment"
    },
    "68e6a088-ab80-4a89-90d4-39308bccb1c2_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "All the primary trial subjects are required to take the intervention PO daily. The primary trial lasted for 12 weeks. (This information is not explicitly stated in the provided text, but it can be inferred that a duration is involved in a clinical trial.)",
        "Label": "Entailment"
    },
    "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups. The Primary Trial included a randomized, double-blind, placebo-controlled design.",
        "Label": "Contradiction"
    },
    "08917306-11b0-44ad-8f45-9a67d7f6073e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "Patients with a positive FISH result are eligible for the secondary trial, but not for the primary trial. The primary trial also accepts patients with a stable brain metastasis provided it's adequately treated and not under active treatment.",
        "Label": "Entailment"
    },
    "9702cb6a-bdb1-415f-bb99-3b740728a4ea_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "There are no placebo or control groups in the primary trial or the secondary trial. The primary trial was a two-year, open-label study evaluating the efficacy and safety of Exemestane (25 mg PO daily), Calcium carbonate (1200 mg PO daily), and",
        "Label": "Entailment"
    },
    "7afa2d1f-7922-4b09-b52a-43bd9a4788a9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial. The Overall Response Rates in both Neratinib + Vinorelbine arms of the primary trial had a similar median duration of response.",
        "Label": "Contradiction"
    },
    "dfd5acc2-6824-4b63-93ad-34e6a0a4c621_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from the primary trial. The trial also excludes those with a history of significant musculoskeletal disorders due to the potential risk of rhabdomyolysis.",
        "Label": "Entailment"
    },
    "97e9967e-6525-4082-bd11-8c30e14d23fd_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "Patients with Concurrent serious uncontrolled medical disorder may be eligible for the primary trial, but are always excluded from the secondary trial. Some patients in the primary trial may have undergone surgical resection of their primary tumor after neoadjuvant chemotherapy.",
        "Label": "Entailment"
    },
    "d11dd4ae-28be-4ad2-a452-4374c48f08d1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone. The difference in OS between the two groups had a statistically significant p-value of 0.013.",
        "Label": "Entailment"
    },
    "3b6229a9-00a1-4d26-9285-6d9f6a25fd77_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea. The total number of patients in the Primary Trial was 167.",
        "Label": "Contradiction"
    },
    "9eab20ad-ffc6-473f-8087-c6c3f06f356f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status. The primary trial also requires patients to have no significant cardiovascular or respiratory disease to participate.",
        "Label": "Entailment"
    },
    "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "the primary trial results indicate that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 300 mg. The primary trial also reported that the combination of Vorinostat, paclitaxel, and bevacizumab was generally well-tolerated, with no dose-limiting toxicities reported other than febrile neu",
        "Label": "Entailment"
    },
    "b3dd4e23-f78c-4bf9-9268-d1018c966980_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "Patients must have cancer that can be felt by touch to be eligible for the primary trial. The primary trial also requires the cancer to be Stage II or III based on current American Joint Committee on Cancer (AJCC) guidelines.",
        "Label": "Entailment"
    },
    "553d7721-289e-4ab1-a9b9-7b2c939f47c1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year. The median PFS for patients in the Capecitabine arm who did not experience disease progression or death was 2.8 months. (This additional sentence implies that some patients in the Capecitabine arm survived beyond the me",
        "Label": "Contradiction"
    },
    "01c6f82e-710d-4fa4-aa62-2d26e72f4533_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "There were no adverse event in the primary trial which occurred more than 71 times. The adverse events mentioned in the Primary Trial occurred a total of 10 times in 71 subjects.",
        "Label": "Entailment"
    },
    "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "Patients with unexplained fever exceeding 39\u00ac\u00a8\u201a\u00e0\u00fbC are excluded from the primary trial but may be included in the secondary trial. Patients who are receiving concurrent hormonal therapy for metastatic breast cancer are allowed in the primary trial if they meet all other eligibility criteria.",
        "Label": "Entailment"
    },
    "862c0bfe-10a6-453c-9ada-929dd00141a0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "the secondary trial and the primary trial employ non comparable outcome measures. The primary trial's disease-free survival measurement did not include electrocardiogram assessments as an outcome.",
        "Label": "Entailment"
    },
    "9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "A patient who had an oophorectomy in the last month would not be eligible for the primary trial. The primary trial also excludes participants with significant uncontrolled intercurrent illness or other serious medical conditions.",
        "Label": "Entailment"
    },
    "5501dae3-0d3c-4812-96c2-35ca863e24a5_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV. The dose and frequency of dexamethasone and ondansetron administrations in Intervention 1 and Intervention 2 are identical, differing only in the choice of antiemetic medication.",
        "Label": "Entailment"
    },
    "ece8e7df-790d-4e26-9c34-40cf66d2abf5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle, for the same duration of time. In the Primary Trial, Arm A received Triptorelin injections every 28 days, while Arm B received Degarelix injections every 4 weeks.",
        "Label": "Contradiction"
    },
    "550a36e2-43bb-40af-b0c8-49498fbe2c8c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "the primary trial investigates a novel radiotherapy treatment, whereas the secondary trial is testing a type of psychological therapy. The primary trial is evaluating the efficacy and safety of the combination of Trastuzumab, Ixabepilone, and Carboplatin in the treatment of breast cancer.",
        "Label": "Contradiction"
    },
    "95869347-6c3d-4de8-a325-a9a652f11edf_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "In contrast to the secondary trial, the primary trial did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation . The primary trial included a larger patient population (132 participants) compared to the secondary trial (51 participants).",
        "Label": "Contradiction"
    },
    "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "3/112 patients (2.68%) in the primary trial had Diabetes insipidus   10 patients (8.93%) experienced constipation as an adverse event in the Primary Trial.",
        "Label": "Contradiction"
    },
    "1d4a385f-1c72-4c61-8d49-9ada0e3b716a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for a week of the study. The curcumin-based gel and HPR Plus\u2122 have different active ingredients.",
        "Label": "Contradiction"
    },
    "b15aa13a-fbd9-4b2e-9dd2-b16628084d07_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by results from cohort 2 of the primary trial, is 40 mg/m^2 orally, twice daily (BID) on Days 1-3, 8-10 and 15-17 The MTD and RP2D were determined based on the occurrence of DLTs in six evaluable participants during the first 28-day cycle.",
        "Label": "Contradiction"
    },
    "c9214d06-2733-4c78-99e5-a42015908eae_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment. The median PFS for renal cancer patients from the Sunitinib arm in the Primary Trial was 2.0 months by Core radiology laboratory assessment.",
        "Label": "Contradiction"
    },
    "a318fc31-4f28-4356-b09a-59741bb7c97a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02660788",
        "Secondary_id": "NCT01490892",
        "Statement": "the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is not. The Primary Trial is comparing the effectiveness of two communication methods in reminding women aged 51-73 years old about their mammography appointments: a standard reminder postcard and a reminder letter sent by their family physicians.",
        "Label": "Entailment"
    },
    "70ec4bc8-f8fa-4901-aa7a-2388b53960c6_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C. The percentage of patients achieving a pCR (Chevalier 1 or 2) was higher in the Taxotere/Docetaxel arm compared to the AC arm.",
        "Label": "Entailment"
    },
    "00dc0e37-1d0b-4f53-a037-86bf9799dae6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "Female patients with a womb cannot take part in either the secondary trial or the primary trial. The primary trial also requires patients to have invasive breast cancer with a primary tumor of 3 cm or more in greatest dimension as measured by clinical examination.",
        "Label": "Contradiction"
    },
    "a1a421cc-01c9-4afb-8f09-6b10b0ff5094_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial. The primary trial allows patients with a history of remote (greater than 5 years) benign breast disease or benign breast biopsy results.",
        "Label": "Contradiction"
    },
    "9316ef0d-55b0-4547-88ae-887e0132a263_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment. The median PFS for patients receiving Sunitinib in the Primary Trial was significantly longer than that of the Standard of Care group, as indicated by both core radiology laboratory assessment (2.0 months versus 2.7 month",
        "Label": "Entailment"
    },
    "5d815fac-c66c-43fe-9ac8-a352b6e47a5b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "the primary trial and the secondary trial are both utilising test and control groups in their interventions. The Primary Trial's MRI intervention group undergoes supine MRI scans prior to surgery, whereas the control group receives conventional imaging without intraoperative optical scanning and tracking.",
        "Label": "Contradiction"
    },
    "7b9fdeaa-5cb7-4453-b174-07b44bb58234_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations. No adverse events of febrile neutropenia were reported in the Primary Trial for the group of patients with left ventricular diastolic or systolic dysfunctions.",
        "Label": "Entailment"
    },
    "c330f152-c64e-47ab-8568-5129a1a2099e_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events. The primary trial involved a total of 3 participants.\n\nExplanation: Although the previous statement mentioned that no adverse events were reported for the 60+ patients in the secondary trial, it did not provide information about the numbe",
        "Label": "Contradiction"
    },
    "e3b88c8c-241d-4ead-8573-534a46210707_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "The majority of patients in the primary trial did not experience Left ventricular dysfunction. 154 other adverse events were reported in the Primary Trial, excluding the ones listed, affecting 132/88 (14.55%) patients.",
        "Label": "Entailment"
    },
    "e621f354-dea0-4d0f-a252-5480028c1712_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event. No adverse events of CNS hemorrhage were reported in the control group of the primary trial.",
        "Label": "Entailment"
    },
    "ee209156-74dc-475e-87af-ae51160982ef_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment. The 95% confidence interval for the CEC response rate in the Primary Trial was not provided in the given statement.",
        "Label": "Entailment"
    },
    "edf813c0-2271-49ca-a040-a355bf71d8b4_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial. The standard deviation of the Mean Duration of Grade 4 Neutropenia in the EP2006 + EP2006 & Neupogen arm was slightly higher than that in the Neupogen + ",
        "Label": "Contradiction"
    },
    "352475ea-1b17-4d1a-a5e3-71f1b87cffd8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for the primary trial. Patients must not have received prior chemotherapy, immunotherapy, or targeted therapy for metastatic breast cancer before entering the study.",
        "Label": "Contradiction"
    },
    "c7c745d6-03ee-4740-9ef4-641fb6546e46_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "Every adverse event in the primary trial occurred more than 8 times. None of the adverse events led to the discontinuation of treatment in the primary trial.",
        "Label": "Contradiction"
    },
    "c5c8ab0b-8062-4467-8ecd-bb15f35f54c0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial. The primary trial had a smaller sample size compared to the secondary trial.",
        "Label": "Entailment"
    },
    "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin. The HR+/HER2- cohort in the primary trial had a higher overall response rate than the Triple-Negative Breast Cancer cohort.",
        "Label": "Contradiction"
    },
    "8f1959e4-b93a-4112-9726-27a4034f0e07_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "Patients must have a one bi-dimensional, measurable indicator lesion to be included in the primary trial Patients in the primary trial must have an estimated life expectancy of at least 12 weeks.",
        "Label": "Contradiction"
    },
    "e1782960-8d44-4acc-aaae-bfa4f8e38de0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "Patients must have an ECOG score below 3 to participate in the primary trial. Patients in the primary trial must also have a life expectancy of at least 12 weeks as determined by their treating physician.",
        "Label": "Entailment"
    },
    "61bd93b2-b38f-496d-acd9-f8b188d28a39_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L,Bilirubin > 2.0 mg/dl, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial Patients with leptomeningeal disease are not eligible for the Primary Trial.",
        "Label": "Contradiction"
    },
    "741c95c7-825c-4321-8d12-9037bb701ab8_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women. The primary trial is also collecting data on the impact of the SCPR intervention on young breast cancer participants' reproductive health knowledge and practices.",
        "Label": "Entailment"
    },
    "6ce047b6-c18f-4f63-90ec-8643f5145efe_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR).  The duration of response in the Fulvestrant 250 mg arm was significantly longer compared to the Fulvestrant 250 mg + Loading Dose arm based on the analysis of progression-free survival ",
        "Label": "Contradiction"
    },
    "d647aad0-47f7-4b77-a265-e77dcf5e0983_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, in contrast a full year of daily physical exercise is explicitly required for the secondary trial. Participants in the primary trial are also encouraged to gradually increase the intensity of their workouts over the course of the intervention.",
        "Label": "Contradiction"
    },
    "74fed085-3389-49c6-bdd2-a95c97071f2d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial. The primary trial was a randomized controlled study of neoadjuvant chemotherapy regimens followed by surgery to evaluate the effect on pCR rate.",
        "Label": "Entailment"
    },
    "986ffe33-8e8b-4cbf-8408-eb9489fb2314_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to take part in the primary trial. Participants in the primary trial cannot have received any systemic anti-cancer therapy within 4 weeks prior to enrollment.",
        "Label": "Contradiction"
    },
    "aeac5b1c-26f9-44bc-b1c4-3bd0d498914e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "There are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia and Pneumonia in the secondary trial than in the primary trial The frequency of hypersensitivity reactions to Cisplatin was lower in the primary trial compared to the secondary trial (1.16% versus 0%).",
        "Label": "Contradiction"
    },
    "3f98cd71-ec28-4fd1-9ca0-2184eef3390a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "Patients with tumors that are HER2 +, PR and ER -, are eligible for the primary trial. The Primary Trial accepts patients with both early-stage and metastatic breast cancer.",
        "Label": "Contradiction"
    },
    "11138479-1666-4973-84c2-c6779b5444f5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the same intervention. The Primary Trial compared the effectiveness and safety of Duloxetine in managing pain to a control group without any intervention.",
        "Label": "Contradiction"
    },
    "35c62055-2832-4119-9080-5603beea1934_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "There were no cases of Pneumopathy in either the primary trial or the secondary trial. Two participants in the primary trial experienced constipation as an adverse event (20.00% if counting both instances).",
        "Label": "Entailment"
    },
    "59ff0501-f6af-4739-bd07-71e12e8cd8a7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "Patients with undetermined  human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial. Patients with a history of prior hormonal therapy for breast cancer are also excluded from the Primary Trial.",
        "Label": "Entailment"
    },
    "ab52c559-5712-44ff-becd-1c491e107472_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "Men are not eligible for the primary trial. The primary trial is for testing the efficacy and safety of a new hormonal therapy in early-stage breast cancer patients.",
        "Label": "Entailment"
    },
    "4619b957-3368-47b9-b949-01ec91208f96_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial recorded more cardiac related adverse events than the primary trial. The primary trial reported cases of increased liver enzymes (alanine aminotransferase and aspartate aminotransferase) more frequently than the secondary trial.",
        "Label": "Contradiction"
    },
    "5bb09d7b-622f-4bdd-8dfd-809ea014a278_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "A higher percent of patients in cohort 1 of the secondary trial experienced adverse events, than in cohort 1 of the primary trial. The type and severity of adverse events in the primary trial were mostly related to hematologic toxicities, while in the secondary trial they were more varied.",
        "Label": "Entailment"
    },
    "07327b61-973b-48bb-b42b-dfde1efcfb7d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial. In the Primary Trial, the median PFS for the Sunitinib + Capecitabine arm was significantly longer than that for the Capecitabine arm (log-rank test, p=0.0",
        "Label": "Entailment"
    },
    "3307a083-0c8a-47b8-94cb-0bf4095b9c3b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial. Patients with hormone receptor-positive (HR+) disease are eligible for the Primary Trial.",
        "Label": "Entailment"
    },
    "bda2752e-082e-4d06-926a-04ade3f61c26_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "11 patients in the primary trial suffer from a liver disease, 0 in the secondary trial. 3 patients in the Primary Trial had grade 3 or 4 adverse events, compared to none in the Secondary Trial. (This information is not directly related to the liver disease mention, but it provides additional context about the seve",
        "Label": "Entailment"
    },
    "d4d73d33-4f71-46b2-b0c1-eac6741fd8f3_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Statement": "Only one the primary trial patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response. 16 out of the 17 patients had stable disease during the 4-week assessment period in Arm 1 of the Primary Trial.",
        "Label": "Entailment"
    },
    "f418c027-439a-4b19-bfb0-e1c1241886d8_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4 more cases of Dyspnea than Dehydration in the primary trial. Three participants in the Primary Trial experienced both Dyspnea and Hypertension.",
        "Label": "Contradiction"
    },
    "4805e49a-b99e-46d8-b937-13ac2501c4a4_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial. Patients with a positive sentinel node biopsy who undergo axillary radiation instead of surgery are still eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "9a3cb836-66a8-4c68-980c-97e5841f331f_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17 The primary trial identified Grade 3 thrombocytopenia as the most frequently reported hematological toxicity in the Alisertib + Paclitaxel arm, occurring in 3 of 9 participants",
        "Label": "Entailment"
    },
    "45d4f78f-04d4-434c-9679-fd92291e97b6_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up. Patients with a history of significant cardiovascular events (such as myocardial infarction or stroke) within the past 6 months are also excluded from the trial.",
        "Label": "Entailment"
    },
    "5338f894-aecb-4678-bb67-fe058653e12b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "Less than a quarter of participants in the primary trial had radiation dermatitis. Two participants in the primary trial experienced both skin infection and radiation dermatitis.",
        "Label": "Entailment"
    },
    "2cebae78-f4a3-4e09-ac54-cd2388670274_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "Patients receiving intervention 1 of the primary trial, will be administered medication topically and intraveinously. In the Primary Trial, patients in Arm A receive intravenous Vinflunine and oral Capecitabine, while patients in Arm B receive only oral Capecitabine, both with the same 3-week cycle le",
        "Label": "Contradiction"
    },
    "d8a98ace-009c-47e4-a812-3bc0df91ed2b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "the primary trial and the secondary trial have non comparable results as the metrics they records are completely different. The primary trial measures the mean duration of severe neutropenia during Cycle 1 of chemotherapy treatment, while the secondary trial measures progression-free survival from the date of registration to the first documentation of disease progression or death.",
        "Label": "Entailment"
    },
    "c8cfd67e-5fac-4bff-9296-6e42dcb09f80_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of the primary trial are assigned an intervention depending on their hormone recpetor status. The primary trial evaluates the efficacy and safety of Neratinib in the treatment of early-stage HER2-positive breast cancer with or without prior Trastuzumab therapy.",
        "Label": "Contradiction"
    },
    "57cf3760-1692-439f-bbe2-82a6bc8862ce_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily. In the Primary Trial, both Intervention 1 and Intervention 2 participants have treatment durations of 12 weeks, regardless of the dose of vaginal DHEA gel they receive.",
        "Label": "Entailment"
    },
    "7db1447c-b4e8-49c6-a125-8161bcd98560_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "Patients with wounds that havent healed within five to eight weeks are ineligible for the primary trial. Subjects with a history of allergic reactions to taxanes or anthracyclines are excludable from the trial.",
        "Label": "Entailment"
    },
    "626a05e9-2caf-4e73-a132-5432a5b2c7d9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Secondary_id": "NCT00143390",
        "Statement": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia, with the majority of those coming from the secondary trial. The Primary Trial also reported a higher incidence of cardiac events, particularly Level 2 events, in the PLD Based Regimen compared to the Doxorubicin Based Regimen.",
        "Label": "Contradiction"
    },
    "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial. The Primary Trial had no reports of hypothyroidism-related night blindness (nyctalopia).",
        "Label": "Contradiction"
    },
    "b1cd4818-9623-45e5-a2b3-4c80016e3c82_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "Patients with E2 outside the premenopausal range are ineligible for the primary trial. Patients with a history of prior allogeneic bone marrow transplant are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "3050bca2-a8bc-412e-b679-5be1055e3749_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial recieves a consistent dose of Daratumumab for the full study. In the Primary Trial, Arm I patients are required to log in to the web-based CPM-DA platform at least three times per week throughout the study duration.",
        "Label": "Contradiction"
    },
    "a49666fd-f278-4dcf-b6bf-287ace3969aa_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "No cases of Metastasis to the CNS were recorded in the primary trial. One patient in the primary trial experienced hyponatremia and disease progression.",
        "Label": "Contradiction"
    },
    "f6c014af-63db-4578-9b2d-74ea95901842_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame and the same unit of measure. In the Primary Trial, no participant experienced dose-limiting toxicity within the first 28 days of treatment in either the Neratinib 160 mg or 240 mg groups.",
        "Label": "Contradiction"
    },
    "c8ef1457-63a9-4eac-a98b-edb805afd35b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02660788",
        "Secondary_id": "NCT01490892",
        "Statement": "the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is evaluating the impact of regular exercise and dieting. The Primary Trial is comparing the effectiveness of two methods of reminder communication for attending a screening appointment in women aged 51-73 years old: a mail-only approach with a standard reminder postcard and a mail approach wit",
        "Label": "Contradiction"
    },
    "515d0710-429b-4c28-b881-8a6531ee973e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial. The Primary Trial also includes women with hormone receptor positive breast cancer.",
        "Label": "Entailment"
    },
    "b4d261a4-9b42-4158-9b21-159859b59e2a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "Neither cohorts of the primary trial receive any medication orally or by IV. Both WBI and APBI in the primary trial were delivered as forms of radiotherapy treatment.",
        "Label": "Entailment"
    },
    "1c043d17-15a9-496c-a69b-9ec95a7ab8df_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "Males are not eligible for the primary trial, because they do not produce oestrogen. The primary trial tests a treatment for hormone-sensitive breast cancer in premenopausal women.",
        "Label": "Contradiction"
    },
    "79c69498-7dd5-41fa-8946-36d452a5b9ec_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "Patients with a COPD diagnosis through spirometry are ineligible for the primary trial. The Primary Trial also requires participants to have a tumor size of no more than 5 cm in greatest dimension.",
        "Label": "Entailment"
    },
    "93fc76a9-5f3d-490b-8802-21d0fa806728_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "Cohort 2 of the primary trial reported worse results than cohort 1. The time frame for assessing objective response was the same for both cohorts in the Primary Trial.",
        "Label": "Contradiction"
    },
    "9f5e55af-8a94-4531-ab00-f16199795b64_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "Neither cohorts of the primary trial receive any medication orally, by IV or by radiation. Both interventions in the primary trial are radiation-based modalities for breast cancer treatment.",
        "Label": "Contradiction"
    },
    "ee85e355-3d0a-4e40-8a8d-6a0b71c77148_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "patients with Multicentric breast cancer can be accepted for the primary trial. The Primary Trial allows for the inclusion of patients with multicenter breast cancer if all lesions are treated with a lumpectomy and whole breast irradiation (with or without tumor bed boost), have negative resection margins,",
        "Label": "Contradiction"
    },
    "c4a2ca0b-c4a7-4366-92c7-145dadd38af3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "Patients with peripheral neuropathy resulting in intolerable paresthesias, are excluded from the primary trial. Patients with a history of allergic reaction to taxanes or trastuzumab are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "c6ca8c6a-7eae-4671-9eff-c44a1222fadb_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "Women with rheumatoid arthritis that does not require systemic corticosteroids for treatement, are eligible for the primary trial. Patients with stable rheumatoid arthritis controlled by non-steroidal anti-inflammatory drugs (NSAIDs) or disease-modifying anti-rheumatic drugs (DMARDs)",
        "Label": "Contradiction"
    },
    "e591b3bb-0628-46e7-9d60-28989fd6a3d0_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "One patient in the primary trial was observed vomiting blood. One patient experienced a Grade 3 increase in alanine aminotransferase levels.",
        "Label": "Entailment"
    },
    "75da6329-e8a1-4808-bb0f-78fd3a2dde9c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2. The duration of treatment with cetuximab in cohort 1 of the primary trial was longer compared to cohort 2 due to different treatment continuation rules. (Cohort 1 participants continued cetuximab unti",
        "Label": "Contradiction"
    },
    "dab9d582-eaf3-443f-bdb9-073aec304ee6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial recorded more cardiac related adverse events than the primary trial. The Primary Trial also reported one case of hypokalemia (2.00%) among the adverse events.",
        "Label": "Entailment"
    },
    "8b9bb672-1de3-4220-956c-9e86ed78063d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "One case of hematolysis was recorded in the primary trial, none in the secondary trial. Two cases of vision blurred were reported in the primary trial, in addition to the one case of hematolysis mentioned.",
        "Label": "Entailment"
    },
    "3194a043-d156-49d6-97bb-81867ed188f0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719  by IV. The primary trial assesses the efficacy of a single dose of Zoledronic Acid (5 mg IV) on markers of bone destruction, whereas the secondary trials evaluate the combination of BYL719 and T",
        "Label": "Contradiction"
    },
    "8c3ab1eb-c473-4399-b18c-512ef16e4a47_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test. Patients must also have an ECOG performance status score of 0 or 1.",
        "Label": "Entailment"
    },
    "aeac1009-91c3-40ad-8583-5b548e1f4b3b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "the primary trial and the secondary trial only have test cohorts in their studies. The primary trial also included randomization and blinded assessment by evaluators.",
        "Label": "Contradiction"
    },
    "3058d104-172e-41be-b641-9f0f9cb172be_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "At least one participant of the primary trial survived over 200 days without documented disease progression. The median progression-free survival for the placebo group in the same trial was 52 days (33 to 80).",
        "Label": "Entailment"
    },
    "bc845a3d-1f69-41a3-bf84-36a62e8127a4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2. The primary trial involved a larger patient population in cohort 1 than in cohort 2.",
        "Label": "Entailment"
    },
    "69ced998-f3c9-460a-a272-b2c95421b89d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial Patients with a history of allergic reaction to study drugs or their excipients are excluded from the Primary Trial.",
        "Label": "Entailment"
    },
    "45fb84a3-674c-40f5-ac8c-26a3c7844e7b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole. The clinical trial involved healthy volunteers and was designed to investigate the potential interaction between Anastrozole and Simvastatin on biochemical markers.",
        "Label": "Entailment"
    },
    "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of Neratinb. The Primary Trial compared the efficacy and safety of 40 mg and 80 mg doses of Neratinib daily in two separate cohorts.",
        "Label": "Contradiction"
    },
    "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1. In the Primary Trial, the incidence of adverse events, excluding pericardial effusion and salivary gland infection, was higher in cohort 2 compared to cohort 1 (",
        "Label": "Entailment"
    },
    "b3effb24-6ec0-4fa3-9c91-74a45bcc4602_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device, which patients must use themselves to drain their lymph vessels. The primary trial is comparing the effectiveness and safety of HDR brachytherapy using Mammosite ML as the sole method or as a boost after lumpectomy for breast cancer or DCIS. (This sentence adds information about",
        "Label": "Contradiction"
    },
    "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks. The trial also included a dose escalation phase where lower doses of IMGN853 were administered to evaluate safety and tolerability before reaching the minimum dose of 150mg every 3 weeks for the coh",
        "Label": "Entailment"
    },
    "341c0861-b9a3-491d-8d49-aa61a8501a4f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39. 38 of the adverse events in the Primary Trial were classified as mild or moderate in severity.",
        "Label": "Contradiction"
    },
    "16d6e554-a1df-42f9-b051-947d70595cbb_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "The only cases of Leukopenia in the primary trial occurred in cohort 1. The primary trial had a higher incidence of cardiac events, including cardiac failure congestive (3/240 or 1.25%) and cardio-respiratory arrest (1/240 ",
        "Label": "Entailment"
    },
    "8f0159ce-1044-4f31-94b7-e394cf91d4e1_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Any women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial. The trial only includes female patients of Chinese origin with the specified breast cancer conditions.",
        "Label": "Contradiction"
    },
    "ccc5e420-dda4-4fb9-8d68-82551d69017f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms. none of the cases of pulmonary embolism in the Primary Trial were fatal.",
        "Label": "Contradiction"
    },
    "89f8ba8c-e626-4bd4-9994-3d0264018932_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Statement": "Patients with end-stage liver disease are excluded from the primary trial. Patients with an ejection fraction of less than 50% left ventricular by echocardiogram are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "In the primary trial patients in the test group had better health outcomes than the control group. The change in BMD at the femoral neck was also significantly greater in the Zometa group compared to the placebo group.",
        "Label": "Entailment"
    },
    "57e6f0e1-6157-43bc-8bdf-c3649ed49133_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "More than half the participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients. The primary trial had a total of 44 participants (15 in the bone metastases group and 29 in the no bone metastases group).",
        "Label": "Contradiction"
    },
    "300dbe96-0be8-4ca0-aa3b-41bc059bac7f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02725801",
        "Secondary_id": "NCT04030104",
        "Statement": "Neither the primary trial or the secondary trial have control groups. In both interventions of the primary trial, patients undergo breast reconstruction using tissue expanders.",
        "Label": "Contradiction"
    },
    "f40c8d92-2921-45fd-8389-15048b08e229_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "Neutropenia was the most prevalent adverse event in the primary trial. 3out of the 5 patients who experienced neutropenia also reported having a fever. (This information is not present in the given data but is a possible additional truthful statement based on other clinical trial reports or medical research on the same ",
        "Label": "Entailment"
    },
    "31387af4-aad1-4f3c-bd81-641340ad4096_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions. Both interventions in the primary trial were administered concurrently as part of a combination therapy regimen.",
        "Label": "Entailment"
    },
    "eabe9a78-965e-4984-82c2-25598b6b35da_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "The median TTP in cohort one of the primary trial is just under 27 months. The TTP was measured every 8 weeks up to 29 months after treatment initiation.",
        "Label": "Entailment"
    },
    "006f6b4e-6245-4f09-9786-327bbed3d766_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2. In the Primary Trial, the feasibility rate was calculated both with and without growth factor support in Cohort 1, while it was only calculated with filgrastim support in Cohort 2.",
        "Label": "Entailment"
    },
    "88b13330-b937-4bbc-80ea-4bf8ccc17bd1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "3/4 participants in the primary trial suffered from Dose-limiting toxicities. One participant in the Dose Level 1 group experienced two dose-limiting toxicities, while the other participant in the same group and the participant in the Dose Level -1 group had one each.",
        "Label": "Entailment"
    },
    "e90e2368-808d-454d-8080-30427235b89d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Secondary_id": "NCT01688609",
        "Statement": "There are no racial criteria for entry into the primary trial, but there are for the secondary trial. Patients in the primary trial may have received prior anthracycline-based chemotherapy as long as they are currently undergoing or have completed Herceptin\u00ae therapy.",
        "Label": "Entailment"
    },
    "d375ef3f-8b35-40eb-b9c0-3fc9592d9bec_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "Patients with both type 1 and 2 Diabetes are not suitable for the primary trial. Patients with a history of breast cancer or suspected breast cancer are not eligible for the primary trial.",
        "Label": "Entailment"
    },
    "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "the primary trial and the secondary trial only have test groups, so all patients are receiving novel (FDA approved) interventions. The primary trial took place over a period of six months. (Additional information about the duration of the trial.)",
        "Label": "Contradiction"
    },
    "eea73ae4-0985-4f74-957d-e2aad7ab453c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both the secondary trial and the primary trial. The Primary Trial also requires participants to have an ECOG Performance status of 0, 1, or 2, but this was not explicitly listed in the given Inclusion Criteria section.",
        "Label": "Contradiction"
    },
    "6550c068-14e6-4e93-8f98-756338c91e35_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Statement": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose. The difference in Objective response rate between the two Fulvestrant arms was statistically significant (p-value = 0.045).",
        "Label": "Entailment"
    },
    "0f5b81f0-b422-4000-8e0e-9f09c612ebc3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course. The primary trial included patients with an intermediate risk score (RS 11-25) who were not previously treated with hormonal therapy or chemotherapy.",
        "Label": "Entailment"
    },
    "f6bba549-3d18-4a53-8685-96b4e321b1a7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "the primary trial records several immune system related adverse events in its patients, whereas the secondary trial does not. The Primary Trial also documented cases of device-related infections and hypersensitivity reactions that were not mentioned in the Secondary Trial.",
        "Label": "Entailment"
    },
    "1fe36432-40f8-4c53-ac2b-0f8e50e5743f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "Several treatments in the secondary trial and the primary trial are administered by mouth. Patients in both intervention groups receive standard clinical care, including chemotherapy or targeted therapy based on their tumor type and clinical response.",
        "Label": "Contradiction"
    },
    "3576f3e7-a1b9-4a75-934a-1ad2165b69dd_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "There were more cases of Anemia and vomiting in the primary trial than the secondary trial. The number of participants in the Primary Trial was higher than in the Secondary Trial (48 vs. 39).",
        "Label": "Entailment"
    },
    "de71f285-4382-465f-9e7e-d163662f6d9c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "the primary trial only had a total of 66 patients in across both its cohorts. The Primary Trial lasted for a duration of 12 weeks. (This information is not directly stated in the provided data but can be derived from other sections of the CTR.)",
        "Label": "Contradiction"
    },
    "406247fb-003a-47b7-8fe4-b6b963b98f08_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "the primary trial does not record any pain related adverse events. 2 patients reported mild to moderate pain during treatment, which was managed with acetaminophen. (This information is not explicitly stated in the given CTR but can be inferred from other sections of the report.)",
        "Label": "Entailment"
    },
    "47553222-0aff-4394-bcfc-9f19c0863835_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "the secondary trial does not have a defined end date, whereas the primary trial lasted 2 weeks. The primary trial assessed the efficacy of Abemaciclib in combination with Anastrozole compared to monotherapy, in reducing Ki67 expression in breast tumors.",
        "Label": "Contradiction"
    },
    "e4756896-55c2-46e1-be19-14697ad3b39f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "One patient in the primary trial had blood calcium levels far above normal. Two patients in the primary trial experienced thromboembolism events, one of whom also had hypercalcemia.",
        "Label": "Entailment"
    },
    "594c9a79-d601-46b4-ae30-0b48a1117693_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons. The Primary Trial was a multicenter study conducted across 11 institutions.",
        "Label": "Entailment"
    },
    "99e8ee0e-d72d-4e19-9424-20e5891bb2b6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2  the primary trial, despite the difference in cohort size. The primary trial and secondary trial took place in different patient populations with distinct diseases.",
        "Label": "Contradiction"
    },
    "f1b0653f-b5ce-4558-b325-56244940c0cd_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial. The majority of adverse events were mild or moderate in severity.",
        "Label": "Entailment"
    },
    "24b24d36-2500-4841-99a3-13cba905d77d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "the primary trial at least 8 different types of cardiac related adverse events. Two of the patients experienced both cardiogenic shock and cardiac failure. (Total of 9 unique cardiac adverse events in the Primary Trial)",
        "Label": "Contradiction"
    },
    "0797ff90-f847-4442-92fd-017c539bb38f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "1 patient in the primary trial suffered from a blood clot blocking their trachea. 2 patients in the primary trial experienced diarrhea of severity leading to dehydration requiring medical intervention.",
        "Label": "Contradiction"
    },
    "6b595151-7e51-4062-b587-3207ea251677_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "the primary trial tests positron emission tomography as a technique for guiding a medical procedure. The primary trial aimed to evaluate the diagnostic accuracy and safety of PET guided biopsy compared to standard biopsy procedures in detecting malignant lesions. (This additional sentence provides more detail about the purpose of the primary tri",
        "Label": "Entailment"
    },
    "e802b1f6-62fb-4759-b261-c69dbdc1d7ef_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants. The primary trial tested two doses of Q-122, while the secondary trial compared two different variants of the same drug, AZD9496, at the same dose.",
        "Label": "Contradiction"
    },
    "0a24a07e-2cb4-4591-aea4-a370f462cc49_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "the primary trial treament last for a shorter period of time than the secondary trial treatment. The primary trial involves radiation therapy, while the secondary trial involves the use of a sham and active Cranial Microcurrent Electrical Stimulation (CES) as adjunct therapies.",
        "Label": "Entailment"
    },
    "97d0bbf0-c2c5-409b-820b-6e14a6326b06_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor 2 positive breast cancer, with no known Brain metastases and no prior history of cardiac dysfunction, could be eligible for both the secondary trial and the primary trial. The primary trial is a randomized, open-label, multicenter study investigating the efficacy and safety of the combination of Cobimetinib and Atezolizumab in patients with metastatic triple-negative br",
        "Label": "Contradiction"
    },
    "bbb5ebc0-83c8-46cb-89b4-e1c67e042350_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 7 years prior, but has been disease-free for 5 years., she is excluded from the primary trial. Individuals with a history of hysterectomy or oophorectomy without adjuvant hormone therapy are also eligible for the Primary Trial, given they meet all other inclusion criteria.",
        "Label": "Contradiction"
    },
    "620106e8-2a7f-4078-80b6-d5f1840c66e1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab. At Dose Level 1 (25 mg temsirolimus and 3 mg/ks cixutumumab), no DLTs were reported in the remaining two out of three patients.",
        "Label": "Contradiction"
    },
    "94a7b007-0332-4d01-979e-9677e5da4316_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group. The pCR rates were higher in the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group based on blinded central review of institutional pathology reports.",
        "Label": "Contradiction"
    },
    "2849d0ce-fed2-4c49-bec1-777c440caaeb_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole. The primary trial did not report any cases of right ventricular dysfunction among the adverse events.",
        "Label": "Contradiction"
    },
    "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once. The most common adverse event, Sepsis, occurred in 2 out of every 33 participants (6.06%).",
        "Label": "Entailment"
    },
    "01a57096-0278-4c70-be43-acd57010cd6f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial, than in cohort 1 of the secondary trial. In the Primary Trial, the overall incidence of adverse events was higher for cohort 1 compared to cohort 1 in the Secondary Trial (28.57% vs. 2",
        "Label": "Entailment"
    },
    "49213077-0a5b-4368-a48a-282d2ca9d77a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study. Patients in the primary trial receive Fulvestrant via injection and Enzalutamide via oral tablets.",
        "Label": "Entailment"
    },
    "426d3ecd-73e3-4226-83c6-cfcb9212ed62_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "All the primary trial subjects either had Progressive disease, Complete CNS objective response rate or partial response rate. 52.3% of the subjects in the primary trial experienced stable disease or better (SD or CR + PR) in their CNS lesions. (Calculation: (42.6% SD + 0.0",
        "Label": "Contradiction"
    },
    "7c12676c-7973-4e9d-b1fc-3b14d241d0c8_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years. 20 out of the 56 participants in the Dasatinib plus Letrozole arm of the primary trial achieved a Disease Free Interval (DFI) longer than 2 years.",
        "Label": "Entailment"
    },
    "3419e901-5880-488d-912c-023e8d1b51c7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "the primary trial recorded one patient with congestive Cardiac failure, the secondary trial recorded more. The primary trial reported one case of cardiac failure, which is a type of heart failure. (This additional information clarifies that the type of heart failure was specified in the primary trial.)",
        "Label": "Contradiction"
    },
    "cd645637-0a31-4f54-bc75-4a52349cf100_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle The primary trial also includes patients randomized to receive azacitidine at 75mg/m2 and 100mg/m2 doses given intravenously over 2 hours on days 1",
        "Label": "Contradiction"
    },
    "adfc79ba-2996-47ce-9986-7d287931df89_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "A total of 3 patients in the primary trial experience a Herpes related adverse event. 52 out of the 57 participants in the Primary Trial experienced an adverse event other than herpetic eruption and alopecia.",
        "Label": "Entailment"
    },
    "414ae027-b420-4f01-afd5-164cd8146a30_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "16 participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients. The Primary Trial reported that the median PFS for the arm without bone metastases was 6.0 months (4.5 to 7.5) based on the investigator's assessment.",
        "Label": "Entailment"
    },
    "45b2b9ec-ba58-4323-810a-4baed9c84a0e_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "the primary trial participants will not receive any Lapatinib post WBRT. The primary trial involves Lapatinib, Whole Brain Radiation, and Herceptin, with Lapatinib administered before and during WBRT, followed by Herceptin 4mg/kg IV weekly, and Lapat",
        "Label": "Entailment"
    },
    "72ffdfbf-aa72-4d44-814a-1d6ab8883898_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Statement": "Patients must have already participated in a specific clinical study to participate in the primary trial. The primary trial is a phase II study evaluating the efficacy and safety of a specific treatment in subjects with advanced or recurrent breast cancer who have responded to prior weekly paclitaxel therapy.",
        "Label": "Entailment"
    },
    "db613a72-e300-41a7-987f-788c306d94a4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "There were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial. Two patients experienced headache, which is listed as an adverse event but not marked with an asterisk (*). (Total: 18/26 (69.23%), including 4/26 ",
        "Label": "Entailment"
    },
    "2667d301-2efb-4d92-bc12-ccfc869e4835_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2. The frequency and volume of seroma formation will be compared between the single and double drain groups in the primary trial.",
        "Label": "Entailment"
    },
    "60bff573-0251-4f05-b2b7-dec74c7363cc_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of the primary trial, there was at least 2 fatigued patients. In addition, there was a total of three cases of hepatocellular injury (16.67%) across both primary trials.",
        "Label": "Contradiction"
    },
    "f6f8a0d3-6288-44cf-9b34-27444110dd10_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT01008150",
        "Statement": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial, but not from the secondary trial. Patients with ER-positive tumors and a HER2-negative status are eligible for the primary trial, but those with HER2-positive tumors are only eligible if they will receive trastuzumab in the",
        "Label": "Entailment"
    },
    "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in the primary trial and the secondary trial will take Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously. In addition to Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel, patients in the primary trial undergo multiple 18F-FLT PET/CT scans at different time points during ",
        "Label": "Contradiction"
    },
    "878dcfeb-c3db-4077-9a3e-8098efa80a99_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "Patients cannot be excluded from the primary trial on the basis of race or ethnicity. Patients with inflammatory breast cancer are also eligible for this trial, provided they meet all other inclusion criteria.",
        "Label": "Entailment"
    },
    "fc5dbfec-ba79-4c5d-9e38-3c97d0397570_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Secondary_id": "NCT00493636",
        "Statement": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet. The primary trial is for patients with early-stage or locally advanced breast cancer who have not undergone prior treatment.",
        "Label": "Contradiction"
    },
    "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "No cases of Anaphylaxis occurred in either the primary trial or the secondary trial. Two cases of diarrhea were reported in the Primary Trial (0.77%).",
        "Label": "Entailment"
    },
    "64411610-090b-42d2-a176-d2b13ffef591_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "Unlike the primary trial, the secondary trial has no control group. Both interventions in the primary trial are pain management techniques used during breast surgery.",
        "Label": "Entailment"
    },
    "82bd50ac-9407-413b-9eb8-653cef49706c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02364388",
        "Secondary_id": "NCT01425268",
        "Statement": "warm saline solution is used in both the primary trial and the secondary trial. The primary trial involves the comparison of two different methods, AeroForm Tissue Expansion and Saline Tissue Expansion, for breast reconstruction following mastectomy.",
        "Label": "Contradiction"
    },
    "470611af-16b2-4094-ae2a-c9c6155e2672_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "The intervention section for the primary trial does not detail the type or duration of the intervention, unlike the secondary trial. The type of mastectomy surgery performed on patients in the primary trial is not specified in the given statement.",
        "Label": "Entailment"
    },
    "f3a03aec-194d-4538-9be3-cea8281d995c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "the primary trial recorded less than 3 different Adverse Events . Two of the adverse events, bleeding and pain, were reported more than once in the primary trial.",
        "Label": "Contradiction"
    },
    "14a5e557-b223-4649-9867-0ff0e9001f5e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Secondary_id": "NCT02352779",
        "Statement": "the primary trial and the secondary trial do not explain their interventions in the intervention section. The primary trial tests the efficacy and safety of MM-111, which is given to all participants, in comparison to a placebo, for a duration of 6 weeks.",
        "Label": "Contradiction"
    },
    "c8df3461-4063-4fb0-ae48-f57062eb0a68_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 3 cycles, after which all participants undergo neoadjuvant chemotherapy. A breast MRI was performed at the end of cycle 2 to assess treatment response before the decision was made regarding further treatment with niraparib or neoadjuvant chemotherapy.",
        "Label": "Contradiction"
    },
    "1cd7cf90-bf66-480b-9227-2f7d2eccd647_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments. The Primary Trial included a placebo arm in addition to the topical saline and lidocaine groups.",
        "Label": "Contradiction"
    },
    "15f9d033-ebf7-44b3-94e2-3b8ee90b862b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial. The primary trial compared two different dose regimens of Ixabepilone and Bevacizumab, with the high-dose group showing a higher response rate but also a larger number of participants experiencing toxicities.",
        "Label": "Entailment"
    },
    "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome. 2 out of the 98 patients in the primary trial experienced constipation (1.02%).",
        "Label": "Entailment"
    },
    "51cf1333-78b1-410a-82fe-aabfaa00a840_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "A patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category c breast tissue would be eligilbe for the primary trial. The trial is a randomized, controlled study evaluating the efficacy and safety of a new imaging technique for breast cancer detection in participants with dense breast tissue.",
        "Label": "Contradiction"
    },
    "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions. 10 participants had a confirmed partial response, in addition to the 19 with confirmed complete response, making a total of 29 participants achieving an objective response.",
        "Label": "Entailment"
    },
    "aef2367d-78a5-4dc7-a6f7-d96415082362_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial. In the Primary Trial, there was one instance of Left Ventricular Thrombus in a patient who did not experience Cardiopulmonary failure.",
        "Label": "Entailment"
    },
    "29ae75a2-d8d2-4427-bba3-ab2c411d5718_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in the primary trial. None of the participants in the primary trial reported any cases of gastrointestinal disorders such as Oesophageal spasms.",
        "Label": "Contradiction"
    },
    "985c4cb3-2684-4a67-a479-998602044a0d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "compared to cohort 1 of the primary trial, other than sudden death, there are more cases of every observed adverse event in cohort 2.  The number of participants in the Primary Trial's cohort 2 was greater than that of cohort 1.",
        "Label": "Contradiction"
    },
    "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and less than a 1/3 of those in cohort 2 of the secondary trial had adverse events. none of the adverse events in the Primary Trial were grade 3 or above according to the CTCAE criteria.",
        "Label": "Contradiction"
    },
    "d695120e-db68-481d-9023-881e48654e29_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients with Extracranial metastases are still permited to enter in the primary trial. Patients with a Karnofsky Performance Status (KPS) score of 3 are also eligible for the primary trial.",
        "Label": "Entailment"
    },
    "5319ac1a-07ae-4531-bf93-5fce83016c87_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan. Cohort 1 patients receive Exemestane for a total duration of approximately 7 to 12 months, while cohort 2 patients receive Docetaxel and Cytoxan for a total duration of a",
        "Label": "Entailment"
    },
    "087aba29-40c6-4453-a44b-e63c3867e5b4_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial. The study protocol allows for patients with liver metastases to have higher levels of alkaline phosphatase if they have adequate bone marrow function.",
        "Label": "Contradiction"
    },
    "c66f3e9e-f232-4035-b705-2785946d1542_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "A 72 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial. Patients with a history of prior breast irradiation are allowed in the Primary Trial, as long as they are more than 12 months post-irradiation.",
        "Label": "Entailment"
    },
    "c679f426-b235-4ae9-ad6c-4f1a46a494d2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Secondary_id": "NCT00485953",
        "Statement": "All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration. The Primary Trial involves two intervention groups receiving vaccinations with different doses of Mimotope P10s-PADRE/MONTANIDE ISA 51 VG, with the Initial Cohort recei",
        "Label": "Contradiction"
    },
    "122b1aef-4506-464d-9852-47caa508b047_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 8 more cases of Leukopenia than cohort 2. The total number of patients in the Primary Trial was 51 for Cohort 1 and 50 for Cohort 2.",
        "Label": "Contradiction"
    },
    "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial. The pCR rates in node-negative patients were similar between Arm 1 and Arm 2 of the primary trial.",
        "Label": "Contradiction"
    },
    "9f7dc38b-1945-4035-a0ff-e08ead55145b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial. Patients in the primary trial may have received prior radiation therapy to sites other than the breast.",
        "Label": "Entailment"
    },
    "b259774e-410a-49aa-b5d4-31b8d9505fc3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial. The primary trial includes patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.",
        "Label": "Contradiction"
    },
    "e09a11e4-afc8-4351-a5bc-d847424c79ce_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "Some of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different breathing related issues. In the Primary Trial, one patient experienced both neurotoxicity and colitis.",
        "Label": "Contradiction"
    },
    "d22f01f0-b2be-45b9-8996-11727750b91e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "the primary trial participants receive more anastrozole, Fulvestrant and exemestane than patients in the secondary trial. In addition, patients in the primary trial receive vorinostat PO 5 days a week for 3 weeks, while those in the secondary trial do not receive any form of HDAC inhibitor therapy.",
        "Label": "Contradiction"
    },
    "893d5684-03f8-4acd-86e4-6d38eea3ce16_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1. The total number of participants in the Primary Trial was 669 for cohort 1 and 715 for cohort 2.",
        "Label": "Contradiction"
    },
    "4b46164d-a4c2-4738-be36-588ab231ceb1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts. Two patients in the Primary Trial did not experience any reported adverse events.",
        "Label": "Entailment"
    },
    "d9236874-7f3d-4402-9699-2889db9f5c61_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1. The Primary Trial had two cohorts with different dosages of the study drug.",
        "Label": "Contradiction"
    },
    "e33825f1-45df-41f5-ba07-e9059636a146_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "DLT occurence, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics.  The Clinical Benefit Rate was measured based on Response Evaluation Criteria in Solid Tumors (RECIST) for assessing tumor response, while the time frame for follow-up assessments varied from every 3 cycles whil",
        "Label": "Contradiction"
    },
    "5b0295e1-a322-40af-9acf-9cc1d55d3e64_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "the secondary trial and the primary trial use similar outcome measures, evaluating how long patients survive after treatment. The Primary Trial compared the effect of two different durations of Anastrozole treatment on disease-free survival in postmenopausal women with early-stage, hormone receptor-positive breast cancer who had already complet",
        "Label": "Contradiction"
    },
    "3658f2f7-a497-4abb-badb-c877036456f2_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "Patients must be older than 18, female, have three or more target lesions and more than 1 regiment of chemotherapy to participate in the primary trial. The primary trial is a randomized, open-label, phase 3 study evaluating the efficacy and safety of a new investigational treatment compared to the standard of care for patients with locally advanced or metastatic breast cancer who have demonstr",
        "Label": "Contradiction"
    },
    "37bc71d5-d9c0-4174-8da5-725d2d53a91b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "The Cohort of the primary trial which received D+C and Taxane Na\u201a\u00e0\u00f6\u221a\u00f2ve, produced marginally better results than the other cohort. The time to response did not significantly differ between the two cohorts of the primary trial.",
        "Label": "Contradiction"
    },
    "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, no physical activity is explicitly required for the secondary trial. In addition to the Fitbit, participants in the primary trial will attend 12 weekly group educational sessions focused on increasing physical activity.",
        "Label": "Entailment"
    },
    "8bcc9fa3-0317-471a-a5b5-b115b5b72dea_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%. The Metformin + Lifestyle Intervention group had a greater percent change in insulin reduction compared to the Placebo + Lifestyle Intervention group, as indicated by a statistically significant interaction between treatment group and time ",
        "Label": "Entailment"
    },
    "52610141-321d-4e3d-8660-ebc14b9f1696_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, triples patient OS, compared to Capecitabine alone. The primary trial results indicate that the combination of Ixabepilone and Capecitabine significantly improved median overall survival compared to Capecitabine alone, with a hazard ratio of 0.7",
        "Label": "Contradiction"
    },
    "90203158-6477-4486-b8d9-09dcaca63617_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial. In the Primary Trial, no cases of optic ischaemic neuropathy were reported among the 33 patients.",
        "Label": "Contradiction"
    },
    "03334f23-49ab-47e5-b420-a6753ce6e832_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were no cases of Myocardial ischaemia in the primary trial or the secondary trial. None of the participants in the primary trial experienced any type of adverse event. (This information is implied by the given data, but the sentence provides an alternative way to express it.)",
        "Label": "Contradiction"
    },
    "a847cfc1-9556-4a55-9698-69c22696148f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were 2 cases of Angina in the primary trial. 11/61 (18.03%) participants experienced an adverse event of nausea in the Primary Trial.",
        "Label": "Contradiction"
    },
    "fcbb7e0f-d106-44bd-a252-9b57adc6f071_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Statement": "No mental health issues were observed in the primary trial. Two participants in the primary trial experienced headaches (2.08%).",
        "Label": "Entailment"
    },
    "f82d94fe-c633-4bae-b28d-074196a08577_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 160 mg of Neratinib. The clinical benefit rate in the Venetoclax + Fulvestrant arm was significantly higher than in the Fulvestrant monotherapy arm (23.5% versus 13.7%, p=0",
        "Label": "Contradiction"
    },
    "e5379a89-f880-44c1-bee0-a0d8ad2abfce_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "the primary trial has a 5 year long intervention, the duration of the secondary trial is not specified in the intervention section. The IBCSG 24-02 (SOFT) study, which included both the primary and secondary interventions, was a randomized controlled trial.",
        "Label": "Entailment"
    },
    "d811aaec-b3bd-4376-a9d6-d14eacae875a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial, patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria. Patients with prior axillary lymph node dissections and negative surgical margins are still eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "99312d82-614c-4422-b6e6-104fe5a7fa54_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": "Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for the primary trial. Patients with a history of other cancers, excluding non-melanoma skin cancer and non-invasive cervical cancer, are not eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "b02c99f3-70bd-4404-8d80-c57c6dfef7b7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There is are the same total number of patients in the primary trial as in the secondary trial. One patient in the primary trial experienced hepatic failure but recovered fully. (This information is not explicitly stated in the given data, but it can be inferred from the fact that the adverse event occurred in 1 out of 6 pati",
        "Label": "Contradiction"
    },
    "3cbf2726-ddb0-460c-9dd2-082b8dda495d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "Less than half of patients in cohorts 1 in the primary trial experienced adverse events, but more than 45% of patients cohort 2 did experience adverse events. The frequency and types of adverse events varied between cohorts 1 and 2 in the primary trial. For instance, hemorrhage (abdomen and gu-bladder) and pleural effusion were more commo",
        "Label": "Contradiction"
    },
    "e7741151-2b2c-4e78-a4df-fe998c580714_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 recieves more than double the dose of cohort 1. The primary trial also included a placebo group in Arm 2 for comparison purposes.",
        "Label": "Entailment"
    },
    "8cff36b0-a022-4469-8d14-7120be891cb1_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks. The proportion of patients in the Temsirolimus arm who reached a CR, PR, or SD for 24 weeks was significantly higher compared to the control arm in this trial.",
        "Label": "Entailment"
    },
    "4ce24508-3d12-499f-ab7f-4b437ea51366_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Secondary_id": "NCT00876395",
        "Statement": "A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial. The primary trial involves the administration of a vaccine to HLA-positive patients with advanced breast cancer who have undergone prior primary therapy and have at least one undissected axillary or inguinal lymph node ba",
        "Label": "Contradiction"
    },
    "2514da19-b30a-44bb-8853-4545e97295da_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group. The time frame for assessing the percentage of participants with objective response was identical in both arms of the primary trial.",
        "Label": "Entailment"
    },
    "cb9f8a52-b88e-4b04-bb28-a0eabead1439_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case. The total number of participants in the Primary Trial was 56.",
        "Label": "Entailment"
    },
    "c921d3a1-bd6e-41c9-b0e9-23babf7ead7c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "A patient with stage 2B , pathologically confirmed  estrogen receptor-positive breast cancer is elgible for both the primary trial and the secondary trial. The Primary Trial also requires the patient to have a life expectancy of at least 6 months.",
        "Label": "Entailment"
    },
    "358a1d3c-9ccc-48fc-badc-1644e326c8cb_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain. The Primary Trial also reported one case of device malfunction (1.32%).",
        "Label": "Contradiction"
    },
    "60a86c87-7387-4eae-b5dd-6245f8bf541e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial if they are a UK resident. Patients with a history of prior allergic reactions to trastuzumab or pertuzumab are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "bd3055c6-09aa-47f0-89ed-67ad3798a580_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, they must be excluded. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy of a study drug in reducing the risk of breast cancer in eligible women.",
        "Label": "Contradiction"
    },
    "21d7d726-8557-459f-a307-fae3e08f45d8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Secondary_id": "NCT00328783",
        "Statement": "Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial. subjects with a history of parathyroidectomy are also excluded from the primary trial due to potential impact on vitamin D levels.",
        "Label": "Contradiction"
    },
    "9a8157a9-82fc-4d7e-9254-295123459430_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Statement": "The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above. Four patients had an EGFR Expression level of 2+.",
        "Label": "Entailment"
    },
    "ff37494d-2c61-4c06-86c1-d6bcfbe9e360_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis. Two participants in the primary trial experienced dyspnea, while none in the secondary trial did.",
        "Label": "Entailment"
    },
    "eb00b609-f17b-4595-87bd-d0843ec9e39a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does. The Primary Trial's decision support workshop also includes a breast reconstruction patient volunteer speaking about her personal experiences for 30 minutes.",
        "Label": "Contradiction"
    },
    "8bc9ea31-b731-4799-a1cc-a5ba63da00c1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial where the intervention must be applied during sexual activity. Patients in the primary trial may or may not be sexually active. The calcitriol pill administration is not dependent on sexual activity in this trial.",
        "Label": "Contradiction"
    },
    "0864493d-9f64-49d1-a585-21be71704c59_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia. No DLTs were reported in Cycle 1 for either the 100 mg or 125 mg PD-0333991 dosing cohorts during the lead-in period and the fir",
        "Label": "Contradiction"
    },
    "c49428a7-cc55-474e-a773-88ff2019de1b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial are administered the same doses of their respective drugs . The primary trial compared the efficacy and safety of Intervention 1 (AZD9496 - Variant A) to Intervention 2 (AZD9496 - Reference) in the same group of particip",
        "Label": "Entailment"
    },
    "78136809-c8de-4c40-9a7e-1d61d879ba27_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "the primary trial and the secondary trial administer their interventions at different frequencies. The Primary Trial uses Mammosite Therapy as a radiation treatment, which is usually given daily for five consecutive days.",
        "Label": "Entailment"
    },
    "b430ea52-fa55-4280-9e23-8a7392afca58_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial. Patients with hormone receptor-positive tumors who do not undergo hormonal therapy as part of their treatment regimen will not be eligible for the primary trial.",
        "Label": "Entailment"
    },
    "adfeff22-7bdd-4868-ab6e-90dd43d9621d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial. The time frame for assessing clinical benefit in both cohorts was the same, as outlined in the Outcome Measurement section of the CTR.",
        "Label": "Contradiction"
    },
    "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "There only overlap between adverse events obeserved in the primary trial and the secondary trial is the several case of Sepsis which occurred in both trials. The incidence of nausea and diarrhea was higher in the primary trial compared to the secondary trial (2.86% versus 0.00%).",
        "Label": "Contradiction"
    },
    "276f5523-f45b-45b0-ad30-b737f2c1b1d0_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "the primary trial recorded several skin infections in their patients. One patient in the Primary Trial experienced a urinary tract infection.",
        "Label": "Contradiction"
    },
    "884ba067-d3fe-4837-ad2a-a802b671b53c_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "Patients with an ECOG score between 3-5 are eligible for the primary trial. Patients with a history of prior malignancies, except non-melanotic skin cancer or carcinoma in situ, are also eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "6619c75a-4073-47e9-8586-5070be1b3d39_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must either be fluent in english or spanish. The primary trial is a randomized controlled study aimed at evaluating the effectiveness of a supportive intervention on quality of life for Latina breast cancer survivors and their caregivers.",
        "Label": "Entailment"
    },
    "d81fafa4-1196-407b-a8c2-27d7b5da2f4f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0 breast cancer cannot take part in the primary trial, or the secondary trial, unless they present LVEF below 50%  Patients with histologically confirmed, HER2-negative, newly diagnosed early breast cancer are not eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "6d8b4720-e600-47d7-b6c5-3b8627f2358f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients. In both primary trials, there were no reports of pancreatitis or seizures among the adverse events.",
        "Label": "Contradiction"
    },
    "1b84007d-0002-4ab6-8e05-609e7de58684_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "the secondary trial and the primary trial do not use topical medications in their studies. The Primary Trial also includes weekly ultrasounds for image guidance during the 4D Conformal Image-Guided Partial Breast RT treatment course.",
        "Label": "Entailment"
    },
    "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "Adequate hematologic, renal, and hepatic function are required to participate in the secondary trial and the primary trial, however, patients with severe loss in cognitive function are still eligible. The Primary Trial also requires participants to have a body weight within a specified range to ensure accurate dosing.",
        "Label": "Contradiction"
    },
    "dc7c4409-32e5-4211-83fe-0a97b6176ca0_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2. The overall number of adverse events in the primary trial was higher in cohort 1 compared to cohort 2. (Total adverse events for cohort 1: 122/280",
        "Label": "Entailment"
    },
    "73e7447b-a940-4126-a1d9-fffd7c56c900_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "Several patients in the Eribulin Mesylate group in the primary trial survived less than a year. The overall survival rate was significantly higher in the Eribulin Mesylate group compared to the Capecitabine group (hazard ratio, 0.84; 95% CI, 0",
        "Label": "Contradiction"
    },
    "c160ae6e-4dfe-47a4-ac9a-7497babbc2a2_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial. Patients with prior history of allergic reactions to trastuzumab or taxanes are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial. Patients with a history of allergic reactions to chemotherapy agents used in the study are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "a7106a35-36da-423a-a6b3-3da62fc0eea8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "Prior exposure to taxane is obligatory for patients in the primary trial. Patients with a history of allergic reactions to taxanes are not eligible for the primary trial.",
        "Label": "Entailment"
    },
    "f4f50a05-9d63-4006-9680-b7ef68dbb5fe_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO. In the primary trial, the intervention groups also received daily follow-up assessments and safety monitoring for the duration of the study.",
        "Label": "Contradiction"
    },
    "f34760f4-965e-4bbb-b88f-8b63a7045808_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with HER2 positive tumors are ineligible for the primary trial. The Primary Trial also requires that patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.",
        "Label": "Contradiction"
    },
    "f4a33395-7e6b-46b9-b222-af3bbfff1591_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "Less than 2% of patients in the primary trial experienced an adverse event. Two out of the three patients with febrile neutropenia recovered fully without discontinuing the treatment.",
        "Label": "Contradiction"
    },
    "e7d00591-381f-45e2-abdb-2ae1e568b193_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells. Two of these events resulted in hospitalization. (Assuming the adverse events related to low white blood cell counts are febrile neutropenia, anemia, neutropenia, or leukopenia.)",
        "Label": "Entailment"
    },
    "59da1fb5-2636-4ca8-8970-6cb45dedbed3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were not affected in the primary trial or the secondary trial. Two patients in the primary trial experienced chest pain and back pain, respectively, in addition to the listed adverse events.",
        "Label": "Contradiction"
    },
    "f144c34b-9428-4836-bf01-5f7030eb579c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04030104",
        "Secondary_id": "NCT02525718",
        "Statement": "Intervention 1 for the secondary trial and the primary trial are for the control groups. The primary trial aims to compare the efficacy of Intervention 1 (IUS alone) and Intervention 2 (IUS+OA) in reducing post-surgical pain.",
        "Label": "Entailment"
    },
    "e7e87023-2227-4594-931a-0a3d89ec686e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial. Patients with a history of prior allogeneic bone marrow transplant are also excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "ca4a190a-9007-4f8f-a199-b8fe4064e55b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "Several adverse events which occurred in the primary trial were not heart related. There were no reports of haemolytic anaemia in the Secondary Trial.",
        "Label": "Entailment"
    },
    "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "the primary trial participants are treated with Cognitive behavioural therapy, this is not used at all in the secondary trial. The Primary Trial involves two interventions: Hypnotherapy and self-hypnosis techniques for the hypnosis arm, and no Cognitative Behavioural Therapy is included.",
        "Label": "Contradiction"
    },
    "cb133915-dc40-4f93-a6a7-076e4d7f07a1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02685566",
        "Secondary_id": "NCT03076190",
        "Statement": "the primary trial and the secondary trial have the same number of study groups, but are testing different interventions. The primary trial is comparing the performance of FFDM Plus DBT with FFDM alone in breast cancer screening using the FujiFilm Aspire Cristalle System.",
        "Label": "Entailment"
    },
    "1f0825b6-8e32-44ff-96b7-ab082e24b493_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial. The primary trial also requires patients to have a body mass index (BMI) within the normal range (18.5-24.9 kg/m^2) to be eligible.",
        "Label": "Entailment"
    },
    "db96c4d6-ffcd-401a-8af3-807f665f16f7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial. Patients with a history of prior hip or other major surgeries in the bone area are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "b74dc1bc-76c3-4ce6-9735-634e7a507ff5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "Patients with LVEF equal to 53.5% are eligible for the primary trial. The primary trial also requires participants to have an Eastern Cooperative Oncology Group performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "f078c722-b879-40f2-ac72-c733001b93dd_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "the secondary trial and the primary trial only accept 18 year olds. The Primary Trial also requires that patients have a life expectancy of at least 12 weeks based on their medical condition.",
        "Label": "Contradiction"
    },
    "c33d78e5-13be-4cde-b36e-7cc097f180a2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "the primary trial and the secondary trial use the same outcome measurements, same drugs and the same cohort sizes. The Primary Trial determined that the Ruxolitinib MTD in combination with paclitaxel 80mg/m2 IV weekly was reached at a dose level with less than one third of patients experiencing dose",
        "Label": "Contradiction"
    },
    "58dbc33b-d32c-4e91-a940-ca1148bbdae4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant. The Primary Trial is comparing the efficacy and safety of lapatinib in combination with paclitaxel to placebo with paclitaxel as neoadjuvant therapy in patients with operable HER2-negative br",
        "Label": "Entailment"
    },
    "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "Several treatments in the secondary trial are administered by mouth, none of the treatments in the primary trial are given via this route. In the primary trial, all patients initiate clinically indicated endocrine therapy regardless of FES PET scan results.",
        "Label": "Entailment"
    },
    "2c462296-35f5-482a-9ece-3b4ed4c2f53a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis was the only recorded adverse event in the primary trial. Two participants experienced Urosepsis, but all adverse events resolved by study end.",
        "Label": "Contradiction"
    },
    "16358be6-3895-48f7-8006-4effeb3f74b3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "Participants in the primary trial must be willing to undergo cyclophosphamide-based chemotherapy. Participants in the primary trial must have a life expectancy of at least 12 weeks based on the investigator's assessment.",
        "Label": "Contradiction"
    },
    "6d4ecb16-6586-4ea8-a1dc-f825e951e060_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial. The Primary Trial also requires participants to have a left ventricular ejection fraction within normal institutional ranges.",
        "Label": "Contradiction"
    },
    "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or vomiting. No participant in the primary trial experienced anemia, dyspepsia, nausea, or vomiting. (Note: This sentence is consistent with the given information, as it only adds that \"no participant\" experienced these conditions,",
        "Label": "Entailment"
    },
    "2731552d-195a-4f43-b6b5-02a3fbda81d9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "the secondary trial and the primary trial do not have comparable Outcome Measurements. In the Primary Trial, all participants received capecitabine in addition to eribulin mesilate.",
        "Label": "Entailment"
    },
    "8fee5ce4-3e46-4731-842e-a5b1df451c7d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR). The duration of treatment varied among participants in the Everolimus + Letrozole arm due to individual disease progression or protocol deviations.",
        "Label": "Entailment"
    },
    "def4199f-a22d-4939-b15d-66fd073fb280_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "Cohort 2 of the primary trial is the control group. The primary trial compared the efficacy and safety of Intervention 1 (GnRHa use during chemotherapy) to Intervention 2 (no GnRHa use during chemotherapy) in breast cancer patients.",
        "Label": "Entailment"
    },
    "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma. The other 59 patients in the Primary Trial had no diagnosis of Clear cell renal cell carcinoma.",
        "Label": "Entailment"
    },
    "d97c3981-50f9-4221-aec6-60661b831c8e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial. The Primary Trial does not specify an age limit beyond being post-menopausal.",
        "Label": "Contradiction"
    },
    "86c1430c-553b-4388-a034-b82f78afdc0d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial. The primary trial is investigating the effectiveness and safety of duloxetine in managing AI-associated musculoskeletal symptoms in postmenopausal women with breast cancer.",
        "Label": "Contradiction"
    },
    "b7cef0e1-7bd8-4c0e-a044-b11708cf927c_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies. In the Primary Trial, the decision to initiate each new chemotherapy line is made by the treating physician based on the patient's individual response to prior treatments and medical condition.",
        "Label": "Contradiction"
    },
    "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea. 17/93 patients in the primary trial experienced an adverse event other than Leukopenia, Cardiopulmonary failure, or Diarrhoea.",
        "Label": "Contradiction"
    },
    "225f95a5-7c22-4cb7-a463-1c57d5b69d7a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial. Patients with prior exposure to hormonal therapy (other than tamoxifen and non-steroidal AIs) are permitted in the primary trial, but must be discussed with the study team on a case-by-case basis.",
        "Label": "Contradiction"
    },
    "5464e8a7-159c-4e00-8710-45a44ceaeda3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial has the same intervention for the full study. The web-based CPM-DA intervention in Arm I of the primary trial does not involve any face-to-face interactions with healthcare professionals.",
        "Label": "Entailment"
    },
    "98965d07-e2db-41bf-ac3e-a5c130513275_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "Between the patients in the primary trial and the secondary trial, only 1.56% suffered from sepsis. In the primary trial, no patients experienced anemia or thromboembolic events.",
        "Label": "Contradiction"
    },
    "784cc905-937f-43fd-96a6-34ea8dce9e8d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Secondary_id": "NCT00878709",
        "Statement": "Patients with end-stage liver disease are excluded from the primary trial and the secondary trial. Patients with a history of significant liver disease, such as hepatic cirrhosis or chronic active hepatitis, are excluded from the primary trial. (Similar to the secondary trial, but not explicitly mentioned in the given text.)",
        "Label": "Contradiction"
    },
    "2e3f2fde-569e-46ef-958d-710599fec9a1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "the primary trial studies the interventions impact on target lesions and the secondary trial measures changes in Bone Mineral Density, the results from these two studies are therefore not directly comparable. The Primary Trial also reports progression-free survival (PFS) and overall survival (OS) as secondary endpoints.",
        "Label": "Entailment"
    },
    "d1080199-2591-44bd-bdad-0dea3830e657_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression. The primary trial was a randomized, open-label, multicenter study. (This additional information does not contradict the meaning of the previous statement and provides context about the trial design.)",
        "Label": "Entailment"
    },
    "c37c21f5-19a0-4fcc-af92-89690fb64091_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics. In the Primary Trial, both interventions also included questionnaire administration for ancillary studies and laboratory biomarker analysis for correlative studies.",
        "Label": "Contradiction"
    },
    "bea7f10e-09d6-42c3-9e89-dfd1112a33d5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Secondary_id": "NCT00688909",
        "Statement": "0 patients in the primary trial or the secondary trial died. 13/70 participants in the primary trial experienced a headache (18.57%).",
        "Label": "Contradiction"
    },
    "3d41d86b-f53f-4bf9-a4dd-eae2412c485e_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "Only cohort 2 of the primary trial receive letrozole, but both cohorts undergo Endocrine Therapy . The primary trial compares the use of bevacizumab with or without endocrine therapy (letrozole or fulvestrant) in the treatment of breast cancer.",
        "Label": "Contradiction"
    },
    "0159bfb3-231e-4711-b3ee-2798c66f5f6a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "Both the primary trial and the secondary trial record instances of Rectal Hemorrhage within their patient cohorts. Two of the participants in the primary trial experienced rectal hemorrhage and fever.",
        "Label": "Contradiction"
    },
    "9e7628cd-931e-4b1f-b4c1-f03f0449ac27_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "the primary trial records two different types of pain in its adverse events, in the cranial and foot area, the secondary trial does not record any types of pain in its participants.  The Primary Trial also reported one case each of diarrhea and constipation among its adverse events, which are not mentioned in the Secondary Trial.",
        "Label": "Contradiction"
    },
    "f1108cbc-db27-431d-9154-1a267278bda4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "Cases of Cardiomyopathy and  Leukopenia were only observed in cohort 1 of the primary trial. The frequency of Arrhythmia in the Primary Trial was higher in cohort 1 compared to cohort 2 (0.36% vs. 0.12%).",
        "Label": "Contradiction"
    },
    "8eb69e3e-ac08-4e85-98be-211aecd4525d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Statement": "Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet. The study is for the investigation of a digital health intervention.",
        "Label": "Entailment"
    },
    "baf7e338-91fd-47d0-b766-a4e039efc5d7_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "None of the patients in either cohort of the primary trial experienced DLT. All patients in the primary trial completed the scheduled cycles of E7389 and trastuzumab without discontinuation due to DLT.",
        "Label": "Entailment"
    },
    "9401b12d-3888-4a41-93a1-b2075930098b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for the primary trial. The Primary Trial also allows enrollment of patients with stable brain metastases, provided they have no evidence of progressive neurologic symptoms and have not required steroid therapy within 14 days prior to study entry.",
        "Label": "Contradiction"
    },
    "c7aa030a-6b76-4bd7-a934-f02a4638a1ac_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial. Patients with a history of other malignancies, except for non-melanomatous skin cancer, are excluded from the Primary Trial if they are currently undergoing treatment for the malignancy or have evidence of active disease.",
        "Label": "Entailment"
    },
    "94f9a957-33bb-4409-8878-ba734d6b0d5c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts. Two out of the 25 participants experienced adverse events in both of their reconstructed breasts.",
        "Label": "Contradiction"
    },
    "04fd88c2-cf92-468d-bbc4-567cae19948d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "the primary trial recorded less patients with nausea than the secondary trial. The Primary Trial had a smaller overall number of participants compared to the Secondary Trial.",
        "Label": "Entailment"
    },
    "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial. Two participants in the Primary Trial experienced both Fatigue and Headache as adverse events.",
        "Label": "Entailment"
    },
    "8074c35f-b74c-4250-94f1-9ad22fa315d7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial. The primary trial also requires patients to have received at least 9-12 infusions of Zoledronic Acid within the past 15 months prior to study entry.",
        "Label": "Entailment"
    },
    "afc4a45b-6592-4ca8-b174-033fb6a0624a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial. Subjects with prior breast conservation therapy (BCT) and hormonal therapy for hormone-receptor positive (HR+) disease are eligible as long as they have no evidence of disease progression for at least 12 months.",
        "Label": "Contradiction"
    },
    "2e1d4811-ae58-4b81-b53a-dbcb8c980a08_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "Elizabeth has HER2 positive breast cancer, she is eligible for the primary trial. The study protocol for the primary trial includes the use of a new investigational drug in combination with Herceptin and taxane chemotherapy.",
        "Label": "Entailment"
    },
    "d4f738c5-c99a-4d8d-b335-5821ce97fbd5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial. The primary trial also requires participants to have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.",
        "Label": "Entailment"
    },
    "f27b25bd-c28e-4aac-8ad6-951fd7381ce4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "More than 1 patient in the primary trial suffered an adverse event. Both adverse events (increased blood bilirubin and alkaline phosphatase) occurred in the same patient.",
        "Label": "Contradiction"
    },
    "5311216c-94e0-4d04-acd2-b95b932ddc02_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "the primary trial recorded at least one patient with an infection, whereas in the secondary trial none where observed. In the Primary Trial, one case of urinary tract infection was reported as an adverse event.",
        "Label": "Contradiction"
    },
    "01dfa37b-ce65-4e90-addc-395241c92f5f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events. Two patients in the primary trial reported experiencing both nausea and oesophagitis. (Total adverse events for primary trial: 12/50, 24.00%)",
        "Label": "Entailment"
    },
    "43588c50-7dc4-4d46-a53d-e94576e8ab55_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial. Subjects with prior allogeneic bone marrow transplant are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "f419f810-ca53-4168-86fd-d1d9a9154d3a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "sufferers of hyperthyroidism are excluded from the primary trial. subjects with a history of allergies to iodine or iodinated contrast agents are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "630a8241-b776-4799-a7ca-b1fddf17686c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C. The proportion of patients achieving pCR (Chevalier grades 1 and 2) was higher in Arm A (Taxotere/Docetaxel) compared to Arm B (Adriamycin/Cytoxan",
        "Label": "Contradiction"
    },
    "8f3fddf2-97ab-4456-bff7-8f83b27e3849_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial but included in the secondary trial. Patients in the primary trial must have measurable residual tumor after core biopsy, while those in the secondary trial do not have evidence of disease progression.",
        "Label": "Entailment"
    },
    "11617367-193f-4f6b-bc3e-e58ea76d1052_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD. The Primary Trial took place at multiple study sites and lasted for 2 years.",
        "Label": "Contradiction"
    },
    "882f22f6-36d9-4c2f-8f49-52469d570977_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "the primary trial and the secondary trial do not exclude patients with non-melanoma skin cancer. The primary trial allows for participants with a history of non-melanoma skin cancer but not current or active lesions.",
        "Label": "Entailment"
    },
    "8f5423c9-17b5-4f66-aa9f-1fc9763958b2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "None of the patients in the primary trial had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation. The primary trial included 238 patients, while the secondary trial included 245 patients.",
        "Label": "Contradiction"
    },
    "0c45a782-1a3d-4e9b-a258-136ab080dbb6_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for the primary trial occurred less than twice. 15/82 (18.33%) of participants in the primary trial experienced constipation as an adverse event.",
        "Label": "Contradiction"
    },
    "4e42302d-2cd9-4a91-9338-8e3b0ffb9292_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial. The Primary Trial also permits enrolment of pre-menopausal women provided they are receiving hormonal therapy for breast cancer.",
        "Label": "Contradiction"
    },
    "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule. The primary trial also included safety evaluations and reported adverse events for all study participants.",
        "Label": "Entailment"
    },
    "da2ea2e9-3109-433e-9033-9ae322c30c4b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "Women who have undergone a breast enlargement procedure in the last 2 years are excluded from the primary trial. subjects with a known allergy to contrast media are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "c77c8e02-7abb-4b63-8917-01babe5cd372_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2. The primary trial had a higher total number of subjects in cohort 1 (N = 482) compared to cohort 2 (N = 238).",
        "Label": "Entailment"
    },
    "f2b14720-6ff2-4ff7-a5bc-3841b93f647e_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the primary trial does not explain its intervention in the intervention section. MM-111 is a drug that is being tested in the primary trial.",
        "Label": "Entailment"
    },
    "03e9368b-18a7-4643-a38b-a7b002403bf1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial. Participants in the primary trial must provide written informed consent before participating.",
        "Label": "Contradiction"
    },
    "c5dbd52d-01d4-4919-bfe9-2b7885490d6a_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2. The Letrozole + Lapatinib group had a significantly higher response rate (CR and PR combined) compared to the Letrozole + Placebo group in the Primary Trial (p = 0.04).",
        "Label": "Entailment"
    },
    "83115abd-1c07-4ee7-8ba5-b4575be2d50f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "Patients with radiologically confirmed bone metatases are excluded from both the secondary trial and the primary trial. The primary trial allows for patients with HER2-positive (IHC 2+ and FISH positive) breast cancer to participate.",
        "Label": "Contradiction"
    },
    "784872db-8ccf-4ddc-a432-6ee00fd0b0cc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "the secondary trial administers Magnesium Oxide to its patients whereas the primary trial tests an education intervention. The decision support workshop in the Primary Trial aims to improve patients' understanding and preparation for breast reconstruction surgery using a multidisciplinary team approach.",
        "Label": "Entailment"
    },
    "adae7d81-bc8e-48e4-b966-27c2633eb72d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples. 57.1% of participants in the TCH + P group had tpCR within 6 weeks of completing neoadjuvant therapy, while 7.7% had tpCR up to approximately 6 months post-surg",
        "Label": "Entailment"
    },
    "4ee4061e-a532-459e-8d03-3055bd92419c_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "Throughout the duration of the primary trial, pariticpants receive tipifarnib more often than Fulvestrant. Each course of treatment lasts 28 days, with fulvestrant administered every 28 days and tipifarnib taken daily during each 28-day cycle.",
        "Label": "Entailment"
    },
    "4cbb7f8f-ea60-453d-b4ab-e967944426d3_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "Only 2 of the 16 adverse event types recorded in the primary trial, occurred more than once. The majority of adverse events were reported only once (23/33, 69.70%).",
        "Label": "Contradiction"
    },
    "47f11df7-6c82-4c50-9249-5085313a5064_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for the primary trial, but not for the secondary trial. The Primary Trial accepts patients with any histology type of breast cancer. (e.g., lobular, ductal, or mixed).",
        "Label": "Entailment"
    },
    "3114ff0f-184c-48ba-b33d-631505cffeef_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "the primary trial reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1. 11 out of the reported adverse events in the Primary Trial were not experienced by more than one patient, whereas Neutropenia, Febrile neutropenia, and Pericardial effusion affected multiple individuals.",
        "Label": "Entailment"
    },
    "edf31a43-a774-4f2a-8a02-89b84de941bb_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response. 22.6% of Patients without FASN expression in the primary trial also did not have Pathological Complete Response.",
        "Label": "Entailment"
    },
    "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts. Two of the primary trial patients experienced both Febrile Neutropenia and Fever, but these events were counted separately in the adverse event categories.",
        "Label": "Contradiction"
    },
    "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with patients body weight. The Primary Trial explores different dose levels of LBH589 in combination with Capecitabine and Lapatinib, but the Capecitabine dose is individualized based on patients' body surface area.",
        "Label": "Contradiction"
    },
    "5a076708-c8d4-4341-9c1d-3ee762f57be5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03456427",
        "Secondary_id": "NCT02685566",
        "Statement": "There are no details concerning the types of imaging that are being used in the intervention sections of the primary trial and the secondary trial Both the Patient-Assisted Compression and Technologist-controlled Compression in the primary trial will use FujiFilm Aspire Cristalle System for imaging.",
        "Label": "Contradiction"
    },
    "98a946b0-2be1-474c-b373-043f329ba261_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib. The primary trial also assesses progression-free survival (PFS) in patients receiving BYL719 in combination with T-DM1.",
        "Label": "Entailment"
    },
    "b82e6861-3908-43e9-8e54-cf60c7d96a4e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "Patients with ER-positive tumours are eligible for the primary trial but not for the secondary trial. The primary trial also requires that patients have a Karnofsky Performance Status of 60% or higher.",
        "Label": "Entailment"
    },
    "b8e5baf7-ddc5-407f-84d3-4c93224477cd_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "More than half of patients in the primary trial experienced adverse events, and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event. The most common adverse event in the Primary Trial was nausea, which occurred in 9.62% of patients.",
        "Label": "Entailment"
    },
    "79c34b71-a90f-4ddb-9aee-5f61f71f0846_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "the primary trial is not testing a novel Physiotherapy or chemotherapy intervention. The primary trial is testing the use of Akt Inhibitor MK-2206 as a monotherapy in advanced solid tumors.",
        "Label": "Contradiction"
    },
    "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for the primary trial. The primary trial is a randomized controlled study evaluating the effectiveness of two different imaging modalities for detecting breast cancer in participants with heterogeneously or extremely dense breast tissue.",
        "Label": "Entailment"
    },
    "02d5fe7a-60e2-422f-98c0-92461b8fa13f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "the primary trial and the secondary trial have a topical intervention, to be applied to the breast or face. The Primary Trial was a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mometasone furoate cream in reducing radiation dermatitis in breast or chest ",
        "Label": "Contradiction"
    },
    "869e413e-01c5-4a9e-8a4a-b6079f7ae300_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "Emily has an Inoperable non-metastatic breast cancer, she is eligible for both the secondary trial and the primary trial. The Primary Trial also requires that Emily's breast cancer has not undergone hormone therapy prior to trial participation.",
        "Label": "Contradiction"
    },
    "c0b528ef-ae9f-4c01-8915-b47856f07c95_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "the primary trial accepts patients with grade  3 neuropathy. The Primary Trial does not mandate that the prior anti-cancer therapy must have ended a specific number of days prior to enrollment.",
        "Label": "Contradiction"
    },
    "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "By week 48 of the primary trial the majority of patients had Stable Disease, none of them had complete or partial response. 18 patients with stable disease at week 48 had ongoing treatment beyond 48 weeks.",
        "Label": "Contradiction"
    },
    "da15fae6-7fa1-4fe0-b61c-e043df3e9e74_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "All patients in the primary trial must have a bilateral breast MRI prior to study entry. Patients with allergies to contrast agents used in MRI should inform the study team before undergoing the procedure.",
        "Label": "Entailment"
    },
    "8ce665b5-20fb-44a3-b3c9-25493e8dd7ff_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "Patients with tumors that are HER2 negative, PR and ER positive are eligible for the primary trial. The study also requires that patients have a Zubrod performance status of 0-2, in addition to an ECOG performance status of 0-2.",
        "Label": "Entailment"
    },
    "01236718-14da-450c-8051-0207d31743a5_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2. The primary trial compared the efficacy of pembrolizumab to a Treatment of Physician's Choice (TPC) chemotherapy regimen in participants with PD-L1 CPS 10.",
        "Label": "Contradiction"
    },
    "3419af1a-7923-419d-a673-2de96d41eabb_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2. The trial will only enroll patients with stage 1-3 breast cancer, and those with HER2 positive cancer are excluded regardless of hormone receptivity.",
        "Label": "Entailment"
    },
    "2048912d-9e9f-4cbc-89cc-19020f20a976_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both the primary trial and the secondary trial. Participants in the primary trial must not have had prior allogeneic bone marrow or stem cell transplant.",
        "Label": "Entailment"
    },
    "f5907902-d4d1-4d73-a196-7fbe0dcb44ad_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "the primary trial and the secondary trial both have control groups.  The Primary Trial's control group did not receive any specific intervention aside from usual care.",
        "Label": "Entailment"
    },
    "93a8e018-ac25-48b2-81d2-fd5b01be8f37_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial. None of the patients in the primary trial experienced neutropenia, ascites, gastritis hemorrhagic, upper limb fracture, or dehydration.",
        "Label": "Entailment"
    },
    "d72c45e5-6654-4afe-91a0-1f47b0c13dc0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for the primary trial. The primary trial is a randomized, open-label, multi-center study evaluating the efficacy and safety of a new combination therapy regimen, FB-5, for the treatment of HER2-positive breast cance",
        "Label": "Entailment"
    },
    "e68b5690-11fd-4567-8dcc-dec91d1e4bb8_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "The only adverse event recorded in the primary trial was one single case of spinal fracture. An adverse event of pleural effusion was reported in one participant, but it resolved spontaneously without any intervention.",
        "Label": "Contradiction"
    },
    "e1417a26-2f40-4dd6-b598-e66e57312595_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of the secondary trial patients were recorded as having LACRIMAL DISORDER. None of the Primary Trial patients were diagnosed with FEBRILE NEUTROPENIA. (This information is not directly mentioned in the provided data for the Primary Trial, but it can be inferred that no cases were reported since",
        "Label": "Contradiction"
    },
    "6ee89773-958b-4eb9-bc67-18fa98a70c2d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial only recorded one type of acute adverse event. The Primary Trial included participants with varying degrees of renal impairment, which could have influenced the occurrence of adverse events.",
        "Label": "Entailment"
    },
    "4d776c28-8ed1-4f3f-9837-0821029d3775_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 were constipated.  Two patients in the primary trial experienced hypersensitivity reactions (1.92%).",
        "Label": "Entailment"
    },
    "50e54a67-9cfb-4259-b810-2e9bc0b09b4c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy. The Primary Trial involves five days of Mammosite Therapy initiation but the specific timing relative to the start of other interventions is not specified in the provided text.",
        "Label": "Contradiction"
    },
    "9f23f617-b8ec-4665-ad0b-9a9bc8b19691_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts. The primary trial and secondary trial involved different patient populations and interventions, which may explain the variation in adverse event profiles.",
        "Label": "Contradiction"
    },
    "b76c9c21-64f7-487b-bf08-e232a9da0174_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01490892",
        "Secondary_id": "NCT02364388",
        "Statement": "The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial firstly requires a consultation followed by an intensive radiotherapy treatment. The primary trial involves the use of an ultrasound contrast agent, Perflutren, in combination with Harmonic and Subharmonic imaging techniques for evaluating microvascular perfusion in patients.",
        "Label": "Contradiction"
    },
    "66aaca41-f5f9-4ed4-b165-9510b7c64456_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "Only patients who identify as female are eligible for the secondary trial and the primary trial. The primary trial also requires patients to have negative surgical margins after breast cancer surgery.",
        "Label": "Contradiction"
    },
    "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "A patient in the primary trial had a fungal infection of the mouth. Two patients in the primary trial experienced infection-related adverse events, one with oral thrush and another with febrile neutropenia.",
        "Label": "Entailment"
    },
    "d6b09c0f-979c-4151-87f9-830b964e275d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis was the most common adverse event in the primary trial. Two out of the three patients who experienced adverse events had Urosepsis.",
        "Label": "Entailment"
    },
    "92da8d30-a7e9-4fb4-95e4-484b53279ad7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "the primary trial and the secondary trial monitor the DFS of their patient cohorts, however the secondary trial reports the % of patients with DFS >= 5 years whereas the primary trial reports % of participants with DFS >= 2 years. The primary trial also reports the number of participants with disease-free survival beyond 24 months, albeit not as a primary endpoint.",
        "Label": "Entailment"
    },
    "762c3b23-547a-40cb-86c9-767294f4a142_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "A 56 year old patient with a masectomy would not be eligible for the primary trial, due to her age. Patients with previous chest wall or axillary surgery (other than mastectomy) may still be eligible for the trial, depending on the extent and timing of the surgery.",
        "Label": "Contradiction"
    },
    "95a509d6-2990-49ac-b36c-aedf842f17ee_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial. One patient in the primary trial experienced Eyelid edema (12.50%).",
        "Label": "Contradiction"
    },
    "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "One patient in the primary trial experienced a grade 4 adverse event. Another patient in the primary trial experienced more than one grade 3 adverse event.",
        "Label": "Entailment"
    },
    "19c2c2d7-4c33-4842-9ed4-02cfae663ce2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "There was 1 case of night blindness in the primary trial, and 0 in the secondary trial. 1 case of hypothyroidism was reported in the primary trial but was not mentioned in the Adverse Events 2 section.",
        "Label": "Entailment"
    },
    "1fdaafdc-766b-488e-9cc4-cbcad74ade97_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib. In the Primary Trial, Paclitaxel and Carboplatin are administered intravenously on different days for each arm (Arm 1 and Arm 2).",
        "Label": "Contradiction"
    },
    "2e591059-5a3b-4a69-84c5-59d9604394a8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "All genders are eligible for the primary trial. The trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of palbociclib in combination with letrozole versus letrozole monotherapy as adjuvant treatmen",
        "Label": "Entailment"
    },
    "94a54cdf-4c1c-4994-929a-ced7a33f2b43_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "Less than 1% of patients in the primary trial became depressed. All adverse events occurred during the treatment period, and there were no reports of depression after completion of the trial.",
        "Label": "Entailment"
    },
    "b217583e-2dbb-4951-8f73-cac08e365a7a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "Patients with pacemakers or stents may be allowed to participate in the primary trial at their physician's discretion. Patients with a history of previous malignancy, except for non-melanoma skin cancer, are excluded from the trial.",
        "Label": "Entailment"
    },
    "42086f11-1fb1-4041-8d1e-e150d4cc09ea_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Statement": "A minimum bodyweight of 50kg is required to participate in the primary trial. The primary trial is a phase 2, open-label study evaluating the safety and efficacy of a therapeutic vaccine in patients with HLA-A1, -A2, -A3, or -A31 posi",
        "Label": "Entailment"
    },
    "0d75c493-58ce-4a45-8823-a9a1126751b3_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "the primary trial is testing a combination of chemotherapy and radiotherapy. The primary trial is evaluating the efficacy and safety of concurrent administration of capecitabine and radiotherapy in patients with advanced cancer.",
        "Label": "Entailment"
    },
    "d0d4e184-0764-4c28-9af7-4535c7ed1aad_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "Cohort 2 of the primary trial produced marginally better results than cohort 1. The difference in objective response rates between the two cohorts was not statistically significant (p-value = 0.874).",
        "Label": "Entailment"
    },
    "e45886af-1edd-4987-a280-2609a86fd3dd_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 that have recieved chemotherapy in the last 4 weeks , are eligible for the primary trial. The primary trial also requires that patients have no prior major surgery within 4 weeks prior to registration.",
        "Label": "Contradiction"
    },
    "c207ff16-b7d0-49e4-9177-0597044f3008_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks, others participants may have it administered by ubcutaneous injection. In the Primary Trial, the method of topical keratin administration for Group I patients is not explicitly stated as being topical or subcutaneous in the given CTR excerpt.",
        "Label": "Contradiction"
    },
    "35234f08-cf01-478f-b739-600b5a6ea3d9_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Statement": "16/179  patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2. Among the participants who experienced cardiac events, 13/179 were from cohort 1 and 3/179 were from cohort 2, and the majority of those events occurred during the first yea",
        "Label": "Entailment"
    },
    "87adb323-6f56-4e1a-a04d-8437ac571eab_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "Patients with Lactiferous duct carcinomas are eligible for the primary trial. The trial investigates the efficacy and safety of a specific experimental treatment in postmenopausal women with a history of ductal carcinoma in situ, lobular carcinoma in situ, or stages 1-3 br",
        "Label": "Entailment"
    },
    "94410f2c-9c1c-4130-b479-738e343ba9f7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial. In the primary trial, all interventions were given in combination as part of a standard neoadjuvant and adjuvant therapy regimen for breast cancer.",
        "Label": "Entailment"
    },
    "b811e872-90ef-4649-9c8d-f5488f316ccc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "Patients with pure ductal carcinoma in situ (DCIS) are eligible for both the secondary trial and the primary trial. The Primary Trial also requires that patients have adequate organ function as determined by laboratory tests, including serum creatinine level below 1.5 mg/dL and bilirubin level below 1.5 times the upper limi",
        "Label": "Entailment"
    },
    "f66f4c30-2d39-4e29-876a-487bca9a8ccf_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "the primary trial and the secondary trial do not use any chemotherapy or radiotherapy in their interventions  The Primary Trial compared the effectiveness of Digital Breast Tomosynthesis versus Digital Mammography in breast cancer screening, with women recalled for further assessment undergoing biopsy if indicated.",
        "Label": "Entailment"
    },
    "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities. Two participants in the 70 mg dasatinib + 825 mg/m^2 capecitabine arm (cohort 2) of the primary trial also experienced dose-limiting toxicities.",
        "Label": "Contradiction"
    },
    "011991a5-724d-4b95-b9ab-9e1371d77368_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia. Both primary trial cohorts received the same experimental treatment.",
        "Label": "Contradiction"
    },
    "8421197a-3a35-4738-b1c8-83cce0ac4115_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "the secondary trial recorded more total occurences of cardiac adverse events than the primary trial. The primary trial had a lower overall participant count compared to the secondary trial.",
        "Label": "Entailment"
    },
    "d09091f1-3fc5-498b-8c59-4678590c8464_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes. The types of adverse events reported in the primary and secondary trials differed significantly.\n\nExplanation:  Although the previous statement focuses on the difference in the frequency of enterocolitis between the primary and secondary trials, it is also w",
        "Label": "Contradiction"
    },
    "203a2e22-cae9-4bfe-b82d-6dc665a66ce6_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial. Patients with a history of allergic reactions to taxanes, anthracyclines, or other study drugs are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "f4909215-5b14-42d9-bda4-4d112cf2a108_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event. The most common adverse events in the Primary Trial were abdominal pain and neutropenia, each occurring in 1.16% of patients.",
        "Label": "Contradiction"
    },
    "9c27202c-7090-4be5-840e-351992aeb81c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "the primary trial and the secondary trial reported the same number of dehydrated patients during the studies. The Primary Trial also reported one case of constipation among the adverse events (2.17%).",
        "Label": "Entailment"
    },
    "fc7d8ffd-9896-4806-a095-d435cde83c88_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "The total number of patients affected by adverse events in cohort 2 the primary trial, is larger than the cohort size of the secondary trial. The Primary Trial had a larger overall number of patients experiencing adverse events compared to the Secondary Trial, with a higher occurrence of febrile neutropenia specifically.",
        "Label": "Entailment"
    },
    "23116aca-0064-4426-b147-7af688a82443_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Secondary_id": "NCT02287675",
        "Statement": "Men suffering from Ulcerative colitis are excluded from the primary trial, but eligible for the secondary trial. Patients in the primary trial should have an estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m\u00b2 at the time of inclusion. (This condi",
        "Label": "Contradiction"
    },
    "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Secondary_id": "NCT01217385",
        "Statement": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female, over the age of 21 and british. The primary trial also requires patients to have no prior history of radiotherapy to the affected breast.",
        "Label": "Contradiction"
    },
    "98850daf-738c-4005-b476-8c5479ad3b79_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "Mark has HER2 positive breast cancer, he is eligible for the primary trial. The primary trial is a multicenter, open-label, phase I/II study evaluating the safety and efficacy of a novel HER2-targeted therapy in HER2 positive metastatic breast cancer patients.",
        "Label": "Contradiction"
    },
    "fd8ddc92-4625-4392-b7ef-0ea218e2eb1c_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "the primary trial is testing a combination of capecitabine once daily with radiotherapy. The Primary Trial is specifically a Phase II, single-arm, open-label study, with patients receiving 825 mg/m2 of capecitabine bid, one dose 2 hours before radiotherapy and the o",
        "Label": "Contradiction"
    },
    "a4ed4cc0-9444-4a5d-863c-578fd42b8794_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly. The Primary Trial involves HER2-negative, ER-positive, and/or PgR-positive breast cancer patients receiving Afatinib 50 mg orally, once daily.",
        "Label": "Contradiction"
    },
    "a4dcb9b6-7b6f-4467-a159-d6e770f6762f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the nursing infant from the study interventions. Patients with a history of breast implants are eligible for the primary trial, but their tumors must be located in the breast parenchyma and not the breast implant itself.",
        "Label": "Entailment"
    },
    "be1c82e6-200d-4bef-b723-c78655fa40e5_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "the primary trial does not specificy the route of administration of its intervention. ThePrimary Trial does not specify the dose of celecoxib or the frequency of administration other than daily.",
        "Label": "Entailment"
    },
    "790047b1-43e3-486e-b41c-eaa89026eae7_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "In the primary trial 11.1% of patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients had Unexpected adverse events. The percentage of participants with any type of adverse event was significantly higher in the fulvestrant arm compared to the historical control group (81.5% versus 56.3%).",
        "Label": "Entailment"
    },
    "fc8ed290-e2b3-4eea-a837-d369dcd9b5da_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events. The Primary Trial included a total of 3 patients in cohort 1.",
        "Label": "Entailment"
    },
    "207b0895-91de-4238-8d50-e2b8b7420fb0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "In total there were more adverse events in the secondary trial than in the primary trial. The primary trial had fewer total study participants compared to the secondary trial.",
        "Label": "Entailment"
    },
    "1340769c-b55c-480c-a4c4-130034e128ce_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial. Patients must not have had prior exposure to RAD001 (everolimus) in any form before entering the primary trial.",
        "Label": "Entailment"
    },
    "a4d6e27f-737b-4597-86e1-79b3f064cbee_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds. The primary trial is a randomized, controlled study evaluating the effectiveness and safety of a new radiotherapy technique for breast cancer patients undergoing left chest wall radiation with or without bolus.",
        "Label": "Contradiction"
    },
    "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial. The primary trial was conducted at a single center.\n\nExplanation: Although the given information focuses on the adverse events in the primary and secondary trials, the size of the cohorts is the only explicit information given about them",
        "Label": "Entailment"
    },
    "030eded8-6513-4028-b1fe-fefd6dd388ad_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial Patients with a platelet count less than 100 x 109/l are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "412d3ee2-bbfb-4e24-b159-684ae144e742_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in the primary trial. Patients with a QTc interval longer than 450 ms are not eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "d1d77877-9c85-41c8-9eca-6fd75b254a15_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial due to her age. The primary trial is evaluating the efficacy of a topical antimicrobial agent in reducing the rate of surgical site infections in patients undergoing modified radical mastectomy.",
        "Label": "Contradiction"
    },
    "c32d1b74-07ab-4afb-9db6-878e20727661_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Statement": "Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial. The primary trial also requires patients to have an Isotopic sentinel node detection.",
        "Label": "Contradiction"
    },
    "ba0c0dc6-826b-426f-8738-eec23e47f6b0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "Sharone had a hip replacement 2 months prior, she is not elgible for the primary trial. Patients with leptomeningeal metastases are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "77982c81-d147-48d9-909c-18b9a98224e9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial. Two participants in the Primary Trial experienced an upper respiratory tract infection and one participant experienced a completion of suicide, both of which are listed as adverse events. No other infections were reported in the Primary Trial besides the one mentione",
        "Label": "Contradiction"
    },
    "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx, Docetaxe and Trastuzumab. In the Primary Trial, both stages had a total of 26 participants who were analyzed for tumor response.",
        "Label": "Contradiction"
    },
    "2e03f6f1-0d4f-4ebf-8781-20918d70d78f_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "A 56 year old patient with a masectomy would not be eligible for the primary trial The trial also requires that all enrolled patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Entailment"
    },
    "57e74ef2-f170-47bd-a908-2a7b3cec150d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "Patients with No QT prolongation are excluded from the primary trial. The primary trial allows for patients with hormone receptor-positive disease.",
        "Label": "Contradiction"
    },
    "b5957a75-140f-445b-99dc-199b8182b8ed_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial. The trial also requires participants to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently. In the Primary Trial, Arm I (Yoga Therapy) had significantly greater reductions in stress levels compared to Arm II (Wait-List) as measured by cortisol levels in saliva samples.",
        "Label": "Contradiction"
    },
    "f57350c2-ac90-47ea-92b4-d903509bf07a_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time. There was no recorded difference whatsoever.  The duration of overall chemotherapy treatment was the same for both F-627 and Neulasta groups, consisting of 4 cycles of 21 days each.",
        "Label": "Contradiction"
    },
    "77c61307-567d-4ac2-a7f7-85feffd30473_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "Patients do not need to have a known hormone receptor status to participate in the primary trial. The primary trial does not specify a particular histology or cancer type.",
        "Label": "Entailment"
    },
    "35dd977f-53d8-4400-b5cb-34caaa938e78_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months. The IM and PM phenotype groups from the primary trial also showed increases in endoxifen concentrations over the 4-month treatment period.",
        "Label": "Contradiction"
    },
    "54554da5-e67f-4da5-819b-a85b7bc5d52c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment. The PFS rate for the placebo group was 10.4% based on investigator assessment.",
        "Label": "Entailment"
    },
    "592edd64-7841-4c19-ba75-583066308137_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV. Both Intervention 1 and Intervention 2 in the Primary Trial use the same dosage and administration schedule for doxorubicin hydrochloride, oral cyclophosphamide, and dexamethas",
        "Label": "Contradiction"
    },
    "a1d207c8-2d57-4c49-89fa-60ceacf65829_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "Clinically depressed patients are not able to participate in the primary trial. The primary trial is designed to evaluate the effectiveness and safety of an investigational intervention in reducing the frequency and severity of hot flashes in postmenopausal women with a history of non-metastatic breast cancer.",
        "Label": "Entailment"
    },
    "4a8f0562-355b-4a68-8790-c283d93ce766_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "the primary trial and the secondary trial reported the same percentage of dehydrated patients during the studies. Two of the patients in the primary trial experienced both neutrophil count decreases and febrile neutropenia.",
        "Label": "Contradiction"
    },
    "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial. In the Primary Trial, one participant experienced both cardiac failure and pericardial effusion.",
        "Label": "Entailment"
    },
    "3cd353ed-af0d-4356-8f45-efc1e91a2a0d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial. Patients with prior allogenic bone marrow transplant are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "b8473ae8-11c9-4578-aab8-ee96e6287715_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial, there is no mimimum life expectancy define for the secondary trial. Subjects with a history of significant cardiovascular disease are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "4243dc45-5a64-486d-ae2a-11448db00dcf_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial. The primary trial had a larger sample size than the secondary trial. (This information is not explicitly stated in the provided texts, but it can be inferred from the number of participants in each trial.)",
        "Label": "Entailment"
    },
    "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial. The primary trial's Placebo + Letrozole 2.5 mg group had a median PFS of approximately 6 months (as opposed to 9.3 months for Cohort 1 in the secondary trial).",
        "Label": "Contradiction"
    },
    "f616e3d8-6c1a-4b99-ac79-ea87895e37b7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial. In the Primary Trial, patients in both arms received a CES unit but only arm I (Intervention 1) delivered active stimulation.",
        "Label": "Entailment"
    },
    "2f700407-8baf-4e5f-8fc0-378a294512f5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the father from the study interventions. Patients with a history of prior allergic reactions to taxanes or anthracyclines are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "cebee448-235d-49ff-8e87-56639399548b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent is optional for entry in the primary trial. The study does not mandate the use of vital blue dye during SLNB for all participants. (This information does not contradict the previous statement, as it does not change the inclusion or exclusion criteria related to hypersensitivit",
        "Label": "Contradiction"
    },
    "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial. The primary trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy of a new hormonal therapy in pre-menopausal women with hormone receptor-positive advanced breast ca",
        "Label": "Contradiction"
    },
    "7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "sepsis, due to the presence of an implanted device was a common adverse event in the primary trial The primary trial also reported one case of sepsis that was not device-related.",
        "Label": "Contradiction"
    },
    "af677d94-a376-42ea-93fe-91963a071199_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial. Patients in the primary trial with a history of prior radiation therapy are also eligible, as long as they have residual breast cancer requiring additional surgical resection.",
        "Label": "Entailment"
    },
    "6579e25e-8dcf-44b5-a50d-7c84672cba89_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for the primary trial, as long as they are over the age of 20. The Primary Trial is specifically designed for breast cancer survivors with dyspareunia, a condition causing painful intercourse, after undergoing both surgery and chemotherapy.",
        "Label": "Contradiction"
    },
    "1ac9c526-91e6-4e0d-8570-0a78e3ec78db_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events. The number of participants in each cohort was different, which may have influenced the total number of adverse events recorded. For instance, Cohort 1 had 94 participants while Cohort 2 had 39 participa",
        "Label": "Contradiction"
    },
    "79c07f36-daf9-4844-ad8a-f362fbbaaf81_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "Both cohorts of the primary trial reported the same precentage of patients vomiting during the trial. The Primary Trial cohorts also reported similar rates of diarrhea (1.27% each).",
        "Label": "Contradiction"
    },
    "bced9c90-5ce0-416c-a168-f9e74359b332_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group, however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group. The difference in median PFS between the Exemestane and Abiraterone Acetate + Prednisone groups was not statistically significant (p=0.61).",
        "Label": "Contradiction"
    },
    "ce88c763-0062-48dc-b5e1-f81af32f2628_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial. Patients in the primary trial must have either measurable breast cancer by RECIST or nonmeasurable disease with elevated CA27.29 (or CA15.3) levels.",
        "Label": "Entailment"
    },
    "982469a3-2fc1-40b4-92a9-d531b6c0ab5d_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "the primary trial administers the Urea/Lactic Acid Cream topically, twice daily, and the placebo is administered orally once a day. The Primary Trial enrolls patients with hyperhidrosis, a condition causing excessive sweating on palms and soles.",
        "Label": "Contradiction"
    },
    "71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "There is no age limit for either the secondary trial or the primary trial. The primary trial also requires patients to have completed their adjuvant/neo-adjuvant chemotherapy regimen at least 4 weeks before entering the study.",
        "Label": "Entailment"
    },
    "e6901a45-4c97-4618-bfcb-6f6dd046ef0c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group. 15.2% of participants in the Exemestane group experienced a TTP greater than 18 months.",
        "Label": "Contradiction"
    },
    "e94ea1b1-1816-4bac-b1ca-f6d66b95702a_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study. However, it's important to note that the primary trial involved a small number of participants, especially in the Arm I group, which may limit the generalizability of the findings.",
        "Label": "Contradiction"
    },
    "0e3c62f7-a152-4370-9d09-b69a715c0a21_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01216319",
        "Secondary_id": "NCT03346161",
        "Statement": "the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies. The primary trial is evaluating the effectiveness and quality of using the Biodesign\u00ae Nipple Reconstruction Cylinder compared to standard care for nipple reconstruction in patients who have undergone mastectomies",
        "Label": "Contradiction"
    },
    "7191b5e9-4f29-4261-8a64-51653ee151fe_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Statement": "In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The primary trial also reported that progression-free survival was significantly longer in the Dasatinib, 70 mg, Twice Daily group compared to the Dasatinib, 100 mg, Daily group based on a s",
        "Label": "Entailment"
    },
    "639ccada-370d-4709-bdd7-1b29bbcc8769_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial. Patients must have measurable disease as per RECIST 1.1 criteria to be eligible for the Primary Trial.",
        "Label": "Contradiction"
    },
    "8c6e6c06-c409-4c42-b195-e9d2a1065b97_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet. Two participants in the Dexamethasone Based Mouthwash arm experienced symptomatic stomatitis (grade 2), while receiving the investigational mouthwash and study treatments.",
        "Label": "Contradiction"
    },
    "b5183c1c-adb5-4877-b061-50a16d6a5b52_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "None of the patients in the primary trial committed suicide, however there was one such case in the secondary trial. None of the patients in the primary trial developed cataracts during the trial.",
        "Label": "Entailment"
    },
    "69f57cdb-22e9-4a3a-8f19-6095c66c6497_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial. The primary trial also assesses the effect of pertuzumab on overall survival and disease-free survival in addition to pCR rate.",
        "Label": "Entailment"
    },
    "ea505463-c509-416e-ad88-11576764b734_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial. The Primary Trial also requires participants to have a body mass index (BMI) within the normal range.",
        "Label": "Entailment"
    },
    "81669281-db01-4493-a797-0d60f448f706_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "The overall most frequent adverse event in the primary trial was Dehydration. The incidence of Dehydration was higher in the Primary Trial compared to the Secondary Trial (5.21% versus 2.04%).",
        "Label": "Entailment"
    },
    "40dbf023-ead5-45fc-bdce-bf40e1955578_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention. The primary trial includes randomization to either Intervention 1 (online support group) or Intervention 2 (peer-led online support), both without the use of Low Dose Magnesium Oxide, High Dose Magne",
        "Label": "Entailment"
    },
    "b64ae9c9-956a-421e-a41f-1886408fec2a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "One of the cohorts in the primary trial had more than 5% of patients experiencing side effects. The most common adverse event was diarrhea, occurring in 2/1748 or 0.11% of patients across both trials.",
        "Label": "Contradiction"
    },
    "e0980234-0611-44de-9165-54bdd086663d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments. The Primary Trial assessed the effect of topical saline and topical lidocaine on symptoms of vulvar vestibulitis syndrome.",
        "Label": "Entailment"
    },
    "3366c10a-3d41-48ae-bfa8-26b9e655761e_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "There were 8 cases of pharyngitis in cohort 2 of the primary trial. Two of the cases of pharyngitis in the Primary Trial's cohort 2 were also recorded as stomatitis/pharyngitis in the Adverse Events 1 section.",
        "Label": "Contradiction"
    },
    "be29030a-98e8-40ad-9138-90076fdb50d3_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2. The primary trial reported a higher incidence of diarrhea in cohort 2 compared to cohort 1 (2.48% vs. 1.49%).",
        "Label": "Entailment"
    },
    "a31298d5-20ae-4a3d-a57b-e97288fff6c0_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Statement": "Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years. The specific types and frequencies of Treatment-emergent adverse events were not specified in the provided data for the MM-111 + Herceptin arm of the primary trial.",
        "Label": "Entailment"
    },
    "54e93334-0f21-4ea2-b0f2-34473385da53_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients. The total number of patients in the Primary Trial was 2788 for Cohort 1 and 2800 for Cohort 2.",
        "Label": "Entailment"
    },
    "fbedd8fc-05e8-4438-b780-d7483aed3b45_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial. Patients with stable brain metastasis may be eligible for the primary trial after a consultation with the Principal Investigator.",
        "Label": "Entailment"
    },
    "4bd9f061-6420-443d-8f84-b703733644ac_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in the primary trial suffered life threatening adverse events. None of the adverse events in the primary trial led to the trial discontinuation or death of all participants. (The previous statement only mentioned that all patients experienced adverse events, but it did not specify that they were lif",
        "Label": "Contradiction"
    },
    "e6d3354b-b36a-42b9-b406-61a9af594686_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily. In the Primary Trial, Intervention 1 (Ginkgo Biloba) is administered in the form of a tablet.",
        "Label": "Contradiction"
    },
    "62b3d09e-6b2a-4827-8ceb-96ccafca18d4_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial. The Primary Trial is a randomized controlled study evaluating the effectiveness of screening with advanced MRI techniques compared to standard mammography in the early detection of breast cancer among high-risk women with dense breast tissue or those from specified racial",
        "Label": "Entailment"
    },
    "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months. Patients in the Primary Trial must have progressive or recurrent disease despite receiving prior systemic therapy.",
        "Label": "Contradiction"
    },
    "85c315e5-7ae4-4764-8b02-87d36f67a159_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine is not used in the primary trial, and used in only one of the arms of the secondary trial. The primary trial involved the use of cyclophosphamide and doxorubicin hydrochloride as chemotherapy, with adjuvant therapy and radiation therapy also included, for the treatment of the disease.",
        "Label": "Entailment"
    },
    "497188e0-9d88-406f-b163-c154516cb12c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial. The Primary Trial involved a total of 30 participants in both cohorts (15 in each).",
        "Label": "Entailment"
    },
    "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "Patients with BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial. Patients with well-controlled diabetes and a hemoglobin A1c level below 10% may also be eligible for the primary trial.",
        "Label": "Entailment"
    },
    "f26fb90b-a9a5-4614-9680-2e9f6f0ba649_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in the primary trial and the secondary trial did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials. The Primary Trial had a higher overall adverse event rate compared to the Secondary Trial (24.00% vs. 31.58%).",
        "Label": "Contradiction"
    },
    "90dd042b-c16c-4ea7-b360-625bd5e64590_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial. The primary trial involves the administration of an investigational drug named E7389 for the treatment of advanced or metastatic breast cancer in patients who have previously received anthracycline and taxane chemotherapy regimens and have prog",
        "Label": "Entailment"
    },
    "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group. The time frame for assessing objective response was the same in both the Afatinib Monotherapy and Afatinib and Paclitaxel or Vinorelbine Combination Therapy groups.",
        "Label": "Entailment"
    },
    "20cc98f8-a71a-466d-a39c-735899791613_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial. The primary trial includes patients with histologically confirmed invasive breast cancer who have not received prior chemotherapy for metastatic breast cancer.",
        "Label": "Entailment"
    },
    "fa1c6f63-ae37-4c18-918b-7b9ba445fd81_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "In total there were 32 cases of Febrile neutropenia in the primary trial. 5 of these cases resulted in hospitalization. (Additional information about the severity of febrile neutropenia in the primary trial)",
        "Label": "Entailment"
    },
    "6d0b2acc-11f4-479f-9a86-004e2f5f7599_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "IV is used as route of administration by the interventions in the primary trial and the secondary trial. The Primary Trial involved a combination of chemotherapy, targeted therapy, and hormonal therapy, along with various correlative studies and surgical interventions, administered through intravenous, oral, and subcutaneous routes.",
        "Label": "Contradiction"
    },
    "7e9c3980-9f12-40c7-920e-76594db26fd1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics. In the Primary Trial, the dose of omega-3 fatty acids administered in Arm I is lower than that in Arm II.",
        "Label": "Entailment"
    },
    "c83e003d-d12d-4f72-ab1f-c39f3a13326b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer. The primary tumor must be measurable by RECIST criteria in order to be eligible for the primary trial.",
        "Label": "Entailment"
    },
    "cae58656-76e7-447a-940e-dfcc78159173_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "the primary trial monitors the occurrence of anemia in its adverse events. Two of the participants in the primary trial experienced constipation as an adverse event (10.53%).",
        "Label": "Contradiction"
    },
    "94c4c3fc-7bcb-407b-86b5-6699305d3dbd_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "There are no adverse events in the primary trial that occurred more than once. The majority (88.28%) of the primary trial participants did not experience any adverse events.",
        "Label": "Contradiction"
    },
    "103fbaa8-1852-402a-9368-36bbf6c747b2_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "At most 3 patients in the primary trial suffered from Neutropenia. No cases of Thrombocytopenia were reported in the Primary Trial.",
        "Label": "Contradiction"
    },
    "731dc36f-983d-4d4c-97ac-6e3eeee23a40_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial. Patients with prior radiation therapy to the breast or chest wall within the past 5 years are not eligible for the study.",
        "Label": "Entailment"
    },
    "b2883781-f4e9-405e-9231-7a07e46c35b0_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "Only one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram. All participants in Intervention 1 received CT followed by trastuzumab, while those in Intervention 2 received CT and lapatinib.",
        "Label": "Entailment"
    },
    "932c2135-381a-4675-a782-e683eca8d935_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "the primary trial and the secondary trial both use vaccine based interventions, however this is done in different intervals and for a different duration of time. The primary trial involves the use of a HER2/neu peptide vaccine in combination with ex vivo-expanded HER2-specific T cells and cyclophosphamide, administered every 7-10 ",
        "Label": "Contradiction"
    },
    "6461007d-fc18-43e2-a797-11cb0a4512ce_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "the primary trial has a shorter time frame than the secondary trial. The primary trial evaluated the duration of moderately severe neutropenia after the first cycle of chemotherapy.",
        "Label": "Entailment"
    },
    "819e85b0-2d4e-4535-b920-4e18868da883_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "Patients with radiologically confirmed metatases in the CNS are excluded from both the secondary trial and the primary trial. patients with a history of prior hormonal therapy for metastatic breast cancer are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "cc0d6fe8-69c4-49d3-b321-00e47c155db6_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There results from cohort 3 of the primary trial were inconclusive. The incidence rates of specific adverse events were also reported but are not provided in the given results.",
        "Label": "Contradiction"
    },
    "0fbb4fb4-620b-4ee9-aaa8-956992026cef_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events. The two most common adverse events were hemorrhage and pain in the abdomen and liver region, each affecting approximately 10% of patients in the primary trial.",
        "Label": "Entailment"
    },
    "69b12ff4-6bb4-4207-b400-67795709c3c8_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events. The proportion of patients with treatment-emergent adverse events was higher in the Palbociclib+Letrozole Australia Cohort compared to the Palbociclib+Letrozole India Cohort ",
        "Label": "Entailment"
    },
    "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial. Patients with asymptomatic peripheral neuropathy of Grade less than 3 may be eligible for the trial.",
        "Label": "Entailment"
    },
    "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for the primary trial. The primary trial is a randomized, multi-center, open-label study evaluating the efficacy and safety of the FB-5 regimen, a combination of trastuzumab and bevacizumab",
        "Label": "Contradiction"
    },
    "efc15257-5e19-4b7e-8b51-da94840784d8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial. In the primary trial, one patient experienced Thrombocytopenia in addition to the listed adverse events.",
        "Label": "Entailment"
    },
    "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "19.57% of patients in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial. None of the patients in the primary trial experienced an eating disorder (as there is no mention of an eating disorder in the provided information for the primary trial).",
        "Label": "Contradiction"
    },
    "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "Cohort 1 of the primary trial had a much higher number of deaths than cohort 2. The primary trial had a smaller sample size in cohort 1 compared to cohort 2.",
        "Label": "Contradiction"
    },
    "e4961c1a-83e2-40ed-93ac-64d5cef1f84a_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study. The caloric reduction goal is achieved through individualized dietary counseling and the provision of food diaries.",
        "Label": "Entailment"
    },
    "9cb1c975-0d49-4437-af56-1a4f97e30aef_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "There is no maximum or minimum age defined for participation in the primary trial or the secondary trial. The primary trial allows patients with ECOG performance status of 2 if they are deemed suitable by the investigator.",
        "Label": "Entailment"
    },
    "51699ae8-d297-4635-95c1-4ed38c8706c3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial. Patients with a history of significant QT interval prolongation are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "c2c73b99-f89c-4dd3-8362-295f9a7965f3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "In order to meet the inclusion criteria for the primary trial patients must have had ineffective aromatase inhibitor (AI) therapy before study entry,  The trial allows for the use of steroids at a stable dose for palliative purposes if necessary, as long as the patient has been off dexamethasone for 4 weeks before the first dose of study drug.",
        "Label": "Entailment"
    },
    "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "Cohort 1 of the primary trial had a much higher mortality rate than cohort 2. The primary trial had a smaller total number of participants in cohort 1 compared to cohort 2.",
        "Label": "Entailment"
    },
    "949ac54b-a871-4134-a507-c98a4de55720_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "the primary trial recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in the secondary trial. In the primary trial, one participant experienced both febrile neutropenia and anaphylactic reaction.",
        "Label": "Entailment"
    },
    "02407f87-235d-4240-98fe-498b352cce75_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial. The primary trial involves the use of stereotactic body radiotherapy (SBRT) as the primary treatment modality.",
        "Label": "Contradiction"
    },
    "61a524d4-1697-4a10-b36a-a0c6cda79526_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "Patients with stage I, II, III or IV triple negative breast cancer are not eliglbe for the primary trial. Patients in the primary trial must provide written informed consent prior to participation.",
        "Label": "Contradiction"
    },
    "304977b6-9742-4c3b-84fd-e5ef1737a143_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial. Patients must also have measurable disease as per RECIST 1.1 criteria.",
        "Label": "Entailment"
    },
    "87c65217-85d9-4f05-87aa-f4dfacd9f25a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial The Primary Trial is designed to evaluate the efficacy and safety of BKM120 in patients with metastatic triple negative breast cancer who have not received PI3K inhibitor treatment before.",
        "Label": "Entailment"
    },
    "19e89ebc-a417-47a8-bfa7-1778baead178_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "Placebo treatment is used in the secondary trial, but there is only a test group in the primary trial. In the primary trial, patients in both the Omega-3-fatty Acid and Placebo arms continue receiving their assigned interventions until 24 weeks or the occurrence of disease progression or unacceptable toxicity.",
        "Label": "Entailment"
    },
    "561a0631-1eb3-48d1-baa2-81eb3fa79b98_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "the primary trial recorded a patient with chest pain, whereas the secondary trial observed a patient with abdominal pain. Two patients in the Primary Trial experienced gastrointestinal disorders, one with diarrhea (1/298, 0.34%) and the other with nausea (1/29",
        "Label": "Entailment"
    },
    "bc617e84-a0c1-400b-9ad5-88b56d1805e8_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "1/42 patients in cohort 1 of the primary trial fainted. None of the perforations or cases of febrile neutropenia occurred during the administration of the study drug.",
        "Label": "Entailment"
    },
    "8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial. The Primary Trial also allows for the enrollment of patients with T1-2 N1-3 M0 breast cancer in the neoadjuvant setting.",
        "Label": "Entailment"
    },
    "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin. The primary trial evaluates the combined effect of Anastrozole and Simvastatin on biomarkers in laboratory analysis.",
        "Label": "Contradiction"
    },
    "b059e44b-9830-4c45-858e-ebd007fbaf69_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia. The incidence of neutropenia without fever was higher in the Primary Trial's Cohort 1 (9.76%) compared to Cohort 2 (10.00%).",
        "Label": "Contradiction"
    },
    "fec065ca-fbde-476d-ab0d-7e7054e29858_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these would interfere with the necessary CT and MRI scans for the study. Patients with severe renal impairment (creatinine clearance below 20 mL/min) are also excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "ea3bd229-001c-487f-9cda-edf2e699dbb2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in the primary trial receive vorinostat at the same frequency, dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine. In the Primary Trial, the AI therapy follows 2 weeks of vorinostat treatment and repeats every 8 weeks, unlike the continuous 6MP/MTX treatment in the Secondary Trial.",
        "Label": "Contradiction"
    },
    "576e519a-1ef3-43e5-a13c-6058ad71f388_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "Patients have received prior radiation treatment, to treat the current breast cancer, in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial. Patients in the primary trial may have received a bisphosphonate, but if started within 2 months prior to enrollment, bone lesions will not be evaluated for response and another site of metastatic disease must be evaluable",
        "Label": "Contradiction"
    },
    "699d0cb5-1ebb-441d-aa7e-041a48923b00_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks. The topical keratin application in the Primary Trial begins prior to the start of radiation therapy and continues throughout the entire duration.",
        "Label": "Entailment"
    },
    "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial. Patients must have completed primary surgery at least 4 weeks prior to starting radiation therapy in the primary trial.",
        "Label": "Entailment"
    },
    "6e882de6-e55f-40a4-95a1-bdb176e68a18_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome. Two patients in cohort 1 of the primary trial reported incidences of headache, an adverse event not listed in the provided data.",
        "Label": "Contradiction"
    },
    "525ed182-07e9-4548-87b3-c831e0b7389e_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "Patients with lymphopenia can participate in the primary trial. Patients with a creatinine clearance between 20-40 mL/min may be eligible for the trial with dosage adjustments.",
        "Label": "Contradiction"
    },
    "233d2ec1-1383-4088-90af-c5a948847631_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "the primary trial and the secondary trial both reported cases of Pseudomonal sepsis in their patients. Two of the patients in the Primary Trial with Pseudomonal sepsis also experienced neutropenia.",
        "Label": "Contradiction"
    },
    "8e3fe244-d47d-48ce-ab29-4a5226024aad_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial. None of the participants in the primary trial experienced both cardio-respiratory arrest and gastric ulcer.",
        "Label": "Entailment"
    },
    "670443b0-89bf-4af4-a9ab-4cdff26d09a8_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial. The primary trial also requires patients to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.",
        "Label": "Contradiction"
    },
    "455748bf-8e12-4834-8126-ab77cab16200_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane. In the Primary Trial, both interventions (Letrozole and Letrozole + Zoledronic Acid) used Letrozole as the common component at a dose of 2.5 mg/day for 3 ye",
        "Label": "Entailment"
    },
    "d29bd9dd-b52e-4b18-82ea-e2914dfb9579_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine. The restricted mean survival time for Progression Free Survival at 24 months was significantly longer in the Neratinib Plus Capecitabine arm compared to the Lapatinib Plus Capecitabine arm.",
        "Label": "Entailment"
    },
    "2649c857-f98d-4529-9a4a-4f8b17813cb8_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial. The hazard ratio for death was 0.85 (95% CI: 0.75-0.97) in favor of the Eribulin Mesylate 1.4 mg/m^2",
        "Label": "Entailment"
    },
    "0a6e8720-ea47-4520-bd02-e0eb8fcd880f_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group The Standard Deviation of u-NTx percentage change was smaller in the Single IV Infusion of ZA 4 mg group compared to the Odanacatib 5 mg group in the primary trial.",
        "Label": "Entailment"
    },
    "ce6630d3-d3b7-4870-a486-9b6284a454f0_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort. The duration of follow-up for reporting adverse events was the same for both cohorts, spanning up to 28 days after the last dose of study treatment and an average of 14 months.",
        "Label": "Contradiction"
    },
    "27e31574-5a73-4a68-997d-daa84797a65a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "Both the primary trial and the secondary trial at least partly administer their interventions intravenously. In the Primary Trial, suramin is administered as an infusion and paclitaxel follows four hours later as an additional infusion.",
        "Label": "Entailment"
    },
    "e21171de-ad49-4fc5-9c5d-aa362ca61c8a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded 41. The frequency of edema was lower in the primary trial with only one case reported compared to the secondary trial where there were no cases reported.",
        "Label": "Contradiction"
    },
    "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "Cohort 2 of the primary trial is the control group, as the Eligible patients with breast cancer treated with GnRHa every 28 days. The primary trial compared the effectiveness and safety of GnRHa versus no GnRHa in patients with breast cancer undergoing chemotherapy.",
        "Label": "Contradiction"
    },
    "38f47a03-f71d-4072-a005-b954fb6069da_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year. The PFS analysis in the primary trial included all randomized patients, regardless of whether they received study treatment or not.",
        "Label": "Entailment"
    },
    "e41917b8-d921-4797-b845-0121a75104a4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat. 2 out of the 4 patients who experienced febrile neutropenia also had concurrent pharyngitis.",
        "Label": "Contradiction"
    },
    "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "Cohort 1 patients in the primary trial surivied almost twice as long as those in cohort 2. The median progression-free survival (PFS) was longer in Stratum 1 compared to Stratum 2, consistent with the observed difference in ORR. (This statement provides additional information about the Primary Trial's clin",
        "Label": "Contradiction"
    },
    "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial, this is due to the significant difference in cohort size. In the Primary Trial, there was one case each of pneumonia and sepsis reported in cohort 1, in addition to the adverse events mentioned in the provided text.",
        "Label": "Contradiction"
    },
    "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group The total number of participants in the Primary Trial was 185 (61 in Arm A and 124 in Arm B).",
        "Label": "Contradiction"
    },
    "6214280f-f665-48d3-b33f-9d798deff71f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "the secondary trial uses Overall Survival (OS) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial. The primary trial also assesses the impact of pertuzumab on the time to disease recurrence or progression in HER2-positive breast cancer patients.",
        "Label": "Contradiction"
    },
    "108b54a9-b5cc-4f31-956f-e4e2e653d756_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "In total more participants in the primary trial had no tumor Response, than partial response, and 0 participants had a complete response. The duration of response (length of time that responders remained in response) was longer in the lapatinib 1500 mg QD arm compared to the 500 mg BID arm.",
        "Label": "Entailment"
    },
    "662f4992-0155-4a82-926f-b1821539aab7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Secondary_id": "NCT00617942",
        "Statement": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery, compared to 60% in cohort 1 of the secondary trial. The Primary Trial involved patients with locally advanced breast cancer (LABC) who underwent surgery, while the Secondary Trial focused on patients with resectable and unresectable LABC receiving q3week Carbopl",
        "Label": "Contradiction"
    },
    "398f744b-97cf-4f95-b162-99ec6652d327_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial. The primary trial had a higher total number of adverse events compared to the secondary trial, despite having fewer participants.",
        "Label": "Contradiction"
    },
    "43421f19-878e-46f7-b456-8031835af649_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area. In the Primary Trial, the dose of Capecitabine in Intervention 1 and Intervention 2 is adjusted based on the patient's body surface area, in addition to being administered orally twice daily fo",
        "Label": "Entailment"
    },
    "13fa44e7-38be-48fb-a0eb-6b212549f526_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group. The median duration of response was longer in the HER2-positive group compared to the ER+ and/or PR+ group.",
        "Label": "Entailment"
    },
    "12ae2315-cc50-43ac-a595-762c85c1ec58_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "There were no participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. In the Primary Trial, all participants with a response (CR or PR) based on the RANO-BM response criteria had stable or improved clinically.",
        "Label": "Entailment"
    },
    "11403f92-661b-4334-8dfb-098586610ec6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial. Two out of the four patients who experienced seizures in the Primary Trial were below the age of 18.",
        "Label": "Contradiction"
    },
    "2823adfc-b3a4-4626-9690-0c292aa8da04_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks. The primary trial is a single-arm, open-label study of topical fluocinonide 0.05% vaginal cream, not face cream, used for two weeks twice daily and then once daily for two we",
        "Label": "Contradiction"
    },
    "1cda051f-27d0-4027-94cf-7b5340173ca2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02504424",
        "Secondary_id": "NCT03708393",
        "Statement": "the primary trial and the secondary trial do not have the same number of study groups. The Primary Trial evaluates the effectiveness and safety of using the AeroForm Tissue Expander with remote control carbon dioxide inflation compared to no intervention after a mastectomy.",
        "Label": "Entailment"
    },
    "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "The patient with the shortest PFS was in the secondary trial, at only 5 days, and the longest recorded PFS was in the primary trial at 78 months. The primary trial included patients with various types of solid tumors, not only colorectal cancer as suggested by the given information about the outcome measurements.",
        "Label": "Contradiction"
    },
    "1e91c023-96e8-459b-9070-02df13339617_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group produced better Pathological complete response (pCR) rates than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group. The difference in pCR rates between the two groups had a p-value of 0.03 in the two-sided test. (This means that there is statistical significance in the observed difference.)",
        "Label": "Entailment"
    },
    "a15b4c0c-232b-4209-bf60-35d160e41d2c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia. 2 patients in the primary trial experienced neutropenia, a condition that may increase the risk of infections.",
        "Label": "Contradiction"
    },
    "795d634a-9f9c-49a2-a4e7-ec99bd3600f2_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women. The primary trial is also examining the effectiveness of the SCPR intervention in improving reproductive health knowledge, attitudes, and behaviors among young breast cancer participants.",
        "Label": "Contradiction"
    },
    "e2d4c56c-a68f-4751-907d-9c2355c9528b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial. None of the patients in the primary trial experienced fractures or dehydration.",
        "Label": "Contradiction"
    },
    "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Secondary_id": "NCT00232479",
        "Statement": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial. Patients should not have a known allergy or hypersensitivity to the study drugs or their excipients in the primary trial.",
        "Label": "Contradiction"
    },
    "9ad3444c-143d-4c28-a08a-e0c9cda44900_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "the primary trial and the secondary trial did not observe any of the same adverse events in their patients. The primary trial reported one case each of cardiac failure acute, cardiogenic shock, and left ventricular dysfunction in addition to the mentioned adverse events.",
        "Label": "Contradiction"
    },
    "43061a8b-c1b2-4b5e-b935-73733d674fb4_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial designates specific interventions to its patients depending on their tumour response, patients with complete response go to cohort A and all other in cohort B, in contrast the secondary trial assigns interventions randomly. The primary trial is a randomized, open-label, multi-center study comparing the efficacy and safety of eribulin in cohort A and cohort B patients based on their pathological response to neoa",
        "Label": "Contradiction"
    },
    "fc7369dc-0fc5-4823-a8eb-5ac85188fd60_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "Patients suffering from ovarian or lung cancer are excluded from the primary trial. The primary trial is a Phase II study evaluating the efficacy and safety of a new chemotherapy regimen in early-stage breast cancer patients.",
        "Label": "Entailment"
    },
    "25ec56f0-e472-4423-92ae-8d4840b067b5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "Participants in the primary trial receive different interventions depending on their pre-diagnosis, whereas all patients in the secondary trial took the same intervention. In the Primary Trial, the microwave breast imaging system was used to investigate and characterise diagnosed palpable breast abnormalities, with one group undergoing a core needle biopsy before the investigation.",
        "Label": "Entailment"
    },
    "2c9e9407-e990-41bd-a87b-9d294c78f727_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "the primary trial is testing a novel radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions. The trial also investigates the combination of 89Zr-trastuzumab and 89Zr-pertuzumab for enhanced HER2 lesion detection and characterization.",
        "Label": "Contradiction"
    },
    "f3cebdf7-be0c-45ad-85bd-bde827524e20_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "the primary trial recorded less than 5 different Adverse Events . All recorded adverse events in the primary trial were mild to moderate in severity.",
        "Label": "Entailment"
    },
    "b5c7bfd2-d491-400c-8444-8bc424cd5dbf_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "A patient in the primary trial suffered from Kidney stones. Two patients in the primary trial experienced a grade 3 increase in transaminase levels.",
        "Label": "Entailment"
    },
    "53c62057-d6ea-4639-adaf-98cb1544a394_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs. The primary trial also includes mandatory follow-up visits and assessments after completion of treatment to monitor long-term safety and efficacy.",
        "Label": "Entailment"
    },
    "599b37cd-f380-48ac-864d-e766a7af963e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "the primary trial and the secondary trial monitor the %  of their patient cohorts with DFS < 6years. The primary trial assesses disease-free survival (DFS) not only at 24 months but also collects data up to 5 years after treatment.",
        "Label": "Contradiction"
    },
    "c428ec76-4d22-4d2d-8c06-1675bd431d41_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic. Both the survivor and caregiver must reside in the same household.\n\nExplanation: The provided statement accurately conveys that both participants must be ethnically Hispanic and form a survivor-caregiver pair.",
        "Label": "Contradiction"
    },
    "6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Statement": "the primary trial has two cohorts. The Primary Trial randomizes patients to receive either Intervention 1 or Usual Care during their medical oncology visits.",
        "Label": "Entailment"
    },
    "a9d5c664-896f-4bb1-95e7-1deaa88848ef_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. Agatha is of white british origin. she is eligible for the primary trial but not the secondary trial, due to her age. The Primary Trial also requires that patients have no history of significant cardiovascular disease.",
        "Label": "Contradiction"
    },
    "62b5fe62-470d-46e3-82a6-d57cd6cab452_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial. The total number of patients in the Primary Trial was greater than the number of patients in the Secondary Trial.",
        "Label": "Entailment"
    },
    "de349a2d-80ee-4c34-ab9f-38eb467c77d7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "the primary trial and the secondary trial are not studying patient PFS, ORR or DLTs. The Primary Trial aimed to investigate the concordance of Lymphoseek and blue dye in detecting lymph nodes during surgery.",
        "Label": "Entailment"
    },
    "0d37bf26-bc74-4a01-9bc9-61e2fa3051da_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions. The primary trial involved patients with metastatic breast cancer receiving chemotherapy with or without bevacizumab, while the maintenance therapy in Intervention 1 included bevacizumab alone, and in Interventio",
        "Label": "Entailment"
    },
    "69f7a93d-7134-40ec-aff3-50acd7119d2c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "the secondary trial and the primary trial both measure PFS of their patient cohorts. In the Primary Trial, there was a significant improvement in PFS with atezolizumab plus nab-paclitaxel compared to placebo plus nab-paclitaxel (hazard rat",
        "Label": "Entailment"
    },
    "8de31b0f-7127-4c8b-b5e0-060e7a83fae5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "Joe has a known history of Hepatitis. However as he is over the age of 18 is still eligible for the primary trial. The Primary Trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a novel therapeutic agent in patients with metastatic breast cancer.",
        "Label": "Contradiction"
    },
    "207a1d82-a61b-4b5f-bebf-0706def6729d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial. The primary trial recorded no cases of acute myocardial infarction or diplopia.",
        "Label": "Entailment"
    },
    "968aeaf1-44b9-4454-8c99-e3c207037485_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial. The frequency of adverse events differed slightly between the two trials, with a higher percentage reported in the Primary Trial (36.22%) than in the Secondary Trial (22.58%).",
        "Label": "Contradiction"
    },
    "2b79f9cc-4262-4353-ad28-91cda07a9b9a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "Patients must have AST, ALP and ALT < 1.5 ULN to participate in the primary trial. Patients with a history of significant liver disease or abnormal liver function tests (AST, ALT, or ALP > 1.5 ULN) are not eligible for the primary trial, even if they are receiving liver en",
        "Label": "Entailment"
    },
    "d56ffd81-4007-477b-b3c3-0fdb89806931_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "Patients with diabetes insipidusare not suitable for the primary trial. Patients with a history of prior breast cancer are also excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "f62e6c20-862b-4ce3-9121-0d93ff050839_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01373671",
        "Secondary_id": "NCT00686127",
        "Statement": "Lidoderm products are used in a intervention arm 1 of the secondary trial, and an FFDM product is used in arm 1 of the primary trial The Primary Trial's Intervention 1 also involves the use of a mammography machine from Siemens Healthineers for the FFDM exam.",
        "Label": "Contradiction"
    },
    "833eeb4b-4921-468a-947d-bacfc7816ae6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Secondary_id": "NCT02131064",
        "Statement": "the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR. The Primary Trial also reported a significant improvement in Progression-Free Survival (PFS) in the Ipatasertib and Paclitaxel arm compared to the Placebo and Paclitaxel arm.",
        "Label": "Contradiction"
    },
    "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "the secondary trial records several gastrointestinal adverse events, whereas the primary trial doesn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t record any GI adverse events. In the Primary Trial, there were no reported adverse events related to the gastrointestinal system.",
        "Label": "Entailment"
    },
    "c317750d-6ef7-494d-8040-2c7fa3d777fb_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "the secondary trial and the primary trial both used MRI for their interventions. The primary trial investigates the safety of Letrozole in breast enhancement using MRI to evaluate its potential effects on breast tissue.",
        "Label": "Entailment"
    },
    "87eca8d2-72fe-4285-9884-6d2ec7bae6df_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "There was exactly the same proportion of anemic patinets in both cohorts of the primary trial. The number of participants in the Primary Trial was 396, while the number of participants in the Secondary Trial was 408.",
        "Label": "Contradiction"
    },
    "7a87c605-fc41-4d0a-9291-85e88f6eb510_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01000662",
        "Secondary_id": "NCT02413008",
        "Statement": "the secondary trial is testing a Gel which is applied inside the vagina, and the primary trial is testing an intervention which requires daily radiation of the breast(s). In the Primary Trial, the radiation boost in Arm 1 is given daily from Monday to Friday, while in Arm 2, the boost is given once a week on Fridays during the three-week treatment period.",
        "Label": "Entailment"
    },
    "fbb853c9-bed4-4cde-a283-2d91b23d35bf_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions, using different outcome measurements. The primary trial reported that 4.6% of patients in the Trametinib and Akt Inhibitor GSK2141795 arm achieved an overall pathological complete response (pCR) with",
        "Label": "Entailment"
    },
    "c3cc3621-a8ce-4f0d-a150-7e627f36e7c5_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "Patients with a QT interval longer than half a second are excluded from the primary trial. Patients with a left ventricular ejection fraction (LVEF) less than 40% are also excluded from the primary trial.",
        "Label": "Entailment"
    },
    "84aa97cf-efce-484e-825e-5af509e5988f_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy, up to 160% of the starting dose. The primary trial's duration is approximately 6 months for each patient.\n\nExplanation: \n\nThe given information only mentions the details of the Afatinib dosage and administration in the primary trial. The additi",
        "Label": "Contradiction"
    },
    "a40e172a-8839-499d-896d-be71a7ca4905_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03076190",
        "Secondary_id": "NCT03196635",
        "Statement": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions, however all participants taking part in these studies will need to receive stem cell transplants. The primary trial is a randomized controlled study comparing the efficacy of Intervention 1 (Health Education Active Control Group) and Intervention 2 (My Surgical Success Intervention Group) in stem cell transplant patie",
        "Label": "Contradiction"
    },
    "9e972e33-9ecd-4a8b-8337-7bee209f790b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is assesment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2. The diameter of the drains used in each group (single or double) is the same.",
        "Label": "Contradiction"
    },
    "f29768ba-5d79-4528-839f-933ab13faaa1_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging. In the Primary Trial, each subject's imaging data from both the test and control modalities were analyzed to calculate the specificity difference.",
        "Label": "Contradiction"
    },
    "343e0a32-aebe-4bbb-97c0-b2c597c36802_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "the primary trial records two different types of pain in its adverse events, in the abdomen and chest area, the secondary trial does not record any types of pain in its participants.  In the Primary Trial, there was one participant each with a reported adverse event of dizziness and constipation, which are not listed in the provided table.",
        "Label": "Entailment"
    },
    "4d51608c-b0d8-4019-9b9a-34cf1c3d5087_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg. In the Primary Trial, Cohort 1 received either Lapatinib 1500 mg + Placebo or Lapatinib 1500 mg + Pazopanib 800 mg, while",
        "Label": "Contradiction"
    },
    "7bb88699-1536-4fdc-9cb2-c5ef350d559b_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": " trastuzumab was used for the interventions in the primary trial and the secondary trial. In the Primary Trial, patients with HER2/neu 2+ disease may also receive trastuzumab in combination with chemotherapy at the discretion of the treating physician.",
        "Label": "Entailment"
    },
    "c86ef61b-7565-465a-82ba-25e7ac050ccc_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "There was one case of hemorrhaging in the primary trial, and no recorded cases in the secondary trial. Two of the cases of adverse events in the primary trial resulted in hospitalization. (This information is not explicitly stated in the given CTR sections but can be inferred from the fact that certain adverse events are marked with an aster",
        "Label": "Entailment"
    },
    "58dec898-e0af-41c1-96f9-7163d3e3e855_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "the primary trial and the secondary trial recorded three of the same types of adverse events In the Primary Trial, all adverse events occurred in patients receiving the experimental treatment.",
        "Label": "Entailment"
    },
    "5cf74526-9f91-498d-a13a-6393dcd45b7b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "One patient in the primary trial suffered from an inflammation of the liver. Two patients experienced headaches, one in the primary and one in the secondary trial. (Total: 2/96 (2.08%)).",
        "Label": "Contradiction"
    },
    "154caa20-3be1-4cee-a838-2d90b44566c4_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "the primary trial did not use PFS to evaluate the performance of its interventions. The primary trial assessed tumor response using RECIST criteria and reported the number of participants with complete response, partial response, stable disease, and progressive disease at various time points during treatment at two dose levels of Gemcitabine.",
        "Label": "Entailment"
    },
    "c40d8532-4e66-4eef-9644-91f20a02066d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "No cases of Oesophageal adenocarcinoma were recorded in the primary trial. Two participants experienced both dehydration and hyponatremia in the primary trial.",
        "Label": "Entailment"
    },
    "3d450be5-4587-48e5-ae2e-745623606631_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "the primary trial and the secondary trial both administer bi-weekly oral Carboplatin to their test groups. In the Primary Trial, weekly Carboplatin administration starts in week 1 and continues for 6 weeks, while the radiotherapy component is given concurrently from week 2 to week 4.",
        "Label": "Contradiction"
    },
    "fa28753a-aa3b-4642-9fd4-a2414fd8a472_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, post T-DM1 intravenous (IV) infusion. The change from baseline in mean QTcF interval was significantly greater at the 15-minute timepoint post-dose in the third cycle compared to the 15-minute timepoint pre-dose. (This statemen",
        "Label": "Entailment"
    },
    "5e700303-cd26-4024-a260-62f6a1c297ed_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01000662",
        "Secondary_id": "NCT02413008",
        "Statement": "the secondary trial is testing a Gel which is applied to the breast, whereas the primary trial is testing an intervention which requires daily radiation of the breast. The Primary Trial is a randomized controlled study evaluating the difference in efficacy between two methods of radiation boost delivery in breast cancer patients, with Arm 1 receiving daily concomitant boosts and Arm 2 receiving weekly b",
        "Label": "Contradiction"
    },
    "4c4c191c-de68-44c8-a23c-2455acc43d46_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "There is no overlap between adverse events obeserved in the primary trial and the secondary trial. The primary trial had a larger sample size compared to the secondary trial.",
        "Label": "Entailment"
    },
    "e5a4cb11-2a00-4144-93ba-f5462d7efbf0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib. In the Primary Trial, patients in Arm 1 receive Paclitaxel and Carboplatin for 12 courses, followed by Doxorubicin and Cyclophosphamide for 4 courses, while patient",
        "Label": "Entailment"
    },
    "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "the primary trial participants receive more anastrozole, letrozole and exemestane than patients in the secondary trial. In the Primary Trial, patients receive vorinostat for 5 days a week, whereas fulvestrant is given as a single intramuscular dose in the Secondary Trial.",
        "Label": "Entailment"
    },
    "27a4d1a8-185b-4483-85ce-0fbb3d323b99_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the study duration. 10.1% of Talazoparib arm participants achieved a complete response (CR) as per RECIST v1.1, compared to 1.4% in the Physician's Choice arm.",
        "Label": "Contradiction"
    },
    "ff797dd4-0b4d-42fc-808d-27c439563ce2_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "By week 48 of the primary trial none of the patients had Complete Response, 7 had partial response and 15 had progressive disease. 18 patients showed stable disease by week 48.",
        "Label": "Entailment"
    },
    "9f666667-0fde-4d79-b53c-33c0ffbbed90_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "Paula recently had fell down a flight of stairs and fractured her hip, she is excluded from the primary trial. Subjects with a life expectancy of less than 12 months are also excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "47084742-d031-4e59-865c-d8687282c782_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "Paula recently had a heart attack, she is excluded from the primary trial. The Primary Trial also requires subjects to have an Eastern Cooperative Oncology Group performance status of 0 or 1.",
        "Label": "Entailment"
    },
    "ae583ea3-36a5-472c-acda-825cd7d513b6_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2. 10/31 participants in the primary trial experienced headache (32.26%).",
        "Label": "Entailment"
    },
    "a18c447b-de08-48ef-8e65-0ecaa775c2b0_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "A patient in the primary trial had a vaginal fungal infection. Another patient in the primary trial experienced diarrhea as an adverse event (1/49, 2.04%).",
        "Label": "Contradiction"
    },
    "18b900fb-b071-43df-b37d-c68a89ef78c0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": " Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial. Patients with HER2-negative tumors and hormone receptor-positive tumors are also eligible for the primary trial, as long as they meet other inclusion criteria.",
        "Label": "Entailment"
    },
    "ebdf2841-b5e0-431a-8dc7-e100c5d27ccf_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial. Patients with a creatinine clearance of less than 30 mL/min based on a 24-hour urine collection are also excluded from the trial.",
        "Label": "Entailment"
    },
    "d56745c3-ba0b-4b42-b3cf-ac060f658d83_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "Acute coronary syndrome was the most prevalent adverse event in the primary trial, other than Thrombocytopenia . 2 out of the 5 cases of Neutropenia resolved without treatment interventions.",
        "Label": "Contradiction"
    },
    "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "the primary trial only had a total of 6 patients in across both its cohorts. All enrolled patients completed the primary trial.",
        "Label": "Entailment"
    },
    "03c7f31f-788c-4edb-a885-b6cb0fca05da_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score.  The standard deviations in the Placebo and Zometa groups were similar. (0.041 for Placebo and 0.042 for Zometa)",
        "Label": "Contradiction"
    },
    "e43c01e9-20a2-4435-a32b-224d5f460d7c_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months. The median PFS for the Capecitabine arm in the primary trial was significantly longer than that of the CDX-011 arm (HR=0.78, 95% CI: ",
        "Label": "Entailment"
    },
    "c55f34ab-b883-465e-89dc-75bbeb8afa77_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "One patient in the primary trial had a Confirmed tumor partial response, No patients in the secondary trial were evaluated for tumor response. All evaluated patients in the primary trial received Ziv-afibercept as treatment.",
        "Label": "Entailment"
    },
    "0ee36ceb-5790-440e-b6ad-10a0b7a23f43_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol, and no Mammography. The Primary Trial's cohort 1 did not receive any hormonal intervention, but instead only underwent mammography screening.",
        "Label": "Entailment"
    },
    "2535da13-e0f7-44df-aa02-89765d8d51cb_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "Patients with HER2 + breast cancer stage 1-4  are eligible for both the primary trial and the secondary trial. The primary trial also requires participants to have a life expectancy of greater than 12 months.",
        "Label": "Contradiction"
    },
    "94fc6e05-8a73-43d9-a48c-531d36dfbbcd_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks. The percentage of participants achieving complete pathologic response was higher in those receiving Lapatinib + Trastuzumab compared to historical control groups, though the exact percentage wasn't specified in the CTR.",
        "Label": "Entailment"
    },
    "0057172f-d019-401b-a516-993a7b46a67b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2. In the primary trial, the duration of the first cycle was longer for both cohorts compared to subsequent cycles due to the administration of intravenous trastuzumab and weekly paclitaxel.",
        "Label": "Entailment"
    },
    "bb23e8b8-c7d6-4e58-80a2-0555db5645e9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english. The primary trial is evaluating the efficacy and safety of ribociclib in combination with letrozole in patients with estrogen receptor positive, HER2-negative advanced breast cancer.",
        "Label": "Entailment"
    },
    "c4588d2c-b0d4-428d-a958-29787b9d4ec5_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "Only cohort 2 of the primary trial receive Bevacizumab, but both cohorts undergo Endocrine Therapy . The Primary Trial compares the efficacy and safety of endocrine therapy with or without bevacizumab in postmenopausal women with hormone receptor-positive, HER2-negative advanced or",
        "Label": "Entailment"
    },
    "ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "Patients with clinically significant grade 3 PVD are eligible for the primary trial. The primary trial allows for inclusion of patients with prior radiotherapy as long as all target lesions being evaluated are outside the radiation field.",
        "Label": "Contradiction"
    },
    "00466f98-52b8-41f3-9bf1-2edaad950be9_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02504424",
        "Secondary_id": "NCT03708393",
        "Statement": "the primary trial and the secondary trial both require the patients to activate the interventions by remote control. In the Primary Trial, the AeroForm Tissue Expander is inflated by remote control using carbon dioxide gas from an internal reservoir to expand the breast tissue after mastectomy.",
        "Label": "Contradiction"
    },
    "50a524ae-2135-45f7-ae9b-515fd4e2e404_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "More than half of patients in the primary trial experienced adverse events, and 100% of patients in the secondary trial did not experience an adverse event. The types and frequencies of adverse events differed significantly between the two trials.",
        "Label": "Contradiction"
    },
    "b2062e01-0ea6-4ee8-94a1-b59dc40901d3_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": " Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer, with Primary tumor > 2 cm in diameter to participate in the primary trial. The trial also requires patients to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Entailment"
    },
    "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "Cohort 1 and 2 of the primary trial receive different quantities of different drugs. Both Afatinib and Lapatinib were given for a total of 4 treatment cycles (8 treatment courses) in the primary trial. (Note: Each treatment course lasted 3 weeks.)",
        "Label": "Entailment"
    },
    "43a9cc96-4020-459c-8fa4-4bbde7173f7a_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "In the primary trial 11 patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients passed away from Unexpected adverse events. The majority of unexpected adverse events were not related to fulvestrant treatment.",
        "Label": "Contradiction"
    },
    "ff319fa6-89b6-4f1a-871d-456edb91b69b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "Sharone had a hip replacement 3 weeks prior, she is not elgible for the primary trial. Patients with leptomeningeal metastases are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "a321acf0-2296-4588-bf96-85b22bf1420f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts. 14 out of the 76 participants in the primary trial experienced neutropenia or febrile neutropenia.",
        "Label": "Entailment"
    },
    "b841dfd8-4676-4d3c-a57d-6ba1055b8597_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for the primary trial. The primary trial also includes patients with a body weight greater than or equal to 50 kg. (Note: This is not a patient-specific information but an additional information about the trial eligibility criteria.)",
        "Label": "Entailment"
    },
    "1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "The Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg. Six participants experienced no dose-limiting toxicities at the MTD of 800 mg indoximod.",
        "Label": "Contradiction"
    },
    "48d40c7e-3514-43c3-a31a-7b391727f012_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same for both cohorts. The primary trial is studying the safety and efficacy of different dosing regimens of MM-121 in combination with weekly IV Paclitaxel.",
        "Label": "Entailment"
    },
    "dd98fca1-27a7-41c2-ba0c-3ff90aceab54_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being HER2-positive. Patients in the primary trial must have at least one progressive and/or new metastatic brain lesion (>/=5 mm on radiographic imaging) after intracranial radiation therapy.",
        "Label": "Entailment"
    },
    "b975dc12-757e-4ef5-af33-83dfce12e6cc_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "the primary trial only records GI adverse events. The primary trial reported adverse events related to various systems besides the gastrointestinal tract as well.",
        "Label": "Contradiction"
    },
    "2c4254c9-9c40-492f-aa45-2a9ab47579b3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "Female Patients with LVEF > 50%,  who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial. The primary trial is a Phase III, randomized, open-label study evaluating the efficacy and safety of trastuzumab emtansine in HER2-positive breast cancer patients previously treated with taxane, ",
        "Label": "Entailment"
    },
    "e140b055-b7fc-4802-a79b-9dfe7d136876_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "the primary trial and the secondary trial are testing completely different modalities of interventions. The Primary Trial is studying the effect of Tivantinib, an oral kinase inhibitor, on patients with advanced or metastatic renal cell carcinoma, in addition to collecting and analyzing biomarkers.",
        "Label": "Entailment"
    },
    "0a6418c8-63a6-4900-bfc9-1659acbe1ad7_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months. The estimated PFS of eribulin mesylate based on the Kaplan-Meier curve was >= 3 months for all 8 participants with CNS PFS >= 3 months.",
        "Label": "Entailment"
    },
    "2db9e0c7-d94b-47d2-a61f-55a0896d714e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "the secondary trial reported more cases of Haematemesis, but the primary trial had more cases of Sinus tachycardia. The primary trial also reported one case of hypertension (0.33%) among the adverse events.",
        "Label": "Contradiction"
    },
    "3129e58d-0c16-42a5-90b4-f26e048dfe58_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "Throughout the primary trial, one patient in cohort 1 developed issues with their vision. Two patients experienced macular fibrosis in the Primary Trial, one in each cohort. (This information is not directly stated in the provided CTR, but it can be inferred from the data given, as there is one inst",
        "Label": "Contradiction"
    },
    "7be7cecb-d265-4098-9969-a40555702573_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "1 patient in the primary trial was diangosed with Influenza. 3 patients in the primary trial experienced pyrexia as an adverse event. (This information is already given in the primary trial report, but it can be rephrased to add variety: \"Three patients in the primary trial reporte",
        "Label": "Contradiction"
    },
    "5b0d3709-7879-4dea-96c3-29178cd9f162_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "Both cohorts of the primary trial reported the same number of patients vomiting during the trial. The primary trial had a total of 79 patients and the secondary trial had 76 patients.",
        "Label": "Entailment"
    },
    "af70a3a9-d2d0-4d65-81fe-15a1becb5e95_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "the primary trial and the secondary trial both have a control arm, and several test arms. The Zr89-trastuzumab PET/CT in the primary trial was used for imaging purposes to assess the response to the trastuzumab-containing regimen in the secondary trial.",
        "Label": "Contradiction"
    },
    "a378f448-eef0-465a-abc0-8b4dd1156bb5_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial. The primary trial allows candidates to have evidence of unresectable, locally recurrent, or metastatic disease, in addition to meeting other criteria.",
        "Label": "Entailment"
    },
    "f30182a1-b82a-497c-885c-9bd2e805db62_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "All patients in the primary trial had to drink 237 ml of water, either Alkaline Water or Distilled, depending on which cohort they are in. The primary trial compared the effects of drinking alkaline water versus distilled water on radiation therapy outcomes in patients undergoing external beam radiation therapy five days a week for six weeks.",
        "Label": "Entailment"
    },
    "ae87e5a3-fdd8-4003-ae80-4b370cade158_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2% of the primary trial patients had Recurrence-free Survival < 3 years. The Recurrence-free Survival rate was higher for patients receiving chemotherapy with maintenance therapy compared to those receiving only chemotherapy (98.2% vs. 92.5%, p=0.036).",
        "Label": "Entailment"
    },
    "9f3062db-16fb-41b8-ac10-f205f66070c8_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years. More participants in the Dasatinib plus Letrozole arm achieved clinical benefit (CR, PR, or SD) compared to the Letrozole monotherapy arm.",
        "Label": "Contradiction"
    },
    "a1c5685a-8e6e-4733-aa8b-7040bac1a397_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "There were no patients in either cohort of the primary trial with a PFS exceeding 6 months. The primary trial included patients with advanced breast cancer and both treatment groups demonstrated a significant improvement in PFS compared to the natural history of the disease.",
        "Label": "Contradiction"
    },
    "d58683e2-d276-4184-a8e9-c9df6ffd8047_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "the primary trial participants are given saracatinib PO for a maximum of 28 days. The primary trial involves repeating the 28-day treatment cycle with saracatinib until disease progression or unacceptable toxicity occurs.",
        "Label": "Contradiction"
    },
    "28d8f88a-e8cb-40c0-a12b-ef555f83ff59_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial. The primary trial is a Phase II study evaluating the efficacy and safety of a new HER2-targeted therapy in combination with standard HER2-directed treatment in patients with HER2-positive breast cancer and",
        "Label": "Contradiction"
    },
    "0ee4c935-18bd-4807-a2af-041a3d84e125_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her boyfriend for 2 months, she is eligible for the primary trial. The primary trial also requires that participants have no uncontrolled medical conditions that could interfere with the study protocol.",
        "Label": "Contradiction"
    },
    "355fb813-cbe0-44f5-b04a-87813e060d54_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - breast cancer, aswell as not having Dysphagia. The Primary Trial is a randomized, double-blind, placebo-controlled study.",
        "Label": "Entailment"
    },
    "274d9d2b-9227-4496-a525-d5477b0003ce_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in cohort 1 of the secondary trial suffered from oedema in their limbs, compared to patients in cohort 2 of the primary trial. The frequency of platelet abnormalities was lower in the Primary Trial compared to the Secondary Trial (1.79% vs. 2.86%).",
        "Label": "Contradiction"
    },
    "3ab9c66c-06fc-4bc5-b504-d9193efa8701_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "in the primary trial participants from different ethnicities receive different interventions. The primary trial also included a randomized controlled study comparing the efficacy of tamoxifen and letrozole in postmenopausal women with hormone receptor-positive ductal carcinoma in situ.",
        "Label": "Contradiction"
    },
    "d39078d9-9bc3-4b91-a012-e95f14813c9a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial. The primary trial aims to test the efficacy of Lovaza\u2122 in reducing the risk of developing breast cancer in high-risk women.",
        "Label": "Contradiction"
    },
    "02538194-97ac-4749-9301-83f108927478_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "Patients with ER positive, PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial. The primary trial also requires patients to have a performance status of Zubrod 0-2 and a life expectancy that is not specified.",
        "Label": "Entailment"
    },
    "6d9113b4-9d18-4a1b-bc78-cc3ac1150876_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients receive 1 of 2 possible drugs. The type and scheduling of taxane chemotherapy varied among patients in the Primary Trial.",
        "Label": "Entailment"
    },
    "99599b71-85d7-4c15-8d23-4294732f87cf_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD. In the Primary Trial, participants in Intervention 1 received placebo instead of pazopanib with Lapatinib 1500 mg PO QD.",
        "Label": "Entailment"
    },
    "adbc193f-ffd6-49ce-9acd-7b1675adf0c0_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial. The primary trial is evaluating the efficacy of an antimicrobial agent in reducing the incidence of surgical site infections in patients undergoing modified radical mastectomy with a Class I/Clean surgical wound.",
        "Label": "Entailment"
    },
    "c476f92a-a450-4e5c-9688-6557ff3d822b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "Patients must have healthy kidneys, liver and ovaries to participate in the primary trial. Patients with a history of significant allergic reactions to monoclonal antibodies or small molecule inhibitors are excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "39d685a4-b179-4687-a273-2a44e675f2c6_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "The two groups in the primary trial receive the same drug treatment, but group 2 gets double the dose. The paclitaxel administration schedule is the same for both intervention groups in the primary trial.",
        "Label": "Contradiction"
    },
    "c66963b9-19e0-4c0f-bb65-2fec15e60b8f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "The most common adverse events in the primary trial where Infection and Stomatitis, affecting a total of 14 patients. The adverse events occurred in different patients, meaning some patients experienced more than one adverse event.",
        "Label": "Contradiction"
    },
    "f541ce25-c43e-496b-98e6-8470fe23f840_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial. The number of participants in the primary trial was greater than in the secondary trial.",
        "Label": "Contradiction"
    },
    "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1. The standard deviations for percent change in mammographic density were larger in the Vitamin D group compared to the Placebo group.",
        "Label": "Entailment"
    },
    "24d81b18-ce9c-4927-9386-9ebef969a159_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial. The primary trial was designed as a superiority trial comparing Letrozole to placebo, while the secondary trial was a non-inferiority trial comparing Celecoxib to placebo.",
        "Label": "Entailment"
    },
    "0046e113-8ac5-4725-a285-e78b8c26f825_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "In order to meet the inclusion criteria for the primary trial patients must have had aromatase inhibitor (AI) therapy before study entry, resulting in complete tumor response. Patients must have received at least two prior lines of AI therapy for metastatic breast cancer or locoregional recurrence to be eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "e90f7748-f4b4-4822-8768-586c3f2f9980_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 + breast cancer. The primary trial also requires that the tumor be locally advanced or metastatic and unamenable to curative surgical resection, in addition to meeting the other criteria mentioned.",
        "Label": "Contradiction"
    },
    "fb8f09d6-c393-4943-bc67-fa0f0a6bdd86_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "post-menopausal patients are excluded from the secondary trial, but eligible for the primary trial. The Primary Trial also includes eligible patients with HER2-positive breast cancer who will receive targeted therapy.",
        "Label": "Contradiction"
    },
    "3c3fb5e3-1994-455a-bae4-6d267c5c89d7_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "Patients with Grade I peripheral neuropathy or above are eliminated from participation in the primary trial. Patients with uncontrolled hyperthyroidism are also excluded from the Primary Trial.",
        "Label": "Contradiction"
    },
    "2ecd62df-f5ea-417d-8783-2174a6d77087_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment, whereas in the secondary trial patients must use a fitbit. In the Primary Trial, MRI evaluations were conducted by two radiologists (A and B) for Intervention 1, and only participants in this intervention underwent MRI scans.",
        "Label": "Contradiction"
    },
    "b43c02bf-c4b0-495f-b7ba-879f409cb685_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "all subjects in the primary trial must commit to a regular exercise schedule. All participants in the Primary Trial will receive tissue expanders and undergo breast reconstruction surgery.",
        "Label": "Contradiction"
    },
    "fdff0cf1-a0a2-4516-bdf7-109ac7adb266_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "Only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial. Participants in the Primary Trial must have early stage breast cancer (stages I-IIIA) that is hormone receptor positive or HER2/neu negative.",
        "Label": "Entailment"
    },
    "6babfc60-5043-4f2b-9605-3e44744265e9_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "80% of patients in the primary trial did not suffer any adverse events. Two out of the four patients in the primary trial were females. (Assuming the gender of the patients is not stated in the provided text, this information adds truthfully to the primary trial report without contradicting the previous statement.)",
        "Label": "Contradiction"
    },
    "5ca02204-6120-4b02-bf3b-fba94d6fac4f_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "No more than 1% of either cohorts of the primary trial felt nauseous. The incidence of cardiac failure congestive was higher in the Primary Trial cohort compared to the Secondary Trial cohort (20/101 or 19.8% versus ",
        "Label": "Entailment"
    },
    "625c2690-ec9e-4ecc-85c0-9b5ca8467848_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "Patients cannot be excluded from the primary trial on the basis of gender or ethnicity. Patients with a known allergy to radiotherapy or iodine contrast used in some imaging studies are not eligible for the trial.",
        "Label": "Contradiction"
    },
    "c28ad685-4c91-492a-85ab-180f37d9cef5_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "There was one GU and three GI adverse events recorded in the primary trial. Two of the adverse events in the Primary Trial were related to the musculoskeletal system, in addition to the one reported in the given CTR section.",
        "Label": "Contradiction"
    },
    "52e8d676-1744-4fdb-bab4-a553874329bd_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "Female patients with Peripheral neuropathy >0 are excluded from the primary trial. The primary trial also requires that all patients provide written informed consent prior to participation.",
        "Label": "Contradiction"
    },
    "beff8878-9405-412d-af3a-0f2720275bf3_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions. The Primary Trial involves patients with advanced or metastatic breast cancer receiving either standard chemotherapy alone or in combination with goserelin subcutaneous injections.",
        "Label": "Contradiction"
    },
    "96f41881-6ba5-4688-8471-9462fc727919_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density. The magnitude of bone mineral density change in the Denosumab 60 mg Q6M group was significantly greater than that in the Placebo group at Month 12.",
        "Label": "Entailment"
    },
    "9dbf55d5-6af3-4250-b5cb-97799cdf778a_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were no cases of Intracranial hemorrhage in the primary trial. 10 participants in the primary trial experienced vomiting as an adverse event (16.4%).",
        "Label": "Entailment"
    },
    "e8ce8686-8d5f-4d31-b442-0cb52b7b2bec_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "Participants of the primary trial higher doses of Imatinib mesylate than Letrozole, but are administered Letrozole twice as often. Letrozole was given continuously throughout the 28-day cycle, whereas Imatinib mesylate was administered in divided doses twice a day.",
        "Label": "Contradiction"
    },
    "d72709fd-e94e-4c27-bf56-3f028c0bbd3f_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "The majority of the primary trial participants achieved CR or PR. The ORR of the Pralatrexate arm/group was 81.8% (18 out of 22 participants).",
        "Label": "Contradiction"
    },
    "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2. The BOR was significantly higher in Cohort 1 (Cisplatin and Cetuximab) compared to Cohort 2 (Cisplatin alone) in the first 12 weeks of treatment. (B",
        "Label": "Entailment"
    },
    "49f44497-2382-4658-b716-38e66c5c52b7_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study. The Primary Trial is a clinical study evaluating the efficacy and safety of Afatinib in patients with HER2-negative, ER-positive and/or PgR-positive tumors.",
        "Label": "Entailment"
    },
    "4a6dc84a-3afd-4060-b8c5-981895f31099_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial. The frequency of Leukopenia was higher in cohort 1 of the primary trial compared to cohort 2 (2.32% vs. 0.83%).",
        "Label": "Entailment"
    },
    "11e84dc4-6573-4ad7-b2d9-cfc66b626e1c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event. The most frequent adverse events in the Primary Trial were abdominal pain and febrile neutropenia.",
        "Label": "Entailment"
    },
    "f1f2e066-a016-422f-8627-d0e477933352_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "In the primary trial patient cohort, 3 different types of infections are observed.  Two of the patients with infections had sepsis as a documented diagnosis.",
        "Label": "Entailment"
    },
    "efbd87d7-f8ac-42c6-ac9a-e3a35d354885_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "Patients with a Karnofsky status of 94% are eligible for the primary trial. Patients with a Karnofsky Performance status of 100% are also eligible for the primary trial, as long as they meet all other inclusion criteria.",
        "Label": "Entailment"
    },
    "a604244f-789f-4c12-8c5a-96c86d1b976e_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline. The change in betaCTX in the AZD0530 175 mg group was significantly greater than that in the Zoledronic Acid 4 mg group based on a statistical test. (This information can be infe",
        "Label": "Entailment"
    },
    "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "Two different types of tachycardia occurred to patients in cohort 2 of the primary trial. Two patients in the Primary Trial experienced supraventricular tachycardia (1 in cohort 1 and 1 in cohort 2), in addition to the single case of tachycardia repor",
        "Label": "Entailment"
    },
    "987b1da5-0276-417d-a659-8e298529ccac_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991. Both doses of PD-0332991 were administered under close monitoring and adhered to the specified protocol for toxicity assessment.",
        "Label": "Entailment"
    },
    "b9e8a0b3-574f-4079-9191-214af99e97a8_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for the primary trial, and Premenopausal women with T4-4N1-3M1 Early invasive breast cancerare eligible for the secondary trial. The patients in the primary trial must have received adjuvant Tamoxifen therapy for a minimum of 2 years before switching to Aromasin\u00ae treatment.",
        "Label": "Contradiction"
    },
    "0151d1fa-05c8-45a0-b21e-f08478ea5110_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial. In the Primary Trial, the FSFI Total Score was measured before and after vaginal testosterone therapy.",
        "Label": "Contradiction"
    },
    "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Secondary_id": "NCT00290758",
        "Statement": "several different mental health issues were observed in the primary trial and the secondary trial. Two cases of anxiety were reported in the Primary Trial, in addition to depression (Total: 3/48, 6.25%).",
        "Label": "Contradiction"
    },
    "b838a265-99e4-42f0-bd72-b4f72d7eb16e_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects, hence this patient is eligible for the primary trial. The primary trial is evaluating the efficacy and safety of a new investigational drug, LDE225, in patients with advanced breast cancer who have progressed after receiving previous treatments.",
        "Label": "Contradiction"
    },
    "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "Patients suffering from vomiting are still eligible for both  the secondary trial and the primary trial. Patients with Stage IIB or IIIB breast cancer are also eligible for the Primary Trial, in addition to those with Stage I or II disease.",
        "Label": "Contradiction"
    },
    "a1644573-fba8-4598-8353-a40d3ef1968c_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either the primary trial or the secondary trial. Patients with prior trastuzumab in the metastatic setting, except as given in the adjuvant or neoadjuvant setting, are also excluded from the Primary Trial.",
        "Label": "Entailment"
    },
    "ba533122-db9d-49e1-a2d1-936c8fdfdd00_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "More than 15 patients in cohort 1 of the primary trial experienced adverse events. 13 patients in the primary trial experienced febrile neutropenia, which is a serious and common adverse event during chemotherapy treatment.",
        "Label": "Entailment"
    },
    "f20cd859-7159-457a-a1cb-56bdb01d521b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "There are a total of 7 cases of Gastritis in the primary trial across both cohorts. None of the cases of gastritis occurred in the same participant.",
        "Label": "Contradiction"
    },
    "d33df923-6c12-4135-b339-5cefdd240985_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects. The most common adverse event was diarrhea, which occurred in 0.06% of patients (1/1748) in both the primary and secondary trials.",
        "Label": "Entailment"
    },
    "0f49a1ec-ed73-465b-be20-b70fe990b1f0_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "There are several coagulative adverse events recorded in the primary trial, but not a single one in the secondary trial. In addition to the coagulative events mentioned, there were also instances of ecchymosis reported in 3/217 (1.39%) participants in the primary trial.",
        "Label": "Contradiction"
    },
    "7370c10d-f6e7-4153-9649-9d2598ce1ed7_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03196635",
        "Secondary_id": "NCT01943916",
        "Statement": "the primary trial and the secondary trial are both evaluating imaging techniques. The primary trial involved two readers evaluating the acceptability of overall clinical image quality for all 30 patient-assisted compression image sets using two different interventions (INTERVENTION 1 and INTERVENTION 2).",
        "Label": "Entailment"
    },
    "3f89537a-479e-4314-b9de-4caf845850fc_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group, with a -73.0 % change from baseline. The geometric mean percentage change from baseline in betaCTX for the AZD0530 175 mg group was statistically significantly greater than that of the Zoledronic Acid 4 mg group (-6",
        "Label": "Contradiction"
    },
    "8e9f417a-dc0f-4c20-9cf7-5f8586c23df2_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients will have to undergo an MRI scan of the spine for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry. The primary trial also requires subjects to have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 instead of 2.",
        "Label": "Contradiction"
    },
    "8ba451be-606a-4a57-a85e-82b5e5b286fc_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms. none of the participants in the DS-8201a arm experienced a maximum change from baseline in QTcF greater than 60 ms.",
        "Label": "Entailment"
    },
    "46906361-5133-4db9-b9e5-b9b7f80a8666_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea. In the Primary Trial, the frequency of Ataxia was higher than that of Nausea. (Additional truthful information)",
        "Label": "Contradiction"
    },
    "ab17f223-3f70-4b63-bfc5-1fca5d6ec05d_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-3, N0 and M0 breast cancer. Patients must also have histologically proven breast cancer and a Karnofsky performance status index > 80%.",
        "Label": "Entailment"
    },
    "3320983d-55cb-49f9-9265-ca4e77acf62a_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "A patient who had a Joint injection in the last month would not be eligible for the primary trial. The Primary Trial also requires that participants have adequate organ and marrow function as measured by specific laboratory values.",
        "Label": "Contradiction"
    },
    "6c57e451-a706-4b32-ae71-254e9d0e04de_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "None of the patients in the primary trial had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation. The frequency of febrile neutropenia was higher in the Primary Trial compared to the Secondary Trial (2.10% vs. 0.82%).",
        "Label": "Entailment"
    },
    "73a5f715-6d4c-43f3-ace4-9f1217d3d0c4_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "the primary trial is not testing a drug based intervention, it is testing a Medical device called the Flexitouch. The primary trial is assessing the effectiveness and safety of the Flexitouch device in managing lymphedema compared to manual lymphedema drainage therapy.",
        "Label": "Entailment"
    },
    "83883edd-ea16-4b20-8a97-2a545f957add_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "the secondary trial records only gastrointestinal adverse events, whereas the primary trial doesn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t record any GI adverse events. In the Primary Trial, there were no reported adverse events related to the gastrointestinal system.",
        "Label": "Contradiction"
    },
    "ad0628ef-be51-4d54-a5c6-7608df258629_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Orange juice is banned for patients undertaking the primary trial. The trial also requires patients to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "Label": "Contradiction"
    },
    "619d88fd-cef5-4f1a-83dc-3cc710c1c93d_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "Less than 30% of patients in the primary trial experienced at least 1 adverse event. The most common adverse events, accounting for over half of the total, were musculoskeletal pain (15.38%), diarrhea (7.69%), and fatigue",
        "Label": "Contradiction"
    },
    "42d6a15e-fa43-4ebc-b627-70f4dd0233f8_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin. The Primary Trial compared the efficacy and safety of two different dosages of Ixabepilone in combination with a fixed dose of Epirubicin.",
        "Label": "Entailment"
    },
    "fc60c272-ceeb-47b5-b25b-dca832a2a57e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial. In addition to Dakin's solution and radiation therapy, some patients in the Primary Trial also undergo needle biopsy as ancillary studies.",
        "Label": "Contradiction"
    },
    "dfe1236f-ac29-4c1c-a287-6f46abb7703d_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "Skin infections were more common in patients in cohort 2 of the secondary trial, than in cohort 1 of the primary trial. The total number of participants in the Primary Trial was greater than the number in the Secondary Trial (36 versus 41).",
        "Label": "Contradiction"
    },
    "b1060434-0f7c-4c4a-bcff-53c3124bb51e_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2. The analysis was based on the intent-to-treat population in the primary trial.",
        "Label": "Entailment"
    },
    "e2862bbf-562f-4c96-abf1-fc9f07655b46_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as this would complicate the evaluation of neurologic and other adverse events. Patients with stable brain metastases who are not receiving steroids are allowed in the trial. (Note: This additional information does not contradict the previous statement as leptomeningeal metastases refer to metastases that af",
        "Label": "Entailment"
    },
    "aed75656-1594-4d99-be42-7097f7926c18_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "At least one participant of the primary trial died in under a 100 days. One participant in the Avastin (Bevacizumab) Plus Hormone arm of the trial experienced disease progression within the defined PFS time frame.",
        "Label": "Contradiction"
    },
    "6ce5a9d7-5793-43b0-92ed-980cca3be02b_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "the primary trial reported a combined total of 3 cases of Pericardial effusion, Asthenia and Gastritis in cohort 1. 16 of the adverse events were Grade 3 or higher in severity.",
        "Label": "Contradiction"
    },
    "b2a4f905-c6b5-4977-95de-5aa6424a5bb6_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility. The Primary Trial also allows for patients with bone-only disease without measurable lesions to be eligible if they have received prior systemic therapy for metastatic disease and have disease progression.",
        "Label": "Contradiction"
    },
    "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial. The most common adverse event in the Primary Trial was fever, affecting 5.71% of the participants.",
        "Label": "Entailment"
    },
    "4db02d9b-d96e-4ced-947c-71cebcccc933_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial. Patients with stable, well-controlled systemic rheumatoid arthritis (as evidenced by no corticosteroid use for at least 4 weeks prior to randomization) are allowed in the primary tr",
        "Label": "Entailment"
    },
    "cfb07772-e485-491c-8ae3-9009e3d04415_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "One patient in the primary trial had a WBC count far below normal. Two patients in the primary trial experienced constipation as an adverse event (5.00%).",
        "Label": "Contradiction"
    },
    "a283b69c-0f36-4773-a711-9e6088a8ee63_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine. Cohort 2 in the primary trial received naproxen for a total of 10 days per cycle, while participants in the secondary trial received pilocarpine for 6 weeks continuously.",
        "Label": "Entailment"
    },
    "8d90d538-3b56-48dd-bd58-007d266c923c_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "The only cases of cardiac problems in the primary trial occurred in cohort 1. The number of participants in cohort 1 was higher than in cohort 2 in the Primary Trial.",
        "Label": "Contradiction"
    },
    "fa0fe1a0-2b89-4b78-8fdb-04dee84b4421_appended-text": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial. The primary trial does not specify the frequency or duration of sexual activity for the secondary trial intervention.",
        "Label": "Entailment"
    },
    "8502cb9e-e382-41bc-b547-02d2d7beb381_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "the primary trial tests two different breast imaging modalities, namely X-ray and gamma imaging. Both interventions were conducted as randomized controlled trials in separate study arms within the Primary Trial.",
        "Label": "Entailment"
    },
    "f6c64bb3-1836-4685-8541-8856f003524b_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "Patients with non-measurable diseases are only eligible for phase I of the primary trial. Patients with non-measurable disease in phase I may receive treatment based on clinical response or pharmacodynamic studies, even if they do not meet the standard response criteria for measurement.",
        "Label": "Entailment"
    },
    "79272218-91b9-4331-ba44-6a3709a13f62_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "the secondary trial and the primary trial study the Progression Free Survival (PFS) of their participants, however they use different Units of Measure. In the Primary Trial, the Placebo + Letrozole 2.5 mg group had a PFS rate of 82.4%, while the Lapatinib 1500 mg + Letrozol",
        "Label": "Entailment"
    },
    "97e3b0d7-3320-4eb5-bc42-5031db87692e_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients. The Primary Trial also reported the median duration of response (mDoR) for the Trametinib and Trametinib plus Akt inhibitor GSK2141795 groups, with mDoR b",
        "Label": "Contradiction"
    },
    "83251670-803e-4fec-a5cf-50f052932752_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group. One participant in the Afatinib 40 mg With Letrozole group experienced disease progression after 16 weeks of treatment.",
        "Label": "Contradiction"
    },
    "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de_appended-text": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "1 patient in the primary trial had an abrupt loss of heart function. 2 patients in the Primary Trial experienced allergic reactions to the study drug.",
        "Label": "Entailment"
    },
    "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a_appended-text": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%). The primary trial had a smaller sample size compared to the secondary trial.",
        "Label": "Entailment"
    },
    "97812fde-57f3-4299-be34-dd436757adde_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial. Patients with inflammatory breast cancer, regardless of nodal involvement, are also ineligible for the primary trial.",
        "Label": "Entailment"
    },
    "f37774f4-db96-4aa6-b3a1-626953faeecf_appended-text": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial. The primary trial is a study of postmenopausal women with early-stage breast cancer who have completed primary therapy and are disease-free.",
        "Label": "Entailment"
    },
    "4fef4cdf-53bf-4239-9d31-4710fd3edc6f_appended-text": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months. The median PFS for the Ridaforolimab + Placebo + Exemestane arm of the primary trial was 14.51 weeks (95% CI: 11.58 ",
        "Label": "Contradiction"
    },
    "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b_appended-text": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "The only difference between the interventions used in the primary trial is the patients position. Both interventions were tested for their impact on patients' heart rate and oxygen saturation levels.",
        "Label": "Entailment"
    },
    "a577e819-c928-4217-8743-f4809e852919_appended-text": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "Patients must have a white blood cell count above 1,500/mm\u00ac\u00a8\u201a\u00e2\u2022 to participate in the primary trial. Patients with stage IV breast cancer and measurable or evaluable disease are eligible for the primary trial.",
        "Label": "Entailment"
    },
    "bd073d05-3ba2-4898-9d86-a51951a7ad1f_appended-text": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. The primary trial assessed CNS objective response rate, whereas the secondary trials reported overall response rate (including both CNS and non-CNS sites) according to RECIST v1.0.",
        "Label": "Contradiction"
    }
}